Identification	O
of	O
the	O
activating	O
and	O
conjugating	O
enzymes	O
of	O
the	O
NEDD8	B-Protein
conjugation	O
pathway	O
.	O

NEDD8	B-Protein
is	O
a	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
that	O
can	O
be	O
covalently	O
conjugated	O
to	O
a	O
limited	O
number	O
of	O
cellular	O
proteins	O
,	O
such	O
as	O
Cdc53	B-Protein
/	O
cullin	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
C	O
terminus	O
of	O
NEDD8	B-Protein
is	O
efficiently	O
processed	O
to	O
expose	O
Gly	O
-	O
76	O
,	O
which	O
is	O
required	O
for	O
conjugation	O
to	O
target	O
proteins	O
.	O

A	O
combination	O
of	O
data	O
base	O
searches	O
and	O
polymerase	O
chain	O
reaction	O
cloning	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
human	O
UBA3	B-Protein
,	O
which	O
is	O
38	O
%	O
identical	O
to	O
the	O
yeast	O
homologue	O
,	O
22	O
%	O
identical	O
to	O
human	O
UBA2	B-Protein
,	O
and	O
19	O
%	O
identical	O
to	O
the	O
C	O
-	O
terminal	O
region	O
of	O
human	O
UBE1	B-Protein
.	O

The	O
human	O
UBA3	B-Protein
gene	O
is	O
located	O
on	O
chromosome	O
3p13	O
and	O
gave	O
rise	O
to	O
a	O
2	O
.	O
2	O
-	O
kilobase	O
pair	O
transcript	O
that	O
was	O
detected	O
in	O
all	O
tissues	O
.	O

Human	O
UBA3	B-Protein
could	O
be	O
precipitated	O
with	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
(	O
GST	B-Protein
)	O
-	O
NEDD8	B-Protein
,	O
but	O
not	O
with	O
GST	B-Protein
-	O
ubiquitin	B-Protein
or	O
GST	B-Protein
-	O
sentrin	B-Protein
-	I-Protein
1	I-Protein
.	O

Moreover	O
,	O
human	O
UBA3	B-Protein
could	O
form	O
a	O
beta	O
-	O
mercaptoethanol	O
-	O
sensitive	O
conjugate	O
with	O
NEDD8	B-Protein
in	O
the	O
presence	O
of	O
APP	B-Protein
-	I-Protein
BP1	I-Protein
,	O
a	O
protein	O
with	O
sequence	O
homology	O
to	O
the	O
N	O
-	O
terminal	O
half	O
of	O
ubiquitin	O
-	O
activating	O
enzyme	O
.	O

We	O
have	O
also	O
cloned	O
human	O
UBC12	B-Protein
and	O
demonstrated	O
that	O
it	O
could	O
form	O
a	O
thiol	O
ester	O
linkage	O
with	O
NEDD8	B-Protein
in	O
the	O
presence	O
of	O
the	O
activating	O
enzyme	O
complex	O
.	O

Identification	O
of	O
the	O
activating	O
and	O
conjugating	O
enzymes	O
of	O
the	O
NEDD8	B-Protein
conjugation	O
pathway	O
should	O
allow	O
for	O
a	O
more	O
detailed	O
study	O
of	O
the	O
role	O
of	O
NEDD8	B-Protein
modification	O
in	O
health	O
and	O
disease	O
.	O

Correlation	O
between	O
MRI	O
and	O
clinico	O
-	O
pathological	O
manifestations	O
in	O
Lewis	O
rats	O
protected	O
from	O
experimental	O
allergic	O
encephalomyelitis	O
by	O
acylated	O
synthetic	O
peptide	O
of	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
.	O

Experimental	O
allergic	O
encephalomyelitis	O
(	O
EAE	O
)	O
is	O
an	O
autoimmune	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
which	O
constitutes	O
an	O
accepted	O
animal	O
model	O
for	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

The	O
disease	O
can	O
take	O
an	O
acute	O
or	O
chronic	O
form	O
depending	O
on	O
the	O
injection	O
route	O
,	O
animal	O
strain	O
and	O
nature	O
of	O
the	O
disease	O
-	O
inducing	O
antigen	O
administered	O
.	O

The	O
neuroinflammation	O
associated	O
with	O
the	O
acute	O
form	O
can	O
be	O
detected	O
with	O
T2	O
-	O
weighted	O
,	O
T1	O
-	O
weighted	O
and	O
diffusion	O
MRI	O
,	O
and	O
blood	O
-	O
brain	O
barrier	O
changes	O
can	O
be	O
investigated	O
with	O
Gd	O
-	O
DTPA	O
-	O
enhanced	O
T1	O
-	O
weighted	O
imaging	O
,	O
similar	O
to	O
that	O
of	O
MS	O
patients	O
.	O

A	O
synthetic	O
peptide	O
of	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
(	O
MBP	B-Protein
)	O
encephalitogenic	O
for	O
the	O
Lewis	O
rat	O
(	O
MBP	O
68	O
-	O
86	O
)	O
was	O
acylated	O
by	O
the	O
attachment	O
of	O
a	O
palmitoyl	O
residue	O
(	O
PAL68	O
-	O
86	O
)	O
,	O
and	O
was	O
shown	O
to	O
confer	O
almost	O
complete	O
protection	O
against	O
EAE	O
,	O
when	O
administered	O
to	O
rats	O
before	O
and	O
after	O
an	O
encephalitogenic	O
challenge	O
.	O

In	O
this	O
study	O
,	O
treatment	O
of	O
Lewis	O
rats	O
with	O
PAL68	O
-	O
86	O
prevented	O
the	O
appearance	O
of	O
clinical	O
signs	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
after	O
challenge	O
with	O
the	O
native	O
peptide	O
(	O
p68	O
-	O
86	O
)	O
in	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
CFA	O
)	O
,	O
and	O
reduced	O
considerably	O
the	O
MRI	O
and	O
histopathological	O
signs	O
of	O
the	O
disease	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Measurement	O
of	O
the	O
gadolinium	O
leakage	O
due	O
to	O
neuroinflammation	O
revealed	O
a	O
significant	O
decrease	O
in	O
permeability	O
from	O
4	O
.	O
09	O
+	O
/	O
-	O
2	O
.	O
1	O
to	O
2	O
.	O
95	O
+	O
/	O
-	O
1	O
.	O
79	O
%	O
pixels	O
>	O
mean	O
+	O
2	O
SD	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

Therefore	O
,	O
quantitative	O
MRI	O
measurements	O
correlate	O
very	O
well	O
with	O
the	O
reduced	O
cellular	O
infiltration	O
in	O
the	O
CNS	O
and	O
the	O
absence	O
of	O
clinical	O
signs	O
in	O
the	O
EAE	O
-	O
protected	O
animal	O
.	O

Synthesis	O
of	O
the	O
palmitoylated	O
and	O
prenylated	O
C	O
-	O
terminal	O
lipopeptides	O
of	O
the	O
human	O
R	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
.	O

For	O
the	O
study	O
of	O
biological	O
phenomena	O
influenced	O
by	O
the	O
R	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
,	O
characteristic	O
peptides	O
which	O
embody	O
the	O
correct	O
lipid	O
modifications	O
of	O
their	O
parent	O
proteins	O
(	O
palmitoyl	O
thioesters	O
,	O
geranylgeranyl	O
thioethers	O
,	O
and	O
farnesyl	O
thioethers	O
)	O
,	O
as	O
well	O
as	O
analogues	O
thereof	O
,	O
may	O
serve	O
as	O
efficient	O
tools	O
.	O

For	O
the	O
construction	O
of	O
such	O
acid	O
-	O
and	O
base	O
labile	O
peptide	O
conjugates	O
the	O
allyl	O
ester	O
was	O
developed	O
as	O
C	O
-	O
terminal	O
protecting	O
group	O
.	O

Allyl	O
esters	O
are	O
cleaved	O
selectively	O
and	O
in	O
high	O
yields	O
from	O
lipidated	O
peptides	O
by	O
Pd	O
(	O
0	O
)	O
-	O
mediated	O
allyl	O
transfer	O
to	O
accepting	O
N	O
-	O
or	O
C	O
-	O
nucleophiles	O
like	O
morpholine	O
and	O
N	O
,	O
N	O
'	O
-	O
dimethylbarbituric	O
acid	O
.	O

This	O
protecting	O
group	O
technique	O
formed	O
the	O
key	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
characteristic	O
S	O
-	O
palmitoylated	O
and	O
S	O
-	O
isoprenylated	O
C	O
-	O
terminus	O
of	O
human	O
R	B-Protein
-	I-Protein
Ras	I-Protein
and	O
human	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
,	O
as	O
well	O
as	O
several	O
analogues	O
thereof	O
.	O

Deprotections	O
are	O
so	O
mild	O
that	O
no	O
undesired	O
side	O
reactions	O
of	O
the	O
lipid	O
conjugates	O
are	O
observed	O
.	O

HIV	O
-	O
1	O
Nef	B-Protein
alters	O
the	O
expression	O
of	O
betaII	O
and	O
epsilon	O
isoforms	O
of	O
protein	O
kinase	O
C	O
and	O
the	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
promoter	O
in	O
human	O
astrocytoma	O
cells	O
.	O

In	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
-	O
infected	O
brain	O
,	O
the	O
virus	O
does	O
not	O
replicate	O
in	O
astrocytes	O
,	O
but	O
a	O
synthesis	O
of	O
viral	O
regulatory	O
proteins	O
occurs	O
in	O
these	O
cells	O
,	O
leading	O
to	O
accumulation	O
of	O
Nef	B-Protein
.	O

As	O
an	O
approach	O
to	O
understand	O
the	O
effects	O
of	O
Nef	B-Protein
on	O
astrocyte	O
functional	O
activity	O
,	O
we	O
analyzed	O
whether	O
intracellular	O
Nef	B-Protein
interferes	O
with	O
the	O
expression	O
and	O
activation	O
of	O
the	O
enzyme	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
which	O
is	O
an	O
important	O
regulator	O
of	O
astroglial	O
functions	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Astrocytoma	O
clones	O
(	O
U251	O
MG	O
)	O
not	O
expressing	O
Nef	B-Protein
(	O
Neo	O
)	O
,	O
or	O
expressing	O
wild	O
-	O
type	O
Nef	B-Protein
(	O
Bru	O
)	O
or	O
nonmyristoylated	O
Nef	B-Protein
(	O
TH	O
)	O
were	O
used	O
to	O
monitor	O
the	O
expression	O
and	O
activation	O
of	O
10	O
PKC	O
isoforms	O
.	O

The	O
same	O
clones	O
were	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
Nef	B-Protein
on	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
after	O
activation	O
of	O
PKC	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

PKC	O
intracellular	O
distribution	O
and	O
activation	O
were	O
evaluated	O
by	O
Western	O
blot	O
analysis	O
of	O
cytosolic	O
and	O
membrane	O
fractions	O
of	O
control	O
and	O
Nef	B-Protein
-	O
expressing	O
clones	O
.	O

PMA	O
-	O
induced	O
LTR	O
activation	O
was	O
analyzed	O
in	O
clones	O
transfected	O
with	O
a	O
plasmid	O
encoding	O
for	O
the	O
CAT	B-Protein
reporter	O
gene	O
controlled	O
by	O
the	O
LTR	O
promoter	O
,	O
by	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
to	O
measure	O
CAT	B-Protein
expression	O
.	O

Nef	B-Protein
selectively	O
downregulated	O
the	O
expression	O
and	O
activation	O
of	O
betaII	B-Protein
and	O
epsilon	B-Protein
PKC	I-Protein
isoforms	O
in	O
astrocytoma	O
cells	O
.	O

Such	O
downregulation	O
correlated	O
with	O
an	O
inhibition	O
of	O
LTR	O
activation	O
after	O
PMA	O
stimulation	O
.	O

The	O
myristoylation	O
of	O
Nef	B-Protein
and	O
its	O
membrane	O
localization	O
were	O
essential	O
for	O
these	O
effects	O
.	O

These	O
results	O
suggest	O
that	O
Nef	B-Protein
may	O
alter	O
astrocytic	O
functions	O
by	O
interfering	O
with	O
PKC	O
expression	O
and	O
activation	O
and	O
contribute	O
to	O
the	O
restriction	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
astrocytes	O
.	O

Farnesyl	O
protein	O
transferase	O
:	O
identification	O
of	O
K164	O
alpha	O
and	O
Y300	O
beta	O
as	O
catalytic	O
residues	O
by	O
mutagenesis	O
and	O
kinetic	O
studies	O
.	O

Farnesyl	O
protein	O
transferase	O
(	O
FPT	O
)	O
is	O
an	O
alpha	O
/	O
beta	O
heterodimeric	O
zinc	O
enzyme	O
that	O
catalyzes	O
posttranslational	O
farnesylation	O
of	O
many	O
key	O
cellular	O
regulatory	O
proteins	O
,	O
including	O
oncogenic	O
Ras	O
.	O

On	O
the	O
basis	O
of	O
the	O
recently	O
reported	O
crystal	O
structure	O
of	O
FPT	O
complexed	O
with	O
a	O
CVIM	O
peptide	O
and	O
alpha	O
-	O
hydroxyfarnesylphosphonic	O
acid	O
,	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
FPT	O
active	O
site	O
was	O
performed	O
so	O
key	O
residues	O
that	O
are	O
responsible	O
for	O
substrate	O
binding	O
and	O
catalysis	O
could	O
be	O
identified	O
.	O

Eight	O
single	O
mutants	O
,	O
including	O
K164N	O
alpha	O
,	O
Y166F	O
alpha	O
,	O
Y166A	O
alpha	O
,	O
Y200F	O
alpha	O
,	O
H201A	O
alpha	O
,	O
H248A	O
beta	O
,	O
Y300F	O
beta	O
,	O
and	O
Y361F	O
beta	O
,	O
and	O
a	O
double	O
mutant	O
,	O
H248A	O
beta	O
/	O
Y300F	O
beta	O
,	O
were	O
prepared	O
.	O

Steady	O
-	O
state	O
kinetic	O
analysis	O
along	O
with	O
structural	O
evidence	O
indicated	O
that	O
residues	O
Y200	O
alpha	O
,	O
H201	O
alpha	O
,	O
H248	O
beta	O
,	O
and	O
Y361	O
beta	O
are	O
mainly	O
involved	O
in	O
substrate	O
binding	O
.	O

In	O
addition	O
,	O
biochemical	O
results	O
confirm	O
structural	O
observations	O
which	O
show	O
that	O
residue	O
Y166	O
alpha	O
plays	O
a	O
key	O
role	O
in	O
stabilizing	O
the	O
active	O
site	O
conformation	O
of	O
several	O
FPT	O
residues	O
through	O
cation	O
-	O
pi	O
interactions	O
.	O

Two	O
mutants	O
,	O
K164N	O
alpha	O
and	O
Y300F	O
beta	O
,	O
have	O
moderately	O
decreased	O
catalytic	O
constants	O
(	O
kcat	O
)	O
.	O

Pre	O
-	O
steady	O
-	O
state	O
kinetic	O
analysis	O
of	O
these	O
mutants	O
from	O
rapid	O
quench	O
experiments	O
showed	O
that	O
the	O
chemical	O
step	O
rate	O
constant	O
was	O
reduced	O
by	O
41	O
-	O
and	O
30	O
-	O
fold	O
,	O
respectively	O
.	O

The	O
product	O
-	O
releasing	O
rate	O
for	O
each	O
dropped	O
approximately	O
10	O
-	O
fold	O
.	O

In	O
pH	O
-	O
dependent	O
kinetic	O
studies	O
,	O
Y300F	O
beta	O
was	O
observed	O
to	O
have	O
both	O
acidic	O
and	O
basic	O
pKa	O
values	O
shifted	O
1	O
log	O
unit	O
from	O
those	O
of	O
the	O
wild	O
-	O
type	O
enzyme	O
,	O
consistent	O
with	O
a	O
possible	O
role	O
for	O
Y300	O
beta	O
as	O
an	O
acid	O
-	O
base	O
catalyst	O
.	O

K164N	O
alpha	O
had	O
a	O
pKa	O
shift	O
from	O
6	O
.	O
0	O
to	O
5	O
.	O
3	O
,	O
which	O
suggests	O
it	O
may	O
function	O
as	O
a	O
general	O
acid	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
along	O
with	O
structural	O
evidence	O
,	O
a	O
possible	O
FPT	O
reaction	O
mechanism	O
is	O
proposed	O
with	O
both	O
Y300	O
beta	O
and	O
K164	O
alpha	O
playing	O
key	O
catalytic	O
roles	O
in	O
enhancing	O
the	O
reactivity	O
of	O
the	O
farnesyl	O
diphosphate	O
leaving	O
group	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
mammalian	O
N	O
-	O
acetylglucosamine	O
-	O
6	O
-	O
sulfotransferase	O
that	O
is	O
highly	O
restricted	O
to	O
intestinal	O
tissue	O
.	O

Using	O
the	O
sequences	O
of	O
a	O
galactose	O
6	O
-	O
O	O
-	O
sulfotransferase	O
and	O
an	O
N	O
-	O
acetylglucosamine	O
6	O
-	O
O	O
-	O
sulfotransferase	O
as	O
probes	O
in	O
an	O
EST	O
approach	O
,	O
we	O
have	O
identified	O
a	O
highly	O
related	O
cDNA	O
in	O
human	O
and	O
an	O
apparent	O
orthologue	O
in	O
mouse	O
.	O

The	O
cDNAs	O
predict	O
type	O
II	O
transmembrane	O
proteins	O
that	O
constitute	O
new	O
members	O
of	O
the	O
Gal	O
/	O
GalNAc	O
/	O
GlcNAc	O
6	O
-	O
O	O
-	O
sulfotransferase	O
(	O
GST	O
)	O
family	O
.	O

Members	O
of	O
this	O
family	O
have	O
previously	O
been	O
implicated	O
in	O
the	O
sulfation	O
of	O
GAG	O
chains	O
within	O
proteoglycans	O
and	O
the	O
sulfation	O
of	O
O	O
-	O
linked	O
chains	O
within	O
sialomucin	O
ligands	O
for	O
l	B-Protein
-	I-Protein
selectin	I-Protein
.	O

Expression	O
of	O
the	O
newly	O
identified	O
cDNA	O
in	O
COS	O
cells	O
led	O
to	O
the	O
addition	O
of	O
sulfate	O
to	O
C	O
-	O
6	O
of	O
GlcNAc	O
in	O
an	O
acceptor	O
glycoprotein	O
.	O

The	O
tissue	O
expression	O
of	O
transcripts	O
corresponding	O
to	O
the	O
cDNA	O
was	O
highly	O
restricted	O
to	O
the	O
small	O
intestine	O
and	O
colon	O
in	O
humans	O
.	O

Based	O
on	O
these	O
characteristics	O
,	O
the	O
novel	O
sulfotransferase	O
is	O
designated	O
I	B-Protein
-	I-Protein
GlcNAc6ST	I-Protein
for	O
intestinal	B-Protein
GlcNAc	I-Protein
6	I-Protein
-	I-Protein
O	I-Protein
-	I-Protein
sulfotransferase	I-Protein
.	O

Inhibition	O
of	O
protein	O
palmitoylation	O
,	O
raft	O
localization	O
,	O
and	O
T	O
cell	O
signaling	O
by	O
2	O
-	O
bromopalmitate	O
and	O
polyunsaturated	O
fatty	O
acids	O
.	O

The	O
ability	O
of	O
the	O
Src	O
family	O
kinases	O
Fyn	B-Protein
and	O
Lck	B-Protein
to	O
participate	O
in	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
is	O
critically	O
dependent	O
on	O
their	O
dual	O
fatty	O
acylation	O
with	O
myristate	O
and	O
palmitate	O
.	O

Here	O
we	O
identify	O
a	O
palmitate	O
analog	O
,	O
2	O
-	O
bromopalmitate	O
,	O
that	O
effectively	O
blocks	O
Fyn	B-Protein
fatty	O
acylation	O
in	O
general	O
and	O
palmitoylation	O
in	O
particular	O
.	O

Treatment	O
of	O
COS	O
-	O
1	O
cells	O
with	O
2	O
-	O
bromopalmitate	O
blocked	O
myristoylation	O
and	O
palmitoylation	O
of	O
Fyn	B-Protein
and	O
inhibited	O
membrane	O
binding	O
and	O
localization	O
of	O
Fyn	B-Protein
to	O
detergent	O
-	O
resistant	O
membranes	O
(	O
DRMs	O
)	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
2	O
-	O
bromopalmitate	O
blocked	O
localization	O
of	O
the	O
endogenous	O
palmitoylated	O
proteins	O
Fyn	B-Protein
,	O
Lck	B-Protein
,	O
and	O
LAT	B-Protein
to	O
DRMs	O
.	O

This	O
resulted	O
in	O
impaired	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
as	O
evidenced	O
by	O
reductions	O
in	O
tyrosine	O
phosphorylation	O
,	O
calcium	O
release	O
,	O
and	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

We	O
also	O
examined	O
the	O
ability	O
of	O
long	O
chain	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
to	O
inhibit	O
protein	O
fatty	O
acylation	O
.	O

PUFAs	O
have	O
been	O
reported	O
to	O
inhibit	O
T	O
cell	O
signaling	O
by	O
excluding	O
Src	O
family	O
kinases	O
from	O
DRMs	O
.	O

Here	O
we	O
show	O
that	O
the	O
PUFAs	O
arachidonic	O
acid	O
and	O
eicosapentaenoic	O
acid	O
inhibit	O
Fyn	B-Protein
palmitoylation	O
and	O
consequently	O
block	O
Fyn	B-Protein
localization	O
to	O
DRMs	O
.	O

We	O
propose	O
that	O
inhibition	O
of	O
protein	O
palmitoylation	O
represents	O
a	O
novel	O
mechanism	O
by	O
which	O
PUFAs	O
exert	O
their	O
immunosuppressive	O
effects	O
.	O

Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
into	O
rabbit	O
cornea	O
induces	O
HSV	O
-	O
1	O
reactivation	O
:	O
evidence	O
that	O
neuronal	O
signaling	O
changes	O
after	O
infection	O
.	O

PURPOSE	O
:	O
Lysophosphatidic	O
acid	O
induces	O
neurite	O
retraction	O
;	O
it	O
is	O
also	O
present	O
in	O
tears	O
and	O
aqueous	O
humor	O
.	O

We	O
determined	O
whether	O
lysophosphatidic	O
acid	O
induces	O
HSV	O
-	O
1	O
reactivation	O
in	O
latently	O
infected	O
rabbits	O
and	O
whether	O
the	O
nerve	O
growth	O
associated	O
protein	O
GAP	B-Protein
-	I-Protein
43	I-Protein
undergoes	O
posttranslational	O
modification	O
during	O
the	O
course	O
of	O
HSV	O
-	O
1	O
infection	O
.	O

METHODS	O
:	O
Rabbits	O
were	O
infected	O
with	O
HSV	O
-	O
1	O
and	O
acute	O
infection	O
was	O
documented	O
by	O
slit	O
lamp	O
examination	O
.	O

Corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
treated	O
with	O
lysophosphatidic	O
acid	O
or	O
lysophosphatidylserine	O
(	O
structurally	O
similar	O
but	O
lacking	O
biological	O
potency	O
)	O
.	O

For	O
application	O
to	O
the	O
cornea	O
,	O
these	O
compounds	O
were	O
impregnated	O
into	O
collagen	O
shields	O
,	O
applied	O
as	O
topical	O
drops	O
,	O
or	O
iontophoresed	O
.	O

In	O
another	O
experiment	O
,	O
corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
either	O
untreated	O
or	O
treated	O
iontophoretically	O
with	O
lysophosphatidic	O
acid	O
,	O
lysophosphatidylserine	O
,	O
or	O
saline	O
.	O

Ocular	O
swabs	O
detected	O
shedding	O
of	O
infectious	O
virus	O
.	O

Western	O
blot	O
and	O
immunoprecipitation	O
identified	O
GAP	B-Protein
-	I-Protein
43	I-Protein
in	O
corneal	O
extracts	O
and	O
densitometry	O
of	O
silver	O
-	O
stained	O
isoelectric	O
focusing	O
gels	O
measured	O
changes	O
in	O
GAP	B-Protein
-	I-Protein
43	I-Protein
isoform	O
abundance	O
.	O

RESULTS	O
:	O
Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
induced	O
HSV	O
-	O
1	O
shedding	O
more	O
frequently	O
than	O
lysophosphatidylserine	O
or	O
saline	O
.	O

Viral	O
shedding	O
induced	O
by	O
collagen	O
shield	O
and	O
topical	O
drop	O
administration	O
was	O
low	O
and	O
not	O
significantly	O
different	O
for	O
lysophosphatidic	O
acid	O
and	O
lysophosphatidylserine	O
.	O

Five	O
discrete	O
GAP	B-Protein
-	I-Protein
43	I-Protein
isoforms	O
predominated	O
in	O
the	O
IEF	O
gels	O
.	O

Most	O
abundant	O
were	O
the	O
pI	O
4	O
.	O
7	O
band	O
in	O
uninfected	O
cornea	O
and	O
the	O
pI	O
5	O
.	O
05	O
band	O
in	O
latently	O
-	O
infected	O
cornea	O
.	O

Compared	O
to	O
latently	O
-	O
infected	O
cornea	O
,	O
there	O
was	O
no	O
significant	O
change	O
in	O
isoform	O
abundance	O
1	O
h	O
after	O
lysophosphatidic	O
acid	O
iontophoresis	O
,	O
but	O
24	O
and	O
72	O
h	O
later	O
,	O
the	O
pI	O
5	O
.	O

05	O
band	O
was	O
diminished	O
.	O

CONCLUSIONS	O
:	O
Lysophosphatidic	O
acid	O
can	O
induce	O
HSV	O
-	O
1	O
reactivation	O
and	O
changes	O
in	O
GAP	B-Protein
-	I-Protein
43	I-Protein
pI	O
suggest	O
that	O
posttranslational	O
modifications	O
,	O
possibly	O
related	O
to	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
,	O
are	O
occurring	O
during	O
HSV	O
-	O
1	O
latency	O
and	O
after	O
LPA	O
is	O
iontophoretically	O
applied	O
to	O
the	O
cornea	O
.	O

How	O
lysophosphatidic	O
acid	O
-	O
induced	O
signaling	O
,	O
HSV	O
-	O
1	O
reactivation	O
,	O
and	O
GAP	B-Protein
-	I-Protein
43	I-Protein
pI	O
are	O
related	O
remains	O
to	O
be	O
determined	O
.	O

Nedd8	B-Protein
modification	O
of	O
cul	B-Protein
-	I-Protein
1	I-Protein
activates	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
.	O

Regulation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
phosphorylation	O
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
,	O
which	O
is	O
degraded	O
by	O
the	O
26S	O
proteasome	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
is	O
carried	O
out	O
by	O
a	O
ubiquitin	B-Protein
-	O
ligase	O
enzyme	O
complex	O
called	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
.	O

Here	O
we	O
show	O
that	O
Nedd8	B-Protein
modification	O
of	O
the	O
Cul	B-Protein
-	I-Protein
1	I-Protein
component	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
is	O
important	O
for	O
function	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
in	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
.	O

In	O
cells	O
,	O
Nedd8	B-Protein
-	O
conjugated	O
Cul	B-Protein
-	I-Protein
1	I-Protein
was	O
complexed	O
with	O
two	O
substrates	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
,	O
phosphorylated	O
IkappaBalpha	B-Protein
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
,	O
indicating	O
that	O
Nedd8	B-Protein
-	O
Cul	B-Protein
-	I-Protein
1	I-Protein
conjugates	O
are	O
part	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
in	O
vivo	O
.	O

Although	O
only	O
a	O
minute	O
fraction	O
of	O
total	O
cellular	O
Cul	B-Protein
-	I-Protein
1	I-Protein
is	O
modified	O
by	O
Nedd8	B-Protein
,	O
the	O
Cul	B-Protein
-	I-Protein
1	I-Protein
associated	O
with	O
ectopically	O
expressed	O
betaTrCP	B-Protein
was	O
highly	O
enriched	O
for	O
the	O
Nedd8	B-Protein
-	O
conjugated	O
form	O
.	O

Moreover	O
,	O
optimal	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
required	O
Nedd8	B-Protein
and	O
the	O
Nedd8	B-Protein
-	O
conjugating	O
enzyme	O
,	O
Ubc12	B-Protein
.	O

The	O
site	O
of	O
Nedd8	B-Protein
ligation	O
to	O
Cul	B-Protein
-	I-Protein
1	I-Protein
is	O
essential	O
,	O
as	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
containing	O
a	O
K720R	O
mutant	O
of	O
Cul	B-Protein
-	I-Protein
1	I-Protein
only	O
weakly	O
supported	O
IkappaBalpha	B-Protein
ubiquitination	O
compared	O
to	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
containing	O
WT	O
Cul	B-Protein
-	I-Protein
1	I-Protein
,	O
suggesting	O
that	O
the	O
Nedd8	B-Protein
ligation	O
of	O
Cul	B-Protein
-	I-Protein
1	I-Protein
affects	O
the	O
ubiquitination	O
activity	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
.	O

These	O
observations	O
provide	O
a	O
functional	O
link	O
between	O
the	O
highly	O
related	O
ubiquitin	B-Protein
and	O
Nedd8	B-Protein
pathways	O
of	O
protein	O
modification	O
and	O
show	O
how	O
they	O
operate	O
together	O
to	O
selectively	O
target	O
the	O
signal	O
-	O
dependent	O
degradation	O
of	O
IkappaBalpha	B-Protein
.	O

v	B-Protein
-	I-Protein
Src	I-Protein
suppresses	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
via	O
the	O
Ras	O
-	O
MAP	O
kinase	O
pathway	O
to	O
promote	O
the	O
oncogenic	O
growth	O
of	O
cells	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
cell	O
transformation	O
by	O
v	B-Protein
-	I-Protein
src	I-Protein
on	O
the	O
expression	O
and	O
tyrosine	O
phosphorylation	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
putative	O
docking	O
protein	O
for	O
SHP	B-Protein
-	I-Protein
1	I-Protein
and	O
SHP	B-Protein
-	I-Protein
2	I-Protein
.	O

We	O
found	O
that	O
transformation	O
by	O
v	B-Protein
-	I-Protein
src	I-Protein
virtually	O
inhibited	O
the	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
at	O
mRNA	O
level	O
.	O

While	O
nontransforming	O
Src	O
kinases	O
including	O
c	B-Protein
-	I-Protein
Src	I-Protein
,	O
nonmyristoylated	O
forms	O
of	O
v	B-Protein
-	I-Protein
Src	I-Protein
had	O
no	O
inhibitory	O
effect	O
on	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
,	O
transforming	O
Src	O
kinases	O
including	O
wild	O
-	O
type	O
v	B-Protein
-	I-Protein
Src	I-Protein
and	O
chimeric	O
mutant	O
of	O
c	B-Protein
-	I-Protein
Src	I-Protein
bearing	O
v	B-Protein
-	I-Protein
Src	I-Protein
SH3	O
substantially	O
suppressed	O
the	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
.	O

In	O
cells	O
expressing	O
temperature	O
sensitive	O
mutant	O
of	O
v	B-Protein
-	I-Protein
Src	I-Protein
,	O
suppression	O
of	O
the	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
was	O
temperature	O
-	O
dependent	O
.	O

In	O
contrast	O
,	O
tyrosine	O
phosphorylation	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
was	O
rather	O
activated	O
in	O
cells	O
expressing	O
c	B-Protein
-	I-Protein
Src	I-Protein
or	O
nonmyristoylated	O
forms	O
of	O
v	B-Protein
-	I-Protein
Src	I-Protein
.	O

SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
SR3Y1	O
was	O
restored	O
by	O
treatment	O
with	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	O
kinase	O
,	O
or	O
by	O
the	O
expression	O
of	O
dominant	O
negative	O
form	O
of	O
Ras	O
.	O

Contrary	O
,	O
active	O
form	O
of	O
Mekl	B-Protein
markedly	O
suppressed	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
.	O

Finally	O
,	O
overexpression	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
in	O
SR3Y1	O
led	O
to	O
the	O
drastic	O
reduction	O
of	O
anchorage	O
independent	O
growth	O
of	O
the	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
is	O
a	O
pivotal	O
event	O
for	O
cell	O
transformation	O
by	O
v	B-Protein
-	I-Protein
src	I-Protein
,	O
and	O
the	O
Ras	O
-	O
MAP	O
kinase	O
cascade	O
plays	O
a	O
critical	O
role	O
in	O
the	O
suppression	O
.	O

A	O
Nedd8	B-Protein
conjugation	O
pathway	O
is	O
essential	O
for	O
proteolytic	O
targeting	O
of	O
p27Kip1	B-Protein
by	O
ubiquitination	O
.	O

Temporal	O
control	O
of	O
p27	B-Protein
(	I-Protein
Kip1	I-Protein
)	I-Protein
(	O
p27	B-Protein
)	O
degradation	O
imposes	O
periodicity	O
in	O
its	O
activity	O
during	O
cell	O
cycle	O
progression	O
and	O
its	O
accumulation	O
during	O
cell	O
cycle	O
exit	O
.	O

Degradation	O
of	O
p27	B-Protein
is	O
initiated	O
by	O
phosphorylation	O
of	O
p27	B-Protein
at	O
Thr	O
-	O
187	O
,	O
which	O
marks	O
the	O
protein	O
for	O
ubiquitination	O
by	O
SCF	O
(	O
Skp2	B-Protein
)	O
and	O
subsequent	O
proteolysis	O
by	O
the	O
26S	O
proteasome	O
.	O

Here	O
we	O
show	O
that	O
the	O
p27	B-Protein
ubiquitination	O
activity	O
in	O
cell	O
extracts	O
depends	O
on	O
the	O
presence	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
and	O
enzymes	O
that	O
catalyze	O
Nedd8	B-Protein
conjugation	O
to	O
proteins	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
reconstitution	O
of	O
the	O
p27	B-Protein
ubiquitination	O
activity	O
of	O
recombinant	O
SCF	O
(	O
Skp2	B-Protein
)	O
also	O
requires	O
Nedd8	B-Protein
conjugation	O
pathway	O
components	O
.	O

Inactivation	O
of	O
the	O
Nedd8	B-Protein
conjugation	O
pathway	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
the	O
Nedd8	B-Protein
-	O
conjugating	O
enzyme	O
Nce1	B-Protein
/	O
Ubc12	B-Protein
blocks	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
p27	B-Protein
in	O
cell	O
extracts	O
.	O

Consistent	O
with	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
Nedd8	B-Protein
is	O
expressed	O
in	O
proliferating	O
cells	O
and	O
is	O
itself	O
down	O
-	O
regulated	O
upon	O
cellular	O
differentiation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Nedd8	B-Protein
conjugation	O
pathway	O
may	O
regulate	O
the	O
turnover	O
of	O
p27	B-Protein
(	I-Protein
Kip1	I-Protein
)	I-Protein
,	O
independently	O
of	O
p27	B-Protein
phosphorylation	O
,	O
and	O
further	O
establishes	O
the	O
identity	O
of	O
protein	O
components	O
involved	O
in	O
p27	B-Protein
ubiquitination	O
.	O

Finally	O
,	O
these	O
findings	O
provide	O
a	O
direct	O
demonstration	O
of	O
a	O
function	O
for	O
Nedd8	B-Protein
in	O
a	O
biological	O
process	O
.	O

Isoprenylation	O
/	O
methylation	O
and	O
transducin	O
function	O
.	O

Freshly	O
prepared	O
proteolyzed	O
(	O
deprenylated	O
)	O
T	O
beta	O
gamma	O
and	O
material	O
isolated	O
from	O
retina	O
are	O
inert	O
with	O
respect	O
to	O
activating	O
T	O
alpha	O
in	O
the	O
presence	O
of	O
R	O
*	O
in	O
detergent	O
and	O
in	O
disk	O
membranes	O
.	O

In	O
addition	O
,	O
proteolyzed	O
T	O
beta	O
gamma	O
is	O
also	O
incapable	O
of	O
supporting	O
the	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
T	O
alpha	O
-	O
GDP	O
.	O

These	O
experiments	O
show	O
that	O
isoprenylation	O
/	O
methylation	O
is	O
essential	O
for	O
the	O
fruitful	O
interactions	O
between	O
T	O
alpha	O
and	O
T	O
beta	O
gamma	O
at	O
the	O
membrane	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
support	O
GTP	O
-	O
for	O
-	O
GDP	O
exchange	O
catalyzed	O
by	O
R	O
*	O
,	O
demethylated	O
T	O
beta	O
gamma	O
proved	O
to	O
be	O
approximately	O
50	O
%	O
as	O
active	O
as	O
methylated	O
T	O
beta	O
gamma	O
in	O
photoreceptor	O
disk	O
membranes	O
(	O
Fig	O
.	O
3	O
)	O
and	O
in	O
reconstituted	O
liposomes	O
containing	O
rhodopsin	B-Protein
.	O

In	O
detergent	O
,	O
no	O
difference	O
was	O
observed	O
between	O
methylated	O
and	O
demethylated	O
T	O
beta	O
gamma	O
,	O
suggesting	O
no	O
role	O
at	O
all	O
for	O
the	O
methyl	O
group	O
in	O
functional	O
interactions	O
between	O
T	O
alpha	O
,	O
T	O
beta	O
gamma	O
,	O
and	O
R	O
*	O
.	O

The	O
twofold	O
activity	O
difference	O
observed	O
in	O
membranes	O
can	O
be	O
accounted	O
for	O
by	O
the	O
twofold	O
lessened	O
affinity	O
of	O
the	O
demethylated	O
T	O
beta	O
gamma	O
,	O
compared	O
with	O
its	O
methylated	O
counterpart	O
,	O
for	O
membranes	O
in	O
the	O
presence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
a	O
substantially	O
larger	O
difference	O
(	O
>	O
10	O
-	O
fold	O
)	O
in	O
the	O
relative	O
binding	O
of	O
methylated	O
versus	O
demethylated	O
T	O
beta	O
gamma	O
to	O
membranes	O
is	O
observed	O
in	O
the	O
absence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

However	O
,	O
R	O
*	O
has	O
a	O
substantial	O
affinity	O
for	O
T	O
alpha	O
beta	O
gamma	O
,	O
and	O
the	O
influence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
greatly	O
reduces	O
any	O
differences	O
resulting	O
from	O
the	O
presence	O
or	O
absence	O
of	O
a	O
methyl	O
group	O
on	O
T	O
beta	O
gamma	O
.	O

The	O
results	O
from	O
studies	O
of	O
demethylated	O
T	O
beta	O
gamma	O
demonstrate	O
that	O
specific	O
lipid	O
-	O
receptor	O
interactions	O
are	O
unlikely	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
rhodopsin	B-Protein
-	O
transducin	O
system	O
,	O
and	O
further	O
show	O
that	O
the	O
effect	O
of	O
methylation	O
is	O
probably	O
due	O
to	O
the	O
increased	O
hydrophobicity	O
of	O
methylated	O
T	O
beta	O
gamma	O
versus	O
its	O
unmethylated	O
counterpart	O
.	O

These	O
studies	O
are	O
,	O
of	O
course	O
,	O
relevant	O
to	O
heterotrimeric	O
G	O
proteins	O
,	O
and	O
specifically	O
to	O
the	O
interactions	O
of	O
receptor	O
(	O
R	O
*	O
)	O
with	O
T	O
alpha	O
and	O
T	O
beta	O
gamma	O
.	O

If	O
a	O
hydrophobic	O
lipid	O
-	O
lipid	O
mechanism	O
is	O
operative	O
,	O
the	O
state	O
of	O
methylation	O
would	O
be	O
expected	O
to	O
have	O
a	O
more	O
profound	O
effect	O
on	O
the	O
membrane	O
-	O
associative	O
properties	O
of	O
farnesylated	O
proteins	O
,	O
but	O
not	O
on	O
those	O
of	O
geranylgeranylated	O
proteins	O
.	O

The	O
increased	O
hydrophobicity	O
of	O
the	O
C20	O
geranylgeranyl	O
group	O
relative	O
to	O
the	O
C15	O
farnesyl	O
group	O
will	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
methyl	O
substituent	O
.	O

The	O
results	O
obtained	O
in	O
the	O
transducin	O
-	O
rhodopsin	B-Protein
system	O
can	O
be	O
contrasted	O
with	O
the	O
effect	O
of	O
gamma	O
-	O
subunit	O
methylation	O
on	O
effector	O
enzyme	O
activation	O
.	O

In	O
the	O
case	O
of	O
the	O
geranylgeranylated	O
beta	B-Protein
1	I-Protein
gamma	B-Protein
2	I-Protein
,	O
methylation	O
proved	O
to	O
have	O
only	O
a	O
small	O
effect	O
on	O
PIPLC	O
beta	O
activation	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

An	O
approximately	O
25	O
%	O
diminution	O
in	O
efficacy	O
,	O
but	O
not	O
potency	O
,	O
was	O
observed	O
for	O
the	O
demethylated	O
geranylgeranylated	O
beta	B-Protein
1	I-Protein
gamma	B-Protein
2	I-Protein
versus	O
its	O
methylated	O
counterpart	O
.	O

This	O
again	O
shows	O
that	O
specific	O
lipid	O
-	O
protein	O
interactions	O
are	O
unimportant	O
.	O

The	O
effect	O
of	O
methylation	O
on	O
membrane	O
binding	O
would	O
be	O
expected	O
to	O
be	O
small	O
,	O
given	O
that	O
beta	B-Protein
1	I-Protein
gamma	B-Protein
2	I-Protein
is	O
geranylgeranylated	O
.	O

It	O
is	O
of	O
interest	O
to	O
compare	O
these	O
results	O
with	O
those	O
found	O
with	O
methylated	O
and	O
unmethylated	O
T	O
beta	O
gamma	O
as	O
activators	O
of	O
PIPLC	O
beta	O
.	O

In	O
this	O
instance	O
there	O
was	O
a	O
large	O
effect	O
noted	O
,	O
with	O
methylated	O
T	O
beta	O
gamma	O
being	O
at	O
least	O
10	O
-	O
fold	O
more	O
potent	O
than	O
its	O
unmethylated	O
counterpart	O
with	O
respect	O
to	O
activating	O
either	O
enzyme	O
(	O
Fig	O
.	O
4A	O
)	O
.	O

This	O
result	O
is	O
readily	O
understandable	O
in	O
light	O
of	O
the	O
role	O
of	O
methylation	O
in	O
selectively	O
enhancing	O
hydrophobicity	O
of	O
farnesylated	O
proteins	O
as	O
opposed	O
to	O
geranyl	O
-	O
geranylated	O
proteins	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
the	O
activation	O
of	O
PI3K	O
,	O
further	O
strengthening	O
the	O
conclusion	O
that	O
it	O
is	O
lipid	O
-	O
lipid	O
interactions	O
that	O
direct	O
beta	O
gamma	O
subunit	O
membrane	O
association	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
)	O

A	O
dominant	O
-	O
negative	O
UBC12	B-Protein
mutant	O
sequesters	O
NEDD8	B-Protein
and	O
inhibits	O
NEDD8	B-Protein
conjugation	O
in	O
vivo	O
.	O

NEDD8	B-Protein
,	O
a	O
novel	O
ubiquitin	B-Protein
-	O
like	O
protein	O
,	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

Recently	O
,	O
human	O
UBC12	B-Protein
was	O
identified	O
as	O
a	O
putative	O
NEDD8	B-Protein
conjugation	O
enzyme	O
(	O
E2	O
)	O
.	O

While	O
investigating	O
the	O
in	O
vivo	O
function	O
of	O
UBC12	B-Protein
,	O
we	O
found	O
that	O
the	O
point	O
mutant	O
,	O
UBC12	B-Protein
(	O
C111S	O
)	O
,	O
showed	O
a	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	B-Protein
conjugation	O
.	O

This	O
mutant	O
,	O
with	O
a	O
single	O
Cys	O
-	O
to	O
-	O
Ser	O
substitution	O
at	O
the	O
conserved	O
Cys	O
residue	O
in	O
the	O
E2	O
family	O
,	O
could	O
specifically	O
inhibit	O
NEDD8	B-Protein
conjugation	O
.	O

We	O
observed	O
the	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	B-Protein
conjugation	O
to	O
substrates	O
,	O
including	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
cullin	B-Protein
-	I-Protein
2	I-Protein
(	O
Cul	B-Protein
-	I-Protein
2	I-Protein
-	O
DeltaN	O
)	O
,	O
full	O
-	O
length	O
cullin	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
also	O
other	O
uncharacterized	O
target	O
proteins	O
.	O

Interestingly	O
,	O
UBC12	B-Protein
(	O
C111S	O
)	O
formed	O
a	O
heterodimeric	O
conjugate	O
with	O
NEDD8	B-Protein
.	O

This	O
conjugate	O
was	O
stable	O
under	O
stringent	O
conditions	O
,	O
including	O
6	O
m	O
guanidine	O
HCl	O
,	O
8	O
m	O
urea	O
,	O
2	O
%	O
SDS	O
,	O
or	O
5	O
%	O
beta	O
-	O
mercaptoethanol	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
UBC12	B-Protein
(	O
C111S	O
)	O
sequesters	O
the	O
NEDD8	B-Protein
monomer	O
by	O
forming	O
a	O
UBC12	B-Protein
(	O
C111S	O
)	O
-	O
NEDD8	B-Protein
conjugate	O
and	O
,	O
in	O
turn	O
,	O
inhibits	O
the	O
subsequent	O
transfer	O
of	O
NEDD8	B-Protein
to	O
its	O
targets	O
.	O

To	O
examine	O
the	O
biological	O
role	O
of	O
NEDD8	B-Protein
conjugation	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	B-Protein
was	O
applied	O
to	O
a	O
cell	O
growth	O
assay	O
.	O

Overexpression	O
of	O
UBC12	B-Protein
(	O
C111S	O
)	O
led	O
to	O
inhibition	O
of	O
growth	O
in	O
U2OS	O
and	O
HEK293	O
cells	O
.	O

Thus	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	B-Protein
could	O
be	O
useful	O
in	O
defining	O
the	O
role	O
of	O
NEDD8	B-Protein
modification	O
in	O
other	O
biological	O
systems	O
.	O

Heterogeneity	O
of	O
cardiac	O
rat	O
and	O
human	O
elongation	B-Protein
factor	I-Protein
2	I-Protein
.	O

Elongation	B-Protein
factor	I-Protein
2	I-Protein
(	O
EF	B-Protein
-	I-Protein
2	I-Protein
)	O
catalyses	O
the	O
last	O
step	O
of	O
the	O
elongation	O
cycle	O
,	O
translocation	O
,	O
in	O
the	O
course	O
of	O
protein	O
biosynthesis	O
.	O

A	O
system	O
for	O
analyzing	O
post	O
-	O
translational	O
modifications	O
of	O
EF	B-Protein
-	I-Protein
2	I-Protein
,	O
which	O
is	O
a	O
single	O
polypeptide	O
of	O
857	O
amino	O
acids	O
,	O
is	O
reported	O
and	O
its	O
application	O
to	O
cytosolic	O
extracts	O
of	O
cultured	O
neonatal	O
rat	O
heart	O
myocytes	O
,	O
neonatal	O
and	O
adult	O
rat	O
cardiac	O
tissue	O
,	O
and	O
extracts	O
of	O
human	O
left	O
ventricular	O
myocardium	O
is	O
described	O
.	O

Comparing	O
different	O
pH	O
ranges	O
in	O
immobilized	O
pH	O
gradient	O
-	O
isoelectric	O
focusing	O
(	O
IPG	O
-	O
IEF	O
)	O
,	O
a	O
range	O
of	O
pH	O
3	O
-	O
10	O
and	O
4	O
-	O
9	O
resulted	O
in	O
a	O
highly	O
defined	O
and	O
reproducible	O
resolution	O
of	O
six	O
different	O
EF	B-Protein
-	I-Protein
2	I-Protein
variants	O
of	O
all	O
extracts	O
in	O
the	O
first	O
dimension	O
.	O

These	O
six	O
variants	O
were	O
detected	O
by	O
the	O
"	O
imaging	O
plate	O
"	O
(	O
phosphor	O
radiation	O
image	O
sensor	O
)	O
after	O
specific	O
labeling	O
with	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
catalyzed	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylation	O
.	O

This	O
finding	O
could	O
be	O
confirmed	O
in	O
Western	O
blot	O
analysis	O
with	O
a	O
specific	O
polyclonal	O
rabbit	O
antibody	O
.	O

Using	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
2	O
-	O
D	O
-	O
PAGE	O
)	O
,	O
five	O
to	O
six	O
EF	B-Protein
-	I-Protein
2	I-Protein
variants	O
could	O
be	O
demonstrated	O
in	O
all	O
extracts	O
.	O

By	O
application	O
of	O
a	O
second	O
IPG	O
indicator	O
strip	O
to	O
the	O
2	O
-	O
D	O
gel	O
,	O
they	O
could	O
be	O
aligned	O
with	O
corresponding	O
spots	O
in	O
a	O
silver	O
-	O
stained	O
2	O
-	O
D	O
separation	O
of	O
human	O
myocardial	O
tissue	O
,	O
revealing	O
that	O
the	O
EF	B-Protein
-	I-Protein
2	I-Protein
variants	O
belong	O
to	O
the	O
group	O
of	O
low	O
-	O
abundance	O
proteins	O
.	O

Heteronuclear	O
NMR	O
studies	O
of	O
the	O
specificity	O
of	O
the	O
post	O
-	O
translational	O
modification	O
of	O
biotinyl	O
domains	O
by	O
biotinyl	B-Protein
protein	I-Protein
ligase	I-Protein
.	O

The	O
lipoyl	O
domains	O
of	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
multienzyme	O
complexes	O
and	O
the	O
biotinyl	O
domains	O
of	O
biotin	O
-	O
dependent	O
enzymes	O
have	O
homologous	O
structures	O
,	O
but	O
the	O
target	O
lysine	O
residue	O
in	O
each	O
domain	O
is	O
correctly	O
selected	O
for	O
posttranslational	O
modification	O
by	O
lipoyl	B-Protein
protein	I-Protein
ligase	I-Protein
and	O
biotinyl	B-Protein
protein	I-Protein
ligase	I-Protein
,	O
respectively	O
.	O

We	O
have	O
applied	O
two	O
-	O
dimensional	O
heteronuclear	O
NMR	O
spectroscopy	O
to	O
investigate	O
the	O
interaction	O
between	O
the	O
apo	O
form	O
of	O
the	O
biotinyl	O
domain	O
of	O
the	O
biotin	B-Protein
carboxyl	I-Protein
carrier	I-Protein
protein	I-Protein
of	I-Protein
acetyl	I-Protein
-	I-Protein
CoA	I-Protein
carboxylase	I-Protein
and	O
the	O
biotinyl	B-Protein
protein	I-Protein
ligase	I-Protein
(	O
BPL	B-Protein
)	O
from	O
Escherichia	O
coli	O
.	O

Heteronuclear	O
multiple	O
quantum	O
coherence	O
NMR	O
spectra	O
of	O
the	O
15N	O
-	O
labelled	O
biotinyl	O
domain	O
were	O
recorded	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
ligase	O
and	O
backbone	O
amide	O
1H	O
and	O
15N	O
chemical	O
shifts	O
were	O
evaluated	O
.	O

Small	O
,	O
but	O
significant	O
,	O
changes	O
in	O
chemical	O
shift	O
were	O
found	O
in	O
two	O
regions	O
,	O
including	O
the	O
tight	O
beta	O
-	O
turn	O
that	O
houses	O
the	O
lysine	O
residue	O
targetted	O
for	O
biotinylation	O
,	O
and	O
the	O
beta	O
-	O
strand	O
2	O
and	O
the	O
loop	O
that	O
precedes	O
it	O
in	O
the	O
domain	O
.	O

When	O
compared	O
with	O
the	O
three	O
-	O
dimensional	O
structure	O
,	O
sequence	O
alignments	O
of	O
other	O
biotinyl	O
and	O
lipoyl	O
domains	O
,	O
and	O
mutagenesis	O
data	O
,	O
these	O
results	O
give	O
a	O
clear	O
indication	O
of	O
how	O
the	O
biotinyl	O
domain	O
is	O
both	O
recognised	O
by	O
BPL	B-Protein
and	O
distinguished	O
from	O
the	O
structurally	O
related	O
lipoyl	O
domain	O
to	O
ensure	O
correct	O
posttranslational	O
modification	O
.	O

Alternative	O
O	O
-	O
glycosylation	O
/	O
O	O
-	O
phosphorylation	O
of	O
the	O
murine	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
.	O

Estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
,	O
a	O
homologue	O
to	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
,	O
is	O
a	O
new	O
member	O
of	O
the	O
steroid	O
hormone	O
receptor	O
family	O
.	O

Recently	O
,	O
we	O
documented	O
that	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
,	O
like	O
other	O
transcription	O
factors	O
,	O
is	O
modified	O
by	O
O	O
-	O
linked	O
N	O
-	O
acetylglucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
,	O
a	O
ubiquitous	O
transitory	O
posttranslational	O
modification	O
on	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
.	O

Here	O
,	O
we	O
report	O
that	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
is	O
alternatively	O
modified	O
by	O
either	O
O	O
-	O
GlcNAc	O
or	O
O	O
-	O
phosphate	O
.	O

Lectin	O
chromatography	O
of	O
in	O
vitro	O
translated	O
protein	O
first	O
suggested	O
that	O
murine	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
(	O
mER	B-Protein
-	I-Protein
beta	I-Protein
)	O
is	O
O	O
-	O
GlcNAcylated	O
.	O

Structural	O
characterization	O
of	O
the	O
carbohydrate	O
moieties	O
on	O
mER	B-Protein
-	I-Protein
beta	I-Protein
,	O
overexpressed	O
in	O
insect	O
Sf9	O
cells	O
,	O
confirmed	O
the	O
presence	O
of	O
O	O
-	O
GlcNAc	O
.	O

mER	B-Protein
-	I-Protein
beta	I-Protein
,	O
overexpressed	O
in	O
mammalian	O
cells	O
,	O
is	O
also	O
O	O
-	O
GlcNAcylated	O
.	O

The	O
major	O
site	O
of	O
O	O
-	O
GlcNAc	O
on	O
mER	B-Protein
-	I-Protein
beta	I-Protein
from	O
Sf9	O
cells	O
is	O
Ser	O
(	O
16	O
)	O
near	O
the	O
N	O
-	O
terminus	O
.	O

Concomitant	O
analyses	O
also	O
documented	O
the	O
O	O
-	O
phosphorylation	O
of	O
mER	B-Protein
-	I-Protein
beta	I-Protein
at	O
Ser	O
(	O
16	O
)	O
.	O

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
showed	O
alternative	O
occupancy	O
of	O
this	O
locus	O
by	O
these	O
two	O
abundant	O
and	O
dynamic	O
posttranslational	O
modifications	O
.	O

The	O
localization	O
of	O
a	O
major	O
O	O
-	O
GlcNAc	O
/	O
O	O
-	O
phosphate	O
site	O
in	O
proximity	O
of	O
the	O
transactivation	O
domain	O
and	O
as	O
part	O
of	O
a	O
PEST	O
region	O
(	O
target	O
sequences	O
for	O
rapid	O
protein	O
degradation	O
)	O
on	O
mER	B-Protein
-	I-Protein
beta	I-Protein
suggests	O
that	O
these	O
modifications	O
may	O
play	O
a	O
role	O
in	O
regulating	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
transactivation	O
and	O
turnover	O
.	O

Inhibitors	O
of	O
prenylation	O
of	O
Ras	O
and	O
other	O
G	O
-	O
proteins	O
and	O
their	O
application	O
as	O
therapeutics	O
.	O

Anchoring	O
of	O
small	O
G	O
-	O
proteins	O
to	O
cellular	O
membranes	O
via	O
a	O
covalently	O
bound	O
lipophylic	O
prenyl	O
group	O
is	O
essential	O
for	O
the	O
functioning	O
of	O
these	O
proteins	O
.	O

For	O
example	O
,	O
the	O
farnesylation	O
of	O
Ras	O
by	O
the	O
action	O
of	O
the	O
enzyme	O
protein	O
:	O
farnesyl	O
transferase	O
(	O
PFT	O
)	O
is	O
pivotal	O
for	O
its	O
signalling	O
function	O
in	O
cell	O
growth	O
and	O
differentiation	O
.	O

The	O
development	O
of	O
inhibitors	O
of	O
PFT	O
was	O
triggered	O
by	O
the	O
role	O
of	O
mutated	O
Ras	O
in	O
certain	O
types	O
of	O
cancer	O
and	O
by	O
the	O
observation	O
that	O
non	O
-	O
farnesylated	O
Ras	O
is	O
inactive	O
.	O

Besides	O
the	O
screening	O
of	O
existing	O
compounds	O
for	O
PFT	O
inhibition	O
,	O
rational	O
drug	O
design	O
has	O
also	O
led	O
to	O
new	O
inhibitors	O
.	O

Our	O
research	O
is	O
in	O
the	O
field	O
of	O
atherosclerosis	O
and	O
concerns	O
the	O
development	O
of	O
inhibitors	O
of	O
the	O
growth	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

The	O
latter	O
process	O
gives	O
rise	O
to	O
reocclusion	O
of	O
the	O
coronary	O
artery	O
(	O
restenosis	O
)	O
after	O
balloon	O
angioplasty	O
.	O

We	O
and	O
others	O
have	O
developed	O
several	O
analogues	O
of	O
the	O
two	O
substrates	O
of	O
PFT	O
,	O
i	O
.	O
e	O
.	O
farnesyl	O
pyrophosphate	O
(	O
FPP	O
)	O
and	O
the	O
so	O
-	O
called	O
CAAX	O
peptide	O
consensus	O
sequence	O
,	O
which	O
were	O
tested	O
in	O
vitro	O
for	O
the	O
inhibition	O
of	O
PFT	O
and	O
of	O
other	O
enzymes	O
involved	O
in	O
protein	O
prenylation	O
,	O
such	O
as	O
protein	O
:	O
geranylgeranyl	O
transferase	O
-	O
1	O
(	O
PGGT	O
-	O
1	O
)	O
.	O

The	O
FPP	O
analogue	O
TR006	O
,	O
a	O
strong	O
inhibitor	O
of	O
PFT	O
(	O
IC	O
(	O
50	O
)	O
of	O
67	O
nM	O
)	O
,	O
blocked	O
the	O
proliferation	O
of	O
cultured	O
human	O
smooth	O
muscle	O
cells	O
and	O
inhibited	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
-	O
induced	O
DNA	O
synthesis	O
.	O

Similar	O
but	O
more	O
highly	O
charged	O
compounds	O
failed	O
in	O
this	O
respect	O
,	O
probably	O
because	O
of	O
an	O
impaired	O
uptake	O
in	O
the	O
cells	O
.	O

Less	O
charged	O
derivatives	O
were	O
designed	O
to	O
circumvent	O
this	O
problem	O
.	O

The	O
effect	O
on	O
the	O
GF	O
-	O
induced	O
activation	O
of	O
intermediates	O
in	O
signal	O
transduction	O
pathways	O
was	O
investigated	O
in	O
order	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
action	O
within	O
the	O
cells	O
.	O

TR006	O
decreased	O
the	O
bFGF	B-Protein
activation	O
of	O
extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
kinase	I-Protein
1	I-Protein
(	O
ERK1	B-Protein
)	O
,	O
suggesting	O
its	O
involvement	O
in	O
inhibiting	O
Ras	O
activity	O
.	O

Although	O
other	O
analogues	O
inhibited	O
DNA	O
synthesis	O
,	O
they	O
affected	O
neither	O
ERK1	B-Protein
activation	O
nor	O
p38	B-Protein
/	O
stress	B-Protein
-	I-Protein
activated	I-Protein
protein	I-Protein
kinase	I-Protein
2	I-Protein
or	O
Jun	B-Protein
N	I-Protein
-	I-Protein
terminal	I-Protein
kinase	I-Protein
1	I-Protein
activation	O
.	O

Since	O
some	O
of	O
these	O
compounds	O
were	O
also	O
shown	O
to	O
be	O
inhibitors	O
of	O
in	O
vitro	O
PGGT	O
-	O
1	O
activity	O
,	O
the	O
geranylgeranylation	O
of	O
other	O
G	O
-	O
proteins	O
may	O
be	O
decreased	O
by	O
these	O
compounds	O
.	O

Rho	O
seems	O
to	O
be	O
a	O
good	O
candidate	O
as	O
a	O
target	O
for	O
inhibitors	O
of	O
PGGT	O
-	O
1	O
.	O

This	O
uncertainty	O
as	O
to	O
the	O
mechanism	O
of	O
action	O
within	O
non	O
-	O
transformed	O
as	O
well	O
as	O
transformed	O
cells	O
applies	O
to	O
all	O
prenylation	O
inhibitors	O
,	O
but	O
is	O
not	O
holding	O
back	O
their	O
further	O
development	O
as	O
drugs	O
.	O

Their	O
current	O
and	O
possible	O
future	O
application	O
as	O
therapeutics	O
in	O
cancer	O
,	O
restenosis	O
,	O
angiogenesis	O
,	O
and	O
osteoporosis	O
is	O
briefly	O
discussed	O
.	O

Role	O
of	O
metals	O
in	O
the	O
reaction	O
catalyzed	O
by	O
protein	O
farnesyltransferase	O
.	O

Protein	O
farnesyltransferase	O
catalyzes	O
the	O
posttranslational	O
farnesylation	O
of	O
several	O
proteins	O
involved	O
in	O
signal	O
transduction	O
,	O
including	O
Ras	O
,	O
and	O
is	O
a	O
target	O
enzyme	O
for	O
antitumor	O
therapies	O
.	O

Efficient	O
product	O
formation	O
catalyzed	O
by	O
protein	O
farnesyltransferase	O
requires	O
an	O
enzyme	O
-	O
bound	O
zinc	O
cation	O
and	O
high	O
concentrations	O
of	O
magnesium	O
ions	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
measured	O
the	O
pH	O
dependence	O
of	O
the	O
chemical	O
step	O
of	O
product	O
formation	O
,	O
determined	O
under	O
single	O
-	O
turnover	O
conditions	O
,	O
and	O
have	O
demonstrated	O
that	O
the	O
prenylation	O
rate	O
constant	O
is	O
enhanced	O
by	O
two	O
deprotonations	O
.	O

Substitution	O
of	O
the	O
active	O
site	O
zinc	O
by	O
cadmium	O
demonstrated	O
that	O
one	O
of	O
the	O
ionizations	O
reflects	O
deprotonation	O
of	O
the	O
metal	O
-	O
coordinated	O
thiol	O
of	O
the	O
peptide	O
"	O
CaaX	O
"	O
motif	O
,	O
pK	O
(	O
a1	O
)	O
=	O
6	O
.	O
0	O
.	O

These	O
data	O
provide	O
additional	O
evidence	O
for	O
the	O
direct	O
involvement	O
of	O
a	O
metal	O
-	O
coordinated	O
sulfur	O
nucleophile	O
in	O
catalysis	O
.	O

The	O
second	O
ionization	O
was	O
assigned	O
to	O
a	O
hydroxyl	O
on	O
the	O
pyrophosphate	O
moiety	O
of	O
farnesyl	O
pyrophosphate	O
,	O
pK	O
(	O
a2	O
)	O
=	O
7	O
.	O
4	O
.	O

Deprotonation	O
of	O
this	O
group	O
is	O
important	O
for	O
binding	O
of	O
magnesium	O
.	O

This	O
second	O
ionization	O
is	O
not	O
observed	O
for	O
catalysis	O
in	O
the	O
absence	O
of	O
magnesium	O
or	O
when	O
the	O
substrate	O
is	O
farnesyl	O
monophosphate	O
.	O

These	O
data	O
indicate	O
that	O
the	O
maximal	O
rate	O
constant	O
for	O
prenylation	O
requires	O
formation	O
of	O
a	O
zinc	O
-	O
coordinated	O
thiolate	O
nucleophile	O
and	O
enhancement	O
of	O
the	O
electrophilic	O
character	O
at	O
C1	O
of	O
the	O
farnesyl	O
chain	O
by	O
magnesium	O
ion	O
coordination	O
of	O
the	O
pyrophosphate	O
leaving	O
group	O
.	O

Prenylated	B-Protein
Rab	I-Protein
acceptor	I-Protein
protein	I-Protein
is	O
a	O
receptor	O
for	O
prenylated	O
small	O
GTPases	O
.	O

Localization	O
of	O
Ras	O
and	O
Ras	O
-	O
like	O
proteins	O
to	O
the	O
correct	O
subcellular	O
compartment	O
is	O
essential	O
for	O
these	O
proteins	O
to	O
mediate	O
their	O
biological	O
effects	O
.	O

Many	O
members	O
of	O
the	O
Ras	O
superfamily	O
(	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
,	O
N	B-Protein
-	I-Protein
Ras	I-Protein
,	O
TC21	B-Protein
,	O
and	O
RhoA	B-Protein
)	O
are	O
prenylated	O
in	O
the	O
cytoplasm	O
and	O
then	O
transit	O
through	O
the	O
endomembrane	O
system	O
on	O
their	O
way	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
proteins	O
that	O
aid	O
in	O
the	O
trafficking	O
of	O
the	O
small	O
GTPases	O
have	O
not	O
been	O
well	O
characterized	O
.	O

We	O
report	O
here	O
that	O
prenylated	B-Protein
Rab	I-Protein
acceptor	I-Protein
protein	I-Protein
(	O
PRA1	B-Protein
)	O
,	O
which	O
others	O
previously	O
identified	O
as	O
a	O
prenylation	O
-	O
dependent	O
receptor	O
for	O
Rab	O
proteins	O
,	O
also	O
interacts	O
with	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
,	O
RhoA	B-Protein
,	O
TC21	B-Protein
,	O
and	O
Rap1a	B-Protein
.	O

The	O
interaction	O
of	O
these	O
small	O
GTPases	O
with	O
PRA1	B-Protein
requires	O
their	O
post	O
-	O
translational	O
modification	O
by	O
prenylation	O
.	O

The	O
prenylation	O
-	O
dependent	O
association	O
of	O
PRA1	B-Protein
with	O
multiple	O
GTPases	O
is	O
conserved	O
in	O
evolution	O
;	O
the	O
yeast	O
PRA1	B-Protein
protein	O
associates	O
with	O
both	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
and	O
RhoA	B-Protein
.	O

Earlier	O
studies	O
reported	O
the	O
presence	O
of	O
PRA1	B-Protein
in	O
the	O
Golgi	O
,	O
and	O
we	O
show	O
here	O
that	O
PRA1	B-Protein
co	O
-	O
localizes	O
with	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
and	O
RhoA	B-Protein
in	O
the	O
Golgi	O
compartment	O
.	O

We	O
suggest	O
that	O
PRA1	B-Protein
acts	O
as	O
an	O
escort	O
protein	O
for	O
small	O
GTPases	O
by	O
binding	O
to	O
the	O
hydrophobic	O
isoprenoid	O
moieties	O
of	O
the	O
small	O
GTPases	O
and	O
facilitates	O
their	O
trafficking	O
through	O
the	O
endomembrane	O
system	O
.	O

Cloning	O
and	O
identification	O
of	O
MYPT3	B-Protein
:	O
a	O
prenylatable	O
myosin	O
targetting	O
subunit	O
of	O
protein	O
phosphatase	O
1	O
.	O

To	O
identify	O
novel	O
protein	O
phosphatase	O
1	O
(	O
PP1	O
)	O
-	O
interacting	O
proteins	O
,	O
a	O
yeast	O
two	O
-	O
hybrid	O
3T3	O
-	O
L1	O
adipocyte	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
catalytic	O
subunit	O
of	O
PP1	O
as	O
bait	O
.	O

In	O
the	O
present	O
work	O
,	O
the	O
isolation	O
,	O
identification	O
and	O
initial	O
biochemical	O
characterization	O
of	O
a	O
novel	O
PP1	O
-	O
interacting	O
protein	O
,	O
MYPT3	B-Protein
,	O
which	O
is	O
homologous	O
with	O
the	O
myosin	O
phosphatase	O
targetting	O
subunit	O
(	O
MYPT	O
)	O
family	O
,	O
is	O
described	O
.	O

MYPT3	B-Protein
aligns	O
>	O
99	O
%	O
with	O
a	O
region	O
of	O
mouse	O
genomic	O
DNA	O
clone	O
RP23	O
-	O
156P23	O
and	O
localizes	O
to	O
chromosome	O
15	O
,	O
between	O
markers	O
at	O
44	O
.	O
1	O
-	O
46	O
.	O
5	O
cM	O
,	O
as	O
demonstrated	O
by	O
radiation	O
hybrid	O
mapping	O
.	O

The	O
gene	O
consists	O
of	O
ten	O
exons	O
that	O
encode	O
for	O
a	O
524	O
-	O
amino	O
acid	O
sequence	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
57529	O
Da	O
.	O

The	O
N	O
-	O
terminal	O
region	O
of	O
MYPT3	B-Protein
consists	O
of	O
a	O
consensus	O
PP1	O
-	O
binding	O
site	O
and	O
multiple	O
ankyrin	O
repeats	O
.	O

MYPT3	B-Protein
is	O
distinguished	O
from	O
related	O
approximately	O
110	O
-	O
130	O
kDa	O
MYPT	O
subunits	O
by	O
its	O
molecular	O
mass	O
of	O
58	O
kDa	O
,	O
and	O
a	O
unique	O
C	O
-	O
terminal	O
region	O
that	O
contains	O
several	O
potential	O
signalling	O
motifs	O
and	O
a	O
CaaX	O
prenylation	O
site	O
.	O

We	O
have	O
shown	O
that	O
affinity	O
-	O
purified	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
(	O
GST	B-Protein
)	O
-	O
MYPT3	B-Protein
is	O
prenylated	O
by	O
purified	O
recombinant	O
farnesyltransferase	O
in	O
vitro	O
.	O

Endogenous	O
PP1	O
from	O
3T3	O
-	O
L1	O
lysates	O
specifically	O
interacts	O
with	O
MYPT3	B-Protein
.	O

Additionally	O
,	O
purified	O
PP1	O
activity	O
was	O
inhibited	O
by	O
GST	B-Protein
-	O
MYPT3	B-Protein
toward	O
phosphorylase	O
a	O
,	O
myosin	O
light	O
chain	O
and	O
myosin	O
substrate	O
in	O
vitro	O
.	O

Overall	O
,	O
our	O
findings	O
identify	O
a	O
novel	O
prenylatable	O
subunit	O
of	O
PP1	O
that	O
defines	O
a	O
new	O
subfamily	O
of	O
MYPT	O
.	O

Physiological	O
substrates	O
for	O
human	O
lysosomal	O
beta	O
-	O
hexosaminidase	O
S	O
.	O

Human	O
lysosomal	O
beta	O
-	O
hexosaminidases	O
remove	O
terminal	O
beta	O
-	O
glycosidically	O
bound	O
N	O
-	O
acetylhexosamine	O
residues	O
from	O
a	O
number	O
of	O
glycoconjugates	O
.	O

Three	O
different	O
isozymes	O
composed	O
of	O
two	O
noncovalently	O
linked	O
subunits	O
alpha	O
and	O
beta	O
exist	O
:	O
Hex	O
A	O
(	O
alphabeta	O
)	O
,	O
Hex	O
B	O
(	O
betabeta	O
)	O
,	O
and	O
Hex	O
S	O
(	O
alphaalpha	O
)	O
.	O

While	O
the	O
role	O
of	O
Hex	O
A	O
and	O
B	O
for	O
the	O
degradation	O
of	O
several	O
anionic	O
and	O
neutral	O
glycoconjugates	O
has	O
been	O
well	O
established	O
,	O
the	O
physiological	O
significance	O
of	O
labile	O
Hex	O
S	O
has	O
remained	O
unclear	O
.	O

However	O
,	O
the	O
striking	O
accumulation	O
of	O
anionic	O
oligosaccharides	O
in	O
double	O
knockout	O
mice	O
totally	O
deficient	O
in	O
hexosaminidase	O
activity	O
but	O
not	O
in	O
mice	O
expressing	O
Hex	O
S	O
(	O
Sango	O
,	O
K	O
.	O
,	O
McDonald	O
,	O
M	O
.	O
P	O
.	O
,	O
Crawley	O
,	O
J	O
.	O
N	O
.	O
,	O
Mack	O
,	O
M	O
.	O
L	O
.	O
,	O
Tifft	O
,	O
C	O
.	O
J	O
.	O
,	O
Skop	O
,	O
E	O
.	O
,	O
Starr	O
,	O
C	O
.	O
M	O
.	O
,	O
Hoffmann	O
,	O
A	O
.	O
,	O
Sandhoff	O
,	O
K	O
.	O
,	O
Suzuki	O
,	O
K	O
.	O
,	O
and	O
Proia	O
,	O
R	O
.	O
L	O
.	O
,	O
(	O
1996	O
)	O
Nat	O
.	O
Genet	O
.	O
14	O
,	O
348	O
-	O
352	O
)	O
prompted	O
us	O
to	O
reinvestigate	O
the	O
substrate	O
specificity	O
of	O
Hex	O
S	O
.	O

To	O
identify	O
physiological	O
substrates	O
of	O
Hex	O
S	O
,	O
anionic	O
and	O
neutral	O
oligosaccharides	O
excreted	O
in	O
the	O
urine	O
of	O
the	O
double	O
knockout	O
mice	O
were	O
isolated	O
and	O
analyzed	O
.	O

Using	O
ESI	O
-	O
MS	O
/	O
MS	O
and	O
glycosidase	O
digestion	O
the	O
anionic	O
glycans	O
were	O
identified	O
as	O
products	O
of	O
incomplete	O
dermatan	O
sulfate	O
degradation	O
whereas	O
the	O
neutral	O
storage	O
oligosaccharides	O
were	O
found	O
to	O
be	O
fragments	O
of	O
N	O
-	O
glycan	O
degradation	O
.	O

In	O
vitro	O
,	O
recombinant	O
Hex	O
S	O
was	O
highly	O
active	O
on	O
water	O
-	O
soluble	O
and	O
amphiphilic	O
glycoconjugates	O
including	O
artificial	O
substrates	O
,	O
sulfated	O
GAG	O
fragments	O
,	O
and	O
the	O
sulfated	O
glycosphingolipid	O
SM2	O
.	O

Hydrolysis	O
of	O
membrane	O
-	O
bound	O
SM2	O
by	O
the	O
recombinant	O
Hex	O
S	O
was	O
synergistically	O
stimulated	O
by	O
the	O
GM2	B-Protein
activator	I-Protein
protein	I-Protein
and	O
the	O
lysosomal	O
anionic	O
phospholipid	O
bis	O
(	O
monoacylglycero	O
)	O
phosphate	O
.	O

An	O
intact	O
NEDD8	B-Protein
pathway	O
is	O
required	O
for	O
Cullin	O
-	O
dependent	O
ubiquitylation	O
in	O
mammalian	O
cells	O
.	O

Skp1	B-Protein
-	O
Cdc53	B-Protein
/	O
Cul1	B-Protein
-	O
F	O
-	O
box	O
(	O
SCF	O
)	O
complexes	O
constitute	O
a	O
class	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
.	O

Recently	O
,	O
a	O
multiprotein	O
complex	O
containing	O
pVHL	B-Protein
,	O
elongin	B-Protein
C	I-Protein
and	O
Cul2	B-Protein
(	O
VEC	O
)	O
was	O
shown	O
to	O
structurally	O
and	O
functionally	O
resemble	O
SCF	O
complexes	O
.	O

Cdc53	B-Protein
and	O
the	O
Cullins	O
can	O
become	O
covalently	O
linked	O
to	O
the	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
Rub1	B-Protein
/	O
NEDD8	B-Protein
.	O

Inhibition	O
of	O
neddylation	O
inhibits	O
SCF	O
function	O
in	O
vitro	O
and	O
in	O
yeast	O
and	O
plants	O
.	O

Here	O
we	O
show	O
that	O
ongoing	O
neddylation	O
is	O
likewise	O
required	O
for	O
VEC	O
function	O
in	O
vitro	O
and	O
for	O
the	O
degradation	O
of	O
SCF	O
and	O
VEC	O
targets	O
in	O
mammalian	O
cells	O
.	O

Thus	O
,	O
neddylation	O
regulates	O
the	O
activity	O
of	O
two	O
specific	O
subclasses	O
of	O
mammalian	O
ubiquitin	B-Protein
ligases	O
.	O

Effect	O
of	O
modification	O
on	O
physicochemical	O
and	O
biological	O
properties	O
of	O
haptoglobin	B-Protein
.	O

VI	O
.	O

Reaction	O
with	O
azlactone	O
of	O
p	O
-	O
nitrobenzoyl	O
-	O
valine	O
.	O

The	O
azlactone	O
of	O
p	O
-	O
nitrobenzoyl	O
-	O
valine	O
(	O
Nbz	O
-	O
Val	O
)	O
has	O
been	O
used	O
for	O
modification	O
of	O
xi	O
-	O
amino	O
groups	O
of	O
lysine	O
in	O
haptoglobin	B-Protein
type	I-Protein
1	I-Protein
-	I-Protein
1	I-Protein
,	O
in	O
hemoglobin	O
,	O
and	O
in	O
the	O
haptoglobin	B-Protein
-	O
hemoglobin	O
complex	O
.	O

By	O
the	O
use	O
of	O
this	O
reagent	O
95	O
%	O
of	O
amino	O
groups	O
in	O
haptoglobin	B-Protein
and	O
90	O
%	O
in	O
hemoglobin	O
have	O
been	O
blocked	O
without	O
any	O
changes	O
in	O
peroxidase	O
activity	O
of	O
the	O
formed	O
complexes	O
:	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
with	O
hemoglobin	O
,	O
Nbz	O
-	O
Val	O
.	O
hemoglobin	O
with	O
haptoglobin	B-Protein
,	O
and	O
Nbz	O
-	O
Val	O
.	O
(	O
haptoglonin	B-Protein
-	O
hemoglobin	O
)	O
.	O

After	O
reduction	O
and	O
reoxidation	O
,	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
was	O
found	O
to	O
retain	O
90	O
%	O
of	O
peroxidase	O
activity	O
when	O
complexed	O
with	O
hemoglobin	O
.	O

Beta	O
chains	O
separated	O
either	O
from	O
haptoglobin	B-Protein
or	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
showed	O
15	O
%	O
of	O
peroxidase	O
activity	O
in	O
the	O
complex	O
with	O
hemoglobin	O
,	O
alpha	O
chains	O
of	O
the	O
same	O
origin	O
were	O
completely	O
inactive	O
.	O

Whereas	O
recombination	O
of	O
haptoglobin	B-Protein
from	O
alpha	O
and	O
beta	O
chains	O
resulted	O
in	O
42	O
%	O
hemoglobin	O
-	O
binding	O
capacity	O
,	O
renaturation	O
of	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
from	O
separated	O
subunits	O
was	O
found	O
to	O
proceed	O
with	O
almost	O
100	O
%	O
yield	O
.	O

In	O
immunodiffusion	O
with	O
rabbit	O
anti	O
-	O
haptoglobin	B-Protein
or	O
anti	O
-	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
sera	O
,	O
preparations	O
of	O
haptoglobin	B-Protein
and	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
after	O
reduction	O
and	O
reoxidation	O
or	O
after	O
recombination	O
from	O
separated	O
subunits	O
gave	O
similar	O
precipitation	O
arcs	O
showing	O
the	O
reaction	O
of	O
immunological	O
identity	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
platelet	B-Protein
glycoprotein	I-Protein
Ib	I-Protein
alpha	I-Protein
demonstrating	O
residues	O
involved	O
in	O
the	O
sulfation	O
of	O
tyrosines	O
276	O
,	O
278	O
,	O
and	O
279	O
.	O

The	O
interaction	O
between	O
platelet	B-Protein
glycoprotein	I-Protein
(	I-Protein
GP	I-Protein
)	I-Protein
Ib	I-Protein
alpha	I-Protein
and	O
von	B-Protein
Willebrand	I-Protein
factor	I-Protein
(	O
VWF	B-Protein
)	O
is	O
essential	O
for	O
initiation	O
of	O
hemostasis	O
.	O

The	O
sulfation	O
of	O
the	O
3	O
tyrosine	O
residues	O
276	O
,	O
278	O
,	O
and	O
279	O
in	O
GPIb	B-Protein
alpha	I-Protein
is	O
an	O
important	O
posttranslational	O
modification	O
that	O
seems	O
to	O
promote	O
the	O
interaction	O
with	O
VWF	B-Protein
.	O

The	O
environment	O
where	O
sulfation	O
of	O
tyrosines	O
occurs	O
has	O
been	O
proposed	O
to	O
contain	O
highly	O
acidic	O
residues	O
.	O

This	O
investigation	O
has	O
examined	O
the	O
highly	O
acidic	O
region	O
from	O
Asp249	O
to	O
Asp287	O
in	O
the	O
mature	O
GPIb	B-Protein
alpha	I-Protein
protein	O
.	O

Changes	O
to	O
most	O
of	O
the	O
carboxylic	O
acids	O
in	O
this	O
region	O
resulted	O
in	O
decreased	O
reactivity	O
to	O
VWF	B-Protein
.	O

Only	O
3	O
mutants	O
(	O
Glu270Gln	O
,	O
Asp283Asn	O
,	O
Asp283Asn	O
/	O
Glu285Gln	O
/	O
Asp287Asn	O
)	O
resulted	O
in	O
the	O
abolition	O
of	O
sulfation	O
.	O

Two	O
novel	O
mutations	O
were	O
also	O
created	O
.	O

First	O
,	O
a	O
deletion	O
of	O
the	O
7	O
amino	O
acids	O
from	O
Tyr276	O
to	O
Glu282	O
led	O
to	O
a	O
loss	O
of	O
sulfation	O
and	O
totally	O
abolished	O
VWF	B-Protein
binding	O
in	O
the	O
presence	O
of	O
botrocetin	O
.	O

This	O
confirms	O
that	O
it	O
is	O
these	O
3	O
tyrosines	O
that	O
undergo	O
sulfation	O
and	O
that	O
this	O
region	O
is	O
crucial	O
for	O
botrocetin	O
-	O
mediated	O
VWF	B-Protein
binding	O
.	O

The	O
second	O
mutation	O
involves	O
changing	O
the	O
lysine	O
residues	O
at	O
253	O
,	O
258	O
,	O
and	O
262	O
to	O
alanine	O
.	O

This	O
also	O
led	O
to	O
distinct	O
changes	O
in	O
VWF	B-Protein
binding	O
and	O
abolition	O
of	O
sulfation	O
.	O

Farnesylation	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
is	O
required	O
for	O
G2	O
/	O
M	O
progression	O
and	O
degradation	O
after	O
mitosis	O
.	O

Farnesyl	O
transferase	O
inhibitors	O
induce	O
G2	O
/	O
M	O
cell	O
cycle	O
delays	O
that	O
cannot	O
be	O
explained	O
by	O
inhibition	O
of	O
the	O
Ras	O
GTPase	O
.	O

Recently	O
,	O
the	O
kinetochore	O
protein	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
has	O
been	O
shown	O
to	O
be	O
farnesylated	O
.	O

Here	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
kinetochore	O
targeting	O
domain	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
delays	O
progression	O
through	O
G2	O
/	O
M	O
.	O

Significantly	O
,	O
this	O
is	O
dependent	O
on	O
the	O
CAAX	O
farnesylation	O
motif	O
.	O

We	O
also	O
show	O
that	O
localisation	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
to	O
the	O
nuclear	O
envelope	O
at	O
G2	O
/	O
M	O
and	O
kinetochores	O
in	O
prometaphase	O
is	O
dependent	O
both	O
on	O
its	O
CAAX	O
motif	O
and	O
farnesyl	O
transferase	O
activity	O
.	O

Strikingly	O
,	O
farnesyl	O
transferase	O
activity	O
is	O
also	O
required	O
for	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
degradation	O
after	O
mitosis	O
.	O

Thus	O
,	O
these	O
observations	O
suggest	O
that	O
farnesylation	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
is	O
required	O
not	O
only	O
for	O
its	O
localisation	O
to	O
the	O
nuclear	O
envelope	O
and	O
kinetochores	O
but	O
also	O
for	O
timely	O
progression	O
through	O
G2	O
/	O
M	O
and	O
its	O
degradation	O
after	O
mitosis	O
.	O

In	O
addition	O
,	O
these	O
observations	O
raise	O
the	O
possibility	O
that	O
the	O
anti	O
-	O
proliferative	O
effects	O
induced	O
by	O
farnesyl	O
transferase	O
inhibitors	O
may	O
be	O
due	O
to	O
inhibition	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
function	O
and	O
/	O
or	O
turnover	O
.	O

Structural	O
basis	O
for	O
the	O
beta	O
lactam	O
resistance	O
of	O
PBP2a	B-Protein
from	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

The	O
multiple	O
antibiotic	O
resistance	O
of	O
methicillin	O
-	O
resistant	O
strains	O
of	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
has	O
become	O
a	O
major	O
clinical	O
problem	O
worldwide	O
.	O

The	O
key	O
determinant	O
of	O
the	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactam	O
resistance	O
in	O
MRSA	O
strains	O
is	O
the	O
penicillin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
2a	I-Protein
(	O
PBP2a	B-Protein
)	O
.	O

Because	O
of	O
its	O
low	O
affinity	O
for	O
beta	O
-	O
lactams	O
,	O
PBP2a	B-Protein
provides	O
transpeptidase	O
activity	O
to	O
allow	O
cell	O
wall	O
synthesis	O
at	O
beta	O
-	O
lactam	O
concentrations	O
that	O
inhibit	O
the	O
beta	O
-	O
lactam	O
-	O
sensitive	O
PBPs	O
normally	O
produced	O
by	O
S	O
.	O
aureus	O
.	O

The	O
crystal	O
structure	O
of	O
a	O
soluble	O
derivative	O
of	O
PBP2a	B-Protein
has	O
been	O
determined	O
to	O
1	O
.	O
8	O
A	O
resolution	O
and	O
provides	O
the	O
highest	O
resolution	O
structure	O
for	O
a	O
high	O
molecular	O
mass	O
PBP	O
.	O

Additionally	O
,	O
structures	O
of	O
the	O
acyl	O
-	O
PBP	O
complexes	O
of	O
PBP2a	B-Protein
with	O
nitrocefin	O
,	O
penicillin	O
G	O
and	O
methicillin	O
allow	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
comparison	O
of	O
an	O
apo	O
and	O
acylated	O
resistant	O
PBP	O
.	O

An	O
analysis	O
of	O
the	O
PBP2a	B-Protein
active	O
site	O
in	O
these	O
forms	O
reveals	O
the	O
structural	O
basis	O
of	O
its	O
resistance	O
and	O
identifies	O
features	O
in	O
newly	O
developed	O
beta	O
-	O
lactams	O
that	O
are	O
likely	O
important	O
for	O
high	O
affinity	O
binding	O
.	O

Shift	O
of	O
serum	O
osteocalcin	B-Protein
components	O
between	O
cord	O
blood	O
and	O
blood	O
at	O
day	O
5	O
of	O
life	O
.	O

Vitamin	O
K	O
deficiency	O
is	O
a	O
relatively	O
common	O
condition	O
in	O
neonates	O
.	O

However	O
,	O
the	O
role	O
of	O
vitamin	O
K	O
in	O
neonatal	O
bone	O
metabolism	O
remains	O
to	O
be	O
determined	O
.	O

Osteocalcin	B-Protein
(	O
OC	B-Protein
)	O
is	O
the	O
most	O
abundant	O
noncollagenous	O
protein	O
in	O
bone	O
,	O
and	O
is	O
regulated	O
to	O
be	O
gamma	O
-	O
carboxylated	O
by	O
vitamin	O
K	O
.	O

In	O
this	O
study	O
,	O
we	O
measured	O
gamma	O
-	O
carboxylated	O
osteocalcin	B-Protein
(	O
Gla	O
-	O
OC	B-Protein
)	O
and	O
non	O
-	O
or	O
undercarboxylated	O
osteocalcin	B-Protein
(	O
Glu	O
-	O
OC	B-Protein
)	O
separately	O
,	O
and	O
examined	O
the	O
effects	O
of	O
vitamin	O
K	O
on	O
osteocalcin	B-Protein
metabolism	O
.	O

Eighteen	O
full	O
-	O
term	O
healthy	O
neonates	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

In	O
the	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
the	O
OC	B-Protein
levels	O
were	O
determined	O
by	O
three	O
different	O
methods	O
to	O
examine	O
the	O
intact	O
OC	B-Protein
by	O
immunoradiometric	O
assay	O
(	O
IRMA	O
)	O
,	O
Gla	O
-	O
OC	B-Protein
,	O
and	O
Glu	O
-	O
OC	B-Protein
.	O

Serum	O
vitamin	O
K	O
fractions	O
,	O
hepaplastin	O
test	O
,	O
and	O
type	O
1	O
procollagen	O
carboxyl	O
extension	O
peptide	O
were	O
also	O
determined	O
.	O

Urine	O
samples	O
were	O
also	O
collected	O
from	O
the	O
first	O
voiding	O
and	O
on	O
d	O
5	O
to	O
determine	O
urinary	O
pyridinoline	O
,	O
deoxypyridinoline	O
,	O
and	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
.	O

Serum	O
levels	O
of	O
phylloquinone	O
(	O
PK	O
)	O
and	O
menaquinone	O
(	O
MK	O
)	O
-	O
4	O
increased	O
on	O
d	O
5	O
following	O
vitamin	O
K	O
administration	O
and	O
increased	O
intake	O
in	O
breast	O
milk	O
and	O
/	O
or	O
formula	O
.	O

The	O
OC	B-Protein
levels	O
determined	O
by	O
IRMA	O
did	O
not	O
change	O
between	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
but	O
the	O
Gla	O
-	O
OC	B-Protein
level	O
increased	O
remarkably	O
and	O
Glu	O
-	O
OC	B-Protein
reduced	O
to	O
a	O
negligible	O
level	O
.	O

OC	B-Protein
in	O
cord	O
blood	O
is	O
mainly	O
Glu	O
-	O
OC	B-Protein
,	O
and	O
Glu	O
-	O
OC	B-Protein
is	O
replaced	O
with	O
Gla	O
-	O
OC	B-Protein
within	O
5	O
d	O
of	O
life	O
after	O
vitamin	O
K	O
supplement	O
.	O

The	O
IRMA	O
assay	O
fails	O
to	O
distinguish	O
Gla	O
-	O
OC	B-Protein
from	O
Glu	O
-	O
OC	B-Protein
and	O
caution	O
is	O
needed	O
to	O
estimate	O
bone	O
turnover	O
with	O
this	O
method	O
in	O
the	O
perinatal	O
period	O
.	O

Ubc9	B-Protein
is	O
essential	O
for	O
viability	O
of	O
higher	O
eukaryotic	O
cells	O
.	O

Ubc9	B-Protein
is	O
an	O
enzyme	O
involved	O
in	O
the	O
conjugation	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
(	O
small	B-Protein
ubiquitin	I-Protein
related	I-Protein
modifier	I-Protein
1	I-Protein
)	O
to	O
target	O
proteins	O
.	O

The	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
conjugation	O
system	O
is	O
well	O
conserved	O
from	O
yeasts	O
to	O
higher	O
eukaryotes	O
,	O
but	O
many	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
target	O
proteins	O
reported	O
recently	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
including	O
IkappaBalpha	B-Protein
,	O
MDM2	B-Protein
,	O
p53	B-Protein
,	O
and	O
PML	B-Protein
,	O
are	O
not	O
present	O
in	O
yeasts	O
.	O

To	O
determine	O
the	O
physiological	O
roles	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
conjugation	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
we	O
constructed	O
a	O
conditional	O
UBC9	B-Protein
mutant	O
of	O
chicken	O
DT40	O
cells	O
containing	O
the	O
UBC9	B-Protein
transgene	O
under	O
control	O
of	O
a	O
tetracycline	O
-	O
repressible	O
promoter	O
and	O
characterized	O
their	O
loss	O
of	O
function	O
phenotypes	O
.	O

Ubc9	B-Protein
disappeared	O
3	O
days	O
after	O
the	O
addition	O
of	O
tetracycline	O
and	O
the	O
increase	O
in	O
viable	O
cell	O
number	O
stopped	O
4	O
days	O
after	O
the	O
addition	O
of	O
drug	O
.	O

In	O
contrast	O
to	O
the	O
cases	O
of	O
ubc9	B-Protein
mutants	O
of	O
budding	O
and	O
fission	O
yeasts	O
,	O
which	O
show	O
defects	O
in	O
progression	O
of	O
G2	O
or	O
early	O
M	O
phase	O
and	O
in	O
chromosome	O
segregation	O
,	O
respectively	O
,	O
we	O
did	O
not	O
observe	O
accumulation	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phase	O
or	O
a	O
considerable	O
increase	O
in	O
the	O
frequency	O
of	O
chromosome	O
missegregation	O
upon	O
depletion	O
of	O
Ubc9	B-Protein
but	O
we	O
did	O
observe	O
an	O
increase	O
in	O
the	O
number	O
of	O
cells	O
containing	O
multiple	O
nuclei	O
,	O
indicating	O
defects	O
in	O
cytokinesis	O
.	O

A	O
considerable	O
portion	O
of	O
the	O
Ubc9	B-Protein
-	O
depleted	O
cell	O
population	O
was	O
committed	O
to	O
apoptosis	O
without	O
accumulating	O
in	O
a	O
specific	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
chromosome	O
damages	O
are	O
accumulated	O
in	O
Ubc9	B-Protein
-	O
depleted	O
cells	O
,	O
and	O
apoptosis	O
is	O
triggered	O
without	O
activating	O
checkpoint	O
mechanisms	O
under	O
conditions	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
conjugation	O
system	O
impairment	O
.	O

Involvement	O
of	O
Src	O
family	O
protein	O
tyrosine	O
kinases	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
coronary	O
artery	O
contraction	O
mediated	O
by	O
a	O
sphingosylphosphorylcholine	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O

We	O
recently	O
reported	O
that	O
sphingosylphosphorylcholine	O
(	O
SPC	O
)	O
is	O
a	O
novel	O
messenger	O
for	O
Rho	O
-	O
kinase	O
-	O
mediated	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
vascular	O
smooth	O
muscle	O
(	O
VSM	O
)	O
contraction	O
.	O

Subcellular	O
localization	O
and	O
kinase	O
activity	O
of	O
Src	O
family	O
protein	O
kinases	O
(	O
SrcPTKs	O
)	O
,	O
except	O
for	O
c	B-Protein
-	I-Protein
Src	I-Protein
,	O
is	O
controlled	O
by	O
a	O
reversible	O
S	O
-	O
palmitoylation	O
,	O
an	O
event	O
inhibited	O
by	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
.	O

We	O
examined	O
the	O
possible	O
involvement	O
of	O
SrcPTKs	O
in	O
SPC	O
-	O
induced	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
and	O
effects	O
of	O
EPA	O
.	O

We	O
used	O
porcine	O
coronary	O
VSM	O
and	O
rat	O
aortic	O
VSM	O
cells	O
(	O
VSMCs	O
)	O
in	O
primary	O
culture	O
.	O

An	O
SrcPTKs	O
inhibitor	O
,	O
PP1	O
,	O
and	O
EPA	O
inhibited	O
SPC	O
-	O
induced	O
contraction	O
,	O
concentration	O
-	O
dependently	O
,	O
without	O
affecting	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
levels	O
and	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
contraction	O
induced	O
by	O
high	O
K	O
(	O
+	O
)	O
depolarization	O
.	O

A	O
digitized	O
immunocytochemical	O
analysis	O
in	O
VSMCs	O
revealed	O
that	O
SPC	O
induced	O
translocation	O
of	O
Fyn	B-Protein
,	O
but	O
not	O
of	O
c	B-Protein
-	I-Protein
Src	I-Protein
,	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
,	O
an	O
event	O
abolished	O
by	O
EPA	O
.	O

Translocation	O
of	O
Rho	O
-	O
kinase	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
by	O
SPC	O
was	O
also	O
inhibited	O
by	O
EPA	O
and	O
PP1	O
.	O

The	O
SPC	O
-	O
induced	O
activation	O
of	O
SrcPTKs	O
was	O
blocked	O
by	O
EPA	O
and	O
PP1	O
,	O
but	O
not	O
by	O
Y27632	O
,	O
an	O
Rho	O
-	O
kinase	O
inhibitor	O
.	O

Rho	O
-	O
kinase	O
-	O
dependent	O
phosphorylation	O
of	O
myosin	O
phosphatase	O
induced	O
by	O
SPC	O
was	O
inhibited	O
by	O
EPA	O
,	O
PP1	O
,	O
and	O
Y27632	O
.	O

Translocation	O
and	O
activation	O
of	O
SrcPTKs	O
,	O
including	O
Fyn	B-Protein
,	O
play	O
an	O
important	O
role	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
VSM	O
contractions	O
mediated	O
by	O
a	O
SPC	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O

The	O
central	O
role	O
of	O
the	O
trans	O
-	O
Golgi	O
network	O
as	O
a	O
gateway	O
of	O
the	O
early	O
secretory	O
pathway	O
:	O
physiologic	O
vs	O
nonphysiologic	O
protein	O
transit	O
.	O

The	O
current	O
review	O
focuses	O
upon	O
recent	O
advances	O
concerning	O
the	O
interrelationship	O
between	O
the	O
ER	O
and	O
the	O
trans	O
-	O
Golgi	O
network	O
(	O
ER	O
-	O
TGN	O
)	O
,	O
the	O
ER	O
and	O
the	O
nucleus	O
(	O
ER	O
-	O
nucleus	O
)	O
,	O
and	O
the	O
ER	O
-	O
ubiquitin	B-Protein
-	O
proteasomal	O
pathways	O
at	O
the	O
level	O
of	O
basic	O
cell	O
biology	O
.	O

The	O
overall	O
emphasis	O
of	O
this	O
paper	O
centers	O
upon	O
the	O
high	O
likelihood	O
that	O
measurements	O
of	O
ER	O
-	O
associated	O
protein	O
or	O
gene	O
expression	O
levels	O
are	O
not	O
representative	O
of	O
a	O
strict	O
ER	O
alone	O
phenotype	O
.	O

Rather	O
,	O
that	O
ER	O
phenotype	O
reflects	O
a	O
synthesis	O
of	O
phenotypes	O
derived	O
from	O
intracellular	O
compartments	O
and	O
phosphorylated	O
messengers	O
in	O
rapport	O
with	O
the	O
ER	O
.	O

The	O
ER	O
-	O
TGN	O
,	O
ER	O
-	O
nuclear	O
,	O
and	O
ER	O
-	O
ubiquitin	B-Protein
-	O
proteasomal	O
transit	O
paths	O
share	O
the	O
ability	O
to	O
feed	O
into	O
the	O
decision	O
of	O
whether	O
TGN	O
vesicles	O
can	O
interact	O
with	O
specific	O
phosphorylated	O
residues	O
in	O
order	O
to	O
drive	O
physiologic	O
,	O
constitutive	O
,	O
anterograde	O
traffic	O
,	O
retrograde	O
traffic	O
,	O
and	O
degradation	O
.	O

TGN	O
vesicles	O
can	O
:	O
(	O
a	O
)	O
traffic	O
to	O
endosomes	O
versus	O
plasma	O
membrane	O
phosphodomains	O
depending	O
upon	O
the	O
presence	O
or	O
the	O
absence	O
of	O
select	O
Golgi	O
-	O
localized	O
gamma	O
-	O
ear	O
containing	O
ADP	O
ribosylation	O
factor	O
-	O
binding	O
proteins	O
and	O
/	O
or	O
protein	O
kinase	O
D	O
;	O
(	O
b	O
)	O
be	O
maintained	O
within	O
the	O
TGN	O
in	O
the	O
presence	O
of	O
a	O
phosphosorting	O
acidic	O
cluster	O
motif	O
adaptor	O
;	O
(	O
c	O
)	O
transit	O
back	O
to	O
the	O
ER	O
via	O
specialized	O
TGN	O
/	O
ER	O
glycosyltransferases	O
(	O
which	O
modulate	O
phosphorylated	O
proteins	O
)	O
;	O
(	O
d	O
)	O
transit	O
to	O
the	O
nucleus	O
via	O
phosphatidylinositol	O
-	O
4	O
-	O
kinase	O
-	O
associated	O
phosphodomains	O
;	O
and	O
/	O
or	O
(	O
e	O
)	O
retrotranslocate	O
to	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
equipped	O
with	O
E3	O
ligase	O
potential	O
,	O
in	O
order	O
to	O
further	O
regulate	O
endosomal	O
versus	O
plasma	O
membrane	O
traffic	O
.	O

The	O
TGN	O
is	O
also	O
a	O
critical	O
gateway	O
for	O
protein	O
transit	O
in	O
the	O
sense	O
that	O
,	O
as	O
a	O
function	O
of	O
sorting	O
within	O
this	O
compartment	O
,	O
proteins	O
are	O
sent	O
to	O
the	O
axon	O
,	O
cell	O
body	O
,	O
or	O
dendrites	O
.	O

As	O
the	O
decision	O
to	O
sort	O
to	O
the	O
axon	O
versus	O
the	O
somatodendritic	O
compartment	O
is	O
intimately	O
tied	O
to	O
TGN	O
function	O
,	O
future	O
understanding	O
of	O
TGN	O
biology	O
at	O
the	O
levels	O
of	O
neurogenesis	O
and	O
protein	O
sorting	O
is	O
predicted	O
to	O
also	O
effectively	O
increase	O
our	O
understanding	O
of	O
synaptic	O
sorting	O
/	O
regulation	O
.	O

CAND1	B-Protein
binds	O
to	O
unneddylated	O
CUL1	B-Protein
and	O
regulates	O
the	O
formation	O
of	O
SCF	O
ubiquitin	B-Protein
E3	O
ligase	O
complex	O
.	O

The	O
SCF	O
ubiquitin	B-Protein
E3	O
ligase	O
regulates	O
ubiquitin	B-Protein
-	O
dependent	O
proteolysis	O
of	O
many	O
regulatory	O
proteins	O
such	O
as	O
p27	B-Protein
(	O
Kip1	B-Protein
)	O
,	O
IkappaB	O
,	O
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
.	O

We	O
report	O
the	O
isolation	O
of	O
a	O
CUL1	B-Protein
binding	O
protein	O
,	O
p120	B-Protein
(	O
CAND1	B-Protein
)	O
.	O

We	O
found	O
the	O
majority	O
of	O
CUL1	B-Protein
is	O
in	O
a	O
complex	O
with	O
CAND1	B-Protein
and	O
ROC1	B-Protein
independent	O
of	O
SKP1	B-Protein
and	O
F	O
box	O
protein	O
SKP2	B-Protein
.	O

Both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
CAND1	B-Protein
prevents	O
the	O
binding	O
of	O
SKP1	B-Protein
and	O
SKP2	B-Protein
to	O
CUL1	B-Protein
while	O
dissociation	O
of	O
CAND1	B-Protein
from	O
CUL1	B-Protein
promotes	O
the	O
reverse	O
reaction	O
.	O

Neddylation	O
of	O
CUL1	B-Protein
or	O
the	O
presence	O
of	O
SKP1	B-Protein
and	O
ATP	O
causes	O
CAND1	B-Protein
dissociation	O
.	O

Our	O
data	O
suggest	O
that	O
CAND1	B-Protein
regulates	O
the	O
formation	O
of	O
the	O
SCF	O
complex	O
,	O
and	O
its	O
dissociation	O
from	O
CUL1	B-Protein
is	O
coupled	O
with	O
the	O
incorporation	O
of	O
F	O
box	O
proteins	O
into	O
the	O
SCF	O
complex	O
,	O
causing	O
their	O
destabilization	O
.	O

Rheb	B-Protein
binds	O
tuberous	B-Protein
sclerosis	I-Protein
complex	I-Protein
2	I-Protein
(	O
TSC2	B-Protein
)	O
and	O
promotes	O
S6	B-Protein
kinase	O
activation	O
in	O
a	O
rapamycin	O
-	O
and	O
farnesylation	O
-	O
dependent	O
manner	O
.	O

Recently	O
the	O
tuberous	B-Protein
sclerosis	I-Protein
complex	I-Protein
2	I-Protein
(	O
TSC2	B-Protein
)	O
tumor	O
suppressor	O
gene	O
product	O
has	O
been	O
identified	O
as	O
a	O
negative	O
regulator	O
of	O
protein	O
synthesis	O
upstream	O
of	O
the	O
mTOR	B-Protein
and	O
ribosomal	O
S6	B-Protein
kinases	O
.	O

Because	O
of	O
the	O
homology	O
of	O
TSC2	B-Protein
with	O
GTPase	O
-	O
activating	O
proteins	O
for	O
Rap1	B-Protein
,	O
we	O
examined	O
whether	O
a	O
Ras	O
/	O
Rap	O
-	O
related	O
GTPase	O
might	O
be	O
involved	O
in	O
this	O
process	O
.	O

TSC2	B-Protein
was	O
found	O
to	O
bind	O
to	O
Rheb	B-Protein
-	O
GTP	O
in	O
vitro	O
and	O
to	O
reduce	O
Rheb	B-Protein
GTP	O
levels	O
in	O
vivo	O
.	O

Over	O
-	O
expression	O
of	O
Rheb	B-Protein
but	O
not	O
Rap1	B-Protein
promoted	O
the	O
activation	O
of	O
S6	B-Protein
kinase	O
in	O
a	O
rapamycin	O
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
Rheb	B-Protein
acts	O
upstream	O
of	O
mTOR	B-Protein
.	O

The	O
ability	O
of	O
Rheb	B-Protein
to	O
induce	O
S6	B-Protein
phosphorylation	O
was	O
also	O
inhibited	O
by	O
a	O
farnesyl	O
transferase	O
inhibitor	O
,	O
suggesting	O
that	O
Rheb	B-Protein
may	O
be	O
responsible	O
for	O
the	O
Ras	O
-	O
independent	O
anti	O
-	O
neoplastic	O
properties	O
of	O
this	O
drug	O
.	O

Rab	O
and	O
ARF	O
GTPase	O
regulation	O
of	O
exocytosis	O
.	O

Our	O
understanding	O
of	O
the	O
mechanisms	O
governing	O
of	O
Rab	O
and	O
Arf	O
protein	O
function	O
has	O
exploded	O
in	O
recent	O
years	O
with	O
a	O
convergence	O
of	O
information	O
from	O
model	O
genetic	O
organisms	O
,	O
biochemical	O
studies	O
,	O
cell	O
biological	O
observations	O
and	O
protein	O
structural	O
information	O
.	O

However	O
,	O
the	O
list	O
of	O
known	O
Rab	O
and	O
Arf	O
interacting	O
factors	O
still	O
remains	O
small	O
relative	O
to	O
the	O
number	O
of	O
these	O
small	O
GTPases	O
that	O
have	O
been	O
identified	O
through	O
complete	O
genomic	O
sequencing	O
.	O

It	O
can	O
be	O
anticipated	O
that	O
the	O
factors	O
listed	O
and	O
discussed	O
in	O
this	O
review	O
probably	O
represent	O
a	O
small	O
fraction	O
of	O
the	O
Rab	O
and	O
Arf	O
accessory	O
molecules	O
that	O
remain	O
to	O
be	O
discovered	O
.	O

The	O
identification	O
of	O
regulators	O
and	O
accessory	O
molecules	O
for	O
the	O
Rab	O
and	O
Arf	O
families	O
has	O
allowed	O
investigators	O
to	O
elaborate	O
themes	O
and	O
develop	O
a	O
framework	O
for	O
a	O
mechanistic	O
understanding	O
of	O
these	O
proteins	O
.	O

The	O
themes	O
are	O
highlighted	O
in	O
this	O
review	O
,	O
which	O
aims	O
to	O
concentrate	O
on	O
Rab	O
and	O
Arf	O
function	O
in	O
exocytosis	O
.	O

Studies	O
on	O
G	O
-	O
protein	O
alpha	O
.	O
betagamma	O
heterotrimer	O
formation	O
reveal	O
a	O
putative	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
the	O
alpha	O
subunit	O
.	O

The	O
alpha	O
and	O
betagamma	O
subunits	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
contain	O
specific	O
lipid	O
modifications	O
,	O
which	O
are	O
required	O
for	O
their	O
biological	O
function	O
.	O

However	O
,	O
the	O
relevance	O
of	O
these	O
modifications	O
to	O
the	O
interactions	O
within	O
the	O
heterotrimeric	O
G	O
-	O
protein	O
is	O
not	O
fully	O
understood	O
.	O

In	O
order	O
to	O
explore	O
the	O
role	O
of	O
the	O
S	O
-	O
prenyl	O
moiety	O
of	O
the	O
isoprenylated	O
betagamma	O
dimer	O
of	O
retinal	O
transducin	O
,	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
,	O
in	O
the	O
formation	O
of	O
the	O
heterotrimeric	O
complex	O
with	O
the	O
corresponding	O
N	O
-	O
acylated	O
alpha	O
subunit	O
,	O
alpha	O
(	O
t	O
)	O
,	O
we	O
employed	O
purified	O
fully	O
processed	O
subunits	O
,	O
which	O
are	O
soluble	O
in	O
aqueous	O
solutions	O
without	O
detergents	O
.	O

Pertussis	O
-	O
toxin	O
-	O
mediated	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
alpha	O
(	O
t	O
)	O
is	O
strongly	O
stimulated	O
(	O
approximately	O
10	O
-	O
fold	O
)	O
in	O
the	O
presence	O
of	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
and	O
can	O
thus	O
serve	O
as	O
a	O
measure	O
for	O
heterotrimer	O
formation	O
.	O

Using	O
this	O
assay	O
,	O
preincubation	O
of	O
alpha	O
(	O
t	O
)	O
with	O
S	O
-	O
prenyl	O
analogues	O
containing	O
farnesyl	O
or	O
geranylgeranyl	O
moieties	O
was	O
found	O
to	O
inhibit	O
heterotrimer	O
formation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
inhibition	O
was	O
competitive	O
and	O
reversible	O
,	O
as	O
indicated	O
by	O
its	O
reversal	O
upon	O
increase	O
of	O
the	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
dimer	O
concentration	O
or	O
by	O
removal	O
of	O
the	O
S	O
-	O
prenyl	O
analogue	O
using	O
gel	O
filtration	O
.	O

The	O
competitive	O
nature	O
of	O
the	O
inhibition	O
is	O
supported	O
by	O
the	O
marked	O
attenuation	O
of	O
the	O
inhibition	O
when	O
the	O
S	O
-	O
prenyl	O
analogue	O
was	O
added	O
to	O
alpha	O
(	O
t	O
)	O
together	O
with	O
or	O
after	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
.	O

The	O
inhibition	O
does	O
not	O
involve	O
interaction	O
with	O
the	O
alpha	O
(	O
t	O
)	O
acyl	O
group	O
,	O
since	O
an	O
S	O
-	O
prenyl	O
analogue	O
inhibited	O
the	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
an	O
unlipidated	O
alpha	O
(	O
t	O
)	O
mutant	O
.	O

These	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
hitherto	O
unrecognized	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
alpha	O
(	O
t	O
)	O
,	O
which	O
is	O
critical	O
for	O
its	O
interaction	O
with	O
prenylated	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
.	O

Retroviral	O
insertional	O
mutagenesis	O
identifies	O
a	O
small	O
protein	O
required	O
for	O
synthesis	O
of	O
diphthamide	O
,	O
the	O
target	O
of	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O

Retroviral	O
insertional	O
mutagenesis	O
was	O
used	O
to	O
produce	O
a	O
mutant	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
that	O
is	O
completely	O
resistant	O
to	O
several	O
different	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O

The	O
gene	O
responsible	O
for	O
toxin	O
resistance	O
,	O
termed	O
diphtheria	B-Protein
toxin	I-Protein
(	I-Protein
DT	I-Protein
)	I-Protein
and	I-Protein
Pseudomonas	I-Protein
exotoxin	I-Protein
A	I-Protein
(	I-Protein
ETA	I-Protein
)	I-Protein
sensitivity	I-Protein
required	I-Protein
gene	I-Protein
1	I-Protein
(	O
DESR1	B-Protein
)	O
,	O
encodes	O
two	O
small	O
protein	O
isoforms	O
of	O
82	O
and	O
57	O
residues	O
.	O

DESR1	B-Protein
is	O
evolutionally	O
conserved	O
and	O
ubiquitously	O
expressed	O
.	O

Only	O
the	O
longer	O
isoform	O
is	O
functional	O
because	O
the	O
mutant	O
cell	O
line	O
can	O
be	O
complemented	O
by	O
transfection	O
with	O
the	O
long	O
but	O
not	O
the	O
short	O
isoform	O
.	O

We	O
demonstrate	O
that	O
DESR1	B-Protein
is	O
required	O
for	O
the	O
first	O
step	O
in	O
the	O
posttranslational	O
modification	O
of	O
elongation	B-Protein
factor	I-Protein
-	I-Protein
2	I-Protein
at	O
His	O
(	O
715	O
)	O
that	O
yields	O
diphthamide	O
,	O
the	O
target	O
site	O
for	O
ADP	O
ribosylation	O
by	O
DT	B-Protein
and	O
ETA	B-Protein
.	O

KTI11	B-Protein
,	O
the	O
analog	O
of	O
DESR1	B-Protein
in	O
yeast	O
,	O
which	O
was	O
originally	O
identified	O
as	O
a	O
gene	O
regulating	O
the	O
sensitivity	O
of	O
yeast	O
to	O
zymocin	O
,	O
is	O
also	O
required	O
for	O
diphthamide	O
biosynthesis	O
,	O
implicating	O
DESR1	B-Protein
/	O
KTI11	B-Protein
in	O
multiple	O
biological	O
processes	O
.	O

The	O
redox	O
domain	O
of	O
the	O
Yap1p	B-Protein
transcription	O
factor	O
contains	O
two	O
disulfide	O
bonds	O
.	O

The	O
subcellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
transcription	O
factor	O
Yap1p	B-Protein
is	O
regulated	O
by	O
oxidation	O
and	O
reduction	O
.	O

We	O
purified	O
Yap1p	B-Protein
from	O
yeast	O
and	O
characterized	O
its	O
properties	O
in	O
vitro	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
the	O
purified	O
protein	O
can	O
specifically	O
bind	O
the	O
TRX2	B-Protein
target	O
promoter	O
.	O

Yap1p	B-Protein
was	O
purified	O
under	O
reducing	O
conditions	O
,	O
but	O
removal	O
of	O
reducing	O
agents	O
resulted	O
in	O
the	O
formation	O
of	O
an	O
oxidized	O
Yap1p	B-Protein
species	O
with	O
properties	O
similar	O
to	O
in	O
vivo	O
oxidized	O
Yap1p	B-Protein
.	O

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
revealed	O
that	O
the	O
oxidized	O
form	O
of	O
Yap1p	B-Protein
contains	O
two	O
disulfide	O
bonds	O
between	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
.	O

A	O
stable	O
domain	O
of	O
approximately	O
15	O
kDa	O
was	O
detected	O
upon	O
limited	O
proteolysis	O
of	O
oxidized	O
but	O
not	O
reduced	O
Yap1p	B-Protein
.	O

This	O
Yap1p	B-Protein
protease	O
resistant	O
domain	O
was	O
purified	O
,	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
showed	O
that	O
it	O
was	O
comprised	O
of	O
two	O
separate	O
cysteine	O
-	O
containing	O
peptides	O
of	O
Yap1p	B-Protein
.	O

These	O
peptides	O
are	O
separated	O
by	O
250	O
amino	O
acids	O
and	O
are	O
joined	O
by	O
the	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
disulfide	O
bonds	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
domain	O
that	O
controls	O
Yap1p	B-Protein
subcellular	O
localization	O
is	O
modular	O
and	O
contains	O
a	O
redox	O
center	O
comprised	O
of	O
four	O
cysteine	O
residues	O
.	O

Rho	B-Protein
A	I-Protein
negatively	O
regulates	O
cytokine	O
-	O
mediated	O
inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
expression	O
in	O
brain	O
-	O
derived	O
transformed	O
cell	O
lines	O
:	O
negative	O
regulation	O
of	O
IKKalpha	B-Protein
.	O

The	O
present	O
study	O
describes	O
the	O
role	O
of	O
RhoA	B-Protein
as	O
a	O
negative	O
regulator	O
of	O
iNOS	B-Protein
expression	O
via	O
the	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
in	O
transformed	O
brain	O
cell	O
lines	O
[	O
C	O
(	O
6	O
)	O
glioma	O
,	O
human	O
astrocytoma	O
(	O
T98G	O
,	O
A172	O
)	O
,	O
neuroblastoma	O
(	O
NEB	O
)	O
,	O
and	O
immortal	O
rat	O
astrocytes	O
]	O
.	O

Treatment	O
with	O
lovastatin	O
resulted	O
in	O
the	O
induction	O
of	O
LPS	O
/	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
mediated	O
iNOS	B-Protein
mRNA	O
and	O
increased	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
.	O

The	O
addition	O
of	O
mevalonate	O
and	O
geranylgeranylpyrophosphate	O
(	O
GGPP	O
)	O
reversed	O
the	O
lovastatin	O
-	O
mediated	O
effect	O
,	O
whereas	O
FPP	O
had	O
no	O
effect	O
.	O

An	O
inhibitor	O
of	O
geranylgeranyltransferase	O
inhibitor	O
(	O
GGTI	O
298	O
)	O
further	O
induced	O
the	O
cytokine	O
and	O
lovastatin	O
-	O
mediated	O
iNOS	B-Protein
expression	O
,	O
suggesting	O
the	O
involvement	O
of	O
geranylgeranylated	O
proteins	O
in	O
the	O
regulation	O
of	O
iNOS	B-Protein
.	O

Bacterial	O
toxin	B-Protein
B	I-Protein
(	O
inactivates	O
RhoA	B-Protein
,	O
B	B-Protein
,	O
and	O
C	B-Protein
;	O
CDC42	B-Protein
;	O
Rac	O
proteins	O
)	O
,	O
C3	B-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
C3	B-Protein
)	O
toxin	O
from	O
C	O
.	O
botulinum	O
(	O
inactivates	O
RhoA	B-Protein
,	O
B	B-Protein
,	O
and	O
C	B-Protein
proteins	O
)	O
,	O
and	O
Y	O
-	O
27632	O
(	O
selective	O
inhibitor	O
of	O
Rho	O
-	O
associated	O
kinases	O
)	O
increased	O
the	O
LPS	O
/	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
mediated	O
iNOS	B-Protein
expression	O
.	O

Lovastatin	O
treatment	O
induced	O
NO	O
by	O
increasing	O
NF	O
-	O
kappaB	O
translocation	O
and	O
its	O
association	O
with	O
the	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	B-Protein
/	O
p300	B-Protein
)	O
via	O
the	O
downregulation	O
of	O
RhoA	B-Protein
.	O

Inhibition	O
of	O
RhoA	B-Protein
resulted	O
in	O
increased	O
activation	O
of	O
IKKalpha	B-Protein
.	O

Cotransfection	O
studies	O
with	O
dominant	O
-	O
negative	O
form	O
of	O
RhoA	B-Protein
and	O
iNOS	B-Protein
-	O
luciferase	B-Protein
or	O
NF	O
-	O
kappaB	O
-	O
luciferase	B-Protein
reporter	O
constructs	O
further	O
support	O
these	O
observations	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
show	O
that	O
downregulation	O
of	O
RhoA	B-Protein
by	O
lovastatin	O
resulted	O
in	O
increased	O
iNOS	B-Protein
expression	O
via	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
CBP	B-Protein
/	O
p300	B-Protein
pathway	O
in	O
transformed	O
brain	O
cells	O
.	O

Caspase	B-Protein
-	I-Protein
2	I-Protein
/	O
NEDD	B-Protein
-	I-Protein
2	I-Protein
protease	O
mediates	O
execution	O
of	O
apoptosis	O
in	O
AK	O
-	O
5	O
tumor	O
cells	O
.	O

AK	O
-	O
5	O
tumour	O
cells	O
have	O
been	O
shown	O
to	O
undergo	O
apoptosis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
efficient	O
killing	O
of	O
tumour	O
cells	O
by	O
necrosis	O
and	O
apoptosis	O
leads	O
to	O
spontaneous	O
regression	O
of	O
the	O
tumour	O
.	O

To	O
investigate	O
a	O
possible	O
involvement	O
of	O
caspase	B-Protein
-	I-Protein
2	I-Protein
/	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
protease	O
in	O
AK	O
-	O
5	O
apoptosis	O
,	O
we	O
introduced	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
gene	O
in	O
antisense	O
orientation	O
and	O
showed	O
inhibition	O
of	O
tumour	O
cell	O
apoptosis	O
.	O

Similarly	O
introduction	O
of	O
the	O
bcl	B-Protein
-	I-Protein
2	I-Protein
gene	O
in	O
tumour	O
cells	O
also	O
inhibited	O
the	O
apoptotic	O
programme	O
.	O

NK	O
cells	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
the	O
effector	O
cells	O
also	O
fail	O
to	O
induce	O
apoptosis	O
in	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
antisense	O
and	O
bcl	B-Protein
-	I-Protein
2	I-Protein
transfected	O
clones	O
whereas	O
NK	O
mediated	O
cytotoxic	O
activity	O
is	O
not	O
altered	O
in	O
the	O
transfectants	O
.	O

These	O
results	O
suggest	O
participation	O
of	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
protease	O
in	O
the	O
induction	O
of	O
apoptosis	O
in	O
AK	O
-	O
5	O
cells	O
leading	O
to	O
tumour	O
regression	O
.	O

Antifungal	O
activity	O
of	O
fluconazole	O
in	O
combination	O
with	O
lovastatin	O
and	O
their	O
effects	O
on	O
gene	O
expression	O
in	O
the	O
ergosterol	O
and	O
prenylation	O
pathways	O
in	O
Candida	O
albicans	O
.	O

The	O
sterol	O
pathway	O
in	O
Candida	O
albicans	O
is	O
the	O
target	O
for	O
several	O
classes	O
of	O
antifungal	O
drugs	O
.	O

Intermediates	O
in	O
the	O
sterol	O
pathway	O
are	O
involved	O
in	O
ergosterol	O
synthesis	O
,	O
prenylation	O
and	O
dolichol	O
synthesis	O
.	O

This	O
study	O
examines	O
gene	O
expression	O
of	O
the	O
sterol	O
pathway	O
in	O
response	O
to	O
lovastatin	O
,	O
an	O
inhibitor	O
of	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
(	O
Hmg1p	B-Protein
)	O
,	O
and	O
fluconazole	O
,	O
an	O
inhibitor	O
of	O
14	B-Protein
alpha	I-Protein
-	I-Protein
lanosterol	I-Protein
demethylase	I-Protein
(	O
Erg11p	B-Protein
)	O
.	O

Minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
studies	O
indicated	O
that	O
lovastatin	O
acts	O
synergistically	O
with	O
fluconazole	O
in	O
vitro	O
.	O

Semi	O
-	O
quantitative	O
reverse	B-Protein
transcriptase	I-Protein
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
results	O
indicated	O
that	O
genes	O
in	O
the	O
early	O
part	O
of	O
the	O
sterol	O
pathway	O
,	O
such	O
as	O
HMG1	B-Protein
and	O
ERG20	B-Protein
,	O
did	O
not	O
alter	O
expression	O
in	O
the	O
presence	O
of	O
both	O
lovastatin	O
and	O
fluconazole	O
,	O
whereas	O
genes	O
in	O
the	O
later	O
part	O
of	O
the	O
sterol	O
pathway	O
,	O
such	O
as	O
ERG9	B-Protein
and	O
ERG11	B-Protein
,	O
had	O
increased	O
expression	O
in	O
response	O
to	O
these	O
drugs	O
in	O
mid	O
-	O
logarithmic	O
growth	O
.	O

Genes	O
involved	O
in	O
prenylation	O
,	O
such	O
as	O
RAM1	B-Protein
and	O
RAM2	B-Protein
,	O
also	O
respond	O
to	O
these	O
drugs	O
in	O
mid	O
-	O
logarithmic	O
growth	O
,	O
although	O
another	O
prenylation	O
gene	O
,	O
CDC43	B-Protein
,	O
was	O
not	O
affected	O
.	O

After	O
24	O
h	O
of	O
growth	O
,	O
the	O
relative	O
expression	O
of	O
ERG20	B-Protein
,	O
ERG9	B-Protein
,	O
and	O
ERG11	B-Protein
remained	O
unchanged	O
or	O
increased	O
in	O
the	O
presence	O
of	O
both	O
drugs	O
,	O
while	O
all	O
other	O
genes	O
decreased	O
in	O
expression	O
under	O
all	O
drug	O
treatments	O
.	O

Neisseria	O
gonorrhoeae	O
penicillin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
3	I-Protein
exhibits	O
exceptionally	O
high	O
carboxypeptidase	O
and	O
beta	O
-	O
lactam	O
binding	O
activities	O
.	O

A	O
soluble	O
form	O
of	O
penicillin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
3	I-Protein
(	O
PBP	B-Protein
3	I-Protein
)	O
from	O
Neisseria	O
gonorrhoeae	O
was	O
expressed	O
and	O
purified	O
from	O
Escherichia	O
coli	O
and	O
characterized	O
for	O
its	O
interaction	O
with	O
beta	O
-	O
lactam	O
antibiotics	O
,	O
its	O
catalytic	O
properties	O
with	O
peptide	O
and	O
peptidoglycan	O
substrates	O
,	O
and	O
its	O
role	O
in	O
cell	O
viability	O
and	O
morphology	O
.	O

PBP	B-Protein
3	I-Protein
had	O
an	O
unusually	O
high	O
k	O
(	O
2	O
)	O
/	O
K	O
'	O
value	O
relative	O
to	O
other	O
PBPs	O
for	O
acylation	O
with	O
penicillin	O
(	O
7	O
.	O
7	O
x	O
10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
)	O
at	O
pH	O
8	O
.	O
5	O
at	O
25	O
degrees	O
C	O
and	O
hydrolyzed	O
bound	O
antibiotic	O
very	O
slowly	O
(	O
k	O
(	O
3	O
)	O
<	O
4	O
.	O
6	O
x	O
10	O
(	O
-	O
5	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
t	O
(	O
1	O
/	O
2	O
)	O
>	O
230	O
min	O
)	O
.	O

PBP	B-Protein
3	I-Protein
also	O
demonstrated	O
exceptionally	O
high	O
carboxypeptidase	O
activity	O
with	O
a	O
k	O
(	O
cat	O
)	O
of	O
580	O
s	O
(	O
-	O
1	O
)	O
and	O
a	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
of	O
1	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
with	O
the	O
substrate	O
N	O
(	O
alpha	O
)	O
-	O
Boc	O
-	O
N	O
(	O
epsilon	O
)	O
-	O
Cbz	O
-	O
L	O
-	O
Lys	O
-	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Ala	O
.	O

This	O
is	O
the	O
highest	O
k	O
(	O
cat	O
)	O
value	O
yet	O
reported	O
for	O
a	O
PBP	O
or	O
other	O
serine	O
peptidases	O
.	O

Activity	O
against	O
a	O
approximately	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Lac	O
peptide	O
substrate	O
was	O
approximately	O
2	O
-	O
fold	O
lower	O
than	O
against	O
the	O
analogous	O
approximately	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Ala	O
peptide	O
substrate	O
,	O
indicating	O
that	O
deacylation	O
is	O
rate	O
determining	O
for	O
both	O
amide	O
and	O
ester	O
hydrolysis	O
.	O

The	O
pH	O
dependence	O
profiles	O
of	O
both	O
carboxypeptidase	O
activity	O
and	O
beta	O
-	O
lactam	O
acylation	O
were	O
bell	O
-	O
shaped	O
with	O
maximal	O
activity	O
at	O
pH	O
8	O
.	O
0	O
-	O
8	O
.	O
5	O
.	O

PBP	B-Protein
3	I-Protein
displayed	O
weak	O
transpeptidase	O
activity	O
in	O
a	O
model	O
transpeptidase	O
reaction	O
but	O
was	O
active	O
as	O
an	O
endopeptidase	O
,	O
cleaving	O
dimeric	O
peptide	O
cross	O
-	O
links	O
.	O

Deletion	O
of	O
PBP	B-Protein
3	I-Protein
alone	O
had	O
little	O
effect	O
on	O
viability	O
,	O
growth	O
rate	O
,	O
and	O
morphology	O
of	O
N	O
.	O
gonorrhoeae	O
,	O
although	O
deletion	O
of	O
both	O
PBP	B-Protein
3	I-Protein
and	O
PBP	B-Protein
4	I-Protein
,	O
the	O
other	O
low	O
-	O
molecular	O
-	O
mass	O
PBP	O
in	O
N	O
.	O
gonorrhoeae	O
,	O
resulted	O
in	O
a	O
decreased	O
growth	O
rate	O
and	O
marked	O
morphological	O
abnormalities	O
.	O

A	O
recombinant	O
form	O
of	O
Pseudomonas	O
exotoxin	O
directed	O
at	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
that	O
is	O
cytotoxic	O
without	O
requiring	O
proteolytic	O
processing	O
.	O

Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
is	O
composed	O
of	O
three	O
structural	O
domains	O
that	O
mediate	O
cell	O
recognition	O
(	O
I	O
)	O
,	O
membrane	O
translocation	O
(	O
II	O
)	O
,	O
and	O
ADP	O
-	O
ribosylation	O
(	O
III	O
)	O
.	O

Within	O
the	O
cell	O
,	O
the	O
toxin	O
is	O
cleaved	O
within	O
domain	O
II	O
to	O
produce	O
a	O
37	O
-	O
kDa	O
carboxyl	O
-	O
terminal	O
fragment	O
,	O
containing	O
amino	O
acids	O
280	O
-	O
613	O
,	O
which	O
is	O
translocated	O
to	O
the	O
cytosol	O
and	O
causes	O
cell	O
death	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
a	O
mutant	O
protein	O
(	O
PE37	O
)	O
,	O
composed	O
of	O
amino	O
acids	O
280	O
-	O
613	O
of	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
,	O
which	O
does	O
not	O
require	O
proteolysis	O
to	O
translocate	O
.	O

PE37	O
was	O
targeted	O
specifically	O
to	O
cells	O
with	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptors	I-Protein
by	O
inserting	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
after	O
amino	O
acid	O
607	O
near	O
the	O
carboxyl	O
terminus	O
of	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
.	O

PE37	O
/	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
very	O
cytotoxic	O
to	O
cells	O
with	O
epidermal	O
growth	O
factor	O
receptors	O
.	O

It	O
was	O
severalfold	O
more	O
cytotoxic	O
than	O
a	O
derivative	O
of	O
full	O
-	O
length	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
containing	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
the	O
same	O
position	O
,	O
probably	O
because	O
the	O
latter	O
requires	O
intracellular	O
proteolytic	O
processing	O
to	O
exhibit	O
its	O
cytotoxicity	O
,	O
and	O
proteolytic	O
processing	O
is	O
not	O
100	O
%	O
efficient	O
.	O

Deletion	O
of	O
2	O
,	O
4	O
,	O
or	O
7	O
amino	O
acids	O
from	O
the	O
amino	O
terminus	O
of	O
PE37	O
/	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
greatly	O
diminished	O
cytotoxic	O
activity	O
,	O
indicating	O
the	O
need	O
for	O
a	O
proper	O
amino	O
-	O
terminal	O
sequence	O
.	O

In	O
addition	O
,	O
a	O
mutant	O
containing	O
an	O
internal	O
deletion	O
of	O
amino	O
acids	O
314	O
-	O
380	O
was	O
minimally	O
active	O
,	O
indicating	O
that	O
other	O
regions	O
of	O
domain	O
II	O
are	O
also	O
required	O
for	O
the	O
cytotoxic	O
activity	O
of	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
.	O

The	O
RAM1	B-Protein
gene	O
encoding	O
a	O
protein	B-Protein
-	I-Protein
farnesyltransferase	I-Protein
beta	I-Protein
-	I-Protein
subunit	I-Protein
homologue	I-Protein
is	O
essential	O
in	O
Cryptococcus	O
neoformans	O
.	O

Many	O
small	O
G	O
proteins	O
require	O
post	O
-	O
translational	O
modification	O
to	O
allow	O
functional	O
association	O
to	O
the	O
cell	O
membrane	O
.	O

This	O
process	O
often	O
involves	O
the	O
enzymic	O
addition	O
of	O
hydrophobic	O
prenyl	O
groups	O
to	O
a	O
conserved	O
cysteine	O
residue	O
near	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

The	O
enzymes	O
that	O
catalyse	O
these	O
reactions	O
include	O
protein	O
farnesyltransferase	O
and	O
protein	O
geranylgeranyltransferases	O
.	O

The	O
human	O
fungal	O
pathogen	O
Cryptococcus	O
neoformans	O
requires	O
functional	O
Ras	B-Protein
and	O
Rho	B-Protein
proteins	O
in	O
order	O
to	O
undergo	O
normal	O
growth	O
and	O
differentiation	O
.	O

Since	O
farnesylation	O
and	O
geranylgeranylation	O
are	O
likely	O
required	O
for	O
the	O
proper	O
function	O
of	O
these	O
small	O
G	O
proteins	O
,	O
we	O
hypothesized	O
that	O
inhibition	O
of	O
these	O
prenylation	O
events	O
would	O
alter	O
the	O
growth	O
and	O
cellular	O
morphogenesis	O
of	O
this	O
fungus	O
.	O

We	O
cloned	O
the	O
RAM1	B-Protein
gene	O
encoding	O
the	O
single	O
protein	B-Protein
-	I-Protein
farnesyltransferase	I-Protein
beta	I-Protein
-	I-Protein
chain	I-Protein
homologue	I-Protein
in	O
C	O
.	O
neoformans	O
.	O

Using	O
a	O
gene	O
-	O
disruption	O
strategy	O
in	O
a	O
diploid	O
C	O
.	O
neoformans	O
strain	O
,	O
we	O
demonstrated	O
that	O
this	O
gene	O
encodes	O
an	O
essential	O
function	O
,	O
in	O
contrast	O
to	O
the	O
case	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
in	O
which	O
the	O
homologous	O
RAM1	B-Protein
gene	O
is	O
not	O
essential	O
for	O
growth	O
.	O

Pharmacological	O
inhibition	O
of	O
farnesyltransferase	O
activity	O
resulted	O
in	O
dose	O
-	O
dependent	O
cytostasis	O
of	O
C	O
.	O
neoformans	O
,	O
as	O
well	O
as	O
prevention	O
of	O
hyphal	O
differentiation	O
.	O

Simultaneous	O
inhibition	O
of	O
farnesylation	O
and	O
calcineurin	O
signalling	O
results	O
in	O
a	O
synthetic	O
effect	O
on	O
growth	O
.	O

Protein	O
farnesylation	O
is	O
required	O
for	O
the	O
growth	O
and	O
cellular	O
differentiation	O
of	O
C	O
.	O
neoformans	O
and	O
may	O
provide	O
novel	O
targets	O
for	O
antifungal	O
therapy	O
.	O

Lipoprotein	O
processing	O
is	O
required	O
for	O
virulence	O
of	O
Mycobacterium	O
tuberculosis	O
.	O

Lipoproteins	O
are	O
a	O
subgroup	O
of	O
secreted	O
bacterial	O
proteins	O
characterized	O
by	O
a	O
lipidated	O
N	O
-	O
terminus	O
,	O
processing	O
of	O
which	O
is	O
mediated	O
by	O
the	O
consecutive	O
activity	O
of	O
prolipoprotein	B-Protein
diacylglyceryl	I-Protein
transferase	I-Protein
(	O
Lgt	B-Protein
)	O
and	O
lipoprotein	B-Protein
signal	I-Protein
peptidase	I-Protein
(	O
LspA	B-Protein
)	O
.	O

The	O
study	O
of	O
LspA	B-Protein
function	O
has	O
been	O
limited	O
mainly	O
to	O
non	O
-	O
pathogenic	O
microorganisms	O
.	O

To	O
study	O
a	O
potential	O
role	O
for	O
LspA	B-Protein
in	O
the	O
pathogenesis	O
of	O
bacterial	O
infections	O
,	O
we	O
have	O
disrupted	O
lspA	B-Protein
by	O
allelic	O
replacement	O
in	O
Mycobacterium	O
tuberculosis	O
,	O
one	O
of	O
the	O
world	O
'	O
s	O
most	O
devastating	O
pathogens	O
.	O

Despite	O
the	O
presence	O
of	O
an	O
impermeable	O
lipid	O
outer	O
layer	O
,	O
it	O
was	O
found	O
that	O
LspA	B-Protein
was	O
dispensable	O
for	O
growth	O
under	O
in	O
vitro	O
culture	O
conditions	O
.	O

In	O
contrast	O
,	O
the	O
mutant	O
was	O
markedly	O
attenuated	O
in	O
virulence	O
models	O
of	O
tuberculosis	O
.	O

Our	O
findings	O
establish	O
lipoprotein	O
metabolism	O
as	O
a	O
major	O
virulence	O
determinant	O
of	O
tuberculosis	O
and	O
define	O
a	O
role	O
for	O
lipoprotein	O
processing	O
in	O
bacterial	O
pathogenesis	O
.	O

In	O
addition	O
,	O
these	O
results	O
hint	O
at	O
a	O
promising	O
new	O
target	O
for	O
therapeutic	O
intervention	O
,	O
as	O
a	O
highly	O
specific	O
inhibitor	O
of	O
bacterial	O
lipoprotein	O
signal	O
peptidases	O
is	O
available	O
.	O

Two	O
closely	O
related	O
ubiquitin	B-Protein
C	O
-	O
terminal	O
hydrolase	O
isozymes	O
function	O
as	O
reciprocal	O
modulators	O
of	O
germ	O
cell	O
apoptosis	O
in	O
cryptorchid	O
testis	O
.	O

The	O
experimentally	O
induced	O
cryptorchid	O
mouse	O
model	O
is	O
useful	O
for	O
elucidating	O
the	O
in	O
vivo	O
molecular	O
mechanism	O
of	O
germ	O
cell	O
apoptosis	O
.	O

Apoptosis	O
,	O
in	O
general	O
,	O
is	O
thought	O
to	O
be	O
partly	O
regulated	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
function	O
of	O
two	O
closely	O
related	O
members	O
of	O
the	O
ubiquitin	B-Protein
C	O
-	O
terminal	O
hydrolase	O
(	O
UCH	O
)	O
family	O
in	O
testicular	O
germ	O
cell	O
apoptosis	O
experimentally	O
induced	O
by	O
cryptorchidism	O
.	O

The	O
two	O
enzymes	O
,	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
and	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
,	O
deubiquitinate	O
ubiquitin	B-Protein
-	O
protein	O
conjugates	O
and	O
control	O
the	O
cellular	O
balance	O
of	O
ubiquitin	B-Protein
.	O

The	O
testes	O
of	O
gracile	O
axonal	O
dystrophy	O
(	O
gad	O
)	O
mice	O
,	O
which	O
lack	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
,	O
were	O
resistant	O
to	O
cryptorchid	O
stress	O
-	O
related	O
injury	O
and	O
had	O
reduced	O
ubiquitin	B-Protein
levels	O
.	O

The	O
level	O
of	O
both	O
anti	O
-	O
apoptotic	O
(	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
family	O
and	O
XIAP	B-Protein
)	O
and	O
prosurvival	O
(	O
pCREB	O
and	O
BDNF	B-Protein
)	O
proteins	O
was	O
significantly	O
higher	O
in	O
gad	O
mice	O
after	O
cryptorchid	O
stress	O
.	O

In	O
contrast	O
,	O
Uchl3	B-Protein
knockout	O
mice	O
showed	O
profound	O
testicular	O
atrophy	O
and	O
apoptotic	O
germ	O
cell	O
loss	O
after	O
cryptorchid	O
injury	O
.	O

Ubiquitin	B-Protein
level	O
was	O
not	O
significantly	O
different	O
between	O
wild	O
-	O
type	O
and	O
Uchl3	B-Protein
knockout	O
mice	O
,	O
whereas	O
the	O
levels	O
of	O
Nedd8	B-Protein
and	O
the	O
apoptotic	O
proteins	O
p53	B-Protein
,	O
Bax	B-Protein
,	O
and	O
caspase3	B-Protein
were	O
elevated	O
in	O
Uchl3	B-Protein
knockout	O
mice	O
.	O

These	O
results	O
demonstrate	O
that	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
and	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
function	O
differentially	O
to	O
regulate	O
the	O
cellular	O
levels	O
of	O
anti	O
-	O
apoptotic	O
,	O
prosurvival	O
,	O
and	O
apoptotic	O
proteins	O
during	O
testicular	O
germ	O
cell	O
apoptosis	O
.	O

Structure	O
of	O
a	O
complex	O
between	O
Nedd8	B-Protein
and	O
the	O
Ulp	O
/	O
Senp	O
protease	O
family	O
member	O
Den1	B-Protein
.	O

The	O
Nedd8	B-Protein
conjugation	O
pathway	O
is	O
conserved	O
from	O
yeast	O
to	O
humans	O
and	O
is	O
essential	O
in	O
many	O
organisms	O
.	O

Nedd8	B-Protein
is	O
conjugated	O
to	O
cullin	O
proteins	O
in	O
a	O
process	O
that	O
alters	O
SCF	O
E3	O
ubiquitin	B-Protein
ligase	O
activity	O
,	O
and	O
it	O
is	O
presumed	O
that	O
Nedd8	B-Protein
deconjugation	O
would	O
reverse	O
these	O
effects	O
.	O

We	O
now	O
report	O
the	O
X	O
-	O
ray	O
structures	O
of	O
the	O
human	O
Nedd8	B-Protein
-	O
specific	O
protease	O
,	O
Den1	B-Protein
,	O
in	O
a	O
complex	O
with	O
the	O
inhibitor	O
Nedd8	B-Protein
aldehyde	O
,	O
thus	O
revealing	O
a	O
model	O
for	O
the	O
tetrahedral	O
transition	O
state	O
intermediate	O
generated	O
during	O
proteolysis	O
.	O

Although	O
Den1	B-Protein
is	O
closely	O
related	O
to	O
the	O
SUMO	O
-	O
specific	O
protease	O
family	O
(	O
Ulp	O
/	O
Senp	O
family	O
)	O
,	O
structural	O
analysis	O
of	O
the	O
interface	O
suggests	O
determinants	O
involved	O
in	O
Nedd8	B-Protein
selectivity	O
by	O
Den1	B-Protein
over	O
other	O
ubiquitin	B-Protein
-	O
like	O
family	O
members	O
and	O
suggests	O
how	O
the	O
Ulp	O
/	O
Senp	O
architecture	O
has	O
been	O
modified	O
to	O
interact	O
with	O
different	O
ubiquitin	B-Protein
-	O
like	O
modifiers	O
.	O

Functional	O
analysis	O
of	O
TbARL1	B-Protein
,	O
an	O
N	O
-	O
myristoylated	O
Golgi	O
protein	O
essential	O
for	O
viability	O
in	O
bloodstream	O
trypanosomes	O
.	O

Myristoyl	B-Protein
-	I-Protein
CoA	I-Protein
:	I-Protein
protein	I-Protein
N	I-Protein
-	I-Protein
myristoyltransferase	I-Protein
(	O
NMT	B-Protein
)	O
,	O
an	O
essential	O
protein	O
in	O
Trypanosoma	O
brucei	O
and	O
Leishmania	O
major	O
,	O
catalyses	O
the	O
covalent	O
attachment	O
of	O
the	O
fatty	O
acid	O
myristate	O
to	O
the	O
N	O
-	O
terminus	O
of	O
a	O
range	O
of	O
target	O
proteins	O
.	O

In	O
order	O
to	O
define	O
the	O
essential	O
targets	O
contributing	O
to	O
lethality	O
in	O
the	O
absence	O
of	O
NMT	B-Protein
activity	O
,	O
we	O
have	O
focused	O
on	O
the	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
Arf	O
)	O
family	O
of	O
GTP	O
-	O
binding	O
proteins	O
,	O
as	O
growth	O
arrest	O
in	O
Saccharomyces	O
cerevisiae	O
mutants	O
with	O
reduced	O
NMT	B-Protein
activity	O
correlates	O
with	O
a	O
decrease	O
in	O
N	O
-	O
myristoylated	O
Arf	O
proteins	O
.	O

We	O
have	O
identified	O
nine	O
Arf	O
/	O
Arls	O
in	O
the	O
T	O
.	O
brucei	O
and	O
T	O
.	O
cruzi	O
genomes	O
and	O
ten	O
in	O
L	O
.	O
major	O
.	O

Characterization	O
of	O
the	O
T	O
.	O
brucei	O
ARL1	B-Protein
homologue	O
has	O
revealed	O
that	O
the	O
protein	O
is	O
localized	O
in	O
the	O
Golgi	O
apparatus	O
and	O
is	O
expressed	O
only	O
in	O
the	O
mammalian	O
bloodstream	O
form	O
of	O
the	O
parasite	O
and	O
not	O
in	O
the	O
insect	O
procyclic	O
stage	O
.	O

This	O
is	O
the	O
only	O
reported	O
example	O
to	O
date	O
of	O
a	O
differentially	O
expressed	O
ARL1	B-Protein
homologue	O
in	O
any	O
species	O
.	O

We	O
have	O
used	O
RNA	O
interference	O
to	O
demonstrate	O
that	O
ARL1	B-Protein
is	O
essential	O
for	O
viability	O
in	O
T	O
.	O
brucei	O
bloodstream	O
parasites	O
.	O

Prior	O
to	O
cell	O
death	O
,	O
depletion	O
of	O
ARL1	B-Protein
protein	O
in	O
bloodstream	O
parasites	O
results	O
in	O
abnormal	O
morphology	O
,	O
including	O
disintegration	O
of	O
the	O
Golgi	O
structure	O
,	O
multiple	O
flagella	O
and	O
nuclei	O
,	O
and	O
the	O
presence	O
of	O
large	O
numbers	O
of	O
vesicles	O
.	O

The	O
cells	O
have	O
only	O
a	O
minor	O
apparent	O
defect	O
in	O
endocytosis	O
but	O
exocytosis	O
of	O
variant	O
surface	O
glycoprotein	O
to	O
the	O
parasite	O
surface	O
is	O
significantly	O
delayed	O
.	O

RNA	O
interference	O
of	O
ARL1	B-Protein
in	O
procyclic	O
cells	O
has	O
no	O
effect	O
on	O
parasite	O
growth	O
or	O
morphology	O
.	O

Our	O
results	O
suggest	O
that	O
there	O
may	O
be	O
different	O
pathways	O
regulating	O
Golgi	O
structure	O
and	O
function	O
in	O
the	O
two	O
major	O
life	O
cycle	O
stages	O
of	O
T	O
.	O
brucei	O
.	O

Effects	O
of	O
over	O
-	O
expression	O
of	O
the	O
regulatory	O
enzymes	O
DraT	B-Protein
and	O
DraG	B-Protein
on	O
the	O
ammonium	O
-	O
dependent	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	O
reductase	O
in	O
Azospirillum	O
brasilense	O
.	O

Nitrogen	O
fixation	O
in	O
Azospirillum	O
brasilense	O
is	O
regulated	O
at	O
transcriptional	O
and	O
post	O
-	O
translational	O
levels	O
.	O

Post	O
-	O
translational	O
control	O
occurs	O
through	O
the	O
reversible	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
(	O
Fe	B-Protein
Protein	I-Protein
)	O
,	O
mediated	O
by	O
the	O
dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
DraT	B-Protein
)	O
and	O
dinitrogenase	B-Protein
reductase	I-Protein
glycohydrolase	I-Protein
(	O
DraG	B-Protein
)	O
.	O

Although	O
the	O
DraT	B-Protein
and	O
DraG	B-Protein
activities	O
are	O
regulated	O
in	O
vivo	O
,	O
the	O
molecules	O
responsible	O
for	O
such	O
regulation	O
remain	O
unknown	O
.	O

We	O
have	O
constructed	O
broad	O
-	O
host	O
-	O
range	O
plasmids	O
capable	O
of	O
over	O
-	O
expressing	O
,	O
upon	O
IPTG	O
induction	O
,	O
the	O
regulatory	O
enzymes	O
DraT	B-Protein
and	O
DraG	B-Protein
as	O
six	O
-	O
histidine	O
-	O
N	O
-	O
terminal	O
fused	O
proteins	O
(	O
His	O
)	O
.	O

Both	O
DraT	B-Protein
-	O
His	O
and	O
DraG	B-Protein
-	O
His	O
are	O
functional	O
in	O
vivo	O
.	O

We	O
have	O
analyzed	O
the	O
effects	O
of	O
DraT	B-Protein
-	O
His	O
and	O
DraG	B-Protein
-	O
His	O
over	O
-	O
expression	O
on	O
the	O
post	O
-	O
translational	O
modification	O
of	O
Fe	B-Protein
Protein	I-Protein
.	O

The	O
DraT	B-Protein
-	O
His	O
over	O
-	O
expression	O
led	O
to	O
Fe	B-Protein
Protein	I-Protein
modification	O
in	O
the	O
absence	O
of	O
ammonium	O
addition	O
,	O
while	O
cells	O
over	O
-	O
expressing	O
DraG	B-Protein
-	O
His	O
showed	O
only	O
partial	O
ADP	O
-	O
ribosylation	O
of	O
Fe	B-Protein
Protein	I-Protein
by	O
adding	O
ammonium	O
.	O

These	O
results	O
suggest	O
that	O
both	O
DraT	B-Protein
-	O
His	O
and	O
DraG	B-Protein
-	O
His	O
lose	O
their	O
regulation	O
upon	O
over	O
-	O
expression	O
,	O
possible	O
by	O
titrating	O
out	O
negative	O
regulators	O
.	O

Nep1	B-Protein
,	O
a	O
Schizosaccharomyces	O
pombe	O
deneddylating	O
enzyme	O
.	O

Nedd8	B-Protein
is	O
a	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
that	O
is	O
attached	O
to	O
the	O
cullin	O
components	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
.	O

More	O
recently	O
,	O
p53	B-Protein
has	O
also	O
been	O
shown	O
to	O
be	O
Nedd8	B-Protein
-	O
modified	O
.	O

Nedd8	B-Protein
attachment	O
occurs	O
in	O
a	O
manner	O
similar	O
to	O
that	O
observed	O
for	O
other	O
ubiquitin	B-Protein
-	O
like	O
modifiers	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
on	O
the	O
characterization	O
of	O
Nep1	B-Protein
,	O
a	O
deneddylating	O
enzyme	O
in	O
fission	O
yeast	O
(	O
Schizosaccharomyces	O
pombe	O
)	O
.	O

Unlike	O
loss	O
of	O
ned8	B-Protein
,	O
deletion	O
of	O
the	O
nep1	B-Protein
gene	O
is	O
not	O
lethal	O
,	O
although	O
nep1	B-Protein
.	O
d	O
cells	O
are	O
heterogeneous	O
in	O
length	O
,	O
suggesting	O
a	O
defect	O
in	O
cell	O
-	O
cycle	O
progression	O
.	O

Viability	O
of	O
nep1	B-Protein
.	O
d	O
cells	O
is	O
dependent	O
on	O
a	O
functional	O
spindle	O
checkpoint	O
but	O
not	O
on	O
the	O
DNA	O
integrity	O
checkpoint	O
.	O

Deletion	O
of	O
a	O
related	O
gene	O
(	O
nep2	B-Protein
)	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
nep1	B-Protein
.	O
d	O
,	O
also	O
has	O
little	O
effect	O
on	O
cell	O
viability	O
.	O

We	O
show	O
that	O
Nep1	B-Protein
can	O
deneddylate	O
the	O
Pcu1	B-Protein
,	O
Pcu3	B-Protein
and	O
Pcu4	B-Protein
cullins	O
in	O
vitro	O
and	O
that	O
its	O
activity	O
is	O
sensitive	O
to	O
N	O
-	O
ethylmaleimide	O
,	O
consistent	O
with	O
the	O
idea	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
cysteine	O
protease	O
family	O
.	O

nep1	B-Protein
.	O
d	O
cells	O
accumulate	O
Nedd8	B-Protein
-	O
modified	O
proteins	O
,	O
although	O
these	O
do	O
not	O
correspond	O
to	O
modified	O
forms	O
of	O
the	O
cullins	O
,	O
suggesting	O
that	O
,	O
although	O
Nep1	B-Protein
can	O
deneddylate	O
cullins	O
in	O
vitro	O
,	O
this	O
is	O
not	O
its	O
main	O
function	O
in	O
vivo	O
.	O

Nep1	B-Protein
can	O
be	O
co	O
-	O
precipitated	O
with	O
the	O
signalosome	O
subunit	O
Csn5	B-Protein
.	O

Nep1	B-Protein
itself	O
is	O
present	O
in	O
a	O
high	O
-	O
molecular	O
-	O
mass	O
complex	O
,	O
but	O
the	O
presence	O
of	O
this	O
complex	O
is	O
not	O
dependent	O
on	O
the	O
production	O
of	O
intact	O
signalosomes	O
.	O

Our	O
results	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
Nep1	B-Protein
may	O
be	O
responsible	O
for	O
deneddylating	O
proteins	O
other	O
than	O
cullins	O
.	O

Requirement	O
of	O
Cul3	B-Protein
for	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
in	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O

Cul3	B-Protein
belongs	O
to	O
the	O
family	O
of	O
cullin	O
proteins	O
,	O
which	O
function	O
as	O
scaffold	O
proteins	O
of	O
E3	O
ubiquitin	B-Protein
ligase	O
complexes	O
.	O

Here	O
we	O
show	O
cell	O
-	O
autonomous	O
involvement	O
of	O
Cul3	B-Protein
in	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
of	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O

Cul3	B-Protein
mutant	O
neurons	O
are	O
defective	O
in	O
terminal	O
morphogenesis	O
of	O
neurites	O
.	O

Interestingly	O
,	O
mutant	O
axons	O
often	O
terminate	O
around	O
branching	O
points	O
.	O

In	O
addition	O
,	O
dendritic	O
elaboration	O
is	O
severely	O
affected	O
in	O
Cul3	B-Protein
mutant	O
neurons	O
.	O

However	O
,	O
loss	O
of	O
Cul3	B-Protein
function	O
does	O
not	O
affect	O
extension	O
of	O
the	O
axons	O
that	O
rarely	O
arborize	O
.	O

Function	O
of	O
cullin	O
-	O
type	O
proteins	O
has	O
been	O
shown	O
to	O
require	O
covalent	O
attachment	O
of	O
Nedd8	B-Protein
(	O
neural	O
precursor	O
cell	O
-	O
expressed	O
developmentally	O
downregulated	O
)	O
,	O
a	O
ubiquitin	B-Protein
-	O
like	O
protein	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
Cul3	B-Protein
is	O
inactivated	O
by	O
a	O
mutation	O
in	O
its	O
conserved	O
neddylation	O
site	O
,	O
and	O
Nedd8	B-Protein
mutant	O
neurons	O
exhibit	O
similar	O
neuronal	O
morphogenetic	O
defects	O
.	O

Together	O
,	O
Cul3	B-Protein
plays	O
an	O
essential	O
role	O
in	O
both	O
axonal	O
arborization	O
and	O
proper	O
elaboration	O
of	O
dendrites	O
and	O
may	O
require	O
neddylation	O
for	O
its	O
proper	O
function	O
.	O

Phosphonocarboxylate	O
inhibitors	O
of	O
Rab	O
geranylgeranyl	O
transferase	O
disrupt	O
the	O
prenylation	O
and	O
membrane	O
localization	O
of	O
Rab	O
proteins	O
in	O
osteoclasts	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Nitrogen	O
-	O
containing	O
bisphosphonate	O
drugs	O
such	O
as	O
risedronate	O
act	O
by	O
inhibiting	O
farnesyl	B-Protein
diphosphate	I-Protein
synthase	I-Protein
,	O
thereby	O
disrupting	O
protein	O
prenylation	O
in	O
osteoclasts	O
.	O

We	O
recently	O
found	O
that	O
an	O
anti	O
-	O
resorptive	O
phosphonocarboxylate	O
analogue	O
of	O
risedronate	O
,	O
3	O
-	O
PEHPC	O
(	O
previously	O
referred	O
to	O
as	O
NE10790	O
)	O
,	O
selectively	O
prevents	O
prenylation	O
of	O
Rab	O
GTPases	O
in	O
vitro	O
by	O
specifically	O
inhibiting	O
Rab	O
geranylgeranyl	O
transferase	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
unprenylated	O
Rab6	B-Protein
could	O
be	O
detected	O
in	O
J774	O
cells	O
after	O
treatment	O
with	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
for	O
as	O
little	O
as	O
4	O
h	O
,	O
and	O
reached	O
50	O
%	O
after	O
24	O
h	O
.	O

Furthermore	O
,	O
treatment	O
of	O
J774	O
cells	O
or	O
osteoclasts	O
with	O
either	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
disrupted	O
membrane	O
association	O
of	O
several	O
Rab	O
family	O
proteins	O
.	O

Like	O
risedronate	O
,	O
the	O
effects	O
of	O
3	O
-	O
PEHPC	O
are	O
likely	O
to	O
be	O
restricted	O
to	O
osteoclasts	O
in	O
vivo	O
,	O
since	O
both	O
risedronate	O
and	O
3	O
-	O
PEHPC	O
inhibited	O
Rab	O
prenylation	O
in	O
osteoclasts	O
,	O
but	O
not	O
in	O
general	O
bone	O
marrow	O
cells	O
,	O
when	O
administered	O
to	O
rabbits	O
in	O
vivo	O
.	O

Analysis	O
of	O
two	O
new	O
phosphonocarboxylate	O
analogues	O
of	O
3	O
-	O
PEHPC	O
(	O
3	O
-	O
PEPC	O
and	O
2	O
-	O
PEPC	O
)	O
revealed	O
that	O
,	O
first	O
,	O
the	O
geminal	O
hydroxyl	O
group	O
is	O
not	O
essential	O
for	O
inhibition	O
of	O
Rab	O
prenylation	O
by	O
phosphonocarboxylates	O
,	O
but	O
does	O
contribute	O
to	O
their	O
anti	O
-	O
resorptive	O
potency	O
,	O
most	O
likely	O
by	O
enhancing	O
their	O
affinity	O
for	O
bone	O
mineral	O
.	O

Second	O
,	O
the	O
position	O
of	O
the	O
nitrogen	O
in	O
the	O
side	O
chain	O
of	O
phosphonocarboxylates	O
is	O
crucial	O
for	O
their	O
ability	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
hence	O
to	O
inhibit	O
bone	O
resorption	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
good	O
correlation	O
between	O
the	O
ability	O
of	O
the	O
phosphonocarboxylates	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
to	O
inhibit	O
bone	O
resorption	O
in	O
vitro	O
,	O
indicating	O
that	O
these	O
compounds	O
are	O
a	O
new	O
class	O
of	O
pharmacological	O
agents	O
that	O
inhibit	O
bone	O
resorption	O
by	O
specifically	O
preventing	O
prenylation	O
of	O
Rab	O
proteins	O
.	O

Furthermore	O
,	O
although	O
phosphonocarboxylates	O
are	O
analogues	O
of	O
bisphosphonates	O
,	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
phosphonocarboxylates	O
for	O
inhibiting	O
Rab	O
geranylgeranyltransferase	O
appear	O
to	O
differ	O
from	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
bisphosphonates	O
for	O
inhibiting	O
farnesyl	B-Protein
diphosphate	I-Protein
synthase	I-Protein
.	O

CAND1	B-Protein
enhances	O
deneddylation	O
of	O
CUL1	B-Protein
by	O
COP9	O
signalosome	O
.	O

Cullin	O
-	O
RING	O
ligases	O
(	O
CRLs	O
)	O
regulate	O
diverse	O
cellular	O
functions	O
such	O
as	O
cell	O
cycle	O
progression	O
and	O
cytokine	O
signaling	O
by	O
ubiquitinating	O
key	O
regulatory	O
proteins	O
.	O

The	O
activity	O
of	O
CRLs	O
is	O
controlled	O
by	O
Nedd8	B-Protein
modification	O
of	O
the	O
cullin	O
subunits	O
.	O

Recent	O
reports	O
have	O
suggested	O
that	O
CAND1	B-Protein
,	O
which	O
specifically	O
binds	O
to	O
unmodified	O
CUL1	B-Protein
but	O
not	O
to	O
neddylated	O
one	O
,	O
is	O
required	O
for	O
the	O
in	O
vivo	O
function	O
of	O
SCFs	O
,	O
the	O
CUL1	B-Protein
-	O
containing	O
CRLs	O
.	O

We	O
show	O
here	O
that	O
CAND1	B-Protein
and	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
the	O
major	O
deneddylase	O
of	O
cullins	O
,	O
bind	O
to	O
unneddylated	O
CUL1	B-Protein
in	O
a	O
mutually	O
exclusive	O
way	O
.	O

The	O
suppression	O
of	O
CAND1	B-Protein
expression	O
by	O
small	O
inhibitory	O
RNA	O
enhanced	O
the	O
interaction	O
between	O
CUL1	B-Protein
and	O
CSN	O
,	O
suggesting	O
that	O
CAND1	B-Protein
inhibited	O
the	O
binding	O
of	O
CSN	O
to	O
CUL1	B-Protein
.	O

We	O
found	O
that	O
the	O
binding	O
of	O
CSN	O
to	O
CUL1	B-Protein
required	O
the	O
four	O
helix	O
bundle	O
in	O
CUL1	B-Protein
C	O
-	O
terminal	O
domain	O
,	O
which	O
was	O
wrapped	O
around	O
by	O
CAND1	B-Protein
in	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
-	O
Rbx1	B-Protein
complex	O
.	O

CAND1	B-Protein
greatly	O
facilitated	O
CSN	O
-	O
mediated	O
deneddylation	O
of	O
CUL1	B-Protein
in	O
vitro	O
,	O
which	O
was	O
dependent	O
on	O
its	O
binding	O
to	O
CUL1	B-Protein
.	O

Our	O
data	O
suggest	O
that	O
enhancement	O
of	O
CSN	O
-	O
mediated	O
deneddylation	O
by	O
CAND1	B-Protein
may	O
contribute	O
to	O
its	O
function	O
as	O
a	O
positive	O
regulator	O
of	O
SCFs	O
in	O
vivo	O
.	O

Interaction	O
of	O
NUB1	B-Protein
with	O
the	O
proteasome	O
subunit	O
S5a	B-Protein
.	O

NUB1	B-Protein
interacts	O
with	O
a	O
ubiquitin	B-Protein
-	O
like	O
protein	O
NEDD8	B-Protein
to	O
target	O
the	O
NEDD8	B-Protein
monomer	O
and	O
neddylated	O
proteins	O
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

Therefore	O
,	O
NUB1	B-Protein
is	O
thought	O
to	O
be	O
a	O
potent	O
downregulator	O
of	O
NEDD8	B-Protein
conjugation	O
system	O
.	O

Since	O
NUB1	B-Protein
possesses	O
a	O
UBL	O
domain	O
,	O
which	O
was	O
previously	O
shown	O
to	O
be	O
an	O
S5a	B-Protein
-	O
interacting	O
motif	O
in	O
RAD23	B-Protein
/	O
HHR23	B-Protein
,	O
we	O
initially	O
hypothesized	O
that	O
NUB1	B-Protein
interacts	O
with	O
the	O
S5a	B-Protein
subunit	O
of	O
the	O
proteasome	O
through	O
its	O
UBL	O
domain	O
.	O

To	O
examine	O
this	O
,	O
we	O
performed	O
an	O
in	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
and	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
.	O

Unexpectedly	O
,	O
our	O
studies	O
revealed	O
that	O
NUB1	B-Protein
directly	O
interacts	O
with	O
the	O
S5a	B-Protein
subunit	O
through	O
its	O
C	O
-	O
terminal	O
region	O
between	O
amino	O
acid	O
residues	O
536	O
and	O
584	O
,	O
not	O
through	O
its	O
UBL	O
domain	O
.	O

Although	O
the	O
UBL	O
domain	O
was	O
not	O
an	O
S5a	B-Protein
-	O
interacting	O
motif	O
in	O
NUB1	B-Protein
,	O
our	O
further	O
studies	O
revealed	O
that	O
the	O
UBL	O
domain	O
is	O
required	O
for	O
the	O
function	O
of	O
NUB1	B-Protein
.	O

S	O
-	O
palmitoylation	O
modulates	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
localization	O
and	O
functions	O
.	O

17beta	O
-	O
Estradiol	O
(	O
E2	O
)	O
acts	O
as	O
a	O
chemical	O
messenger	O
in	O
target	O
tissues	O
inducing	O
both	O
slow	O
nuclear	O
and	O
rapid	O
extra	O
-	O
nuclear	O
responses	O
.	O

E2	O
binds	O
to	O
its	O
cognate	O
nuclear	O
receptors	O
(	O
ER	O
)	O
resulting	O
in	O
the	O
activation	O
of	O
target	O
gene	O
transcription	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
to	O
these	O
genomic	O
effects	O
,	O
E2	O
modulates	O
cell	O
functions	O
through	O
rapid	O
non	O
-	O
genomic	O
actions	O
.	O

Stimulation	O
of	O
G	O
-	O
proteins	O
,	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
,	O
inositol	O
phosphate	O
generation	O
as	O
well	O
as	O
phospholipase	O
C	O
,	O
ERK	O
/	O
MAPK	O
,	O
and	O
PI3K	O
/	O
AKT	O
activation	O
all	O
occur	O
within	O
seconds	O
to	O
minutes	O
after	O
E2	O
binding	O
to	O
a	O
small	O
population	O
of	O
ERalpha	B-Protein
located	O
at	O
the	O
plasma	O
membrane	O
.	O

The	O
great	O
impact	O
of	O
these	O
rapid	O
signals	O
on	O
cell	O
physiology	O
renders	O
central	O
the	O
knowledge	O
of	O
the	O
structural	O
bases	O
and	O
mechanisms	O
that	O
mediate	O
extra	O
-	O
nuclear	O
signaling	O
by	O
E2	O
.	O

Several	O
laboratories	O
,	O
including	O
our	O
own	O
,	O
have	O
recently	O
elucidated	O
the	O
structural	O
requirements	O
for	O
localization	O
and	O
function	O
of	O
plasma	O
membrane	O
ERalpha	B-Protein
.	O

This	O
review	O
summarizes	O
the	O
molecular	O
mechanisms	O
of	O
E2	O
-	O
induced	O
rapid	O
non	O
-	O
genomic	O
actions	O
relevant	O
for	O
cell	O
functions	O
,	O
highlighting	O
the	O
role	O
of	O
lipid	O
modification	O
(	O
i	O
.	O
e	O
.	O
,	O
palmitoylation	O
)	O
in	O
the	O
ERalpha	B-Protein
localization	O
to	O
and	O
residence	O
at	O
the	O
plasma	O
membrane	O
.	O

Functional	O
interactions	O
of	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
and	O
their	O
common	O
substrate	O
small	O
GTP	O
-	O
binding	O
protein	O
.	O

smg	B-Protein
GDS	I-Protein
and	O
rho	O
GDI	O
are	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
,	O
respectively	O
,	O
for	O
a	O
group	O
of	O
ras	B-Protein
p21	I-Protein
-	O
related	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
.	O
rho	B-Protein
p21	I-Protein
is	O
a	O
common	O
substrate	O
small	O
G	O
protein	O
for	O
both	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
.	O

We	O
examined	O
here	O
the	O
functional	O
interactions	O
of	O
these	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
with	O
rho	B-Protein
p21	I-Protein
as	O
a	O
substrate	O
.	O
smg	B-Protein
GDS	I-Protein
and	O
rho	O
GDI	O
interacted	O
with	O
the	O
GDP	O
-	O
bound	O
form	O
of	O
rho	B-Protein
p21	I-Protein
and	O
thereby	O
stimulated	O
and	O
inhibited	O
,	O
respectively	O
,	O
the	O
dissociation	O
of	O
GDP	O
.	O

The	O
inhibitory	O
effect	O
of	O
rho	O
GDI	O
was	O
much	O
stronger	O
than	O
the	O
stimulatory	O
effect	O
of	O
smg	B-Protein
GDS	I-Protein
.	O

The	O
GDP	O
-	O
bound	O
form	O
of	O
rho	B-Protein
p21	I-Protein
formed	O
a	O
complex	O
with	O
rho	O
GDI	O
but	O
not	O
with	O
smg	B-Protein
GDS	I-Protein
in	O
their	O
simultaneous	O
presence	O
.	O

Since	O
the	O
content	O
of	O
smg	B-Protein
GDS	I-Protein
was	O
generally	O
less	O
than	O
that	O
of	O
rho	O
GDI	O
in	O
cells	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
some	O
mechanism	O
to	O
release	O
the	O
inhibitory	O
action	O
of	O
rho	O
GDI	O
and	O
to	O
make	O
rho	B-Protein
p21	I-Protein
sensitive	O
to	O
the	O
smg	B-Protein
GDS	I-Protein
action	O
during	O
the	O
conversion	O
of	O
rhoA	B-Protein
p21	B-Protein
from	O
the	O
GDP	O
-	O
bound	O
inactive	O
form	O
to	O
the	O
GTP	O
-	O
bound	O
active	O
form	O
in	O
intact	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
rho	B-Protein
p21	I-Protein
was	O
previously	O
shown	O
to	O
be	O
ADP	O
-	O
ribosylated	O
by	O
bacterial	O
ADP	O
-	O
ribosyltransferases	O
,	O
named	O
C3	B-Protein
and	O
EDIN	B-Protein
,	O
at	O
Asn41	O
in	O
the	O
putative	O
effector	O
region	O
of	O
rho	B-Protein
p21	I-Protein
.	O

This	O
ADP	O
-	O
ribosylation	O
was	O
inhibited	O
by	O
rho	O
GDI	O
much	O
more	O
efficiently	O
than	O
by	O
smg	B-Protein
GDS	I-Protein
.	O

These	O
results	O
suggest	O
that	O
rho	O
GDI	O
may	O
mask	O
the	O
putative	O
effector	O
region	O
of	O
rho	B-Protein
p21	I-Protein
and	O
thereby	O
inhibit	O
its	O
interaction	O
with	O
the	O
target	O
protein	O
even	O
in	O
the	O
presence	O
of	O
smg	B-Protein
GDS	I-Protein
.	O

Thus	O
,	O
both	O
smg	B-Protein
GDS	I-Protein
and	O
rho	O
GDI	O
are	O
important	O
to	O
regulate	O
the	O
rho	B-Protein
p21	I-Protein
activity	O
and	O
action	O
in	O
cooperation	O
with	O
each	O
other	O
.	O

Structure	O
of	O
a	O
putative	O
lipoate	B-Protein
protein	I-Protein
ligase	I-Protein
from	O
Thermoplasma	O
acidophilum	O
and	O
the	O
mechanism	O
of	O
target	O
selection	O
for	O
post	O
-	O
translational	O
modification	O
.	O

Lipoyl	O
-	O
lysine	O
swinging	O
arms	O
are	O
crucial	O
to	O
the	O
reactions	O
catalysed	O
by	O
the	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
multienzyme	O
complexes	O
.	O

A	O
gene	O
encoding	O
a	O
putative	O
lipoate	B-Protein
protein	I-Protein
ligase	I-Protein
(	O
LplA	B-Protein
)	O
of	O
Thermoplasma	O
acidophilum	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
recombinant	O
protein	O
,	O
a	O
monomer	O
of	O
molecular	O
mass	O
29	O
kDa	O
,	O
was	O
catalytically	O
inactive	O
.	O

Crystal	O
structures	O
in	O
the	O
absence	O
and	O
presence	O
of	O
bound	O
lipoic	O
acid	O
were	O
solved	O
at	O
2	O
.	O
1	O
A	O
resolution	O
.	O

The	O
protein	O
was	O
found	O
to	O
fall	O
into	O
the	O
alpha	O
/	O
beta	O
class	O
and	O
to	O
be	O
structurally	O
homologous	O
to	O
the	O
catalytic	O
domains	O
of	O
class	O
II	O
aminoacyl	O
-	O
tRNA	O
synthases	O
and	O
biotin	B-Protein
protein	I-Protein
ligase	I-Protein
,	O
BirA	B-Protein
.	O

Lipoic	O
acid	O
in	O
LplA	B-Protein
was	O
bound	O
in	O
the	O
same	O
position	O
as	O
biotin	O
in	O
BirA	B-Protein
.	O

The	O
structure	O
of	O
the	O
T	O
.	O
acidophilum	O
LplA	B-Protein
and	O
limited	O
proteolysis	O
of	O
E	O
.	O
coli	O
LplA	B-Protein
together	O
highlighted	O
some	O
key	O
features	O
of	O
the	O
post	O
-	O
translational	O
modification	O
.	O

A	O
loop	O
comprising	O
residues	O
71	O
-	O
79	O
in	O
the	O
T	O
.	O
acidophilum	O
ligase	O
is	O
proposed	O
as	O
interacting	O
with	O
the	O
dithiolane	O
ring	O
of	O
lipoic	O
acid	O
and	O
discriminating	O
against	O
the	O
entry	O
of	O
biotin	O
.	O

A	O
second	O
loop	O
comprising	O
residues	O
179	O
-	O
193	O
was	O
disordered	O
in	O
the	O
T	O
.	O
acidophilum	O
structure	O
;	O
tryptic	O
cleavage	O
of	O
the	O
corresponding	O
loop	O
in	O
the	O
E	O
.	O
coli	O
LplA	B-Protein
under	O
non	O
-	O
denaturing	O
conditions	O
rendered	O
the	O
enzyme	O
catalytically	O
inactive	O
,	O
emphasizing	O
its	O
importance	O
.	O

The	O
putative	O
LplA	B-Protein
of	O
T	O
.	O
acidophilum	O
lacks	O
a	O
C	O
-	O
terminal	O
domain	O
found	O
in	O
its	O
counterparts	O
in	O
E	O
.	O
coli	O
(	O
Gram	O
-	O
negative	O
)	O
or	O
Streptococcus	O
pneumoniae	O
(	O
Gram	O
-	O
positive	O
)	O
.	O

A	O
gene	O
encoding	O
a	O
protein	O
that	O
appears	O
to	O
have	O
structural	O
homology	O
to	O
the	O
additional	O
domain	O
in	O
the	O
E	O
.	O
coli	O
and	O
S	O
.	O
pneumoniae	O
enzymes	O
was	O
detected	O
alongside	O
the	O
structural	O
gene	O
encoding	O
the	O
putative	O
LplA	B-Protein
in	O
the	O
T	O
.	O
acidophilum	O
genome	O
.	O

It	O
is	O
likely	O
that	O
this	O
protein	O
is	O
required	O
to	O
confer	O
activity	O
on	O
the	O
LplA	B-Protein
as	O
currently	O
purified	O
,	O
one	O
protein	O
perhaps	O
catalysing	O
the	O
formation	O
of	O
the	O
obligatory	O
lipoyl	O
-	O
AMP	O
intermediate	O
,	O
and	O
the	O
other	O
transferring	O
the	O
lipoyl	O
group	O
from	O
it	O
to	O
the	O
specific	O
lysine	O
residue	O
in	O
the	O
target	O
protein	O
.	O

Tax	B-Protein
ubiquitylation	O
and	O
sumoylation	O
control	O
critical	O
cytoplasmic	O
and	O
nuclear	O
steps	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
Tax	B-Protein
oncoprotein	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
infected	O
T	O
lymphocytes	O
through	O
various	O
mechanisms	O
,	O
including	O
activation	O
of	O
the	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
pathway	O
.	O

We	O
found	O
that	O
cytoplasmic	O
ubiquitylation	O
of	O
Tax	B-Protein
C	O
-	O
terminal	O
lysines	O
is	O
critical	O
for	O
Tax	B-Protein
binding	O
to	O
the	O
IkappaB	O
kinase	O
complex	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
RelA	B-Protein
.	O

Conversely	O
,	O
we	O
demonstrate	O
that	O
the	O
same	O
lysines	O
are	O
sumoylated	O
in	O
the	O
nucleus	O
,	O
an	O
event	O
required	O
for	O
the	O
formation	O
of	O
RelA	B-Protein
/	O
p300	B-Protein
-	O
enriched	O
Tax	B-Protein
nuclear	O
bodies	O
and	O
full	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
Tax	B-Protein
ubiquitylation	O
and	O
sumoylation	O
are	O
dispensable	O
for	O
its	O
activation	O
of	O
cyclic	B-Protein
adenosine	I-Protein
monophosphate	I-Protein
response	I-Protein
element	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CREB	B-Protein
)	O
-	O
dependent	O
genes	O
.	O

Thus	O
,	O
ubiquitylation	O
and	O
sumoylation	O
of	O
the	O
same	O
residues	O
of	O
Tax	B-Protein
regulate	O
2	O
essential	O
steps	O
controlling	O
NF	O
-	O
kappaB	O
activation	O
,	O
demonstrating	O
how	O
these	O
posttranslational	O
modifications	O
can	O
cooperate	O
to	O
promote	O
Tax	B-Protein
-	O
induced	O
transformation	O
.	O

Understanding	O
GFP	B-Protein
posttranslational	O
chemistry	O
:	O
structures	O
of	O
designed	O
variants	O
that	O
achieve	O
backbone	O
fragmentation	O
,	O
hydrolysis	O
,	O
and	O
decarboxylation	O
.	O

The	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
creates	O
a	O
fluorophore	O
out	O
of	O
three	O
sequential	O
amino	O
acids	O
by	O
promoting	O
spontaneous	O
posttranslational	O
modifications	O
.	O

Here	O
,	O
we	O
use	O
high	O
-	O
resolution	O
crystallography	O
to	O
characterize	O
GFP	B-Protein
variants	O
that	O
not	O
only	O
undergo	O
peptide	O
backbone	O
cyclization	O
but	O
additional	O
denaturation	O
-	O
induced	O
peptide	O
backbone	O
fragmentation	O
,	O
native	O
peptide	O
hydrolysis	O
,	O
and	O
decarboxylation	O
reactions	O
.	O

Our	O
analyses	O
indicate	O
that	O
architectural	O
features	O
that	O
favor	O
GFP	B-Protein
peptide	O
cyclization	O
also	O
drive	O
peptide	O
hydrolysis	O
.	O

These	O
results	O
are	O
relevant	O
for	O
the	O
maturation	O
pathways	O
of	O
GFP	B-Protein
homologues	O
,	O
such	O
as	O
the	O
kindling	O
fluorescent	O
protein	O
and	O
the	O
Kaede	O
protein	O
,	O
which	O
use	O
backbone	O
cleavage	O
to	O
red	O
-	O
shift	O
the	O
spectral	O
properties	O
of	O
their	O
chromophores	O
.	O

We	O
further	O
propose	O
a	O
photochemical	O
mechanism	O
for	O
the	O
decarboxylation	O
reaction	O
,	O
supporting	O
a	O
role	O
for	O
the	O
GFP	B-Protein
protein	O
environment	O
in	O
facilitating	O
radical	O
formation	O
and	O
one	O
-	O
electron	O
chemistry	O
,	O
which	O
may	O
be	O
important	O
in	O
activating	O
oxygen	O
for	O
the	O
oxidation	O
step	O
of	O
chromophore	O
biosynthesis	O
.	O

Together	O
,	O
our	O
results	O
characterize	O
GFP	B-Protein
posttranslational	O
modification	O
chemistry	O
with	O
implications	O
for	O
the	O
energetic	O
landscape	O
of	O
backbone	O
cyclization	O
and	O
subsequent	O
reactions	O
,	O
and	O
for	O
the	O
rational	O
design	O
of	O
predetermined	O
spontaneous	O
backbone	O
cyclization	O
and	O
cleavage	O
reactions	O
.	O

Gs	B-Protein
alpha	I-Protein
availability	O
to	O
cholera	O
toxin	O
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
is	O
decreased	O
in	O
membranes	O
of	O
retinoic	O
acid	O
-	O
treated	O
leukemic	O
cell	O
lines	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
.	O

A	O
posttranslational	O
effect	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
leukemic	O
cell	O
lines	O
to	O
differentiate	O
into	O
granulocyte	O
-	O
like	O
and	O
monocyte	O
-	O
like	O
cells	O
.	O

Limited	O
data	O
are	O
available	O
concerning	O
the	O
effects	O
of	O
RA	O
on	O
components	O
of	O
the	O
cyclic	O
AMP	O
pathway	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
.	O

We	O
showed	O
previously	O
a	O
decrease	O
in	O
adenylate	O
cyclase	O
activity	O
in	O
the	O
presence	O
of	O
histamine	O
,	O
prostaglandin	O
E1	O
and	O
forskolin	O
in	O
RA	O
-	O
treated	O
HL	O
-	O
60	O
cells	O
as	O
compared	O
to	O
untreated	O
cells	O
.	O

We	O
examined	O
the	O
elements	O
of	O
the	O
signal	O
transduction	O
pathway	O
utilized	O
by	O
RA	O
in	O
the	O
human	O
myeloid	O
cell	O
line	O
HL	O
-	O
60	O
and	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

We	O
therefore	O
studied	O
the	O
effect	O
of	O
RA	O
on	O
the	O
activity	O
of	O
the	O
stimulatory	O
G	O
-	O
protein	O
(	O
Gs	O
)	O
.	O

We	O
demonstrate	O
that	O
addition	O
of	O
RA	O
to	O
two	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
,	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
,	O
does	O
not	O
induce	O
a	O
reduction	O
of	O
the	O
2	O
subunit	O
of	O
Gs	O
(	O
Gs	B-Protein
alpha	I-Protein
)	O
RNA	O
or	O
Gs	B-Protein
alpha	I-Protein
protein	O
in	O
the	O
plasma	O
membrane	O
but	O
leads	O
to	O
a	O
rapid	O
decrease	O
in	O
the	O
cholera	O
toxin	O
(	O
CTX	O
)	O
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
of	O
Gs	B-Protein
alpha	I-Protein
.	O

In	O
addition	O
,	O
this	O
effect	O
seems	O
to	O
be	O
specific	O
to	O
RA	O
,	O
since	O
there	O
was	O
no	O
modification	O
in	O
Gs	B-Protein
alpha	I-Protein
ADP	O
-	O
ribosylation	O
in	O
the	O
membranes	O
of	O
cells	O
treated	O
with	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
another	O
inducer	O
of	O
differentiation	O
in	O
HL	O
-	O
60	O
cells	O
.	O

ADP	O
-	O
ribosylation	O
of	O
membrane	O
proteins	O
:	O
unveiling	O
the	O
secrets	O
of	O
a	O
crucial	O
regulatory	O
mechanism	O
in	O
mammalian	O
cells	O
.	O

Many	O
bacterial	O
toxins	O
kill	O
animal	O
cells	O
by	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
-	O
ribosylating	O
intracellular	O
target	O
proteins	O
.	O

Mammalian	O
cells	O
express	O
toxin	O
-	O
related	O
cell	O
surface	O
ADP	O
-	O
ribosyltransferases	O
(	O
ARTs	O
)	O
that	O
transfer	O
ADP	O
-	O
ribose	O
from	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
onto	O
arginine	O
residues	O
of	O
other	O
membrane	O
proteins	O
.	O

The	O
association	O
of	O
these	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
ectoenzymes	O
with	O
glycolipid	O
rafts	O
focuses	O
them	O
onto	O
components	O
of	O
the	O
signal	O
transduction	O
machinery	O
.	O

Exposing	O
murine	O
T	O
cells	O
to	O
NAD	O
,	O
the	O
ART	O
substrate	O
,	O
induces	O
a	O
cascade	O
of	O
reactions	O
that	O
culminates	O
in	O
cell	O
death	O
by	O
apoptosis	O
.	O

This	O
mechanism	O
,	O
dubbed	O
'	O
NAD	O
-	O
induced	O
cell	O
death	O
'	O
or	O
NICD	O
,	O
is	O
initiated	O
when	O
ART2	B-Protein
ADP	O
-	O
ribosylates	O
the	O
cytolytic	O
P2X7	B-Protein
purinergic	O
receptor	O
,	O
inducing	O
formation	O
of	O
a	O
cation	O
channel	O
,	O
opening	O
of	O
a	O
nonselective	O
pore	O
,	O
shedding	O
of	O
CD62L	B-Protein
from	O
the	O
cell	O
surface	O
,	O
exposure	O
of	O
phosphatidylserine	O
on	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
,	O
breakdown	O
of	O
the	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
DNA	O
-	O
fragmentation	O
.	O

The	O
ART	O
substrate	O
NAD	O
is	O
produced	O
in	O
large	O
amounts	O
inside	O
the	O
cell	O
and	O
can	O
be	O
released	O
from	O
damaged	O
cells	O
during	O
inflammation	O
and	O
tissue	O
injury	O
.	O

In	O
the	O
extracellular	O
environment	O
,	O
the	O
signaling	O
function	O
of	O
NAD	O
is	O
terminated	O
by	O
NAD	O
-	O
degrading	O
ectoenzymes	O
such	O
as	O
CD38	B-Protein
.	O

We	O
propose	O
that	O
ART2	B-Protein
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
P2X7	B-Protein
represents	O
the	O
paradigm	O
of	O
a	O
regulatory	O
mechanism	O
by	O
which	O
ART	O
-	O
expressing	O
cells	O
can	O
sense	O
and	O
respond	O
to	O
the	O
release	O
of	O
NAD	O
from	O
damaged	O
cells	O
.	O

SUMO	O
modification	O
enhances	O
p66	O
-	O
mediated	O
transcriptional	O
repression	O
of	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
complex	O
.	O

Human	B-Protein
p66alpha	I-Protein
and	O
p66beta	B-Protein
are	O
two	O
potent	O
transcriptional	O
repressors	O
that	O
interact	O
with	O
the	O
methyl	O
-	O
CpG	O
-	O
binding	O
domain	O
proteins	O
MBD2	B-Protein
and	O
MBD3	B-Protein
.	O

An	O
analysis	O
of	O
the	O
molecular	O
mechanisms	O
mediating	O
repression	O
resulted	O
in	O
the	O
identification	O
of	O
two	O
major	O
repression	O
domains	O
in	O
p66alpha	B-Protein
and	O
one	O
in	O
p66beta	B-Protein
.	O

Both	O
p66alpha	B-Protein
and	O
p66beta	B-Protein
are	O
SUMO	O
-	O
modified	O
in	O
vivo	O
:	O
p66alpha	B-Protein
at	O
two	O
sites	O
(	O
Lys	O
-	O
30	O
and	O
Lys	O
-	O
487	O
)	O
and	O
p66beta	B-Protein
at	O
one	O
site	O
(	O
Lys	O
-	O
33	O
)	O
.	O

Expression	O
of	O
SUMO1	B-Protein
enhanced	O
the	O
transcriptional	O
repression	O
activity	O
of	O
Gal	B-Protein
-	O
p66alpha	B-Protein
and	O
Gal	B-Protein
-	O
p66beta	B-Protein
.	O

Mutation	O
of	O
the	O
SUMO	O
modification	O
sites	O
or	O
using	O
a	O
SUMO1	B-Protein
mutant	O
or	O
a	O
dominant	O
negative	O
Ubc9	B-Protein
ligase	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
transcriptional	O
repression	O
of	O
p66alpha	B-Protein
and	O
p66beta	B-Protein
.	O

The	O
Mi	O
-	O
2	O
/	O
NuRD	O
components	O
MBD3	B-Protein
,	O
RbAp46	B-Protein
,	O
RbAp48	B-Protein
,	O
and	O
HDAC1	B-Protein
were	O
found	O
to	O
bind	O
to	O
both	O
p66alpha	B-Protein
and	O
p66beta	B-Protein
in	O
vivo	O
.	O

Most	O
of	O
the	O
interactions	O
were	O
not	O
affected	O
by	O
the	O
SUMO	O
site	O
mutations	O
in	O
p66alpha	B-Protein
or	O
p66beta	B-Protein
,	O
with	O
two	O
exceptions	O
.	O

HDAC1	B-Protein
binding	O
to	O
p66alpha	B-Protein
was	O
lost	O
in	O
the	O
case	O
of	O
a	O
p66alphaK30R	B-Protein
mutant	O
,	O
and	O
RbAp46	B-Protein
binding	O
was	O
reduced	O
in	O
the	O
case	O
of	O
a	O
p66betaK33R	B-Protein
mutant	O
.	O

These	O
results	O
suggest	O
that	O
interactions	O
within	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
complex	O
as	O
well	O
as	O
optimal	O
repression	O
are	O
mediated	O
by	O
SUMOylation	O
.	O

[	O
Ubiquitins	B-Protein
,	O
proteasomes	O
,	O
sumoylation	O
and	O
therapeutic	O
application	O
today	O
and	O
in	O
future	O
for	O
cancer	O
and	O
other	O
diseases	O
.	O
I	O
.	O
Ubiquitin	B-Protein
-	O
proteasome	O
system	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
]	O
.	O

Proteasome	O
is	O
protein	O
complex	O
with	O
proteolytic	O
activity	O
.	O

Proteasomes	O
are	O
in	O
addition	O
to	O
lysosomes	O
the	O
main	O
proteolytic	O
machinery	O
of	O
the	O
eukaryotic	O
cell	O
.	O

Proteins	O
destined	O
for	O
degradation	O
in	O
proteasomes	O
are	O
marked	O
by	O
ubiquitinylation	O
,	O
which	O
consists	O
in	O
attachment	O
of	O
polyubiquitin	B-Protein
to	O
relevant	O
protein	O
.	O

The	O
transport	O
of	O
polyubiquitinylated	O
protein	O
follows	O
to	O
proteasome	O
,	O
where	O
protein	O
is	O
cleaved	O
into	O
small	O
peptides	O
.	O

Besides	O
polyubiquitin	B-Protein
attachment	O
to	O
protein	O
,	O
monoubiquitinylation	O
of	O
proteins	O
exists	O
and	O
has	O
an	O
important	O
role	O
in	O
DNA	O
repair	O
,	O
transcription	O
of	O
genes	O
,	O
endocytosis	O
and	O
signal	O
transduction	O
.	O

The	O
function	O
of	O
an	O
important	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
connected	O
with	O
proteasome	O
.	O

NF	O
-	O
kappaB	O
is	O
activated	O
after	O
the	O
proteolysis	O
of	O
its	O
inhibitor	O
IkappaB	O
in	O
proteasome	O
.	O

Ubiqutinylation	O
and	O
degradation	O
of	O
protein	O
in	O
proteasome	O
and	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
play	O
significant	O
roles	O
in	O
taking	O
proteins	O
away	O
and	O
in	O
expression	O
of	O
great	O
numbers	O
of	O
genes	O
important	O
for	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
and	O
apoptosis	O
of	O
cells	O
.	O

The	O
inhibition	O
of	O
proteasomes	O
has	O
antiproliferative	O
and	O
antiinflammatory	O
effects	O
and	O
opens	O
new	O
therapeutic	O
approaches	O
to	O
a	O
treatment	O
of	O
cancer	O
and	O
some	O
inflammatory	O
diseases	O
.	O

We	O
divided	O
the	O
review	O
into	O
three	O
parts	O
:	O
I	O
.	O

Ubiquitin	B-Protein
-	O
proteasome	O
system	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
II	O
.	O

Sumoylation	O
and	O
neddylation	O
as	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
similar	O
to	O
ubiquitinylation	O
and	O
their	O
significance	O
and	O
lastly	O
III	O
.	O

Using	O
of	O
the	O
knowledge	O
of	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
in	O
cancer	O
and	O
other	O
diseases	O
therapy	O
.	O

A	O
theoretical	O
study	O
on	O
the	O
substrate	O
deacylation	O
mechanism	O
of	O
class	O
C	O
beta	O
-	O
lactamase	O
.	O

The	O
whole	O
reaction	O
of	O
the	O
deacylation	O
of	O
class	O
C	O
beta	O
-	O
lactamase	O
was	O
investigated	O
by	O
performing	O
quantum	O
chemical	O
calculations	O
under	O
physiological	O
conditions	O
.	O

In	O
this	O
study	O
,	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
of	O
the	O
inhibitor	O
moxalactam	O
-	O
bound	O
class	O
C	O
beta	O
-	O
lactamase	O
(	O
Patera	O
et	O
al	O
.	O
J	O
.	O
Am	O
.	O
Chem	O
.	O
Soc	O
.	O
2000	O
,	O
122	O
,	O
10504	O
-	O
10512	O
.	O
)	O
was	O
utilized	O
and	O
moxalactam	O
was	O
changed	O
into	O
the	O
substrate	O
cefaclor	O
.	O

A	O
model	O
for	O
quantum	O
chemical	O
calculations	O
was	O
constructed	O
using	O
an	O
energy	O
-	O
minimized	O
structure	O
of	O
the	O
substrate	O
-	O
bound	O
enzyme	O
obtained	O
by	O
molecular	O
mechanics	O
calculation	O
,	O
in	O
which	O
the	O
enzyme	O
was	O
soaked	O
in	O
thousands	O
of	O
TIP3P	O
water	O
molecules	O
.	O

It	O
was	O
found	O
that	O
the	O
deacylation	O
reaction	O
consisted	O
of	O
two	O
elementary	O
processes	O
.	O

The	O
first	O
process	O
was	O
formation	O
of	O
a	O
tetrahedral	O
intermediate	O
,	O
which	O
was	O
initiated	O
by	O
the	O
activation	O
of	O
catalytic	O
water	O
by	O
Tyr150	O
,	O
and	O
the	O
second	O
process	O
was	O
detachment	O
of	O
the	O
hydroxylated	O
substrate	O
from	O
the	O
enzyme	O
,	O
which	O
associated	O
with	O
proton	O
transfer	O
from	O
the	O
side	O
chain	O
of	O
Lys67	O
to	O
Ser64O	O
(	O
gamma	O
)	O
.	O

The	O
first	O
process	O
is	O
a	O
rate	O
-	O
determining	O
process	O
,	O
and	O
the	O
activation	O
energy	O
was	O
estimated	O
to	O
be	O
30	O
.	O
47	O
kcal	O
/	O
mol	O
from	O
density	O
functional	O
theory	O
calculations	O
considering	O
electron	O
correlation	O
(	O
B3LYP	O
/	O
6	O
-	O
31G	O
*	O
*	O
)	O
.	O

The	O
side	O
chain	O
of	O
Tyr150	O
was	O
initially	O
in	O
a	O
deprotonated	O
state	O
and	O
was	O
stably	O
present	O
in	O
the	O
active	O
site	O
of	O
the	O
acyl	O
-	O
enzyme	O
complex	O
,	O
being	O
held	O
by	O
Lys67	O
and	O
Lys315	O
cooperatively	O
.	O

Chemical	O
characterization	O
of	O
the	O
parasitophorous	O
vacuole	O
membrane	O
antigen	O
QF	B-Protein
116	I-Protein
from	O
Plasmodium	O
falciparum	O
.	O

On	O
the	O
basis	O
of	O
amino	O
acid	O
sequencing	O
and	O
immunological	O
cross	O
-	O
reactivity	O
,	O
the	O
Plasmodium	O
falciparum	O
parasitophorous	O
vacuole	O
antigens	O
QF116	B-Protein
and	O
exp	B-Protein
-	I-Protein
1	I-Protein
/	O
CRA	B-Protein
are	O
apparently	O
identical	O
.	O

The	O
epitope	O
recognized	O
by	O
an	O
inhibitory	O
monoclonal	O
antibody	O
directed	O
against	O
QF116	B-Protein
is	O
located	O
proximal	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

The	O
QF116	B-Protein
protein	O
is	O
processed	O
during	O
maturation	O
by	O
the	O
cleavage	O
of	O
a	O
22	O
-	O
amino	O
-	O
acid	O
signal	O
peptide	O
and	O
acylated	O
as	O
measured	O
by	O
labeling	O
with	O
myristic	O
acid	O
.	O

Insulin	B-Protein
secretion	O
:	O
SIRT4	B-Protein
gets	O
in	O
on	O
the	O
act	O
.	O

Despite	O
their	O
initial	O
characterization	O
as	O
histone	B-Protein
deacetylases	O
controlling	O
transcription	O
,	O
sirtuins	O
also	O
turn	O
out	O
to	O
be	O
critical	O
regulators	O
of	O
metabolism	O
.	O

In	O
this	O
issue	O
of	O
Cell	O
,	O
Haigis	O
et	O
al	O
.	O

(	O
2006	O
)	O
demonstrate	O
that	O
the	O
mammalian	O
Sir2	B-Protein
homolog	O
SIRT4	B-Protein
acts	O
in	O
the	O
mitochondria	O
of	O
pancreatic	O
beta	O
cells	O
to	O
repress	O
the	O
activity	O
of	O
glutamate	B-Protein
dehydrogenase	I-Protein
through	O
ADP	O
-	O
ribosylation	O
.	O

In	O
this	O
way	O
,	O
SIRT4	B-Protein
downregulates	O
insulin	B-Protein
secretion	O
by	O
beta	O
cells	O
in	O
response	O
to	O
amino	O
acids	O
.	O

Triterpenoid	O
CDDO	O
-	O
Me	O
blocks	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
direct	O
inhibition	O
of	O
IKKbeta	B-Protein
on	O
Cys	O
-	O
179	O
.	O

The	O
novel	O
oleanane	O
triterpenoid	O
2	O
-	O
cyano	O
-	O
3	O
,	O
12	O
-	O
dioxooleana	O
-	O
1	O
,	O
9	O
,	O
-	O
dien	O
-	O
28	O
-	O
oic	O
acid	O
(	O
CDDO	O
)	O
and	O
the	O
C	O
-	O
28	O
methyl	O
ester	O
(	O
CDDO	O
-	O
Me	O
)	O
induce	O
apoptosis	O
of	O
human	O
tumor	O
cells	O
by	O
disruption	O
of	O
redox	O
balance	O
and	O
are	O
currently	O
in	O
clinical	O
trials	O
.	O

The	O
present	O
studies	O
show	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
block	O
tumor	O
necrosis	O
factoralpha	O
-	O
induced	O
targeting	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
to	O
the	O
nucleus	O
.	O

CDDO	O
-	O
Me	O
also	O
blocked	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
-	O
induced	O
phosphorylation	O
of	O
IkappaBalpha	B-Protein
.	O

In	O
concert	O
with	O
these	O
results	O
,	O
we	O
found	O
that	O
CDDO	O
-	O
Me	O
inhibits	O
IkappaBalpha	B-Protein
kinasebeta	I-Protein
(	O
IKKbeta	B-Protein
)	O
activity	O
in	O
cells	O
.	O

In	O
support	O
of	O
a	O
direct	O
mechanism	O
,	O
CDDO	O
-	O
Me	O
inhibited	O
recombinant	O
IKKbeta	B-Protein
activity	O
in	O
vitro	O
.	O

The	O
results	O
also	O
demonstrate	O
that	O
(	O
i	O
)	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
form	O
adducts	O
with	O
IKKbeta	B-Protein
,	O
but	O
not	O
IKKbeta	B-Protein
with	O
mutation	O
of	O
Cys	O
-	O
179	O
to	O
Ala	O
,	O
and	O
(	O
ii	O
)	O
CDDO	O
-	O
Me	O
inhibits	O
IKKbeta	B-Protein
by	O
a	O
mechanism	O
dependent	O
on	O
oxidation	O
of	O
Cys	O
-	O
179	O
.	O

These	O
findings	O
indicate	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
directly	O
block	O
IKKbeta	B-Protein
activity	O
and	O
thereby	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
interacting	O
with	O
Cys	O
-	O
179	O
in	O
the	O
IKKbeta	B-Protein
activation	O
loop	O
.	O

Processing	O
of	O
the	O
gastrin	B-Protein
precursor	O
.	O

Modulation	O
of	O
phosphorylated	O
,	O
sulfated	O
,	O
and	O
amidated	O
products	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
the	O
precursor	O
for	O
rat	O
gastrin	B-Protein
yields	O
products	O
that	O
include	O
peptides	O
phosphorylated	O
at	O
Ser96	O
,	O
amidated	O
at	O
Phe92	O
,	O
and	O
sulfated	O
at	O
Tyr87	O
or	O
Tyr103	O
.	O

The	O
phosphorylation	O
site	O
is	O
immediately	O
adjacent	O
to	O
the	O
processing	O
point	O
that	O
gives	O
rise	O
to	O
the	O
biologically	O
active	O
amidated	O
gastrins	B-Protein
.	O

We	O
have	O
examined	O
changes	O
in	O
post	O
-	O
translational	O
processing	O
which	O
occur	O
in	O
gastrin	B-Protein
cells	O
from	O
rats	O
that	O
are	O
physiologically	O
stimulated	O
(	O
by	O
feeding	O
)	O
or	O
unstimulated	O
(	O
by	O
fasting	O
)	O
.	O

Peptides	O
were	O
identified	O
using	O
site	O
-	O
directed	O
radioimmunoassays	O
and	O
chromatographic	O
systems	O
that	O
resolve	O
phosphorylated	O
,	O
amidated	O
,	O
and	O
sulfated	O
progastrin	B-Protein
products	O
,	O
including	O
intermediates	O
generated	O
prior	O
to	O
amidation	O
(	O
i	O
.	O
e	O
.	O
C	O
-	O
terminal	O
glycine	O
-	O
extended	O
variants	O
)	O
.	O

Assays	O
for	O
Phe92	O
-	O
amidated	O
peptides	O
and	O
for	O
the	O
C	O
-	O
terminal	O
tryptic	O
fragment	O
of	O
progastrin	B-Protein
indicated	O
decreases	O
in	O
the	O
total	O
tissue	O
concentrations	O
of	O
immunoreactive	O
peptide	O
with	O
fasting	O
;	O
in	O
contrast	O
,	O
the	O
tissue	O
concentrations	O
of	O
glycine	O
-	O
extended	O
biosynthetic	O
intermediates	O
were	O
similar	O
in	O
fasted	O
and	O
fed	O
rats	O
.	O

Taken	O
together	O
the	O
data	O
suggest	O
a	O
relative	O
failure	O
in	O
amidation	O
mechanisms	O
in	O
unstimulated	O
cells	O
.	O

The	O
endopeptidase	O
cleavage	O
of	O
progastrin	B-Protein
was	O
not	O
influenced	O
significantly	O
by	O
fasting	O
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
peptide	O
products	O
containing	O
Ser96	O
was	O
depressed	O
significantly	O
in	O
fasted	O
rats	O
.	O

The	O
proportions	O
of	O
amidated	O
peptides	O
sulfated	O
at	O
Tyr87	O
were	O
generally	O
lower	O
than	O
their	O
corresponding	O
glycine	O
-	O
extended	O
biosynthetic	O
precursors	O
,	O
but	O
in	O
both	O
cases	O
the	O
proportion	O
of	O
peptide	O
in	O
the	O
sulfated	O
form	O
was	O
lower	O
than	O
for	O
peptides	O
sulfated	O
at	O
Tyr103	O
.	O

Feeding	O
did	O
not	O
change	O
the	O
sulfation	O
of	O
amidated	O
heptadecapeptide	O
gastrin	B-Protein
or	O
its	O
glycine	O
-	O
extended	O
variant	O
.	O

The	O
results	O
suggest	O
that	O
the	O
mechanisms	O
determining	O
phosphorylation	O
and	O
amidation	O
of	O
progastrin	B-Protein
-	O
related	O
peptides	O
depend	O
on	O
the	O
patterns	O
of	O
stimulation	O
of	O
gastrin	B-Protein
cells	O
.	O

The	O
observation	O
that	O
decreased	O
phosphorylation	O
is	O
associated	O
with	O
a	O
failure	O
to	O
produce	O
active	O
amidated	O
products	O
is	O
consistent	O
with	O
a	O
regulatory	O
function	O
for	O
phosphorylation	O
in	O
gastrin	B-Protein
production	O
.	O

Involvement	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
-	O
related	O
kinases	O
tank	B-Protein
-	I-Protein
binding	I-Protein
kinase	I-Protein
1	I-Protein
/	O
IKKi	B-Protein
and	O
cullin	O
-	O
based	O
ubiquitin	B-Protein
ligases	O
in	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
3	I-Protein
degradation	O
.	O

Activation	O
of	O
the	O
innate	O
arm	O
of	O
the	O
immune	O
system	O
following	O
pathogen	O
infection	O
relies	O
on	O
the	O
recruitment	O
of	O
latent	O
transcription	O
factors	O
involved	O
in	O
the	O
induction	O
of	O
a	O
subset	O
of	O
genes	O
responsible	O
for	O
viral	O
clearance	O
.	O

One	O
of	O
these	O
transcription	O
factors	O
,	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	I-Protein
(	O
IRF	B-Protein
-	I-Protein
3	I-Protein
)	O
,	O
is	O
targeted	O
for	O
proteosomal	O
degradation	O
following	O
virus	O
infection	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
process	O
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
polyubiquitination	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
increases	O
in	O
response	O
to	O
Sendai	O
virus	O
infection	O
.	O

Using	O
an	O
E1	O
temperature	O
-	O
sensitive	O
cell	O
line	O
,	O
we	O
demonstrate	O
that	O
polyubiquitination	O
is	O
required	O
for	O
the	O
observed	O
degradation	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
.	O

Inactivation	O
of	O
NEDD8	B-Protein
-	O
activating	O
E1	O
enzyme	O
also	O
results	O
in	O
stabilization	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
suggesting	O
the	O
NEDDylation	O
also	O
plays	O
a	O
role	O
in	O
IRF	B-Protein
-	I-Protein
3	I-Protein
degradation	O
following	O
Sendai	O
virus	O
infection	O
.	O

In	O
agreement	O
with	O
this	O
observation	O
,	O
IRF	B-Protein
-	I-Protein
3	I-Protein
is	O
recruited	O
to	O
Cullin1	B-Protein
following	O
virus	O
infection	O
and	O
overexpression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
Cullin1	B-Protein
significantly	O
inhibits	O
the	O
degradation	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
observed	O
in	O
infected	O
cells	O
.	O

We	O
also	O
asked	O
whether	O
the	O
C	O
-	O
terminal	O
cluster	O
of	O
phosphoacceptor	O
sites	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
could	O
serve	O
as	O
a	O
destabilization	O
signal	O
and	O
we	O
therefore	O
measured	O
the	O
half	O
-	O
life	O
of	O
C	O
-	O
terminal	O
phosphomimetic	O
IRF	B-Protein
-	I-Protein
3	I-Protein
mutants	O
.	O

Interestingly	O
,	O
we	O
found	O
them	O
to	O
be	O
short	O
-	O
lived	O
in	O
contrast	O
to	O
wild	O
-	O
type	O
IRF	B-Protein
-	I-Protein
3	I-Protein
.	O

In	O
addition	O
,	O
no	O
degradation	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
was	O
observed	O
in	O
TBK1	B-Protein
(	O
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
.	O

All	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
virus	O
infection	O
stimulates	O
a	O
host	O
cell	O
signaling	O
pathway	O
that	O
modulates	O
the	O
expression	O
level	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
through	O
its	O
C	O
-	O
terminal	O
phosphorylation	O
by	O
the	O
IkappaB	O
kinase	O
-	O
related	O
kinases	O
followed	O
by	O
its	O
polyubiquitination	O
,	O
which	O
is	O
mediated	O
in	O
part	O
by	O
a	O
Cullin	O
-	O
based	O
ubiquitin	B-Protein
ligase	O
.	O

Structural	O
basis	O
for	O
SENP2	B-Protein
protease	O
interactions	O
with	O
SUMO	O
precursors	O
and	O
conjugated	O
substrates	O
.	O

SUMO	O
processing	O
and	O
deconjugation	O
are	O
essential	O
proteolytic	O
activities	O
for	O
nuclear	O
metabolism	O
and	O
cell	O
-	O
cycle	O
progression	O
in	O
yeast	O
and	O
higher	O
eukaryotes	O
.	O

To	O
elucidate	O
the	O
mechanisms	O
used	O
during	O
substrate	O
lysine	O
deconjugation	O
,	O
SUMO	O
isoform	O
processing	O
and	O
SUMO	O
isoform	O
interactions	O
,	O
X	O
-	O
ray	O
structures	O
were	O
determined	O
for	O
a	O
catalytically	O
inert	O
SENP2	B-Protein
protease	O
domain	O
in	O
complex	O
with	O
conjugated	O
RanGAP1	B-Protein
-	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
or	O
RanGAP1	B-Protein
-	O
SUMO	B-Protein
-	I-Protein
2	I-Protein
,	O
or	O
in	O
complex	O
with	O
SUMO	B-Protein
-	I-Protein
2	I-Protein
or	O
SUMO	B-Protein
-	I-Protein
3	I-Protein
precursors	O
.	O

Common	O
features	O
within	O
the	O
active	O
site	O
include	O
a	O
90	O
degrees	O
kink	O
proximal	O
to	O
the	O
scissile	O
bond	O
that	O
forces	O
C	O
-	O
terminal	O
amino	O
acid	O
residues	O
or	O
the	O
lysine	O
side	O
chain	O
toward	O
a	O
protease	O
surface	O
that	O
appears	O
optimized	O
for	O
lysine	O
deconjugation	O
.	O

Analysis	O
of	O
this	O
surface	O
reveals	O
SENP2	B-Protein
residues	O
,	O
particularly	O
Met497	O
,	O
that	O
mediate	O
,	O
and	O
in	O
some	O
instances	O
reverse	O
,	O
in	O
vitro	O
substrate	O
specificity	O
.	O

Mutational	O
analysis	O
and	O
biochemistry	O
provide	O
a	O
mechanism	O
for	O
SENP2	B-Protein
substrate	O
preferences	O
that	O
explains	O
why	O
SENP2	B-Protein
catalyzes	O
SUMO	O
deconjugation	O
more	O
efficiently	O
than	O
processing	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
-	O
encoded	O
protein	O
kinase	O
and	O
its	O
interaction	O
with	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
.	O

The	O
oncogenic	O
herpesvirus	O
,	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
,	O
also	O
identified	O
as	O
human	O
herpesvirus	O
8	O
,	O
contains	O
genes	O
producing	O
proteins	O
that	O
control	O
transcription	O
and	O
influence	O
cell	O
signaling	O
.	O

Open	B-Protein
reading	I-Protein
frame	I-Protein
36	I-Protein
(	O
ORF36	B-Protein
)	O
of	O
this	O
virus	O
encodes	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
,	O
which	O
is	O
designated	O
the	O
viral	O
protein	B-Protein
kinase	I-Protein
(	O
vPK	B-Protein
)	O
.	O

Our	O
recent	O
efforts	O
to	O
elucidate	O
the	O
role	O
of	O
vPK	B-Protein
in	O
the	O
viral	O
life	O
cycle	O
have	O
focused	O
on	O
identifying	O
viral	O
protein	O
substrates	O
and	O
determining	O
the	O
effects	O
of	O
vPK	B-Protein
-	O
mediated	O
phosphorylation	O
on	O
specific	O
steps	O
in	O
viral	O
replication	O
.	O

The	O
vPK	B-Protein
gene	O
was	O
transcribed	O
into	O
4	O
.	O
2	O
-	O
kb	O
and	O
3	O
.	O
6	O
-	O
kb	O
mRNAs	O
during	O
the	O
early	O
and	O
late	O
phases	O
of	O
viral	O
reactivation	O
.	O

vPK	B-Protein
is	O
colocalized	O
with	O
viral	O
DNA	O
replication	O
/	O
transcription	O
compartments	O
as	O
marked	O
by	O
a	O
polymerase	O
processivity	O
factor	O
,	O
and	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
,	O
a	O
protein	O
known	O
to	O
bind	O
the	O
viral	O
DNA	O
replication	O
origin	O
(	O
Ori	O
-	O
Lyt	O
)	O
and	O
to	O
regulate	O
viral	O
transcription	O
.	O

The	O
vPK	B-Protein
physically	O
associated	O
with	O
and	O
strongly	O
phosphorylated	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
at	O
threonine	O
111	O
,	O
a	O
site	O
also	O
recognized	O
by	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
Cdk2	B-Protein
.	O

Both	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
and	O
vPK	B-Protein
were	O
corecruited	O
to	O
viral	O
promoters	O
targeted	O
by	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
as	O
well	O
as	O
to	O
the	O
Ori	O
-	O
Lyt	O
region	O
.	O

Phosphorylation	O
of	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
by	O
vPK	B-Protein
had	O
a	O
negative	O
impact	O
on	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
transcription	O
repression	O
activity	O
.	O

The	O
extent	O
of	O
posttranslational	O
modification	O
of	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
by	O
sumoylation	O
,	O
a	O
process	O
that	O
influences	O
its	O
repression	O
function	O
,	O
was	O
decreased	O
by	O
vPK	B-Protein
phosphorylation	O
at	O
threonine	O
111	O
.	O

Our	O
data	O
thus	O
identify	O
a	O
new	O
role	O
of	O
vPK	B-Protein
as	O
a	O
modulator	O
of	O
viral	O
transcription	O
.	O

Preventing	O
apoptotic	O
cell	O
death	O
by	O
a	O
novel	O
small	O
heat	O
shock	O
protein	O
.	O

NCBI	O
database	O
analysis	O
indicated	O
that	O
the	O
human	O
C1orf41	B-Protein
protein	O
(	O
small	O
heat	O
shock	O
-	O
like	O
protein	O
-	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
)	O
has	O
sequence	O
similarity	O
with	O
small	O
heat	O
shock	O
proteins	O
(	O
sHsps	O
)	O
.	O

Since	O
sHsps	O
have	O
chaperone	O
function	O
,	O
and	O
so	O
prevent	O
aggregation	O
of	O
denatured	O
proteins	O
,	O
we	O
determined	O
whether	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
could	O
prevent	O
the	O
heat	O
-	O
induced	O
aggregation	O
of	O
denatured	O
proteins	O
.	O

Under	O
our	O
experimental	O
conditions	O
,	O
recombinant	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
prevented	O
aggregation	O
of	O
aldolase	O
and	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
,	O
and	O
protected	O
Escherichia	O
coli	O
cells	O
from	O
heat	O
stress	O
indicating	O
its	O
chaperone	O
function	O
.	O

Hsp16	B-Protein
.	I-Protein
2	I-Protein
also	O
formed	O
oligomeric	O
complexes	O
in	O
aqueous	O
solution	O
.	O

Hsp16	B-Protein
.	I-Protein
2	I-Protein
was	O
found	O
to	O
be	O
expressed	O
at	O
different	O
levels	O
in	O
cell	O
lines	O
and	O
tissues	O
,	O
and	O
was	O
mainly	O
localized	O
to	O
the	O
nucleus	O
and	O
the	O
cytosol	O
,	O
but	O
to	O
a	O
smaller	O
extent	O
,	O
it	O
could	O
be	O
also	O
found	O
in	O
mitochondria	O
.	O

Hsp16	B-Protein
.	I-Protein
2	I-Protein
could	O
be	O
modified	O
covalently	O
by	O
poly	O
(	O
ADP	O
ribosylation	O
)	O
and	O
acetylation	O
.	O

Hsp16	B-Protein
.	I-Protein
2	I-Protein
over	O
-	O
expression	O
prevented	O
etoposide	O
-	O
induced	O
cell	O
death	O
as	O
well	O
as	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	B-Protein
c	I-Protein
and	O
caspase	O
activation	O
.	O

These	O
data	O
suggest	O
that	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
can	O
prevent	O
the	O
destabilization	O
of	O
mitochondrial	O
membrane	O
systems	O
and	O
could	O
represent	O
a	O
suitable	O
target	O
for	O
modulating	O
cell	O
death	O
pathways	O
.	O

Coupling	O
of	O
the	O
de	O
novo	O
fatty	O
acid	O
biosynthesis	O
and	O
lipoylation	O
pathways	O
in	O
mammalian	O
mitochondria	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
products	O
and	O
possible	O
role	O
of	O
a	O
putative	O
pathway	O
for	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
in	O
mammalian	O
mitochondria	O
.	O

Bovine	O
heart	O
mitochondrial	O
matrix	O
preparations	O
were	O
prepared	O
free	O
from	O
contamination	O
by	O
proteins	O
from	O
other	O
subcellular	O
components	O
and	O
,	O
using	O
a	O
combination	O
of	O
radioisotopic	O
labeling	O
and	O
mass	O
spectrometry	O
,	O
were	O
shown	O
to	O
contain	O
all	O
of	O
the	O
enzymes	O
required	O
for	O
the	O
extension	O
of	O
a	O
2	O
-	O
carbon	O
precursor	O
by	O
malonyl	O
moieties	O
to	O
saturated	O
acyl	O
-	O
ACP	B-Protein
thioesters	O
containing	O
up	O
to	O
14	O
carbon	O
atoms	O
.	O

A	O
major	O
product	O
was	O
octanoyl	O
-	O
ACP	B-Protein
and	O
,	O
in	O
the	O
presence	O
of	O
the	O
apo	O
-	O
H	B-Protein
-	I-Protein
protein	I-Protein
of	O
the	O
glycine	O
cleavage	O
complex	O
,	O
the	O
newly	O
synthesized	O
octanoyl	O
moieties	O
were	O
translocated	O
to	O
the	O
lipoylation	O
site	O
on	O
the	O
acceptor	O
protein	O
.	O

These	O
studies	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
the	O
de	O
novo	O
fatty	O
acid	O
biosynthetic	O
pathway	O
in	O
mammalian	O
mitochondria	O
is	O
to	O
provide	O
the	O
octanoyl	O
precursor	O
required	O
for	O
the	O
essential	O
protein	O
lipoylation	O
pathway	O
.	O

Depletion	O
of	O
GGA3	B-Protein
stabilizes	O
BACE	B-Protein
and	O
enhances	O
beta	O
-	O
secretase	O
activity	O
.	O

Beta	B-Protein
-	I-Protein
site	I-Protein
APP	I-Protein
-	I-Protein
cleaving	I-Protein
enzyme	I-Protein
(	O
BACE	B-Protein
)	O
is	O
required	O
for	O
production	O
of	O
the	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
-	O
associated	O
Abeta	B-Protein
protein	O
.	O

BACE	B-Protein
levels	O
are	O
elevated	O
in	O
AD	O
brain	O
,	O
and	O
increasing	O
evidence	O
reveals	O
BACE	B-Protein
as	O
a	O
stress	O
-	O
related	O
protease	O
that	O
is	O
upregulated	O
following	O
cerebral	O
ischemia	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
responsible	O
is	O
unknown	O
.	O

We	O
show	O
that	O
increases	O
in	O
BACE	B-Protein
and	O
beta	O
-	O
secretase	O
activity	O
are	O
due	O
to	O
posttranslational	O
stabilization	O
following	O
caspase	O
activation	O
.	O

We	O
also	O
found	O
that	O
during	O
cerebral	O
ischemia	O
,	O
levels	O
of	O
GGA3	B-Protein
,	O
an	O
adaptor	O
protein	O
involved	O
in	O
BACE	B-Protein
trafficking	O
,	O
are	O
reduced	O
,	O
while	O
BACE	B-Protein
levels	O
are	O
increased	O
.	O

RNAi	O
silencing	O
of	O
GGA3	B-Protein
also	O
elevated	O
levels	O
of	O
BACE	B-Protein
and	O
Abeta	B-Protein
.	O

Finally	O
,	O
in	O
AD	O
brain	O
samples	O
,	O
GGA3	B-Protein
protein	O
levels	O
were	O
significantly	O
decreased	O
and	O
inversely	O
correlated	O
with	O
increased	O
levels	O
of	O
BACE	B-Protein
.	O

In	O
summary	O
,	O
we	O
have	O
elucidated	O
a	O
GGA3	B-Protein
-	O
dependent	O
mechanism	O
regulating	O
BACE	B-Protein
levels	O
and	O
beta	O
-	O
secretase	O
activity	O
.	O

This	O
mechanism	O
may	O
explain	O
increased	O
cerebral	O
levels	O
of	O
BACE	B-Protein
and	O
Abeta	B-Protein
following	O
cerebral	O
ischemia	O
and	O
existing	O
in	O
AD	O
.	O

Increased	O
acylated	O
plasma	O
ghrelin	B-Protein
,	O
but	O
improved	O
lipid	O
profiles	O
24	O
-	O
h	O
after	O
consumption	O
of	O
carob	O
pulp	O
preparation	O
rich	O
in	O
dietary	O
fibre	O
and	O
polyphenols	O
.	O

We	O
have	O
recently	O
shown	O
that	O
a	O
polyphenol	O
-	O
rich	O
insoluble	O
dietary	O
fibre	O
preparation	O
from	O
carob	O
pulp	O
(	O
Ceratonia	O
siliqua	O
L	O
;	O
carob	O
fibre	O
)	O
decreased	O
postprandial	O
acylated	O
ghrelin	B-Protein
,	O
TAG	O
and	O
NEFA	O
during	O
an	O
acute	O
liquid	O
meal	O
challenge	O
test	O
.	O

However	O
,	O
delayed	O
effects	O
of	O
carob	O
fibre	O
consumption	O
are	O
unknown	O
.	O

Therefore	O
,	O
a	O
randomized	O
controlled	O
crossover	O
study	O
in	O
nineteen	O
healthy	O
volunteers	O
consuming	O
foods	O
with	O
or	O
without	O
50	O
g	O
carob	O
fibre	O
was	O
conducted	O
.	O

On	O
the	O
subsequent	O
day	O
(	O
day	O
2	O
)	O
,	O
glucose	O
,	O
TAG	O
,	O
total	O
and	O
acylated	O
ghrelin	B-Protein
as	O
well	O
as	O
insulin	B-Protein
,	O
NEFA	O
and	O
leptin	B-Protein
were	O
assessed	O
at	O
baseline	O
and	O
at	O
timed	O
intervals	O
for	O
300	O
min	O
after	O
ingestion	O
of	O
standardized	O
bread	O
.	O

Consumption	O
of	O
carob	O
fibre	O
-	O
enriched	O
foods	O
did	O
not	O
affect	O
fasting	O
concentrations	O
of	O
glucose	O
,	O
TAG	O
,	O
total	O
ghrelin	B-Protein
,	O
NEFA	O
,	O
insulin	B-Protein
and	O
leptin	B-Protein
.	O

Fasting	O
acylated	O
ghrelin	B-Protein
was	O
increased	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
compared	O
with	O
control	O
(	O
P	O
=	O
0	O
.	O
046	O
)	O
.	O

After	O
consumption	O
of	O
the	O
standard	O
bread	O
on	O
day	O
2	O
,	O
glucose	O
response	O
(	O
P	O
=	O
0	O
.	O
029	O
)	O
was	O
increased	O
,	O
and	O
TAG	O
(	O
P	O
=	O
0	O
.	O
033	O
)	O
and	O
NEFA	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
responses	O
were	O
decreased	O
compared	O
with	O
control	O
.	O

Postprandial	O
responses	O
of	O
total	O
and	O
acylated	O
ghrelin	B-Protein
,	O
insulin	B-Protein
and	O
leptin	B-Protein
on	O
day	O
2	O
were	O
unaffected	O
by	O
carob	O
fibre	O
consumption	O
the	O
previous	O
day	O
.	O

In	O
conclusion	O
,	O
an	O
increase	O
in	O
total	O
and	O
acylated	O
plasma	O
ghrelin	B-Protein
accompanied	O
by	O
enhanced	O
lipid	O
metabolism	O
after	O
carob	O
fibre	O
consumption	O
suggests	O
higher	O
lipid	O
utilization	O
and	O
suppressed	O
lipolysis	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
.	O

However	O
,	O
elevated	O
glucose	O
levels	O
after	O
carob	O
fibre	O
consumption	O
need	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

Evidence	O
for	O
two	O
protein	O
-	O
lipoylation	O
activities	O
in	O
Escherichia	O
coli	O
.	O

The	O
lipoate	O
acyltransferase	O
subunits	O
of	O
the	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
complexes	O
are	O
post	O
-	O
translationally	O
modified	O
with	O
one	O
or	O
more	O
covalently	O
-	O
bound	O
lipoyl	O
cofactors	O
.	O

Two	O
distinct	O
lipoate	O
-	O
protein	O
ligase	O
activities	O
,	O
LPL	B-Protein
-	I-Protein
A	I-Protein
and	O
LPL	B-Protein
-	I-Protein
B	I-Protein
,	O
have	O
been	O
detected	O
in	O
E	O
.	O
coli	O
by	O
their	O
ability	O
to	O
modify	O
purified	O
lipoyl	O
apo	O
-	O
domains	O
of	O
the	O
bacterial	O
pyruvate	O
dehydrogenase	O
complex	O
.	O

Both	O
enzymes	O
require	O
ATP	O
and	O
Mg2	O
+	O
,	O
use	O
L	O
-	O
lipoate	O
,	O
8	O
-	O
methyllipoate	O
,	O
lipoyl	O
adenylate	O
and	O
octanoyl	O
adenylate	O
as	O
substrates	O
,	O
and	O
both	O
activate	O
lipoyl	O
-	O
deficient	O
pyruvate	O
dehydrogenase	O
complexes	O
.	O

In	O
contrast	O
,	O
only	O
LPL	B-Protein
-	I-Protein
B	I-Protein
uses	O
D	O
-	O
lipoate	O
and	O
octanoate	O
and	O
there	O
are	O
differences	O
in	O
the	O
metal	O
-	O
ion	O
and	O
phosphate	O
requirements	O
.	O

It	O
is	O
suggested	O
that	O
LPL	B-Protein
-	I-Protein
B	I-Protein
may	O
be	O
responsible	O
for	O
the	O
octanoylation	O
of	O
lipoyl	O
domains	O
observed	O
previously	O
under	O
lipoate	O
-	O
deficient	O
conditions	O
.	O

Selectivity	O
in	O
ISG15	B-Protein
and	O
ubiquitin	B-Protein
recognition	O
by	O
the	O
SARS	O
coronavirus	O
papain	B-Protein
-	I-Protein
like	I-Protein
protease	I-Protein
.	O

The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-Protein
-	I-Protein
like	I-Protein
protease	I-Protein
(	O
SARS	O
-	O
CoV	O
PLpro	B-Protein
)	O
carries	O
out	O
N	O
-	O
terminal	O
processing	O
of	O
the	O
viral	O
replicase	B-Protein
polyprotein	I-Protein
,	O
and	O
also	O
exhibits	O
Lys48	O
-	O
linked	O
polyubiquitin	B-Protein
chain	O
debranching	O
and	O
ISG15	B-Protein
precursor	O
processing	O
activities	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
used	O
SDS	O
-	O
PAGE	O
and	O
fluorescence	O
-	O
based	O
assays	O
to	O
demonstrate	O
that	O
ISG15	B-Protein
derivatives	O
are	O
the	O
preferred	O
substrates	O
for	O
the	O
deubiquitinating	O
activity	O
of	O
the	O
PLpro	B-Protein
.	O

With	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
M	O
)	O
of	O
602	O
,	O
000	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
PLpro	B-Protein
hydrolyzes	O
ISG15	B-Protein
-	O
AMC	O
30	O
-	O
and	O
60	O
-	O
fold	O
more	O
efficiently	O
than	O
Ub	B-Protein
-	O
AMC	O
and	O
Nedd8	B-Protein
-	O
AMC	O
,	O
respectively	O
.	O

Data	O
obtained	O
with	O
truncated	O
ISG15	B-Protein
and	O
hybrid	O
Ub	B-Protein
/	O
ISG15	B-Protein
substrates	O
indicate	O
that	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
Ub	B-Protein
-	O
like	O
domains	O
of	O
ISG15	B-Protein
contribute	O
to	O
this	O
preference	O
.	O

The	O
enzyme	O
also	O
displays	O
a	O
preference	O
for	O
debranching	O
Lys48	O
-	O
over	O
Lys63	O
-	O
linked	O
polyubiquitin	B-Protein
chains	O
.	O

Our	O
results	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
PLpro	B-Protein
can	O
differentiate	O
between	O
ubiquitin	B-Protein
-	O
like	O
modifiers	O
sharing	O
a	O
common	O
C	O
-	O
terminal	O
sequence	O
,	O
and	O
that	O
the	O
debranching	O
activity	O
of	O
the	O
PLpro	B-Protein
is	O
linkage	O
type	O
selective	O
.	O

The	O
potential	O
structural	O
basis	O
for	O
the	O
demonstrated	O
specificity	O
of	O
SARS	O
-	O
CoV	O
PLpro	B-Protein
is	O
discussed	O
.	O

Modification	O
of	O
cellular	O
autophagy	O
protein	O
LC3	O
by	O
poliovirus	O
.	O

Poliovirus	O
infection	O
remodels	O
intracellular	O
membranes	O
,	O
creating	O
a	O
large	O
number	O
of	O
membranous	O
vesicles	O
on	O
which	O
viral	O
RNA	O
replication	O
occurs	O
.	O

Poliovirus	O
-	O
induced	O
vesicles	O
display	O
hallmarks	O
of	O
cellular	O
autophagosomes	O
,	O
including	O
delimiting	O
double	O
membranes	O
surrounding	O
the	O
cytosolic	O
lumen	O
,	O
acquisition	O
of	O
the	O
endosomal	O
marker	O
LAMP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
recruitment	O
of	O
the	O
18	O
-	O
kDa	O
host	O
protein	O
LC3	O
.	O

Autophagy	O
results	O
in	O
the	O
covalent	O
lipidation	O
of	O
LC3	O
,	O
conferring	O
the	O
property	O
of	O
membrane	O
association	O
to	O
this	O
previously	O
microtubule	O
-	O
associated	O
protein	O
and	O
providing	O
a	O
biochemical	O
marker	O
for	O
the	O
induction	O
of	O
autophagy	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
similar	O
modification	O
of	O
LC3	O
occurs	O
both	O
during	O
poliovirus	O
infection	O
and	O
following	O
expression	O
of	O
a	O
single	O
viral	O
protein	O
,	O
a	O
stable	O
precursor	O
termed	O
2BC	B-Protein
.	O

Therefore	O
,	O
one	O
of	O
the	O
early	O
steps	O
in	O
cellular	O
autophagy	O
,	O
LC3	O
modification	O
,	O
can	O
be	O
genetically	O
separated	O
from	O
the	O
induction	O
of	O
double	O
-	O
membraned	O
vesicles	O
that	O
contain	O
the	O
modified	O
LC3	O
,	O
which	O
requires	O
both	O
viral	O
proteins	O
2BC	B-Protein
and	O
3A	B-Protein
.	O

The	O
existence	O
of	O
viral	O
inducers	O
that	O
promote	O
a	O
distinct	O
aspect	O
of	O
the	O
formation	O
of	O
autophagosome	O
-	O
like	O
membranes	O
both	O
facilitates	O
the	O
dissection	O
of	O
this	O
cellular	O
process	O
and	O
supports	O
the	O
hypothesis	O
that	O
this	O
branch	O
of	O
the	O
innate	O
immune	O
response	O
is	O
directly	O
subverted	O
by	O
poliovirus	O
.	O

Refined	O
crystal	O
structures	O
of	O
red	B-Protein
and	O
green	B-Protein
fluorescent	I-Protein
proteins	I-Protein
from	O
the	O
button	O
polyp	O
Zoanthus	O
.	O

The	O
three	O
-	O
dimensional	O
structures	O
of	O
the	O
wild	O
-	O
type	O
red	O
(	O
zRFP574	B-Protein
)	O
and	O
green	O
(	O
zGFP506	B-Protein
)	O
fluorescent	O
proteins	O
(	O
FP	O
)	O
from	O
the	O
button	O
polyp	O
Zoanthus	O
have	O
been	O
determined	O
at	O
1	O
.	O
51	O
and	O
2	O
.	O
2	O
A	O
resolution	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
crystal	O
structures	O
of	O
a	O
zGFP506	B-Protein
variant	O
(	O
zGFP506	B-Protein
_	O
N66D	O
)	O
with	O
replacement	O
of	O
the	O
first	O
chromophore	O
-	O
forming	O
residue	O
(	O
Asn66	O
to	O
Asp	O
)	O
have	O
been	O
determined	O
in	O
the	O
transitional	O
'	O
green	O
'	O
and	O
mature	O
'	O
red	O
'	O
states	O
at	O
2	O
.	O
4	O
and	O
2	O
.	O
2	O
A	O
,	O
respectively	O
.	O

The	O
monomers	O
of	O
these	O
proteins	O
adopt	O
the	O
typical	O
fold	O
of	O
the	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	O
)	O
family	O
,	O
consisting	O
of	O
an	O
11	O
-	O
stranded	O
beta	O
-	O
barrel	O
with	O
a	O
chromophore	O
embedded	O
in	O
the	O
middle	O
of	O
an	O
internal	O
alpha	O
-	O
helix	O
directed	O
along	O
the	O
beta	O
-	O
barrel	O
axis	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asn66	O
-	O
Tyr67	O
-	O
Gly68	O
within	O
zGFP506	B-Protein
results	O
in	O
a	O
typical	O
GFP	O
-	O
like	O
coplanar	O
two	O
-	O
ring	O
structure	O
consisting	O
of	O
a	O
five	O
-	O
membered	O
imidazolinone	O
heterocycle	O
with	O
the	O
phenolic	O
ring	O
of	O
Tyr67	O
in	O
a	O
cis	O
orientation	O
to	O
the	O
C	O
(	O
alpha	O
)	O
-	O
N	O
(	O
67	O
)	O
bond	O
.	O

A	O
novel	O
post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asp66	O
-	O
Tyr67	O
-	O
Gly68	O
in	O
zRFP574	B-Protein
expands	O
the	O
protein	O
maturation	O
beyond	O
the	O
green	O
-	O
emitting	O
form	O
and	O
results	O
in	O
decarboxylation	O
of	O
the	O
Asp66	O
side	O
chain	O
.	O

It	O
is	O
suggested	O
that	O
electrostatic	O
conflict	O
between	O
the	O
closely	O
spaced	O
negatively	O
charged	O
side	O
chains	O
of	O
the	O
chromophore	O
Asp66	O
and	O
the	O
proximal	O
catalytic	O
Glu221	O
is	O
most	O
likely	O
to	O
be	O
the	O
trigger	O
for	O
the	O
chain	O
of	O
reactions	O
resulting	O
in	O
the	O
observed	O
decarboxylation	O
.	O

The	O
chromophore	O
structures	O
of	O
wild	O
-	O
type	O
zGFP506	B-Protein
and	O
of	O
its	O
mutant	O
zGFP506	B-Protein
_	O
N66D	O
in	O
the	O
'	O
green	O
'	O
and	O
'	O
red	O
'	O
states	O
support	O
this	O
suggestion	O
.	O

The	O
beta	O
-	O
barrel	O
frames	O
of	O
zRFP574	B-Protein
and	O
zGFP506	B-Protein
reveal	O
the	O
presence	O
of	O
a	O
water	O
-	O
filled	O
pore	O
leading	O
to	O
the	O
chromophore	O
Tyr67	O
,	O
similar	O
to	O
that	O
observed	O
previously	O
in	O
TurboGFP	B-Protein
.	O

An	O
analysis	O
of	O
the	O
residue	O
composition	O
at	O
two	O
inter	O
-	O
monomer	O
interfaces	O
in	O
the	O
tetrameric	O
biological	O
unit	O
of	O
zRFP574	B-Protein
and	O
zGFP506	B-Protein
,	O
as	O
well	O
as	O
of	O
zYFP538	B-Protein
from	O
the	O
same	O
species	O
,	O
has	O
revealed	O
a	O
group	O
of	O
highly	O
conserved	O
residues	O
that	O
are	O
apparently	O
responsible	O
for	O
oligomerization	O
.	O

These	O
residues	O
present	O
initial	O
useful	O
targets	O
for	O
rational	O
mutagenesis	O
aimed	O
at	O
designing	O
monomeric	O
forms	O
of	O
the	O
fluorescent	O
proteins	O
,	O
which	O
are	O
more	O
suitable	O
for	O
practical	O
applications	O
.	O

Genetic	O
characterization	O
of	O
mutants	O
resistant	O
to	O
the	O
antiauxin	O
p	O
-	O
chlorophenoxyisobutyric	O
acid	O
reveals	O
that	O
AAR3	B-Protein
,	O
a	O
gene	O
encoding	O
a	O
DCN1	B-Protein
-	O
like	O
protein	O
,	O
regulates	O
responses	O
to	O
the	O
synthetic	O
auxin	O
2	O
,	O
4	O
-	O
dichlorophenoxyacetic	O
acid	O
in	O
Arabidopsis	O
roots	O
.	O

To	O
isolate	O
novel	O
auxin	O
-	O
responsive	O
mutants	O
in	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
,	O
we	O
screened	O
mutants	O
for	O
root	O
growth	O
resistance	O
to	O
a	O
putative	O
antiauxin	O
,	O
p	O
-	O
chlorophenoxyisobutyric	O
acid	O
(	O
PCIB	O
)	O
,	O
which	O
inhibits	O
auxin	O
action	O
by	O
interfering	O
the	O
upstream	O
auxin	O
-	O
signaling	O
events	O
.	O

Eleven	O
PCIB	O
-	O
resistant	O
mutants	O
were	O
obtained	O
.	O

Genetic	O
mapping	O
indicates	O
that	O
the	O
mutations	O
are	O
located	O
in	O
at	O
least	O
five	O
independent	O
loci	O
,	O
including	O
two	O
known	O
auxin	O
-	O
related	O
loci	O
,	O
TRANSPORT	B-Protein
INHIBITOR	I-Protein
RESPONSE1	I-Protein
and	O
Arabidopsis	O
CULLIN1	B-Protein
.	O
antiauxin	O
-	O
resistant	O
mutants	O
(	O
aars	O
)	O
aar3	O
-	O
1	O
,	O
aar4	O
,	O
and	O
aar5	O
were	O
also	O
resistant	O
to	O
2	O
,	O
4	O
-	O
dichlorophenoxyacetic	O
acid	O
as	O
shown	O
by	O
a	O
root	O
growth	O
assay	O
.	O

Positional	O
cloning	O
of	O
aar3	O
-	O
1	O
revealed	O
that	O
the	O
AAR3	B-Protein
gene	O
encodes	O
a	O
protein	O
with	O
a	O
domain	O
of	O
unknown	O
function	O
(	O
DUF298	O
)	O
,	O
which	O
has	O
not	O
previously	O
been	O
implicated	O
in	O
auxin	O
signaling	O
.	O

The	O
protein	O
has	O
a	O
putative	O
nuclear	O
localization	O
signal	O
and	O
shares	O
homology	O
with	O
the	O
DEFECTIVE	B-Protein
IN	I-Protein
CULLIN	I-Protein
NEDDYLATION	I-Protein
-	I-Protein
1	I-Protein
protein	O
through	O
the	O
DUF298	O
domain	O
.	O

The	O
results	O
also	O
indicate	O
that	O
PCIB	O
can	O
facilitate	O
the	O
identification	O
of	O
factors	O
involved	O
in	O
auxin	O
or	O
auxin	O
-	O
related	O
signaling	O
.	O

Not	O
insulin	B-Protein
but	O
insulin	B-Protein
sensitivity	O
,	O
leptin	B-Protein
,	O
and	O
cortisol	O
are	O
major	O
factors	O
regulating	O
serum	O
acylated	O
ghrelin	B-Protein
level	O
in	O
healthy	O
women	O
.	O

It	O
has	O
been	O
suggested	O
that	O
insulin	B-Protein
and	O
glucose	O
are	O
the	O
most	O
important	O
factors	O
for	O
ghrelin	B-Protein
secretion	O
.	O

Most	O
of	O
these	O
studies	O
were	O
performed	O
using	O
total	O
ghrelin	B-Protein
assays	O
,	O
detecting	O
two	O
forms	O
of	O
ghrelin	B-Protein
(	O
acylated	O
and	O
desacyl	O
)	O
,	O
derived	O
from	O
the	O
same	O
peptide	O
precursor	O
but	O
having	O
different	O
biological	O
effects	O
.	O

This	O
study	O
was	O
therefore	O
designed	O
to	O
characterize	O
associations	O
between	O
serum	O
acylated	O
ghrelin	B-Protein
levels	O
(	O
Ghr	B-Protein
)	O
,	O
selected	O
adipocytokines	O
,	O
hormones	O
,	O
and	O
carbohydrate	O
metabolism	O
parameters	O
in	O
healthy	O
women	O
in	O
stable	O
energy	O
metabolism	O
.	O

The	O
study	O
was	O
performed	O
on	O
32	O
healthy	O
,	O
normal	O
-	O
weight	O
,	O
non	O
-	O
pregnant	O
women	O
with	O
normal	O
[	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
18	O
.	O
9	O
-	O
24	O
.	O
2	O
kg	O
/	O
m2	O
]	O
and	O
stable	O
(	O
the	O
difference	O
between	O
two	O
measurements	O
performed	O
within	O
1	O
month	O
being	O
less	O
than	O
0	O
.	O
5	O
kg	O
)	O
body	O
weight	O
,	O
aged	O
22	O
-	O
47	O
yr	O
.	O

Leptin	B-Protein
,	O
Ghr	B-Protein
,	O
GH	B-Protein
,	O
IGF	B-Protein
-	I-Protein
I	I-Protein
,	O
cortisol	O
,	O
insulin	B-Protein
,	O
and	O
glucose	O
were	O
measured	O
in	O
the	O
early	O
follicular	O
phase	O
of	O
the	O
menstruation	O
cycle	O
.	O

Insulin	B-Protein
sensitivity	O
was	O
measured	O
using	O
quantitative	O
insulin	B-Protein
sensitivity	O
check	O
index	O
(	O
QUICKI	O
)	O
.	O

Body	O
composition	O
was	O
assessed	O
by	O
bioimpedance	O
.	O

We	O
found	O
a	O
positive	O
linear	O
correlation	O
between	O
leptin	B-Protein
and	O
Ghr	B-Protein
(	O
r	O
=	O
0	O
.	O
375	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
and	O
negative	O
correlation	O
between	O
insulin	B-Protein
and	O
Ghr	B-Protein
(	O
r	O
=	O
-	O
0	O
.	O
374	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
.	O

GH	B-Protein
,	O
IGF	B-Protein
-	I-Protein
I	I-Protein
,	O
adiponectin	B-Protein
,	O
and	O
body	O
composition	O
parameters	O
did	O
not	O
correlate	O
with	O
Ghr	B-Protein
.	O

In	O
multiple	O
regression	O
analysis	O
only	O
QUICKI	O
,	O
leptin	B-Protein
,	O
glucose	O
,	O
and	O
cortisol	O
(	O
positively	O
)	O
and	O
age	O
(	O
negatively	O
)	O
accounted	O
for	O
50	O
%	O
variation	O
of	O
Ghr	B-Protein
.	O

Insulin	B-Protein
and	O
BMI	O
did	O
not	O
contribute	O
significantly	O
to	O
the	O
model	O
.	O

Our	O
results	O
suggest	O
that	O
in	O
healthy	O
women	O
basal	O
Ghr	B-Protein
level	O
is	O
regulated	O
by	O
multiple	O
factors	O
,	O
mainly	O
by	O
insulin	B-Protein
sensitivity	O
,	O
leptin	B-Protein
,	O
and	O
adrenal	O
glands	O
activity	O
.	O

However	O
,	O
further	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
physiological	O
mechanisms	O
involved	O
in	O
acylated	O
Ghr	B-Protein
secretion	O
.	O

The	O
role	O
of	O
loop	O
and	O
beta	O
-	O
turn	O
residues	O
as	O
structural	O
and	O
functional	O
determinants	O
for	O
the	O
lipoyl	O
domain	O
from	O
the	O
Escherichia	O
coli	O
2	O
-	O
oxoglutarate	O
dehydrogenase	O
complex	O
.	O

The	O
lipoyl	O
domain	O
of	O
the	O
dihydrolipoyl	B-Protein
succinyltransferase	I-Protein
(	I-Protein
E2o	I-Protein
)	I-Protein
component	I-Protein
of	I-Protein
the	I-Protein
2OGDH	I-Protein
(	I-Protein
2	I-Protein
-	I-Protein
oxoglutarate	I-Protein
dehydrogenase	I-Protein
)	I-Protein
multienzyme	I-Protein
complex	I-Protein
houses	O
the	O
lipoic	O
acid	O
cofactor	O
through	O
covalent	O
attachment	O
to	O
a	O
specific	O
lysine	O
side	O
chain	O
residing	O
at	O
the	O
tip	O
of	O
a	O
beta	O
-	O
turn	O
.	O

Residues	O
within	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
and	O
a	O
nearby	O
prominent	O
loop	O
have	O
been	O
implicated	O
as	O
determinants	O
of	O
lipoyl	O
domain	O
structure	O
and	O
function	O
.	O

Protein	O
engineering	O
of	O
the	O
Escherichia	O
coli	O
E2o	B-Protein
lipoyl	O
domain	O
(	O
E2olip	B-Protein
)	O
revealed	O
that	O
removal	O
of	O
residues	O
from	O
the	O
loop	O
caused	O
a	O
major	O
structural	O
change	O
in	O
the	O
protein	O
,	O
which	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
succinylation	O
by	O
2	B-Protein
-	I-Protein
oxoglutarate	I-Protein
decarboxylase	I-Protein
(	O
E1o	B-Protein
)	O
and	O
reduced	O
the	O
lipoylation	O
efficiency	O
.	O

Insertion	O
of	O
a	O
new	O
loop	O
corresponding	O
to	O
that	O
of	O
the	O
E	O
.	O
coli	O
pyruvate	O
dehydrogenase	O
lipoyl	O
domain	O
(	O
E2plip	B-Protein
)	O
restored	O
lipoylation	O
efficiency	O
and	O
the	O
capacity	O
to	O
undergo	O
reductive	O
succinylation	O
returned	O
,	O
albeit	O
at	O
a	O
lower	O
rate	O
.	O

Exchange	O
of	O
the	O
E2olip	B-Protein
loop	O
sequence	O
significantly	O
improved	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
acetylated	O
by	O
pyruvate	B-Protein
decarboxylase	I-Protein
(	O
E1p	B-Protein
)	O
,	O
retaining	O
approx	O
.	O
10	O
-	O
fold	O
more	O
acetyl	O
groups	O
after	O
25	O
min	O
than	O
wild	O
-	O
type	O
E2olip	B-Protein
.	O

Exchange	O
of	O
the	O
beta	O
-	O
turn	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
E2o	B-Protein
lipoyl	O
-	O
lysine	O
DK	O
(	O
A	O
)	O
/	O
(	O
V	O
)	O
motif	O
to	O
the	O
equivalent	O
residue	O
in	O
E2plip	B-Protein
(	O
T42G	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
reduced	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
succinylated	O
,	O
but	O
led	O
to	O
an	O
increased	O
capacity	O
to	O
be	O
reductively	O
acetylated	O
by	O
the	O
non	O
-	O
cognate	O
E1p	B-Protein
.	O

The	O
T42G	O
mutation	O
also	O
slightly	O
enhanced	O
the	O
lipoylation	O
rate	O
of	O
the	O
domain	O
.	O

The	O
surface	O
loop	O
is	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
protein	O
and	O
together	O
with	O
Thr42	O
plays	O
an	O
important	O
role	O
in	O
specifying	O
the	O
interaction	O
of	O
the	O
lipoyl	O
domain	O
with	O
its	O
partner	O
E1o	O
in	O
the	O
E	O
.	O
coli	O
2OGDH	O
complex	O
.	O

Daxx	B-Protein
mediates	O
SUMO	O
-	O
dependent	O
transcriptional	O
control	O
and	O
subnuclear	O
compartmentalization	O
.	O

SUMO	O
(	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
)	O
modification	O
is	O
emerging	O
as	O
an	O
important	O
post	O
-	O
translational	O
control	O
in	O
transcription	O
.	O

In	O
general	O
,	O
SUMO	O
modification	O
is	O
associated	O
with	O
transcriptional	O
repression	O
.	O

Although	O
many	O
SUMO	O
-	O
modified	O
transcription	O
factors	O
and	O
co	O
-	O
activators	O
have	O
been	O
identified	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
underlying	O
SUMOylation	O
-	O
elicited	O
transcriptional	O
repression	O
.	O

Here	O
,	O
we	O
summarize	O
that	O
SUMO	O
modification	O
of	O
transcription	O
factors	O
such	O
as	O
androgen	B-Protein
receptor	I-Protein
,	O
glucocorticoid	B-Protein
receptor	I-Protein
,	O
Smad4	B-Protein
and	O
CBP	B-Protein
[	O
CREB	B-Protein
(	I-Protein
cAMP	I-Protein
-	I-Protein
response	I-Protein
-	I-Protein
element	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
)	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
]	O
co	O
-	O
activator	O
results	O
in	O
the	O
recruitment	O
of	O
a	O
transcriptional	O
co	O
-	O
repressor	O
Daxx	B-Protein
,	O
thereby	O
causing	O
transcriptional	O
repression	O
.	O

Such	O
a	O
SUMO	O
-	O
dependent	O
recruitment	O
of	O
Daxx	B-Protein
is	O
mediated	O
by	O
the	O
interaction	O
between	O
the	O
SUMO	O
moiety	O
of	O
SUMOylated	O
factors	O
and	O
Daxx	B-Protein
SUMO	O
-	O
interacting	O
motif	O
.	O

Interestingly	O
,	O
the	O
transrepression	O
effect	O
of	O
Daxx	B-Protein
on	O
these	O
SUMOylated	O
transcription	O
factors	O
can	O
be	O
relieved	O
by	O
SUMOylated	O
PML	B-Protein
(	O
promyelocytic	B-Protein
leukaemia	I-Protein
)	O
via	O
altering	O
Daxx	B-Protein
partition	O
from	O
the	O
targeted	O
gene	O
promoter	O
to	O
PML	B-Protein
nuclear	O
bodies	O
.	O

Because	O
Daxx	B-Protein
SUMO	O
-	O
interacting	O
motif	O
is	O
a	O
common	O
binding	O
site	O
for	O
SUMOylated	O
factors	O
,	O
a	O
model	O
of	O
competition	O
for	O
Daxx	B-Protein
recruitment	O
between	O
SUMOylated	O
PML	B-Protein
and	O
SUMOylated	O
transcription	O
factors	O
was	O
proposed	O
.	O

Together	O
,	O
our	O
findings	O
strongly	O
suggest	O
that	O
Daxx	B-Protein
functions	O
as	O
a	O
SUMO	O
reader	O
in	O
the	O
SUMO	O
-	O
dependent	O
regulation	O
of	O
transcription	O
and	O
subnuclear	O
compartmentalization	O
.	O

Drugs	O
affecting	O
prelamin	B-Protein
A	I-Protein
processing	O
:	O
effects	O
on	O
heterochromatin	O
organization	O
.	O

Increasing	O
interest	O
in	O
drugs	O
acting	O
on	O
prelamin	B-Protein
A	I-Protein
has	O
derived	O
from	O
the	O
finding	O
of	O
prelamin	B-Protein
A	I-Protein
involvement	O
in	O
severe	O
laminopathies	O
.	O

Amelioration	O
of	O
the	O
nuclear	O
morphology	O
by	O
inhibitors	O
of	O
prelamin	B-Protein
A	I-Protein
farnesylation	O
has	O
been	O
widely	O
reported	O
in	O
progeroid	O
laminopathies	O
.	O

We	O
investigated	O
the	O
effects	O
on	O
chromatin	O
organization	O
of	O
two	O
drugs	O
inhibiting	O
prelamin	B-Protein
A	I-Protein
processing	O
by	O
an	O
ultrastructural	O
and	O
biochemical	O
approach	O
.	O

The	O
farnesyltransferase	O
inhibitor	O
FTI	O
-	O
277	O
and	O
the	O
non	O
-	O
peptidomimetic	O
drug	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
farnesyl	O
-	O
l	O
-	O
cysteine	O
methylester	O
(	O
AFCMe	O
)	O
were	O
administered	O
to	O
cultured	O
control	O
human	O
fibroblasts	O
for	O
6	O
or	O
18	O
h	O
.	O

FTI	O
-	O
277	O
interferes	O
with	O
protein	O
farnesylation	O
causing	O
accumulation	O
of	O
non	O
-	O
farnesylated	O
prelamin	B-Protein
A	I-Protein
,	O
while	O
AFCMe	O
impairs	O
the	O
last	O
cleavage	O
of	O
the	O
lamin	B-Protein
A	I-Protein
precursor	O
and	O
is	O
expected	O
to	O
accumulate	O
farnesylated	O
prelamin	B-Protein
A	I-Protein
.	O

FTI	O
-	O
277	O
caused	O
redistribution	O
of	O
heterochromatin	O
domains	O
at	O
the	O
nuclear	O
interior	O
,	O
while	O
AFCMe	O
caused	O
loss	O
of	O
heterochromatin	O
domains	O
,	O
increase	O
of	O
nuclear	O
size	O
and	O
nuclear	O
lamina	O
thickening	O
.	O

At	O
the	O
biochemical	O
level	O
,	O
heterochromatin	O
-	O
associated	O
proteins	O
and	O
LAP2	B-Protein
alpha	I-Protein
were	O
clustered	O
at	O
the	O
nuclear	O
interior	O
following	O
FTI	O
-	O
277	O
treatment	O
,	O
while	O
they	O
were	O
unevenly	O
distributed	O
or	O
absent	O
in	O
AFCMe	O
-	O
treated	O
nuclei	O
.	O

The	O
reported	O
effects	O
show	O
that	O
chromatin	O
is	O
an	O
immediate	O
target	O
of	O
FTI	O
-	O
277	O
and	O
AFCMe	O
and	O
that	O
dramatic	O
remodeling	O
of	O
chromatin	O
domains	O
occurs	O
following	O
treatment	O
with	O
the	O
drugs	O
.	O

These	O
effects	O
appear	O
to	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
the	O
accumulation	O
of	O
prelamin	B-Protein
A	I-Protein
forms	O
,	O
since	O
impairment	O
of	O
prelamin	B-Protein
A	I-Protein
accumulation	O
,	O
here	O
obtained	O
by	O
5	O
-	O
azadeoxycytidine	O
treatment	O
,	O
abolishes	O
the	O
chromatin	O
effects	O
.	O

These	O
results	O
may	O
be	O
used	O
to	O
evaluate	O
downstream	O
effects	O
of	O
FTIs	O
or	O
other	O
prelamin	B-Protein
A	I-Protein
inhibitors	O
potentially	O
useful	O
for	O
the	O
therapy	O
of	O
laminopathies	O
.	O

H2O2	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	O
determined	O
by	O
mass	O
spectrometry	O
:	O
redox	O
regulation	O
of	O
tyrosine	O
nitration	O
and	O
3	O
-	O
nitrotyrosine	O
reduction	O
by	O
antioxidants	O
.	O

Covalent	O
modifications	O
of	O
proteins	O
by	O
endogenous	O
reactive	O
nitrogen	O
oxide	O
species	O
lead	O
to	O
cytotoxic	O
effects	O
that	O
are	O
implicated	O
in	O
diseases	O
associated	O
with	O
chronic	O
infections	O
and	O
inflammation	O
.	O

Tyrosine	O
nitration	O
is	O
a	O
major	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
by	O
reactive	O
nitrogen	O
oxide	O
species	O
.	O

Recent	O
studies	O
suggest	O
that	O
nitrotyrosine	O
is	O
not	O
a	O
permanent	O
protein	O
modification	O
.	O

We	O
previously	O
demonstrated	O
that	O
lipoyl	O
dehydrogenase	O
is	O
capable	O
of	O
converting	O
3	O
-	O
nitrotyrosine	O
into	O
3	O
-	O
aminotyrosine	O
in	O
the	O
presence	O
of	O
certain	O
reducing	O
agents	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
various	O
hemoproteins	O
,	O
hemin	O
,	O
and	O
the	O
cobalt	O
-	O
containing	O
cofactor	O
cyanocobalamin	O
to	O
mediate	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
dependent	O
tyrosine	O
nitration	O
and	O
found	O
that	O
these	O
hemoproteins	O
and	O
metal	O
-	O
containing	O
cofactors	O
also	O
catalyzed	O
the	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
various	O
extents	O
in	O
the	O
presence	O
of	O
thiol	O
reducing	O
agents	O
or	O
ascorbate	O
.	O

The	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	O
identified	O
by	O
nanoLC	O
/	O
nanospray	O
ionization	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
digest	O
include	O
nitration	O
of	O
tyrosine	O
and	O
tryptophan	O
,	O
as	O
well	O
as	O
oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
.	O

Nitration	O
of	O
human	O
hemoglobin	O
by	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
was	O
detected	O
on	O
Tyr24	O
and	O
Tyr42	O
(	O
alpha	B-Protein
-	I-Protein
chain	I-Protein
)	O
and	O
on	O
Tyr130	O
and	O
Trp15	O
(	O
beta	B-Protein
-	I-Protein
chain	I-Protein
)	O
in	O
the	O
alphabeta	O
-	O
dimer	O
.	O

Oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
was	O
also	O
observed	O
.	O

Furthermore	O
,	O
hemoglobin	O
also	O
catalyzed	O
nitro	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
form	O
3	O
-	O
aminotyrosine	O
,	O
at	O
Tyr24	O
in	O
the	O
alpha	B-Protein
-	I-Protein
chain	I-Protein
peptide	O
of	O
human	O
Hb	O
in	O
the	O
presence	O
of	O
ascorbate	O
.	O

The	O
enhanced	O
peroxidase	O
activity	O
of	O
nitrated	O
hemoglobin	O
can	O
be	O
reversed	O
by	O
the	O
antioxidant	O
ascorbate	O
.	O

These	O
results	O
suggest	O
a	O
possible	O
in	O
vivo	O
pathway	O
for	O
hemoglobin	O
contributing	O
to	O
denitration	O
of	O
nitrated	O
proteins	O
through	O
redox	O
regulation	O
.	O

Specific	O
ion	O
influences	O
on	O
self	O
-	O
association	O
of	O
pyruvate	B-Protein
dehydrogenase	I-Protein
kinase	I-Protein
isoform	I-Protein
2	I-Protein
(	O
PDHK2	B-Protein
)	O
,	O
binding	O
of	O
PDHK2	B-Protein
to	O
the	O
L2	O
lipoyl	O
domain	O
,	O
and	O
effects	O
of	O
the	O
lipoyl	O
group	O
-	O
binding	O
site	O
inhibitor	O
,	O
Nov3r	O
.	O

Association	O
of	O
the	O
PDHK2	B-Protein
and	O
GST	B-Protein
-	O
L2	O
(	O
glutathione	B-Protein
-	I-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
fused	O
to	O
the	O
inner	O
lipoyl	O
domain	O
(	O
L2	O
)	O
of	O
dihydrolipoyl	B-Protein
acetyltransferase	I-Protein
(	O
E2	B-Protein
)	O
)	O
dimers	O
was	O
enhanced	O
by	O
K	O
+	O
with	O
higher	O
affinity	O
K	O
+	O
binding	O
than	O
occurs	O
at	O
the	O
PDHK2	B-Protein
active	O
site	O
.	O

Supporting	O
a	O
distinct	O
K	O
+	O
binding	O
site	O
,	O
the	O
NH4	O
+	O
ion	O
did	O
not	O
effectively	O
replace	O
K	O
+	O
in	O
aiding	O
GST	B-Protein
-	O
L2	O
binding	O
.	O

With	O
50	O
mM	O
K	O
+	O
,	O
Pi	O
enhanced	O
interference	O
by	O
ADP	O
,	O
ATP	O
,	O
or	O
pyruvate	O
of	O
PDHK2	B-Protein
binding	O
to	O
GST	B-Protein
-	O
L2	O
.	O

The	O
inclusion	O
of	O
Pi	O
with	O
ADP	O
or	O
ATP	O
plus	O
pyruvate	O
greatly	O
hindered	O
PDHK2	B-Protein
binding	O
to	O
GST	B-Protein
-	O
L2	O
and	O
promoted	O
PDHK2	O
forming	O
a	O
tetramer	O
.	O

Reciprocally	O
,	O
GST	B-Protein
-	O
L2	O
interference	O
with	O
ATP	O
/	O
ADP	O
binding	O
also	O
required	O
elevated	O
K	O
+	O
and	O
was	O
increased	O
by	O
Pi	O
.	O

Potent	O
inhibition	O
by	O
Nov3r	O
of	O
E2	B-Protein
-	O
activated	O
PDHK2	B-Protein
activity	O
(	O
IC50	O
of	O
approximately	O
7	O
.	O
8	O
nM	O
)	O
required	O
elevated	O
K	O
+	O
and	O
Pi	O
.	O

Nov3r	O
only	O
modestly	O
inhibited	O
the	O
low	O
activity	O
of	O
PDHK2	B-Protein
without	O
E2	B-Protein
.	O

By	O
binding	O
at	O
the	O
lipoyl	O
group	O
binding	O
site	O
,	O
Nov3r	O
prevented	O
PDHK2	O
binding	O
to	O
E2	B-Protein
and	O
GST	B-Protein
-	O
L2	O
.	O

Nov3r	O
interfered	O
with	O
high	O
-	O
affinity	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
via	O
a	O
Pi	O
-	O
dependent	O
mechanism	O
.	O

Thus	O
,	O
GST	B-Protein
-	O
L2	O
binding	O
to	O
PDHK2	B-Protein
is	O
supported	O
by	O
K	O
+	O
binding	O
at	O
a	O
site	O
distinct	O
from	O
the	O
active	O
site	O
.	O

Pi	O
makes	O
major	O
contributions	O
to	O
ligands	O
interfering	O
with	O
PDHK2	B-Protein
binding	O
to	O
GST	B-Protein
-	O
L2	O
,	O
the	O
conversion	O
of	O
PDHK2	B-Protein
dimer	O
to	O
a	O
tetramer	O
,	O
and	O
Nov3r	O
(	O
an	O
acetyl	O
-	O
lipoate	O
analog	O
)	O
interfering	O
with	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
.	O

Pi	O
is	O
suggested	O
to	O
facilitate	O
transmission	O
within	O
PDHK2	B-Protein
of	O
the	O
stimulatory	O
signal	O
of	O
acetylation	O
from	O
the	O
distal	O
lipoyl	O
-	O
group	O
binding	O
site	O
to	O
the	O
active	O
site	O
.	O

Studies	O
of	O
the	O
ubiquitin	B-Protein
proteasome	O
system	O
.	O

A	O
concept	O
that	O
has	O
arisen	O
over	O
the	O
last	O
decade	O
is	O
that	O
proteins	O
can	O
,	O
in	O
general	O
,	O
be	O
covalently	O
modified	O
by	O
polypeptides	O
,	O
resulting	O
in	O
alterations	O
in	O
their	O
fate	O
and	O
function	O
.	O

The	O
first	O
-	O
identified	O
and	O
most	O
well	O
studied	O
of	O
these	O
modifying	O
polypeptides	O
is	O
ubiquitin	B-Protein
.	O

Although	O
targeting	O
for	O
proteasomal	O
degradation	O
is	O
the	O
best	O
studied	O
outcome	O
of	O
ubiquitylation	O
,	O
we	O
now	O
understand	O
that	O
modification	O
of	O
proteins	O
with	O
ubiquitin	B-Protein
has	O
numerous	O
other	O
cellular	O
roles	O
that	O
alter	O
protein	O
function	O
and	O
that	O
are	O
unrelated	O
to	O
proteasomal	O
degradation	O
.	O

Ubiquitylation	O
is	O
a	O
complex	O
process	O
that	O
is	O
regulated	O
at	O
the	O
level	O
of	O
both	O
addition	O
and	O
removal	O
of	O
ubiquitin	B-Protein
from	O
target	O
proteins	O
.	O

This	O
unit	O
includes	O
a	O
number	O
of	O
different	O
basic	O
protocols	O
that	O
will	O
facilitate	O
the	O
study	O
of	O
components	O
of	O
the	O
ubiquitin	B-Protein
system	O
and	O
substrate	O
ubiquitylation	O
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Because	O
another	O
protein	O
modifier	O
,	O
NEDD8	B-Protein
,	O
itself	O
regulates	O
aspects	O
of	O
the	O
ubiquitin	B-Protein
system	O
,	O
basic	O
protocols	O
on	O
neddylation	O
are	O
also	O
included	O
in	O
this	O
unit	O
.	O

Fine	O
mapping	O
of	O
posttranslational	O
modifications	O
of	O
the	O
linker	O
histone	B-Protein
H1	I-Protein
from	O
Drosophila	O
melanogaster	O
.	O

The	O
linker	O
histone	B-Protein
H1	I-Protein
binds	O
to	O
the	O
DNA	O
in	O
between	O
adjacent	O
nucleosomes	O
and	O
contributes	O
to	O
chromatin	O
organization	O
and	O
transcriptional	O
control	O
.	O

It	O
is	O
known	O
that	O
H1	B-Protein
carries	O
diverse	O
posttranslational	O
modifications	O
(	O
PTMs	O
)	O
,	O
including	O
phosphorylation	O
,	O
lysine	O
methylation	O
and	O
ADP	O
-	O
ribosylation	O
.	O

Their	O
biological	O
functions	O
,	O
however	O
,	O
remain	O
largely	O
unclear	O
.	O

This	O
is	O
in	O
part	O
due	O
to	O
the	O
fact	O
that	O
most	O
of	O
the	O
studies	O
have	O
been	O
performed	O
in	O
organisms	O
that	O
have	O
several	O
H1	B-Protein
variants	O
,	O
which	O
complicates	O
the	O
analyses	O
.	O

We	O
have	O
chosen	O
Drosophila	O
melanogaster	O
,	O
a	O
model	O
organism	O
,	O
which	O
has	O
a	O
single	O
H1	B-Protein
variant	O
,	O
to	O
approach	O
the	O
study	O
of	O
the	O
role	O
of	O
H1	B-Protein
PTMs	O
during	O
embryonic	O
development	O
.	O

Mass	O
spectrometry	O
mapping	O
of	O
the	O
entire	O
sequence	O
of	O
the	O
protein	O
showed	O
phosphorylation	O
only	O
in	O
the	O
ten	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
mostly	O
at	O
S10	O
.	O

For	O
the	O
first	O
time	O
,	O
changes	O
in	O
the	O
PTMs	O
of	O
a	O
linker	O
H1	B-Protein
during	O
the	O
development	O
of	O
a	O
multicellular	O
organism	O
are	O
reported	O
.	O

The	O
abundance	O
of	O
H1	B-Protein
monophosphorylated	O
at	O
S10	O
decreases	O
as	O
the	O
embryos	O
age	O
,	O
which	O
suggests	O
that	O
this	O
PTM	O
is	O
related	O
to	O
cell	O
cycle	O
progression	O
and	O
/	O
or	O
cell	O
differentiation	O
.	O

Additionally	O
,	O
we	O
have	O
found	O
a	O
polymorphism	O
in	O
the	O
protein	O
sequence	O
that	O
can	O
be	O
mistaken	O
with	O
lysine	O
methylation	O
if	O
the	O
analysis	O
is	O
not	O
rigorous	O
.	O

NEDD8	B-Protein
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	B-Protein
.	O

The	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumour	I-Protein
suppressor	I-Protein
protein	O
is	O
important	O
in	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
ECV	O
(	O
Elongin	B-Protein
B	I-Protein
/	O
C	B-Protein
-	O
CUL2	B-Protein
-	O
VHL	B-Protein
)	O
-	O
mediated	O
destruction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
and	O
the	O
promotion	O
of	O
fibronectin	B-Protein
(	O
FN	B-Protein
)	O
extracellular	O
matrix	O
assembly	O
.	O

Although	O
the	O
precise	O
molecular	O
mechanism	O
controlling	O
the	O
selectivity	O
of	O
VHL	B-Protein
function	O
remains	O
unknown	O
,	O
a	O
failure	O
in	O
either	O
process	O
is	O
associated	O
with	O
oncogenic	O
progression	O
.	O

Here	O
,	O
we	O
show	O
that	O
VHL	B-Protein
performs	O
its	O
FN	B-Protein
-	O
associated	O
function	O
independently	O
of	O
the	O
ECV	O
complex	O
,	O
highlighting	O
the	O
autonomy	O
of	O
these	O
pathways	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
NEDD8	B-Protein
,	O
a	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
,	O
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
in	O
which	O
its	O
covalent	O
conjugation	O
to	O
VHL	B-Protein
prohibits	O
the	O
engagement	O
of	O
the	O
scaffold	O
component	O
CUL2	B-Protein
and	O
,	O
concomitantly	O
,	O
activates	O
the	O
association	O
with	O
FN	B-Protein
.	O

These	O
findings	O
provide	O
the	O
first	O
mechanistic	O
step	O
in	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	B-Protein
and	O
explain	O
a	O
previously	O
unrecognized	O
function	O
of	O
NEDD8	B-Protein
.	O

Redox	O
-	O
mediated	O
modification	O
of	O
PLZF	B-Protein
by	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
ubiquitin	B-Protein
.	O

Earlier	O
,	O
we	O
reported	O
that	O
the	O
transcriptional	O
repressor	O
promyelocytic	B-Protein
leukemia	I-Protein
zinc	I-Protein
-	I-Protein
finger	I-Protein
protein	I-Protein
(	O
PLZF	B-Protein
)	O
is	O
sumoylated	O
at	O
position	O
K242	O
,	O
and	O
the	O
sumoylation	O
regulated	O
its	O
biological	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
sumoylation	O
site	O
can	O
be	O
modified	O
by	O
ubiquitin	B-Protein
.	O

The	O
stability	O
and	O
nuclear	O
localization	O
of	O
PLZF	B-Protein
were	O
regulated	O
by	O
the	O
antagonistic	O
relationship	O
between	O
sumoylation	O
and	O
ubiquitination	O
.	O

We	O
observed	O
the	O
antagonistic	O
effects	O
of	O
ubiquitin	B-Protein
and	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
on	O
PLZF	B-Protein
under	O
oxidative	O
stress	O
induced	O
by	O
serum	O
deprivation	O
.	O

Thus	O
,	O
the	O
choice	O
between	O
modification	O
of	O
PLZF	B-Protein
by	O
SUMO	O
or	O
ubiquitin	B-Protein
was	O
determined	O
by	O
the	O
intracellular	O
level	O
of	O
ROS	O
,	O
which	O
was	O
generated	O
by	O
serum	O
deprivation	O
that	O
inactivated	O
the	O
SUMO	O
-	O
conjugating	O
enzymes	O
Uba2	B-Protein
and	O
Ubc9	B-Protein
,	O
and	O
resulted	O
in	O
decrease	O
of	O
sumoylation	O
.	O

The	O
ubiquitination	O
was	O
increased	O
under	O
these	O
conditions	O
.	O

The	O
expression	O
of	O
BID	B-Protein
,	O
a	O
known	O
transcriptional	O
target	O
protein	O
of	O
PLZF	B-Protein
,	O
was	O
decreased	O
,	O
and	O
the	O
consequent	O
apoptosis	O
was	O
induced	O
by	O
the	O
ROS	O
generated	O
during	O
serum	O
starvation	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
PLZF	B-Protein
post	O
-	O
translational	O
modification	O
is	O
controlled	O
by	O
intracellular	O
ROS	O
,	O
and	O
the	O
biological	O
function	O
of	O
PLZF	B-Protein
is	O
regulated	O
by	O
sumoylation	O
and	O
ubiquitination	O
.	O

Sumoylation	O
and	O
the	O
function	O
of	O
CCAAT	B-Protein
enhancer	I-Protein
binding	I-Protein
protein	I-Protein
alpha	I-Protein
(	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
)	O
.	O

CCAAT	B-Protein
enhancer	I-Protein
binding	I-Protein
protein	I-Protein
alpha	I-Protein
(	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
)	O
is	O
the	O
founding	O
member	O
of	O
a	O
family	O
of	O
basic	O
region	O
/	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
transcription	O
factors	O
and	O
is	O
a	O
master	O
regulator	O
of	O
granulopoiesis	O
.	O

It	O
is	O
expressed	O
at	O
high	O
levels	O
throughout	O
myeloid	O
differentiation	O
and	O
binds	O
to	O
the	O
promoters	O
of	O
multiple	O
myeloid	O
-	O
specific	O
genes	O
at	O
different	O
stages	O
of	O
myeloid	O
maturation	O
.	O

Profound	O
hematopoietic	O
abnormalities	O
occur	O
in	O
mice	O
nullizygous	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
including	O
a	O
selective	O
early	O
block	O
in	O
the	O
differentiation	O
of	O
granulocytes	O
.	O

Mutations	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
are	O
present	O
in	O
a	O
subset	O
of	O
patients	O
with	O
AML	O
presenting	O
with	O
a	O
normal	O
karyotype	O
.	O

These	O
mutations	O
can	O
result	O
in	O
the	O
expression	O
of	O
a	O
30	O
kDa	O
dominant	O
negative	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
isoform	O
,	O
which	O
contributes	O
to	O
loss	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
function	O
.	O

The	O
molecular	O
basis	O
for	O
this	O
observation	O
remains	O
unknown	O
.	O

In	O
addition	O
to	O
phosphorylation	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
is	O
modified	O
,	O
post	O
-	O
translationally	O
by	O
a	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
at	O
a	O
lysine	O
residue	O
(	O
K159	O
)	O
,	O
which	O
lies	O
within	O
the	O
growth	O
inhibitory	O
region	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
protein	O
.	O

Sumoylation	O
at	O
K159	O
in	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
protein	O
prevents	O
association	O
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
remodeling	O
complex	O
with	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
,	O
thereby	O
hampering	O
transactivation	O
.	O

In	O
this	O
review	O
,	O
the	O
functional	O
implications	O
of	O
post	O
-	O
translational	O
modification	O
,	O
particularly	O
sumoylation	O
,	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
in	O
normal	O
granulopoiesis	O
and	O
leukemia	O
are	O
considered	O
.	O

Interaction	O
of	O
a	O
peptide	O
derived	O
from	O
glycoprotein	O
gp36	B-Protein
of	O
feline	O
immunodeficiency	O
virus	O
and	O
its	O
lipoylated	O
analogue	O
with	O
phospholipid	O
membranes	O
.	O

P59	O
,	O
a	O
20	O
-	O
mer	O
peptide	O
modeled	O
on	O
the	O
membrane	O
-	O
proximal	O
external	O
region	O
(	O
MPER	O
)	O
of	O
the	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
)	O
gp36	B-Protein
ectodomain	O
,	O
has	O
potent	O
antiviral	O
activity	O
.	O

The	O
lipoylated	O
analogue	O
,	O
lipo	O
-	O
P59	O
,	O
displays	O
a	O
similar	O
activity	O
,	O
which	O
is	O
preferentially	O
retained	O
by	O
cellular	O
substrates	O
.	O

A	O
mechanism	O
has	O
been	O
proposed	O
recently	O
in	O
which	O
the	O
peptide	O
,	O
being	O
positioned	O
on	O
the	O
surface	O
of	O
the	O
cell	O
membrane	O
,	O
inhibits	O
its	O
fusion	O
with	O
the	O
virus	O
;	O
the	O
lipophilic	O
chain	O
of	O
lipo	O
-	O
P59	O
is	O
thought	O
to	O
insert	O
into	O
the	O
membrane	O
interior	O
,	O
thus	O
anchoring	O
the	O
peptide	O
at	O
the	O
surface	O
.	O

In	O
the	O
present	O
work	O
,	O
lipid	O
-	O
peptide	O
interactions	O
of	O
P59	O
and	O
lipo	O
-	O
P59	O
with	O
phospholipid	O
liposomes	O
are	O
investigated	O
using	O
spin	O
-	O
label	O
electron	O
spin	O
resonance	O
spectroscopy	O
.	O

Two	O
phospholipids	O
have	O
been	O
examined	O
,	O
the	O
zwitterionic	O
dimyristoyl	O
phosphatidylcholine	O
and	O
the	O
anionic	O
dimyristoyl	O
phosphatidylglycerol	O
,	O
and	O
a	O
wide	O
range	O
of	O
lipid	O
spin	O
labels	O
,	O
including	O
positional	O
isomers	O
.	O

Independent	O
of	O
the	O
membrane	O
charge	O
,	O
both	O
peptides	O
bind	O
to	O
lipid	O
bilayers	O
;	O
however	O
,	O
whereas	O
P59	O
insertion	O
between	O
the	O
lipid	O
headgroups	O
leads	O
to	O
significant	O
liposome	O
destabilization	O
,	O
eventually	O
resulting	O
in	O
vesicle	O
fragmentation	O
with	O
the	O
formation	O
of	O
smaller	O
aggregates	O
,	O
lipo	O
-	O
P59	O
inserts	O
with	O
the	O
lipophilic	O
tail	O
among	O
the	O
lipid	O
chains	O
,	O
while	O
the	O
peptidic	O
portion	O
remains	O
adsorbed	O
onto	O
the	O
membrane	O
,	O
where	O
it	O
can	O
effectively	O
exert	O
its	O
antiviral	O
activity	O
.	O

MEC	B-Protein
-	I-Protein
2	I-Protein
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
in	O
the	O
Caenorhabditis	O
elegans	O
sensory	O
mechanotransduction	O
complex	O
:	O
auxiliary	O
subunits	O
that	O
enable	O
channel	O
activity	O
.	O

The	O
ion	O
channel	O
formed	O
by	O
the	O
homologous	O
proteins	O
MEC	B-Protein
-	I-Protein
4	I-Protein
and	O
MEC	B-Protein
-	I-Protein
10	I-Protein
forms	O
the	O
core	O
of	O
a	O
sensory	O
mechanotransduction	O
channel	O
in	O
Caenorhabditis	O
elegans	O
.	O

Although	O
the	O
products	O
of	O
other	O
mec	O
genes	O
are	O
key	O
players	O
in	O
the	O
biophysics	O
of	O
transduction	O
,	O
the	O
mechanism	O
by	O
which	O
they	O
contribute	O
to	O
the	O
properties	O
of	O
the	O
channel	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
two	O
auxiliary	O
channel	O
subunits	O
,	O
MEC	B-Protein
-	I-Protein
2	I-Protein
(	O
stomatin	O
-	O
like	O
)	O
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
(	O
paraoxonase	O
-	O
like	O
)	O
,	O
by	O
coexpressing	O
them	O
with	O
constitutively	O
active	O
MEC	B-Protein
-	I-Protein
4	I-Protein
/	O
MEC	B-Protein
-	I-Protein
10	I-Protein
heteromeric	O
channels	O
in	O
Xenopus	O
oocytes	O
.	O

This	O
work	O
extends	O
prior	O
work	O
demonstrating	O
that	O
MEC	B-Protein
-	I-Protein
2	I-Protein
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
synergistically	O
increase	O
macroscopic	O
current	O
.	O

We	O
use	O
single	O
-	O
channel	O
recordings	O
and	O
biochemistry	O
to	O
show	O
that	O
these	O
auxiliary	O
subunits	O
alter	O
function	O
by	O
increasing	O
the	O
number	O
of	O
channels	O
in	O
an	O
active	O
state	O
rather	O
than	O
by	O
dramatically	O
affecting	O
either	O
single	O
-	O
channel	O
properties	O
or	O
surface	O
expression	O
.	O

We	O
also	O
use	O
two	O
-	O
electrode	O
voltage	O
clamp	O
and	O
outside	O
-	O
out	O
macropatch	O
recording	O
to	O
examine	O
the	O
effects	O
of	O
divalent	O
cations	O
and	O
proteases	O
,	O
known	O
regulators	O
of	O
channel	O
family	O
members	O
.	O

Finally	O
,	O
we	O
examine	O
the	O
role	O
of	O
cholesterol	O
binding	O
in	O
the	O
mechanism	O
of	O
MEC	B-Protein
-	I-Protein
2	I-Protein
action	O
by	O
measuring	O
whole	O
-	O
cell	O
and	O
single	O
-	O
channel	O
currents	O
in	O
MEC	B-Protein
-	I-Protein
2	I-Protein
mutants	O
deficient	O
in	O
cholesterol	O
binding	O
.	O

We	O
suggest	O
that	O
MEC	B-Protein
-	I-Protein
2	I-Protein
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
play	O
essential	O
roles	O
in	O
modulating	O
both	O
the	O
local	O
membrane	O
environment	O
of	O
MEC	B-Protein
-	I-Protein
4	I-Protein
/	O
MEC	B-Protein
-	I-Protein
10	I-Protein
channels	O
and	O
the	O
availability	O
of	O
such	O
channels	O
to	O
be	O
gated	O
by	O
force	O
in	O
vivo	O
.	O

Constitutively	O
active	O
Rheb	B-Protein
induces	O
oncogenic	O
transformation	O
.	O

Rheb	B-Protein
(	O
Ras	B-Protein
-	I-Protein
homolog	I-Protein
enriched	I-Protein
in	I-Protein
brain	I-Protein
)	O
is	O
a	O
component	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
target	B-Protein
of	I-Protein
rapamycin	I-Protein
(	O
TOR	B-Protein
)	O
signaling	O
pathway	O
,	O
functioning	O
as	O
a	O
positive	O
regulator	O
of	O
TOR	B-Protein
.	O

Constitutively	O
active	O
mutants	O
of	O
Rheb	B-Protein
induce	O
oncogenic	O
transformation	O
in	O
cell	O
culture	O
.	O

The	O
transformed	O
cells	O
are	O
larger	O
and	O
contain	O
more	O
protein	O
than	O
their	O
normal	O
counterparts	O
.	O

They	O
show	O
constitutive	O
phosphorylation	O
of	O
the	O
ribosomal	O
protein	O
S6	O
kinase	O
and	O
the	O
eukaryotic	B-Protein
initiation	I-Protein
factor	I-Protein
4E	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
,	O
two	O
downstream	O
targets	O
of	O
TOR	B-Protein
.	O

The	O
TOR	B-Protein
-	O
specific	O
inhibitor	O
rapamycin	O
strongly	O
interferes	O
with	O
transformation	O
induced	O
by	O
constitutively	O
active	O
Rheb	B-Protein
,	O
suggesting	O
that	O
TOR	B-Protein
activity	O
is	O
essential	O
for	O
the	O
oncogenic	O
effects	O
of	O
mutant	O
Rheb	B-Protein
.	O

Rheb	B-Protein
-	O
induced	O
transformation	O
is	O
also	O
dependent	O
on	O
a	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
that	O
mediates	O
localization	O
to	O
a	O
cellular	O
membrane	O
.	O

An	O
engineered	O
N	O
-	O
terminal	O
myristylation	O
signal	O
can	O
substitute	O
for	O
the	O
farnesylation	O
.	O

Immunofluorescence	O
localizes	O
wild	O
-	O
type	O
and	O
mutant	O
Rheb	B-Protein
to	O
vesicular	O
structures	O
in	O
the	O
cytoplasm	O
,	O
overlapping	O
with	O
the	O
endoplasmic	O
reticulum	O
.	O

Hhat	B-Protein
is	O
a	O
palmitoylacyltransferase	O
with	O
specificity	O
for	O
N	O
-	O
palmitoylation	O
of	O
Sonic	B-Protein
Hedgehog	I-Protein
.	O

Palmitoylation	O
of	O
Sonic	B-Protein
Hedgehog	I-Protein
(	O
Shh	B-Protein
)	O
is	O
critical	O
for	O
effective	O
long	O
-	O
and	O
short	O
-	O
range	O
signaling	O
.	O

Genetic	O
screens	O
uncovered	O
a	O
potential	O
palmitoylacyltransferase	O
(	O
PAT	O
)	O
for	O
Shh	B-Protein
,	O
Hhat	B-Protein
,	O
but	O
the	O
molecular	O
mechanism	O
of	O
Shh	B-Protein
palmitoylation	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
have	O
developed	O
and	O
exploited	O
an	O
in	O
vitro	O
Shh	B-Protein
palmitoylation	O
assay	O
to	O
purify	O
Hhat	B-Protein
to	O
homogeneity	O
.	O

We	O
provide	O
direct	O
biochemical	O
evidence	O
that	O
Hhat	B-Protein
is	O
a	O
PAT	O
with	O
specificity	O
for	O
attaching	O
palmitate	O
via	O
amide	O
linkage	O
to	O
the	O
N	O
-	O
terminal	O
cysteine	O
of	O
Shh	B-Protein
.	O

Other	O
palmitoylated	O
proteins	O
(	O
e	O
.	O
g	O
.	O
PSD95	B-Protein
and	O
Wnt	O
)	O
are	O
not	O
substrates	O
for	O
Hhat	B-Protein
,	O
and	O
Porcupine	O
,	O
a	O
putative	O
Wnt	O
PAT	O
,	O
does	O
not	O
palmitoylate	O
Shh	B-Protein
.	O

Neither	O
autocleavage	O
nor	O
cholesterol	O
modification	O
is	O
required	O
for	O
Shh	B-Protein
palmitoylation	O
.	O

Both	O
the	O
Shh	B-Protein
precursor	O
and	O
mature	O
protein	O
are	O
N	O
-	O
palmitoylated	O
by	O
Hhat	B-Protein
,	O
and	O
the	O
reaction	O
occurs	O
during	O
passage	O
through	O
the	O
secretory	O
pathway	O
.	O

This	O
study	O
establishes	O
Hhat	B-Protein
as	O
a	O
bona	O
fide	O
Shh	B-Protein
PAT	O
and	O
serves	O
as	O
a	O
model	O
for	O
understanding	O
how	O
secreted	O
morphogens	O
are	O
modified	O
by	O
distinct	O
PATs	O
.	O

Effect	O
of	O
metal	O
binding	O
and	O
posttranslational	O
lysine	O
carboxylation	O
on	O
the	O
activity	O
of	O
recombinant	O
hydantoinase	B-Protein
.	O

Bacterial	O
hydantoinase	B-Protein
possesses	O
a	O
binuclear	O
metal	O
center	O
in	O
which	O
two	O
metal	O
ions	O
are	O
bridged	O
by	O
a	O
posttranslationally	O
carboxylated	O
lysine	O
.	O

How	O
the	O
carboxylated	O
lysine	O
and	O
metal	O
binding	O
affect	O
the	O
activity	O
of	O
hydantoinase	B-Protein
was	O
investigated	O
.	O

A	O
significant	O
amount	O
of	O
iron	O
was	O
always	O
found	O
in	O
Agrobacterium	O
radiobacter	O
hydantoinase	B-Protein
purified	O
from	O
unsupplemented	O
cobalt	O
-	O
,	O
manganese	O
-	O
,	O
or	O
zinc	O
-	O
amended	O
Escherichia	O
coli	O
cell	O
cultures	O
.	O

A	O
titration	O
curve	O
for	O
the	O
reactivation	O
of	O
apohydantoinase	B-Protein
with	O
cobalt	O
indicates	O
that	O
the	O
first	O
metal	O
was	O
preferentially	O
bound	O
but	O
did	O
not	O
give	O
any	O
enzyme	O
activity	O
until	O
the	O
second	O
metal	O
was	O
also	O
attached	O
to	O
the	O
hydantoinase	B-Protein
.	O

The	O
pH	O
profiles	O
of	O
the	O
metal	O
-	O
reconstituted	O
hydantoinase	O
were	O
dependent	O
on	O
the	O
specific	O
metal	O
ion	O
bound	O
to	O
the	O
active	O
site	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
metal	O
in	O
catalysis	O
.	O

Mutation	O
of	O
the	O
metal	O
binding	O
site	O
residues	O
,	O
H57A	O
,	O
H59A	O
,	O
K148A	O
,	O
H181A	O
,	O
H237A	O
,	O
and	O
D313A	O
,	O
completely	O
abolished	O
hydantoinase	B-Protein
activity	O
but	O
preserved	O
about	O
half	O
of	O
the	O
metal	O
content	O
,	O
except	O
for	O
K148A	O
,	O
which	O
lost	O
both	O
metals	O
in	O
its	O
active	O
site	O
.	O

However	O
,	O
the	O
activity	O
of	O
K148A	O
could	O
be	O
chemically	O
rescued	O
by	O
short	O
-	O
chain	O
carboxylic	O
acids	O
in	O
the	O
presence	O
of	O
cobalt	O
,	O
indicating	O
that	O
the	O
carboxylated	O
lysine	O
was	O
needed	O
to	O
coordinate	O
the	O
binuclear	O
ion	O
within	O
the	O
active	O
site	O
of	O
hydantoinase	B-Protein
.	O

The	O
mutant	O
D313E	O
enzyme	O
was	O
also	O
active	O
but	O
resulted	O
in	O
a	O
pH	O
profile	O
different	O
from	O
that	O
of	O
wild	O
-	O
type	O
hydantoinase	B-Protein
.	O

A	O
mechanism	O
for	O
hydantoinase	B-Protein
involving	O
metal	O
,	O
carboxylated	O
K148	O
,	O
and	O
D313	O
was	O
proposed	O
.	O

Versatile	O
role	O
of	O
the	O
yeast	O
ubiquitin	B-Protein
ligase	O
Rsp5p	B-Protein
in	O
intracellular	O
trafficking	O
.	O

The	O
ubiquitin	B-Protein
ligase	O
(	O
E3	O
)	O
Rsp5p	B-Protein
is	O
the	O
only	O
member	O
of	O
the	O
Nedd	B-Protein
(	I-Protein
neural	I-Protein
-	I-Protein
precursor	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
expressed	I-Protein
,	I-Protein
developmentally	I-Protein
down	I-Protein
-	I-Protein
regulated	I-Protein
)	I-Protein
4	I-Protein
family	O
of	O
E3s	O
present	O
in	O
yeast	O
.	O

Rsp5p	B-Protein
has	O
several	O
proteasome	O
-	O
independent	O
functions	O
in	O
membrane	O
protein	O
trafficking	O
,	O
including	O
a	O
role	O
in	O
the	O
ubiquitination	O
of	O
most	O
plasma	O
membrane	O
proteins	O
,	O
leading	O
to	O
their	O
endocytosis	O
.	O

Rsp5p	B-Protein
is	O
also	O
required	O
for	O
the	O
ubiquitination	O
of	O
endosomal	O
proteins	O
,	O
leading	O
to	O
their	O
sorting	O
to	O
the	O
internal	O
vesicles	O
of	O
MVBs	O
(	O
multivesicular	O
bodies	O
)	O
.	O

Rsp5p	B-Protein
catalyses	O
the	O
attachment	O
of	O
non	O
-	O
conventional	O
ubiquitin	B-Protein
chains	O
,	O
linked	O
through	O
ubiquitin	B-Protein
Lys	O
-	O
63	O
,	O
to	O
some	O
endocytic	O
and	O
MVB	O
cargoes	O
.	O

This	O
modification	O
appears	O
to	O
be	O
required	O
for	O
efficient	O
sorting	O
,	O
possibly	O
because	O
these	O
chains	O
have	O
a	O
greater	O
affinity	O
for	O
the	O
ubiquitin	B-Protein
-	O
binding	O
domains	O
present	O
within	O
endocytic	O
or	O
MVB	O
sorting	O
complexes	O
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
recognition	O
of	O
plasma	O
membrane	O
and	O
MVB	O
substrates	O
by	O
Rsp5p	B-Protein
remain	O
unclear	O
.	O

A	O
subset	O
of	O
Rsp5	B-Protein
/	O
Nedd4	B-Protein
substrates	O
have	O
a	O
'	O
PY	O
motif	O
'	O
and	O
are	O
recognized	O
directly	O
by	O
the	O
WW	O
(	O
Trp	O
-	O
Trp	O
)	O
domains	O
of	O
Rsp5p	B-Protein
.	O

Most	O
Rsp5p	B-Protein
substrates	O
do	O
not	O
carry	O
PY	O
motifs	O
,	O
but	O
some	O
may	O
depend	O
on	O
PY	O
-	O
containing	O
proteins	O
for	O
their	O
ubiquitination	O
by	O
Rsp5p	B-Protein
,	O
consistent	O
with	O
the	O
latter	O
'	O
s	O
acting	O
as	O
specificity	O
factors	O
or	O
adaptors	O
.	O

As	O
in	O
other	O
ubiquitin	B-Protein
-	O
conjugating	O
systems	O
,	O
these	O
adaptors	O
are	O
also	O
Rsp5p	B-Protein
substrates	O
and	O
undergo	O
ubiquitin	B-Protein
-	O
dependent	O
trafficking	O
.	O

In	O
the	O
present	O
review	O
,	O
we	O
discuss	O
recent	O
examples	O
illustrating	O
the	O
role	O
of	O
Rsp5p	B-Protein
in	O
membrane	O
protein	O
trafficking	O
and	O
providing	O
new	O
insights	O
into	O
the	O
regulation	O
of	O
this	O
E3	O
by	O
adaptor	O
proteins	O
.	O

Characterization	O
of	O
the	O
35	O
-	O
kilodalton	O
Treponema	O
pallidum	O
subsp	O
.	O
pallidum	O
recombinant	O
lipoprotein	O
TmpC	B-Protein
and	O
antibody	O
response	O
to	O
lipidated	O
and	O
nonlipidated	O
T	O
.	O
pallidum	O
antigens	O
.	O

The	O
gene	O
encoding	O
the	O
35	O
-	O
kDa	O
immunogenic	O
Treponema	O
pallidium	O
subsp	O
.	O
pallidum	O
(	O
T	O
.	O
pallidum	O
)	O
membrane	O
protein	O
C	O
,	O
TmpC	B-Protein
,	O
was	O
cloned	O
,	O
sequenced	O
,	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
carries	O
on	O
N	O
-	O
terminal	O
signal	O
sequence	O
with	O
a	O
four	O
-	O
amino	O
-	O
acid	O
motif	O
,	O
which	O
is	O
characteristic	O
for	O
bacterial	O
lipoproteins	O
.	O

Metabolic	O
labeling	O
with	O
radioactive	O
palmitic	O
acid	O
of	O
E	O
.	O
coli	O
expressing	O
TmpC	B-Protein
revealed	O
incorporation	O
of	O
the	O
fatty	O
acid	O
into	O
the	O
antigen	O
.	O

The	O
antigen	O
was	O
overproduced	O
,	O
purified	O
to	O
near	O
homogeneity	O
and	O
used	O
in	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
to	O
evaluate	O
its	O
potential	O
for	O
the	O
serodiagnosis	O
of	O
syphilis	O
.	O

Although	O
all	O
sera	O
from	O
untreated	O
secondary	O
syphilis	O
patients	O
were	O
reactive	O
in	O
this	O
TmpC	B-Protein
ELISA	O
,	O
only	O
a	O
minority	O
of	O
the	O
serum	O
samples	O
from	O
untreated	O
patients	O
in	O
the	O
primary	O
or	O
early	O
latent	O
stage	O
of	O
the	O
disease	O
contained	O
significant	O
anti	O
-	O
TmpC	B-Protein
antibodies	O
.	O

To	O
study	O
the	O
influence	O
of	O
the	O
lipid	O
moiety	O
on	O
the	O
antigenic	O
properties	O
of	O
the	O
TmpC	B-Protein
,	O
TmpA	B-Protein
,	O
and	O
TpD	B-Protein
lipoproteins	O
,	O
plasmids	O
encoding	O
nonlipidated	O
forms	O
of	O
these	O
antigens	O
were	O
constructed	O
.	O

In	O
addition	O
,	O
a	O
plasmid	O
expressing	O
a	O
lipidated	O
form	O
of	O
the	O
otherwise	O
non	O
-	O
lipid	O
-	O
modified	O
antigen	O
TmpB	B-Protein
was	O
constructed	O
.	O

Immunization	O
and	O
absorption	O
experiments	O
with	O
these	O
lipidated	O
and	O
nonlipidated	O
antigens	O
showed	O
that	O
antibodies	O
against	O
the	O
lipid	O
moiety	O
of	O
lipoproteins	O
could	O
not	O
be	O
detected	O
on	O
immunoblots	O
,	O
neither	O
in	O
sera	O
from	O
infected	O
rabbits	O
nor	O
in	O
sera	O
from	O
animals	O
immunized	O
with	O
the	O
lipoproteins	O
.	O

In	O
addition	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
cross	O
-	O
reactivity	O
between	O
antibodies	O
against	O
the	O
T	O
.	O
pallidum	O
lipoproteins	O
and	O
those	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
,	O
suggesting	O
that	O
antibodies	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
are	O
unrelated	O
to	O
antilipoprotein	O
antibodies	O
.	O

Xenobiotic	O
incorporation	O
into	O
pyruvate	O
dehydrogenase	O
complex	O
can	O
occur	O
via	O
the	O
exogenous	O
lipoylation	O
pathway	O
.	O

Lipoylated	O
enzymes	O
such	O
as	O
the	O
E2	O
component	O
of	O
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
)	O
are	O
targets	O
for	O
autoreactive	O
immune	O
responses	O
in	O
primary	O
biliary	O
cirrhosis	O
,	O
with	O
lipoic	O
acid	O
itself	O
forming	O
a	O
component	O
of	O
the	O
dominant	O
auto	O
-	O
epitopes	O
.	O

A	O
candidate	O
mechanism	O
for	O
the	O
initiation	O
of	O
tolerance	O
breakdown	O
in	O
this	O
disease	O
is	O
immune	O
recognition	O
of	O
neo	O
-	O
antigens	O
formed	O
by	O
xenobiotic	O
substitution	O
of	O
normal	O
proteins	O
.	O

Importantly	O
,	O
sensitization	O
with	O
proteins	O
artificially	O
substituted	O
with	O
the	O
lipoic	O
acid	O
analogue	O
xenobiotic	O
6	O
-	O
bromohexanoic	O
acid	O
(	O
6BH	O
)	O
can	O
induce	O
an	O
immune	O
response	O
that	O
cross	O
-	O
reacts	O
with	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
.	O

This	O
study	O
investigated	O
the	O
potential	O
of	O
recombinant	O
lipoylation	O
enzymes	O
lipoate	O
activating	O
enzyme	O
and	O
lipoyl	O
-	O
AMP	O
(	O
GMP	O
)	O
:	O
N	O
-	O
lysine	O
lipoyl	O
transferase	O
to	O
aberrantly	O
incorporate	O
xenobiotics	O
into	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
.	O

It	O
was	O
found	O
that	O
these	O
enzymes	O
could	O
incorporate	O
lipoic	O
acid	O
analogues	O
including	O
octanoic	O
and	O
hexanoic	O
acids	O
and	O
the	O
xenobiotic	O
6BH	O
into	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
.	O

The	O
efficiency	O
of	O
incorporation	O
of	O
these	O
analogues	O
showed	O
a	O
variable	O
dependence	O
on	O
activation	O
by	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
or	O
guanosine	O
triphosphate	O
(	O
GTP	O
)	O
,	O
with	O
ATP	O
favoring	O
the	O
incorporation	O
of	O
hexanoic	O
acid	O
and	O
6BH	O
whereas	O
GTP	O
enhanced	O
substitution	O
by	O
octanoic	O
acid	O
.	O

Importantly	O
,	O
competition	O
studies	O
showed	O
that	O
the	O
relative	O
incorporation	O
of	O
both	O
6BH	O
and	O
lipoic	O
acid	O
could	O
be	O
regulated	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
,	O
with	O
the	O
formation	O
of	O
6BH	O
-	O
substituted	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
predominating	O
in	O
an	O
ATP	O
-	O
rich	O
environment	O
.	O

Conclusion	O
:	O
Using	O
a	O
well	O
-	O
defined	O
system	O
in	O
vitro	O
we	O
have	O
shown	O
that	O
an	O
important	O
xenobiotic	O
can	O
be	O
incorporated	O
into	O
PDC	O
in	O
place	O
of	O
lipoic	O
acid	O
by	O
the	O
exogenous	O
lipoylation	O
system	O
;	O
the	O
relative	O
levels	O
of	O
lipoic	O
acid	O
and	O
xenobiotic	O
incorporation	O
may	O
be	O
determined	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
.	O

These	O
observations	O
suggest	O
a	O
clear	O
mechanism	O
for	O
the	O
generation	O
of	O
an	O
auto	O
-	O
immunogenic	O
neo	O
-	O
antigen	O
of	O
relevance	O
for	O
the	O
pathogenesis	O
of	O
primary	O
biliary	O
cirrhosis	O
.	O

SUMOylation	O
inhibits	O
SF	B-Protein
-	I-Protein
1	I-Protein
activity	O
by	O
reducing	O
CDK7	B-Protein
-	O
mediated	O
serine	O
203	O
phosphorylation	O
.	O

Steroidogenic	B-Protein
factor	I-Protein
1	I-Protein
(	O
SF	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
an	O
orphan	O
nuclear	O
receptor	O
selectively	O
expressed	O
in	O
the	O
adrenal	O
cortex	O
and	O
gonads	O
,	O
where	O
it	O
mediates	O
the	O
hormonal	O
stimulation	O
of	O
multiple	O
genes	O
involved	O
in	O
steroid	O
hormone	O
biosynthesis	O
.	O

SF	B-Protein
-	I-Protein
1	I-Protein
is	O
the	O
target	O
of	O
both	O
phosphorylation	O
and	O
SUMOylation	O
,	O
but	O
how	O
these	O
modifications	O
interact	O
or	O
contribute	O
to	O
SF	B-Protein
-	I-Protein
1	I-Protein
regulation	O
of	O
endogenous	O
genes	O
remains	O
poorly	O
defined	O
.	O

We	O
found	O
that	O
SF	B-Protein
-	I-Protein
1	I-Protein
is	O
selectively	O
SUMOylated	O
at	O
K194	O
in	O
Y1	O
adrenocarcinoma	O
cells	O
and	O
that	O
although	O
SUMOylation	O
does	O
not	O
alter	O
the	O
subcellular	O
localization	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
,	O
the	O
modification	O
inhibits	O
the	O
ability	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
to	O
activate	O
target	O
genes	O
.	O

Notably	O
,	O
whereas	O
SF	B-Protein
-	I-Protein
1	I-Protein
SUMOylation	O
is	O
independent	O
of	O
S203	O
phosphorylation	O
and	O
is	O
unaffected	O
by	O
adrenocorticotropin	B-Protein
(	O
ACTH	B-Protein
)	O
treatment	O
,	O
loss	O
of	O
SUMOylation	O
leads	O
to	O
enhanced	O
SF	B-Protein
-	I-Protein
1	I-Protein
phosphorylation	O
at	O
serine	O
203	O
.	O

Furthermore	O
,	O
preventing	O
SF	B-Protein
-	I-Protein
1	I-Protein
SUMOylation	O
increases	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
multiple	O
steroidogenic	O
enzyme	O
genes	O
.	O

Analysis	O
of	O
the	O
StAR	B-Protein
promoter	O
indicates	O
that	O
blockade	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
SUMOylation	O
leads	O
to	O
an	O
increase	O
in	O
overall	O
promoter	O
occupancy	O
but	O
does	O
not	O
alter	O
the	O
oscillatory	O
recruitment	O
dynamics	O
in	O
response	O
to	O
ACTH	B-Protein
.	O

Notably	O
,	O
we	O
find	O
that	O
CDK7	B-Protein
binds	O
preferentially	O
to	O
the	O
SUMOylation	O
-	O
deficient	O
form	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
and	O
that	O
CDK7	B-Protein
inhibition	O
reduces	O
phosphorylation	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
propose	O
a	O
coordinated	O
modification	O
model	O
in	O
which	O
inhibition	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
-	O
mediated	O
transcription	O
by	O
SUMOylation	O
in	O
adrenocortical	O
cancer	O
cells	O
is	O
mediated	O
through	O
reduced	O
CDK7	B-Protein
-	O
induced	O
phosphorylation	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
.	O

Dynamic	O
compartmentalization	O
of	O
base	O
excision	O
repair	O
proteins	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O

DNAs	O
harbored	O
in	O
both	O
nuclei	O
and	O
mitochondria	O
of	O
eukaryotic	O
cells	O
are	O
subject	O
to	O
continuous	O
oxidative	O
damage	O
resulting	O
from	O
normal	O
metabolic	O
activities	O
or	O
environmental	O
insults	O
.	O

Oxidative	O
DNA	O
damage	O
is	O
primarily	O
reversed	O
by	O
the	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
pathway	O
,	O
initiated	O
by	O
N	O
-	O
glycosylase	O
apurinic	O
/	O
apyrimidinic	O
(	O
AP	O
)	O
lyase	O
proteins	O
.	O

To	O
execute	O
an	O
appropriate	O
repair	O
response	O
,	O
BER	O
components	O
must	O
be	O
distributed	O
to	O
accommodate	O
levels	O
of	O
genotoxic	O
stress	O
that	O
may	O
vary	O
considerably	O
between	O
nuclei	O
and	O
mitochondria	O
,	O
depending	O
on	O
the	O
growth	O
state	O
and	O
stress	O
environment	O
of	O
the	O
cell	O
.	O

Numerous	O
examples	O
exist	O
where	O
cells	O
respond	O
to	O
signals	O
,	O
resulting	O
in	O
relocalization	O
of	O
proteins	O
involved	O
in	O
key	O
biological	O
transactions	O
.	O

To	O
address	O
whether	O
such	O
dynamic	O
localization	O
contributes	O
to	O
efficient	O
organelle	O
-	O
specific	O
DNA	O
repair	O
,	O
we	O
determined	O
the	O
intracellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
N	O
-	O
glycosylase	O
/	O
AP	O
lyases	O
,	O
Ntg1	B-Protein
and	O
Ntg2	B-Protein
,	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O

Fluorescence	O
microscopy	O
revealed	O
that	O
Ntg1	B-Protein
is	O
differentially	O
localized	O
to	O
nuclei	O
and	O
mitochondria	O
,	O
likely	O
in	O
response	O
to	O
the	O
oxidative	O
DNA	O
damage	O
status	O
of	O
the	O
organelle	O
.	O

Sumoylation	O
is	O
associated	O
with	O
targeting	O
of	O
Ntg1	B-Protein
to	O
nuclei	O
containing	O
oxidative	O
DNA	O
damage	O
.	O

These	O
studies	O
demonstrate	O
that	O
trafficking	O
of	O
DNA	O
repair	O
proteins	O
to	O
organelles	O
containing	O
high	O
levels	O
of	O
oxidative	O
DNA	O
damage	O
may	O
be	O
a	O
central	O
point	O
for	O
regulating	O
BER	O
in	O
response	O
to	O
oxidative	O
stress	O
.	O

Lipid	O
-	O
mediated	O
presentation	O
of	O
MHC	O
class	O
II	O
molecules	O
guides	O
thymocytes	O
to	O
the	O
CD4	B-Protein
lineage	O
.	O

Previous	O
studies	O
on	O
the	O
MHC	O
class	O
-	O
specific	O
differentiation	O
of	O
CD4	B-Protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocytes	O
into	O
CD4	B-Protein
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
have	O
focused	O
on	O
the	O
role	O
of	O
coreceptor	O
molecules	O
.	O

However	O
,	O
CD4	B-Protein
and	O
CD8	O
T	O
cells	O
develop	O
according	O
to	O
their	O
MHC	O
class	O
specificities	O
even	O
in	O
these	O
mice	O
lacking	O
coreceptors	O
.	O

This	O
study	O
investigated	O
the	O
possibility	O
that	O
lineage	O
is	O
determined	O
not	O
only	O
by	O
coreceptors	O
,	O
but	O
is	O
also	O
guided	O
by	O
the	O
way	O
how	O
MHC	O
molecules	O
are	O
presented	O
.	O

MHC	O
class	O
II	O
molecules	O
possess	O
a	O
highly	O
conserved	O
Cys	O
in	O
their	O
transmembrane	O
domain	O
,	O
which	O
is	O
palmitoylated	O
and	O
thereby	O
associates	O
with	O
lipid	O
rafts	O
,	O
whereas	O
neither	O
palmitoylation	O
nor	O
raft	O
association	O
was	O
observed	O
with	O
MHC	O
class	O
I	O
molecules	O
.	O

The	O
generation	O
of	O
CD4	B-Protein
T	O
cells	O
was	O
impaired	O
and	O
that	O
of	O
CD8	O
T	O
cells	O
was	O
augmented	O
when	O
the	O
rafts	O
on	O
the	O
thymic	O
epithelial	O
cells	O
were	O
disrupted	O
.	O

This	O
was	O
due	O
to	O
the	O
conversion	O
of	O
MHC	O
class	O
II	O
-	O
specific	O
thymocytes	O
from	O
the	O
CD4	B-Protein
lineage	O
to	O
CD8	O
.	O

The	O
ability	O
of	O
I	B-Protein
-	I-Protein
A	I-Protein
(	O
d	O
)	O
molecule	O
to	O
associate	O
with	O
rafts	O
was	O
lost	O
when	O
its	O
transmembrane	O
Cys	O
was	O
replaced	O
.	O

The	O
development	O
of	O
DO11	O
.	O
10	O
thymocytes	O
recognizing	O
this	O
mutant	O
I	B-Protein
-	I-Protein
A	I-Protein
(	O
dm	O
)	O
was	O
converted	O
from	O
CD4	B-Protein
to	O
CD8	O
.	O

These	O
results	O
suggest	O
that	O
the	O
CD4	B-Protein
lineage	O
commitment	O
is	O
directed	O
by	O
the	O
raft	O
-	O
associated	O
presentation	O
of	O
MHC	O
class	O
II	O
molecules	O
.	O

Protein	O
acylation	O
and	O
localization	O
in	O
T	O
cell	O
signaling	O
(	O
Review	O
)	O
.	O

Many	O
proteins	O
with	O
pivotal	O
roles	O
in	O
T	O
cell	O
activation	O
are	O
modified	O
by	O
fatty	O
acylation	O
.	O

Examples	O
of	O
these	O
include	O
transmembrane	O
proteins	O
such	O
as	O
the	O
co	O
-	O
receptors	O
CD4	B-Protein
and	O
CD8	O
,	O
the	O
adaptors	O
LAT	B-Protein
and	O
Cbp	B-Protein
/	O
PAG	B-Protein
,	O
the	O
pre	O
-	O
TCR	O
as	O
well	O
as	O
proteins	O
synthesized	O
on	O
free	O
cytosolic	O
ribosomes	O
,	O
such	O
as	O
the	O
Src	O
-	O
related	O
tyrosine	O
kinases	O
Lck	B-Protein
and	O
Fyn	B-Protein
.	O

The	O
two	O
main	O
types	O
of	O
fatty	O
acylations	O
in	O
eukaryotic	O
cells	O
are	O
N	O
-	O
myristoylation	O
and	O
S	O
-	O
acylation	O
,	O
the	O
latter	O
being	O
more	O
commonly	O
referred	O
to	O
as	O
palmitoylation	O
.	O

N	O
-	O
Myristoylation	O
occurs	O
exclusively	O
on	O
proteins	O
synthesized	O
on	O
soluble	O
ribosomes	O
and	O
provides	O
substrates	O
with	O
an	O
affinity	O
for	O
membranes	O
.	O

Palmitoylation	O
modifies	O
a	O
wide	O
range	O
of	O
substrates	O
that	O
includes	O
both	O
cytosolic	O
and	O
transmembrane	O
proteins	O
,	O
its	O
functions	O
are	O
diverse	O
and	O
in	O
many	O
cases	O
not	O
yet	O
understood	O
.	O

Like	O
myristoylation	O
,	O
palmitoylation	O
promotes	O
membrane	O
-	O
binding	O
of	O
cytosolic	O
proteins	O
,	O
but	O
it	O
has	O
also	O
been	O
implicated	O
in	O
protein	O
targeting	O
,	O
trafficking	O
,	O
stability	O
and	O
activity	O
.	O

In	O
addition	O
,	O
many	O
palmitoylated	O
proteins	O
are	O
insoluble	O
in	O
cold	O
non	O
-	O
ionic	O
detergent	O
,	O
and	O
have	O
therefore	O
been	O
proposed	O
to	O
localize	O
to	O
lipid	O
rafts	O
.	O

The	O
organization	O
of	O
receptors	O
and	O
signaling	O
proteins	O
into	O
microdomains	O
such	O
as	O
lipid	O
rafts	O
provides	O
an	O
attractive	O
model	O
for	O
the	O
initiation	O
and	O
propagation	O
of	O
T	O
cell	O
signaling	O
,	O
although	O
many	O
aspects	O
of	O
this	O
are	O
still	O
poorly	O
understood	O
.	O

This	O
review	O
will	O
discuss	O
the	O
current	O
evidence	O
for	O
the	O
involvement	O
of	O
acylations	O
in	O
the	O
localizations	O
and	O
functions	O
of	O
T	O
cell	O
signaling	O
proteins	O
.	O

Palmitoylation	O
modification	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
depresses	O
its	O
susceptibility	O
to	O
GAP	B-Protein
-	I-Protein
43	I-Protein
activation	O
.	O

Interaction	O
between	O
GAP	B-Protein
-	I-Protein
43	I-Protein
(	O
growth	B-Protein
associated	I-Protein
protein	I-Protein
-	I-Protein
43	I-Protein
)	O
and	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
(	O
alpha	O
subunit	O
of	O
Go	O
protein	O
)	O
influences	O
the	O
signal	O
transduction	O
pathways	O
leading	O
to	O
differentiation	O
of	O
neural	O
cells	O
.	O

GAP	B-Protein
-	I-Protein
43	I-Protein
is	O
known	O
to	O
increase	O
guanine	O
nucleotide	O
exchange	O
by	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
,	O
which	O
is	O
a	O
major	O
component	O
of	O
neuronal	O
growth	O
cone	O
membranes	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
GAP	B-Protein
-	I-Protein
43	I-Protein
stimulation	O
is	O
related	O
to	O
the	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
palmitoylation	O
or	O
the	O
conversion	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
from	O
oligmers	O
to	O
monomers	O
,	O
which	O
was	O
shown	O
to	O
be	O
a	O
necessary	O
regulatory	O
factor	O
in	O
GDP	O
/	O
GTP	O
exchange	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

Here	O
we	O
expressed	O
and	O
purified	O
GAP	B-Protein
-	I-Protein
43	I-Protein
,	O
GST	B-Protein
-	O
GAP	B-Protein
-	I-Protein
43	I-Protein
and	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
proteins	O
,	O
detected	O
their	O
stimulatory	O
effect	O
on	O
[	O
(	O
35	O
)	O
S	O
]	O
-	O
GTPgammaS	O
binding	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

It	O
was	O
found	O
that	O
the	O
EC	O
(	O
50	O
)	O
of	O
both	O
GAP	B-Protein
-	I-Protein
43	I-Protein
and	O
GST	B-Protein
-	O
GAP	B-Protein
-	I-Protein
43	I-Protein
activation	O
were	O
tenfold	O
lower	O
in	O
case	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
than	O
palmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

Non	O
-	O
denaturing	O
gel	O
electrophoresis	O
and	O
p	O
-	O
PDM	O
cross	O
-	O
linking	O
analysis	O
revealed	O
that	O
addition	O
of	O
GST	B-Protein
-	O
GAP	B-Protein
-	I-Protein
43	I-Protein
induced	O
disassociation	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
from	O
oligomers	O
to	O
monomers	O
,	O
but	O
did	O
not	O
influence	O
the	O
oligomeric	O
state	O
of	O
palmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
,	O
which	O
suggests	O
that	O
palmitoylation	O
is	O
a	O
key	O
regulatory	O
factor	O
in	O
GAP	B-Protein
-	I-Protein
43	I-Protein
stimulation	O
on	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

These	O
results	O
indicated	O
the	O
interaction	O
of	O
GAP	B-Protein
-	I-Protein
43	I-Protein
and	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
could	O
accelerate	O
conversion	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
but	O
not	O
palmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
from	O
oligomers	O
to	O
monomers	O
,	O
so	O
as	O
to	O
increase	O
the	O
GTPgammaS	O
binding	O
activity	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

Results	O
here	O
provide	O
new	O
evidence	O
about	O
how	O
signaling	O
protein	O
palmitoylation	O
is	O
involved	O
in	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
signal	O
transduction	O
cascade	O
,	O
and	O
give	O
a	O
useful	O
clue	O
on	O
the	O
participation	O
of	O
GAP	B-Protein
-	I-Protein
43	I-Protein
in	O
G	O
-	O
protein	O
cycle	O
by	O
its	O
preferential	O
activation	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

Identification	O
of	O
a	O
palmitoyl	O
acyltransferase	O
required	O
for	O
protein	O
sorting	O
to	O
the	O
flagellar	O
membrane	O
.	O

Protein	O
palmitoylation	O
has	O
diverse	O
effects	O
in	O
regulating	O
protein	O
membrane	O
affinity	O
,	O
localization	O
,	O
binding	O
partner	O
interactions	O
,	O
turnover	O
and	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
palmitoylation	O
also	O
contributes	O
to	O
the	O
sorting	O
of	O
proteins	O
to	O
the	O
eukaryotic	O
flagellum	O
.	O

African	O
trypanosomes	O
are	O
protozoan	O
pathogens	O
that	O
express	O
a	O
family	O
of	O
unique	O
Ca	O
(	O
2	O
+	O
)	O
-	O
binding	O
proteins	O
,	O
the	O
calflagins	O
,	O
which	O
undergo	O
N	O
-	O
terminal	O
myristoylation	O
and	O
palmitoylation	O
.	O

The	O
localization	O
of	O
calflagins	O
depends	O
on	O
their	O
acylation	O
status	O
.	O

Myristoylation	O
alone	O
is	O
sufficient	O
for	O
membrane	O
association	O
,	O
but	O
,	O
in	O
the	O
absence	O
of	O
palmitoylation	O
,	O
the	O
calflagins	O
localize	O
to	O
the	O
pellicular	O
(	O
cell	O
body	O
)	O
membrane	O
.	O

Palmitoylation	O
,	O
which	O
is	O
mediated	O
by	O
a	O
specific	O
palmitoyl	O
acyltransferase	O
,	O
is	O
then	O
required	O
for	O
subsequent	O
trafficking	O
of	O
calflagin	O
to	O
the	O
flagellar	O
membrane	O
.	O

Coincident	O
with	O
the	O
redistribution	O
of	O
calflagin	O
from	O
the	O
pellicular	O
to	O
the	O
flagellar	O
membrane	O
is	O
their	O
association	O
with	O
lipid	O
rafts	O
,	O
which	O
are	O
highly	O
enriched	O
in	O
the	O
flagellar	O
membrane	O
.	O

Screening	O
of	O
candidate	O
palmitoyl	O
acyltranferases	O
identified	O
a	O
single	O
enzyme	O
,	O
TbPAT7	B-Protein
,	O
that	O
is	O
necessary	O
for	O
calflagin	O
palmitoylation	O
and	O
flagellar	O
membrane	O
targeting	O
.	O

Our	O
results	O
implicate	O
protein	O
palmitoylation	O
in	O
flagellar	O
trafficking	O
,	O
and	O
demonstrate	O
the	O
conservation	O
and	O
specificity	O
of	O
palmitoyl	O
acyltransferase	O
activity	O
by	O
DHHC	O
-	O
CRD	O
proteins	O
across	O
kingdoms	O
.	O

Mutation	O
of	O
juxtamembrane	O
cysteines	O
in	O
the	O
tetraspanin	O
CD81	B-Protein
affects	O
palmitoylation	O
and	O
alters	O
interaction	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O

Palmitoylation	O
of	O
tetraspanins	O
affects	O
protein	O
-	O
protein	O
interactions	O
,	O
suggesting	O
a	O
key	O
role	O
in	O
the	O
assembly	O
of	O
the	O
tetraspanin	O
web	O
.	O

Since	O
palmitoylation	O
occurs	O
on	O
intracellular	O
cysteine	O
residues	O
,	O
we	O
examined	O
whether	O
mutating	O
these	O
residues	O
in	O
the	O
human	O
tetraspanin	O
CD81	B-Protein
would	O
affect	O
the	O
association	O
of	O
CD81	B-Protein
with	O
other	O
surface	O
membrane	O
proteins	O
.	O

Mutation	O
of	O
at	O
least	O
six	O
of	O
the	O
eight	O
juxtamembrane	O
cysteines	O
was	O
required	O
to	O
completely	O
eliminate	O
detectable	O
CD81	B-Protein
palmitoylation	O
,	O
indicating	O
that	O
several	O
sites	O
can	O
be	O
palmitoylated	O
.	O

Interestingly	O
,	O
these	O
mutated	O
proteins	O
exhibited	O
reduced	O
cell	O
surface	O
detection	O
by	O
antibody	O
compared	O
to	O
wild	O
-	O
type	O
CD81	B-Protein
,	O
but	O
this	O
was	O
not	O
due	O
to	O
differences	O
in	O
the	O
level	O
of	O
protein	O
expression	O
,	O
trafficking	O
to	O
the	O
cell	O
surface	O
,	O
protein	O
stability	O
,	O
or	O
anti	O
-	O
CD81	B-Protein
antibody	O
binding	O
affinity	O
.	O

Instead	O
,	O
the	O
mutant	O
CD81	B-Protein
proteins	O
appeared	O
to	O
be	O
partially	O
hidden	O
from	O
detection	O
by	O
anti	O
-	O
CD81	B-Protein
antibody	O
,	O
presumably	O
due	O
to	O
altered	O
interactions	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O

Associations	O
with	O
the	O
known	O
CD81	B-Protein
-	O
interacting	O
proteins	O
CD9	B-Protein
and	O
EWI	B-Protein
-	I-Protein
2	I-Protein
were	O
also	O
impaired	O
with	O
the	O
mutant	O
CD81	B-Protein
proteins	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
mutation	O
of	O
juxtamembrane	O
cysteines	O
alters	O
the	O
interaction	O
of	O
CD81	B-Protein
with	O
other	O
proteins	O
,	O
either	O
because	O
of	O
reduced	O
palmitoylation	O
,	O
structural	O
alterations	O
in	O
the	O
mutant	O
proteins	O
,	O
or	O
a	O
combination	O
of	O
both	O
factors	O
,	O
and	O
this	O
affects	O
the	O
CD81	B-Protein
microenvironment	O
on	O
the	O
cell	O
surface	O
.	O

INF2	B-Protein
is	O
an	O
endoplasmic	O
reticulum	O
-	O
associated	O
formin	O
protein	O
.	O

In	O
addition	O
to	O
its	O
ability	O
to	O
accelerate	O
filament	O
assembly	O
,	O
which	O
is	O
common	O
to	O
formins	O
,	O
INF2	B-Protein
is	O
a	O
formin	O
protein	O
with	O
the	O
unique	O
biochemical	O
ability	O
to	O
accelerate	O
actin	O
filament	O
depolymerization	O
.	O

The	O
depolymerization	O
activity	O
of	O
INF2	B-Protein
requires	O
its	O
actin	O
monomer	O
-	O
binding	O
WASP	O
homology	O
2	O
(	O
WH2	O
)	O
motif	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
INF2	B-Protein
is	O
peripherally	O
bound	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
in	O
Swiss	O
3T3	O
cells	O
.	O

Both	O
endogenous	O
INF2	B-Protein
and	O
GFP	B-Protein
-	O
fusion	O
constructs	O
display	O
ER	O
localization	O
.	O

INF2	B-Protein
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
C	O
-	O
terminal	O
farnesyl	O
group	O
,	O
and	O
this	O
modification	O
is	O
required	O
for	O
ER	O
interaction	O
.	O

However	O
,	O
farnesylation	O
is	O
not	O
sufficient	O
for	O
ER	O
association	O
,	O
and	O
membrane	O
extraction	O
experiments	O
suggest	O
that	O
ionic	O
interactions	O
are	O
also	O
important	O
.	O

The	O
WH2	O
motif	O
also	O
serves	O
as	O
a	O
diaphanous	O
autoregulatory	O
domain	O
(	O
DAD	O
)	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
diaphanous	O
inhibitory	O
domain	O
(	O
DID	O
)	O
,	O
with	O
an	O
apparent	O
dissociation	O
constant	O
of	O
1	O
.	O
1	O
muM	O
.	O

Surprisingly	O
,	O
the	O
DID	O
-	O
DAD	O
interaction	O
does	O
not	O
inhibit	O
the	O
actin	O
nucleation	O
activity	O
of	O
INF2	B-Protein
;	O
however	O
,	O
it	O
does	O
inhibit	O
the	O
depolymerization	O
activity	O
.	O

Point	O
mutations	O
to	O
the	O
DAD	O
/	O
WH2	O
inhibit	O
both	O
the	O
DID	O
-	O
DAD	O
interaction	O
and	O
depolymerization	O
activity	O
.	O

Expression	O
of	O
GFP	B-Protein
-	O
INF2	B-Protein
containing	O
these	O
DAD	O
/	O
WH2	O
mutations	O
causes	O
the	O
ER	O
to	O
collapse	O
around	O
the	O
nucleus	O
,	O
with	O
accumulation	O
of	O
actin	O
filaments	O
around	O
the	O
collapsed	O
ER	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
association	O
of	O
an	O
actin	O
-	O
assembly	O
factor	O
with	O
the	O
ER	O
.	O

Mouse	O
recombinant	O
phenylalanine	B-Protein
monooxygenase	I-Protein
and	O
the	O
S	O
-	O
oxygenation	O
of	O
thioether	O
substrates	O
.	O

The	O
substrate	O
specificity	O
of	O
mouse	O
recombinant	O
phenylalanine	B-Protein
monooxygenase	I-Protein
(	O
mPAH	B-Protein
)	O
has	O
been	O
investigated	O
with	O
respect	O
to	O
the	O
mucoactive	O
drug	O
,	O
S	O
-	O
carboxymethyl	O
-	O
L	O
-	O
cysteine	O
(	O
SCMC	O
)	O
and	O
its	O
thioether	O
metabolites	O
.	O

Phenylalanine	B-Protein
monooxygenase	I-Protein
was	O
shown	O
to	O
be	O
able	O
to	O
catalyze	O
the	O
S	O
-	O
oxygenation	O
of	O
SCMC	O
,	O
its	O
decarboxylated	O
metabolite	O
,	O
S	O
-	O
methyl	O
-	O
L	O
-	O
cysteine	O
and	O
both	O
their	O
corresponding	O
N	O
-	O
acetylated	O
forms	O
.	O

However	O
,	O
thiodiglycolic	O
acid	O
was	O
found	O
not	O
to	O
be	O
a	O
substrate	O
.	O

The	O
enzyme	O
profiles	O
for	O
both	O
phenylalanine	O
and	O
SCMC	O
showed	O
Michaelis	O
-	O
Menten	O
with	O
noncompetitive	O
substrate	O
inhibition	O
for	O
both	O
the	O
substrate	O
-	O
activated	O
and	O
the	O
lysophosphatidylcholine	O
-	O
activated	O
mPAH	B-Protein
assays	O
.	O

The	O
tetrameric	O
enzyme	O
was	O
shown	O
to	O
undergo	O
posttranslational	O
activation	O
by	O
preincubation	O
with	O
substrate	O
,	O
lysophosphatidylcholine	O
,	O
N	O
-	O
ethylmaleimide	O
(	O
a	O
thiol	O
alkylating	O
agent	O
)	O
,	O
and	O
the	O
proteolytic	O
enzymes	O
alpha	B-Protein
-	I-Protein
chymotrypsin	I-Protein
and	O
trypsin	O
.	O

Similar	O
posttranslational	O
activation	O
of	O
PAH	B-Protein
activity	O
in	O
the	O
rat	O
and	O
human	O
has	O
also	O
been	O
reported	O
.	O

These	O
results	O
suggest	O
that	O
in	O
the	O
mouse	O
,	O
PAH	B-Protein
was	O
responsible	O
for	O
the	O
S	O
-	O
oxidation	O
of	O
SCMC	O
and	O
that	O
the	O
mouse	O
models	O
of	O
the	O
hyperphenylalaninemias	O
may	O
be	O
a	O
potential	O
tool	O
in	O
the	O
investigation	O
of	O
the	O
S	O
-	O
oxidation	O
polymorphism	O
in	O
man	O
.	O

The	O
cataract	O
-	O
associated	O
R14C	O
mutant	O
of	O
human	O
gamma	B-Protein
D	I-Protein
-	I-Protein
crystallin	I-Protein
shows	O
a	O
variety	O
of	O
intermolecular	O
disulfide	O
cross	O
-	O
links	O
:	O
a	O
Raman	O
spectroscopic	O
study	O
.	O

The	O
Arg14	O
to	O
Cys	O
(	O
R14C	O
)	O
mutation	O
in	O
the	O
human	O
gammaD	B-Protein
-	I-Protein
crystallin	I-Protein
(	O
HGD	B-Protein
)	O
gene	O
has	O
been	O
associated	O
with	O
a	O
juvenile	O
-	O
onset	O
hereditary	O
cataract	O
.	O

We	O
showed	O
previously	O
[	O
Pande	O
,	O
A	O
.	O
,	O
et	O
al	O
.	O
(	O
2000	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
97	O
,	O
1993	O
-	O
1998	O
]	O
that	O
rapid	O
oxidation	O
of	O
Cys14	O
in	O
the	O
mutant	O
leads	O
to	O
the	O
formation	O
of	O
intermolecular	O
,	O
disulfide	O
-	O
cross	O
-	O
linked	O
aggregates	O
at	O
physiological	O
pH	O
.	O

Here	O
we	O
present	O
a	O
Raman	O
spectroscopic	O
analysis	O
of	O
R14C	O
and	O
HGD	B-Protein
and	O
show	O
that	O
R14C	O
forms	O
such	O
aggregates	O
even	O
at	O
pH	O
4	O
.	O
5	O
.	O

The	O
lower	O
pH	O
enabled	O
us	O
to	O
monitor	O
the	O
evolution	O
of	O
a	O
variety	O
of	O
disulfide	O
cross	O
-	O
links	O
with	O
distinct	O
conformations	O
around	O
the	O
CC	O
-	O
SS	O
-	O
CC	O
dihedral	O
angles	O
.	O

At	O
least	O
three	O
cysteine	O
residues	O
are	O
involved	O
,	O
forming	O
protein	O
-	O
protein	O
cross	O
-	O
links	O
through	O
disulfide	O
-	O
exchange	O
reactions	O
.	O

From	O
the	O
pattern	O
of	O
the	O
S	O
-	O
S	O
and	O
Trp	O
Raman	O
bands	O
,	O
we	O
infer	O
that	O
Cys32	O
is	O
likely	O
to	O
be	O
involved	O
in	O
the	O
cross	O
-	O
linking	O
.	O

The	O
data	O
suggest	O
that	O
protein	O
precipitation	O
in	O
the	O
mutant	O
may	O
not	O
be	O
the	O
direct	O
result	O
of	O
disulfide	O
cross	O
-	O
linking	O
,	O
although	O
such	O
cross	O
-	O
linking	O
is	O
the	O
initiating	O
event	O
.	O

Thus	O
,	O
our	O
Raman	O
data	O
not	O
only	O
enhance	O
the	O
understanding	O
of	O
the	O
reactivity	O
of	O
Cys14	O
in	O
the	O
R14C	O
mutant	O
and	O
the	O
mechanism	O
of	O
opacity	O
,	O
but	O
also	O
shed	O
light	O
on	O
the	O
mechanism	O
of	O
oxidative	O
degradation	O
during	O
long	O
-	O
term	O
storage	O
of	O
thiol	O
-	O
containing	O
pharmaceuticals	O
.	O

Bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
:	O
molecular	O
structures	O
and	O
signal	O
transducing	O
functions	O
.	O

Mono	O
-	O
ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
modification	O
of	O
proteins	O
employed	O
by	O
a	O
variety	O
of	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
to	O
modify	O
the	O
metabolism	O
of	O
target	O
cells	O
.	O

The	O
ADP	O
-	O
ribosyltransferases	O
of	O
bacterial	O
toxins	O
,	O
in	O
general	O
,	O
use	O
NAD	O
as	O
a	O
substrate	O
for	O
covalent	O
modification	O
by	O
ADP	O
-	O
ribose	O
to	O
certain	O
GTP	O
-	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
as	O
signal	O
transducers	O
resulting	O
in	O
altered	O
enzymatic	O
activity	O
of	O
the	O
membrane	O
enzymes	O
as	O
effectors	O
.	O

Such	O
a	O
mechanism	O
has	O
the	O
potential	O
of	O
being	O
of	O
importance	O
in	O
the	O
physiological	O
regulation	O
of	O
cellular	O
metabolism	O
,	O
particularly	O
if	O
the	O
process	O
is	O
reversible	O
.	O

These	O
ADP	O
-	O
ribosylating	O
toxins	O
are	O
characterized	O
in	O
Table	O
1	O
.	O

Concerted	O
action	O
of	O
the	O
cytosolic	O
sulfotransferase	O
,	O
SULT1A3	B-Protein
,	O
and	O
catechol	B-Protein
-	I-Protein
O	I-Protein
-	I-Protein
methyltransferase	I-Protein
in	O
the	O
metabolism	O
of	O
dopamine	O
in	O
SK	O
-	O
N	O
-	O
MC	O
human	O
neuroblastoma	O
cells	O
.	O

Conjugation	O
reactions	O
catalyzed	O
by	O
the	O
cytosolic	O
sulfotransferase	O
,	O
SULT1A3	B-Protein
,	O
or	O
catechol	B-Protein
-	I-Protein
O	I-Protein
-	I-Protein
methyltransferase	I-Protein
(	O
COMT	B-Protein
)	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
and	O
homeostasis	O
of	O
dopamine	O
and	O
other	O
monoamine	O
neurotransmitters	O
.	O

Whether	O
different	O
conjugation	O
reactions	O
may	O
act	O
in	O
a	O
concerted	O
manner	O
,	O
however	O
,	O
remains	O
unclear	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
concerted	O
action	O
of	O
SULT1A3	B-Protein
and	O
COMT	B-Protein
in	O
dopamine	O
metabolism	O
.	O

Analysis	O
of	O
the	O
medium	O
of	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
,	O
metabolically	O
labeled	O
with	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfate	O
in	O
the	O
presence	O
of	O
dopamine	O
,	O
revealed	O
the	O
generation	O
and	O
release	O
of	O
predominantly	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
3	O
-	O
methyldopamine	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
dopamine	O
.	O

Addition	O
to	O
the	O
labeling	O
medium	O
of	O
tropolone	O
,	O
a	O
COMT	B-Protein
inhibitor	O
,	O
enhanced	O
the	O
production	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
dopamine	O
,	O
with	O
a	O
concomitant	O
decrease	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
3	O
-	O
methyldopamine	O
.	O

Enzymatic	O
assays	O
using	O
the	O
eleven	O
known	O
human	O
cytosolic	O
SULTs	O
revealed	O
SULT1A3	B-Protein
as	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
sulfation	O
of	O
both	O
dopamine	O
and	O
3	O
-	O
methyldopamine	O
.	O

Kinetic	O
analysis	O
showed	O
that	O
the	O
catalytic	O
efficiency	O
of	O
SULT1A3	B-Protein
with	O
3	O
-	O
methyldopamine	O
was	O
1	O
.	O
6	O
times	O
than	O
that	O
with	O
dopamine	O
.	O

Using	O
subcellular	O
fractions	O
prepared	O
from	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
,	O
the	O
majority	O
of	O
COMT	B-Protein
dopamine	O
-	O
methylating	O
activity	O
was	O
found	O
to	O
be	O
present	O
in	O
the	O
cytosol	O
.	O

Collectively	O
,	O
these	O
results	O
imply	O
a	O
concerted	O
action	O
of	O
sulfation	O
and	O
methylation	O
in	O
the	O
irreversible	O
inactivation	O
and	O
disposal	O
of	O
excess	O
dopamine	O
in	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
.	O

Palmitoylation	O
of	O
the	O
synaptic	O
vesicle	O
fusion	O
machinery	O
.	O

The	O
fusion	O
of	O
synaptic	O
vesicles	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
mediates	O
the	O
secretion	O
of	O
neurotransmitters	O
at	O
nerve	O
terminals	O
.	O

This	O
pathway	O
is	O
regulated	O
by	O
an	O
array	O
of	O
protein	O
-	O
protein	O
interactions	O
.	O

Of	O
central	O
importance	O
are	O
the	O
soluble	O
NSF	B-Protein
(	O
N	B-Protein
-	I-Protein
ethylmaleimide	I-Protein
-	I-Protein
sensitive	I-Protein
factor	I-Protein
)	O
attachment	O
protein	O
receptor	O
(	O
SNARE	O
)	O
proteins	O
syntaxin	O
1	O
and	O
SNAP25	B-Protein
,	O
which	O
are	O
associated	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
and	O
vesicle	O
-	O
associated	O
membrane	O
protein	O
(	O
VAMP2	B-Protein
)	O
,	O
a	O
synaptic	O
vesicle	O
SNARE	O
.	O

Syntaxin	O
1	O
,	O
SNAP25	B-Protein
and	O
VAMP2	B-Protein
interact	O
to	O
form	O
a	O
tight	O
complex	O
bridging	O
the	O
vesicle	O
and	O
plasma	O
membranes	O
,	O
which	O
has	O
been	O
suggested	O
to	O
represent	O
the	O
minimal	O
membrane	O
fusion	O
machinery	O
.	O

Synaptic	O
vesicle	O
fusion	O
is	O
stimulated	O
by	O
a	O
rise	O
in	O
intraterminal	O
Ca2	O
+	O
levels	O
,	O
and	O
a	O
major	O
Ca2	O
+	O
sensor	O
for	O
vesicle	O
fusion	O
is	O
synaptotagmin	B-Protein
I	I-Protein
.	O

Synaptotagmin	O
is	O
likely	O
to	O
couple	O
Ca2	O
+	O
entry	O
to	O
vesicle	O
fusion	O
via	O
Ca2	O
+	O
-	O
dependent	O
and	O
independent	O
interactions	O
with	O
membrane	O
phospholipids	O
and	O
the	O
SNARE	O
proteins	O
.	O

Intriguingly	O
,	O
syntaxin	O
1	O
,	O
SNAP25	B-Protein
,	O
VAMP2	B-Protein
and	O
synaptotagmin	B-Protein
I	I-Protein
have	O
all	O
been	O
reported	O
to	O
be	O
modified	O
by	O
palmitoylation	O
in	O
neurons	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
and	O
dynamics	O
of	O
palmitoylation	O
of	O
these	O
proteins	O
and	O
speculate	O
on	O
how	O
palmitoylation	O
might	O
contribute	O
to	O
the	O
regulation	O
of	O
synaptic	O
vesicle	O
fusion	O
.	O

Palmitoylation	O
-	O
dependent	O
plasma	O
membrane	O
transport	O
but	O
lipid	O
raft	O
-	O
independent	O
signaling	O
by	O
linker	B-Protein
for	I-Protein
activation	I-Protein
of	I-Protein
T	I-Protein
cells	I-Protein
.	O

Linker	B-Protein
for	I-Protein
activation	I-Protein
of	I-Protein
T	I-Protein
cells	I-Protein
(	O
LAT	B-Protein
)	O
is	O
a	O
dually	O
palmitoylated	O
transmembrane	O
adaptor	O
protein	O
essential	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

However	O
,	O
whether	O
LAT	B-Protein
palmitoylation	O
and	O
/	O
or	O
lipid	O
raft	O
localization	O
are	O
required	O
for	O
its	O
function	O
is	O
controversial	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
used	O
a	O
combination	O
of	O
biochemical	O
,	O
imaging	O
,	O
and	O
genetic	O
approaches	O
,	O
including	O
LAT	B-Protein
retrovirus	O
-	O
transduced	O
mouse	O
T	O
cells	O
and	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

A	O
nonpalmitoylated	O
,	O
non	O
-	O
lipid	O
raft	O
-	O
residing	O
mutant	O
of	O
transmembrane	O
LAT	B-Protein
could	O
not	O
reconstitute	O
T	O
cell	O
development	O
in	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

This	O
mutant	O
was	O
absent	O
from	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
and	O
was	O
restricted	O
mainly	O
to	O
the	O
Golgi	O
apparatus	O
.	O

A	O
chimeric	O
,	O
nonpalmitoylated	O
LAT	B-Protein
protein	O
consisting	O
of	O
the	O
PM	O
-	O
targeting	O
N	O
-	O
terminal	O
sequence	O
of	O
Src	O
kinase	O
and	O
the	O
LAT	B-Protein
cytoplasmic	O
domain	O
(	O
Src	O
-	O
LAT	O
)	O
localized	O
as	O
a	O
peripheral	O
membrane	O
protein	O
in	O
the	O
PM	O
,	O
but	O
outside	O
lipid	O
rafts	O
.	O

Nevertheless	O
,	O
Src	O
-	O
LAT	O
restored	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Lastly	O
,	O
monopalmitoylation	O
of	O
LAT	B-Protein
on	O
Cys	O
(	O
26	O
)	O
(	O
but	O
not	O
Cys	O
(	O
29	O
)	O
)	O
was	O
required	O
and	O
sufficient	O
for	O
its	O
PM	O
transport	O
and	O
function	O
.	O

Thus	O
,	O
the	O
function	O
of	O
LAT	B-Protein
in	O
T	O
cells	O
requires	O
its	O
PM	O
,	O
but	O
not	O
raft	O
,	O
localization	O
,	O
even	O
when	O
expressed	O
as	O
a	O
peripheral	O
membrane	O
protein	O
.	O

Furthermore	O
,	O
LAT	B-Protein
palmitoylation	O
functions	O
primarily	O
as	O
a	O
sorting	O
signal	O
required	O
for	O
its	O
PM	O
transport	O
.	O

Mobile	O
DHHC	O
palmitoylating	O
enzyme	O
mediates	O
activity	O
-	O
sensitive	O
synaptic	O
targeting	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
.	O

Protein	O
palmitoylation	O
is	O
the	O
most	O
common	O
posttranslational	O
lipid	O
modification	O
;	O
its	O
reversibility	O
mediates	O
protein	O
shuttling	O
between	O
intracellular	O
compartments	O
.	O

A	O
large	O
family	O
of	O
DHHC	O
(	O
Asp	O
-	O
His	O
-	O
His	O
-	O
Cys	O
)	O
proteins	O
has	O
emerged	O
as	O
protein	O
palmitoyl	O
acyltransferases	O
(	O
PATs	O
)	O
.	O

However	O
,	O
mechanisms	O
that	O
regulate	O
these	O
PATs	O
in	O
a	O
physiological	O
context	O
remain	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
efficiently	O
monitored	O
the	O
dynamic	O
palmitate	O
cycling	O
on	O
synaptic	O
scaffold	O
PSD	B-Protein
-	I-Protein
95	I-Protein
.	O

We	O
found	O
that	O
blocking	O
synaptic	O
activity	O
rapidly	O
induces	O
PSD	B-Protein
-	I-Protein
95	I-Protein
palmitoylation	O
and	O
mediates	O
synaptic	O
clustering	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
and	O
associated	O
AMPA	O
(	O
alpha	O
-	O
amino	O
-	O
3	O
-	O
hydroxy	O
-	O
5	O
-	O
methyl	O
-	O
4	O
-	O
isoxazole	O
propionic	O
acid	O
)	O
-	O
type	O
glutamate	O
receptors	O
.	O

A	O
dendritically	O
localized	O
DHHC2	B-Protein
but	O
not	O
the	O
Golgi	O
-	O
resident	O
DHHC3	B-Protein
mediates	O
this	O
activity	O
-	O
sensitive	O
palmitoylation	O
.	O

Upon	O
activity	O
blockade	O
,	O
DHHC2	B-Protein
translocates	O
to	O
the	O
postsynaptic	O
density	O
to	O
transduce	O
this	O
effect	O
.	O

These	O
data	O
demonstrate	O
that	O
individual	O
DHHC	O
members	O
are	O
differentially	O
regulated	O
and	O
that	O
dynamic	O
recruitment	O
of	O
protein	O
palmitoylation	O
machinery	O
enables	O
compartmentalized	O
regulation	O
of	O
protein	O
trafficking	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O

The	O
trafficking	O
/	O
interaction	O
of	O
eNOS	B-Protein
and	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
induced	O
by	O
insulin	B-Protein
modulates	O
endothelial	O
nitric	O
oxide	O
production	O
.	O

Endothelial	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
(	O
eNOS	B-Protein
)	O
activity	O
is	O
tightly	O
regulated	O
by	O
posttranscriptional	O
modification	O
and	O
its	O
subcellular	O
localization	O
.	O

Here	O
we	O
examined	O
whether	O
insulin	B-Protein
modulates	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
by	O
regulating	O
eNOS	B-Protein
subcellular	O
localization	O
.	O

We	O
used	O
confocal	O
microscopy	O
and	O
immunoblots	O
to	O
examine	O
the	O
time	O
course	O
for	O
1	O
)	O
subcellular	O
targeting	O
/	O
association	O
of	O
eNOS	B-Protein
and	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
(	O
CAV	B-Protein
-	I-Protein
1	I-Protein
)	O
;	O
2	O
)	O
eNOS	B-Protein
Ser	O
(	O
1179	O
)	O
phosphorylation	O
;	O
and	O
3	O
)	O
NO	O
production	O
in	O
cultured	O
bovine	O
aorta	O
endothelial	O
cells	O
.	O

Serum	O
starvation	O
increased	O
eNOS	B-Protein
/	O
CAV	B-Protein
-	I-Protein
1	I-Protein
localization	O
to	O
the	O
perinuclear	O
region	O
.	O

Adding	O
insulin	B-Protein
provoked	O
their	O
prompt	O
translocation	O
to	O
and	O
association	O
at	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
.	O

Specific	O
monoclonal	O
antibodies	O
against	O
either	O
CAV	B-Protein
-	I-Protein
1	I-Protein
or	O
eNOS	B-Protein
coimmunoprecipitated	O
the	O
other	O
from	O
bovine	O
aorta	O
endothelial	O
cell	O
membrane	O
extracts	O
,	O
and	O
insulin	B-Protein
increased	O
this	O
interaction	O
.	O

Insulin	B-Protein
stimulated	O
NO	O
production	O
transiently	O
despite	O
a	O
persistent	O
eNOS	B-Protein
Ser	O
(	O
1179	O
)	O
phosphorylation	O
.	O

The	O
decline	O
of	O
NO	O
production	O
correlated	O
temporally	O
to	O
insulin	B-Protein
-	O
induced	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
.	O

Knockdown	O
of	O
CAV	B-Protein
-	I-Protein
1	I-Protein
expression	O
with	O
a	O
specific	O
small	O
interfering	O
RNA	O
duplex	O
resulted	O
in	O
eNOS	B-Protein
redistributing	O
to	O
the	O
perinuclear	O
region	O
and	O
nearly	O
doubled	O
insulin	B-Protein
-	O
induced	O
NO	O
production	O
.	O

Inhibition	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
activity	O
with	O
wortmannin	O
not	O
only	O
significantly	O
inhibited	O
insulin	B-Protein
-	O
induced	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
but	O
also	O
blocked	O
insulin	B-Protein
-	O
induced	O
interaction	O
of	O
CAV	B-Protein
-	I-Protein
1	I-Protein
with	O
eNOS	B-Protein
at	O
PM	O
.	O

Insulin	B-Protein
increased	O
incorporation	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
palmitic	O
acid	O
into	O
eNOS	B-Protein
immunoprecipitates	O
by	O
approximately	O
140	O
%	O
.	O

Insulin	B-Protein
-	O
induced	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
was	O
palmitoylation	O
dependent	O
.	O

Inhibiting	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
palmitoylation	O
enhanced	O
the	O
NO	O
production	O
while	O
blocking	O
the	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
induced	O
by	O
insulin	B-Protein
.	O

These	O
data	O
show	O
that	O
insulin	B-Protein
acutely	O
regulates	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
trafficking	O
to	O
PM	O
of	O
vascular	O
endothelial	O
cells	O
where	O
their	O
interaction	O
can	O
regulate	O
eNOS	B-Protein
activity	O
.	O

Crosstalk	O
between	O
the	O
NF	O
-	O
kappaB	O
activating	O
IKK	O
-	O
complex	O
and	O
the	O
CSN	O
signalosome	O
.	O

A	O
great	O
variety	O
of	O
signalling	O
pathways	O
regulating	O
inflammation	O
,	O
cell	O
development	O
and	O
cell	O
survival	O
require	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
,	O
which	O
are	O
normally	O
inactive	O
due	O
to	O
binding	O
to	O
inhibitors	O
,	O
such	O
as	O
IkappaBalpha	B-Protein
.	O

The	O
canonical	O
activation	O
pathway	O
of	O
NF	O
-	O
kappaB	O
is	O
initiated	O
by	O
phosphorylation	O
of	O
the	O
inhibitor	O
by	O
an	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
triggering	O
ubiquitination	O
of	O
IkappaB	O
molecules	O
by	O
SCF	O
-	O
type	O
E3	O
-	O
ligase	O
complexes	O
and	O
rapid	O
degradation	O
by	O
26S	O
-	O
proteasomes	O
.	O

The	O
ubiquitination	O
machinery	O
is	O
regulated	O
by	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
.	O

We	O
show	O
that	O
IkappaB	O
kinases	O
interact	O
with	O
the	O
CSN	O
-	O
complex	O
,	O
as	O
well	O
as	O
the	O
SCF	O
-	O
ubiquitination	O
machinery	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
rapid	O
signalling	O
-	O
induced	O
ubiquitination	O
and	O
degradation	O
of	O
IkappaBalpha	B-Protein
.	O

Furthermore	O
,	O
we	O
reveal	O
that	O
IKK	O
'	O
s	O
phosphorylate	O
not	O
only	O
IkappaBalpha	B-Protein
,	O
but	O
also	O
the	O
CSN	O
-	O
subunit	O
Csn5	B-Protein
/	O
JAB1	B-Protein
(	O
c	B-Protein
-	I-Protein
Jun	I-Protein
activation	I-Protein
domain	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
)	O
and	O
that	O
IKK2	B-Protein
influences	O
ubiquitination	O
of	O
Csn5	B-Protein
/	O
JAB1	B-Protein
.	O

Our	O
observations	O
imply	O
that	O
the	O
CSN	O
complex	O
acts	O
as	O
an	O
inhibitor	O
of	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
in	O
non	O
-	O
activated	O
cells	O
.	O

Knock	O
-	O
down	O
of	O
Csn5	B-Protein
/	O
JAB1	B-Protein
clearly	O
enhanced	O
basal	O
NF	O
-	O
kappaB	O
activity	O
and	O
improved	O
cell	O
survival	O
under	O
stress	O
.	O

The	O
inhibitory	O
effect	O
of	O
Csn5	B-Protein
/	O
JAB1	B-Protein
requires	O
a	O
functional	O
MPN	O
(	O
+	O
)	O
metalloprotease	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
cleaving	O
ubiquitin	B-Protein
-	O
like	O
Nedd8	B-Protein
-	O
modifications	O
.	O

Upon	O
activation	O
of	O
cells	O
with	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
,	O
the	O
CSN	O
complex	O
dissociates	O
from	O
IKK	O
'	O
s	O
allowing	O
full	O
and	O
rapid	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
the	O
concerted	O
action	O
of	O
interacting	O
protein	O
complexes	O
.	O

Prenylation	O
-	O
deficient	O
G	O
protein	O
gamma	O
subunits	O
disrupt	O
GPCR	O
signaling	O
in	O
the	O
zebrafish	O
.	O

Prenylation	O
of	O
G	O
protein	O
gamma	O
(	O
gamma	O
)	O
subunits	O
is	O
necessary	O
for	O
the	O
membrane	O
localization	O
of	O
heterotrimeric	O
G	O
proteins	O
and	O
for	O
functional	O
heterotrimeric	O
G	O
protein	O
coupled	O
receptor	O
(	O
GPCR	O
)	O
signaling	O
.	O

To	O
evaluate	O
GPCR	O
signaling	O
pathways	O
during	O
development	O
,	O
we	O
injected	O
zebrafish	O
embryos	O
with	O
mRNAs	O
encoding	O
Ggamma	O
subunits	O
mutated	O
so	O
that	O
they	O
can	O
no	O
longer	O
be	O
prenylated	O
.	O

Low	O
-	O
level	O
expression	O
of	O
these	O
prenylation	O
-	O
deficient	O
Ggamma	O
subunits	O
driven	O
either	O
ubiquitously	O
or	O
specifically	O
in	O
the	O
primordial	O
germ	O
cells	O
(	O
PGCs	O
)	O
disrupts	O
GPCR	O
signaling	O
and	O
manifests	O
as	O
a	O
PGC	O
migration	O
defect	O
.	O

This	O
disruption	O
results	O
in	O
a	O
reduction	O
of	O
calcium	O
accumulation	O
in	O
the	O
protrusions	O
of	O
migrating	O
PGCs	O
and	O
a	O
failure	O
of	O
PGCs	O
to	O
directionally	O
migrate	O
.	O

When	O
co	O
-	O
expressed	O
with	O
a	O
prenylation	O
-	O
deficient	O
Ggamma	O
,	O
8	O
of	O
the	O
17	O
wildtype	O
Ggamma	O
isoforms	O
individually	O
confer	O
the	O
ability	O
to	O
restore	O
calcium	O
accumulation	O
and	O
directional	O
migration	O
.	O

These	O
results	O
suggest	O
that	O
while	O
the	O
Ggamma	O
subunits	O
possess	O
the	O
ability	O
to	O
interact	O
with	O
G	O
Beta	O
(	O
beta	O
)	O
proteins	O
,	O
only	O
a	O
subset	O
of	O
wildtype	O
Ggamma	O
proteins	O
are	O
stable	O
within	O
PGCs	O
and	O
can	O
interact	O
with	O
key	O
signaling	O
components	O
necessary	O
for	O
PGC	O
migration	O
.	O

This	O
in	O
vivo	O
study	O
highlights	O
the	O
functional	O
redundancy	O
of	O
these	O
signaling	O
components	O
and	O
demonstrates	O
that	O
prenylation	O
-	O
deficient	O
Ggamma	O
subunits	O
are	O
an	O
effective	O
tool	O
to	O
investigate	O
the	O
roles	O
of	O
GPCR	O
signaling	O
events	O
during	O
vertebrate	O
development	O
.	O

Statins	O
inhibit	O
protein	O
lipidation	O
and	O
induce	O
the	O
unfolded	O
protein	O
response	O
in	O
the	O
non	O
-	O
sterol	O
producing	O
nematode	O
Caenorhabditis	O
elegans	O
.	O

Statins	O
are	O
compounds	O
prescribed	O
to	O
lower	O
blood	O
cholesterol	O
in	O
millions	O
of	O
patients	O
worldwide	O
.	O

They	O
act	O
by	O
inhibiting	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
mevalonate	O
pathway	O
that	O
leads	O
to	O
the	O
synthesis	O
of	O
farnesyl	O
pyrophosphate	O
,	O
a	O
precursor	O
for	O
cholesterol	O
synthesis	O
and	O
the	O
source	O
of	O
lipid	O
moieties	O
for	O
protein	O
prenylation	O
.	O

The	O
nematode	O
Caenorhabditis	O
elegans	O
possesses	O
a	O
mevalonate	O
pathway	O
that	O
lacks	O
the	O
branch	O
leading	O
to	O
cholesterol	O
synthesis	O
,	O
and	O
thus	O
represents	O
an	O
ideal	O
organism	O
to	O
specifically	O
study	O
the	O
noncholesterol	O
roles	O
of	O
the	O
pathway	O
.	O

Inhibiting	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
in	O
C	O
.	O
elegans	O
using	O
statins	O
or	O
RNAi	O
leads	O
to	O
developmental	O
arrest	O
and	O
loss	O
of	O
membrane	O
association	O
of	O
a	O
GFP	B-Protein
-	O
based	O
prenylation	O
reporter	O
.	O

The	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
is	O
also	O
strongly	O
activated	O
,	O
suggesting	O
that	O
impaired	O
prenylation	O
of	O
small	O
GTPases	O
leads	O
to	O
the	O
accumulation	O
of	O
unfolded	O
proteins	O
and	O
ER	O
stress	O
.	O

UPR	O
induction	O
was	O
also	O
observed	O
upon	O
pharmacological	O
inhibition	O
of	O
farnesyl	O
transferases	O
or	O
RNAi	O
inhibition	O
of	O
a	O
specific	O
isoprenoid	O
transferase	O
(	O
M57	B-Protein
.	I-Protein
2	I-Protein
)	O
and	O
found	O
to	O
be	O
dependent	O
on	O
both	O
ire	B-Protein
-	I-Protein
1	I-Protein
and	O
xbp	B-Protein
-	I-Protein
1	I-Protein
but	O
not	O
on	O
pek	B-Protein
-	I-Protein
1	I-Protein
or	O
atf	B-Protein
-	I-Protein
6	I-Protein
,	O
which	O
are	O
all	O
known	O
regulators	O
of	O
the	O
UPR	O
.	O

The	O
lipid	O
stores	O
and	O
fatty	O
acid	O
composition	O
were	O
unaffected	O
in	O
statin	O
-	O
treated	O
worms	O
,	O
even	O
though	O
they	O
showed	O
reduced	O
staining	O
with	O
Nile	O
red	O
.	O

We	O
conclude	O
that	O
inhibitors	O
of	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
or	O
of	O
farnesyl	O
transferases	O
induce	O
the	O
UPR	O
by	O
inhibiting	O
the	O
prenylation	O
of	O
M57	B-Protein
.	I-Protein
2	I-Protein
substrates	O
,	O
resulting	O
in	O
developmental	O
arrest	O
in	O
C	O
.	O
elegans	O
.	O

These	O
results	O
provide	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
statins	O
and	O
suggest	O
that	O
statins	O
could	O
be	O
used	O
clinically	O
where	O
UPR	O
activation	O
may	O
be	O
of	O
therapeutic	O
benefit	O
.	O

SUMOylation	O
attenuates	O
the	O
aggregation	O
propensity	O
and	O
cellular	O
toxicity	O
of	O
the	O
polyglutamine	O
expanded	O
ataxin	B-Protein
-	I-Protein
7	I-Protein
.	O

Post	O
-	O
translational	O
modification	O
by	O
SUMO	O
(	O
small	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
)	O
was	O
proposed	O
to	O
modulate	O
the	O
pathogenesis	O
of	O
several	O
neurodegenerative	O
diseases	O
.	O

Spinocerebellar	O
ataxia	O
type	O
7	O
(	O
SCA7	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
,	O
whose	O
pathology	O
is	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
polyglutamine	O
stretch	O
in	O
the	O
protein	O
ataxin	B-Protein
-	I-Protein
7	I-Protein
(	O
ATXN7	B-Protein
)	O
.	O

Here	O
,	O
we	O
identified	O
ATXN7	B-Protein
as	O
new	O
target	O
for	O
SUMOylation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
major	O
SUMO	O
acceptor	O
site	O
was	O
mapped	O
to	O
lysine	O
257	O
,	O
which	O
is	O
part	O
of	O
an	O
evolutionarily	O
conserved	O
consensus	O
SUMOylation	O
motif	O
.	O

SUMOylation	O
did	O
not	O
influence	O
the	O
subcellular	O
localization	O
of	O
ATXN7	B-Protein
nor	O
its	O
interaction	O
with	O
components	O
of	O
the	O
TFTC	O
/	O
STAGA	O
complex	O
.	O

Expansion	O
of	O
the	O
polyglutamine	O
stretch	O
did	O
not	O
impair	O
the	O
SUMOylation	O
of	O
ATXN7	B-Protein
.	O

Furthermore	O
,	O
SUMO1	B-Protein
and	O
SUMO2	B-Protein
colocalized	O
with	O
ATXN7	B-Protein
in	O
a	O
subset	O
of	O
neuronal	O
intranuclear	O
inclusions	O
in	O
the	O
brain	O
of	O
SCA7	O
patients	O
and	O
SCA7	O
knock	O
-	O
in	O
mice	O
.	O

In	O
a	O
COS	O
-	O
7	O
cellular	O
model	O
of	O
SCA7	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
staining	O
we	O
identified	O
two	O
populations	O
of	O
nuclear	O
inclusions	O
:	O
homogenous	O
or	O
non	O
-	O
homogenous	O
.	O

Non	O
-	O
homogenous	O
inclusions	O
showed	O
significantly	O
reduced	O
colocalization	O
with	O
SUMO1	B-Protein
and	O
SUMO2	B-Protein
,	O
but	O
were	O
highly	O
enriched	O
in	O
Hsp70	B-Protein
,	O
19S	O
proteasome	O
and	O
ubiquitin	B-Protein
.	O

Interestingly	O
,	O
they	O
were	O
characterized	O
by	O
increased	O
staining	O
with	O
the	O
apoptotic	O
marker	O
caspase	B-Protein
-	I-Protein
3	I-Protein
and	O
by	O
disruption	O
of	O
PML	B-Protein
nuclear	O
bodies	O
.	O

Importantly	O
,	O
preventing	O
the	O
SUMOylation	O
of	O
expanded	O
ATXN7	B-Protein
by	O
mutating	O
the	O
SUMO	O
site	O
increased	O
both	O
the	O
amount	O
of	O
SDS	O
-	O
insoluble	O
aggregates	O
and	O
of	O
caspase	B-Protein
-	I-Protein
3	I-Protein
positive	O
non	O
-	O
homogenous	O
inclusions	O
,	O
which	O
act	O
toxic	O
to	O
the	O
cells	O
.	O

Our	O
results	O
demonstrate	O
an	O
influence	O
of	O
SUMOylation	O
on	O
the	O
multistep	O
aggregation	O
process	O
of	O
ATXN7	B-Protein
and	O
implicate	O
a	O
role	O
for	O
ATXN7	B-Protein
SUMOylation	O
in	O
SCA7	O
pathogenesis	O
.	O

Orientation	O
of	O
palmitoylated	O
CaVbeta2a	B-Protein
relative	O
to	O
CaV2	O
.	O
2	O
is	O
critical	O
for	O
slow	O
pathway	O
modulation	O
of	O
N	O
-	O
type	O
Ca2	O
+	O
current	O
by	O
tachykinin	O
receptor	O
activation	O
.	O

The	O
G	O
(	O
q	O
)	O
-	O
coupled	O
tachykinin	O
receptor	O
(	O
neurokinin	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
[	O
NK	B-Protein
-	I-Protein
1R	I-Protein
]	O
)	O
modulates	O
N	O
-	O
type	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
(	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
or	O
N	O
channel	O
)	O
activity	O
at	O
two	O
distinct	O
sites	O
by	O
a	O
pathway	O
involving	O
a	O
lipid	O
metabolite	O
,	O
most	O
likely	O
arachidonic	O
acid	O
(	O
AA	O
)	O
.	O

In	O
another	O
study	O
published	O
in	O
this	O
issue	O
(	O
Heneghan	O
et	O
al	O
.	O
2009	O
.	O
J	O
.	O
Gen	O
Physiol	O
.	O
doi	O
:	O
10	O
.	O
1085	O
/	O
jgp	O
.	O
200910203	O
)	O
,	O
we	O
found	O
that	O
the	O
form	O
of	O
modulation	O
observed	O
depends	O
on	O
which	O
Ca	O
(	O
V	O
)	O
beta	O
is	O
coexpressed	O
with	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
.	O

When	O
palmitoylated	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
is	O
coexpressed	O
,	O
activation	O
of	O
NK	B-Protein
-	I-Protein
1Rs	I-Protein
by	O
substance	B-Protein
P	I-Protein
(	O
SP	B-Protein
)	O
enhances	O
N	O
current	O
.	O

In	O
contrast	O
,	O
when	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta3	I-Protein
is	O
coexpressed	O
,	O
SP	B-Protein
inhibits	O
N	O
current	O
.	O

However	O
,	O
exogenously	O
applied	O
palmitic	O
acid	O
minimizes	O
this	O
inhibition	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
palmitoyl	O
groups	O
of	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
may	O
occupy	O
an	O
inhibitory	O
site	O
on	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
or	O
prevent	O
AA	O
from	O
interacting	O
with	O
that	O
site	O
,	O
thereby	O
minimizing	O
inhibition	O
.	O

If	O
so	O
,	O
changing	O
the	O
orientation	O
of	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
relative	O
to	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
may	O
displace	O
the	O
palmitoyl	O
groups	O
and	O
prevent	O
them	O
from	O
antagonizing	O
AA	O
'	O
s	O
actions	O
,	O
thereby	O
allowing	O
inhibition	O
even	O
in	O
the	O
presence	O
of	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
this	O
hypothesis	O
by	O
deleting	O
one	O
(	O
Bdel1	O
)	O
or	O
two	O
(	O
Bdel2	O
)	O
amino	O
acids	O
proximal	O
to	O
the	O
alpha	O
interacting	O
domain	O
(	O
AID	O
)	O
of	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
'	O
s	O
I	O
-	O
II	O
linker	O
.	O

Ca	O
(	O
V	O
)	O
betas	O
bind	O
tightly	O
to	O
the	O
AID	O
,	O
whereas	O
the	O
rigid	O
region	O
proximal	O
to	O
the	O
AID	O
is	O
thought	O
to	O
couple	O
Ca	O
(	O
V	O
)	O
beta	O
'	O
s	O
movements	O
to	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
gating	O
.	O

Although	O
Bdel1	O
/	O
beta2a	O
currents	O
exhibited	O
more	O
variable	O
enhancement	O
by	O
SP	B-Protein
,	O
Bdel2	O
/	O
beta2a	O
current	O
enhancement	O
was	O
lost	O
at	O
all	O
voltages	O
.	O

Instead	O
,	O
inhibition	O
was	O
observed	O
that	O
matched	O
the	O
profile	O
of	O
N	O
-	O
current	O
inhibition	O
from	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
coexpressed	O
with	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta3	I-Protein
.	O

Moreover	O
,	O
adding	O
back	O
exogenous	O
palmitic	O
acid	O
minimized	O
inhibition	O
of	O
Bdel2	O
/	O
beta2a	O
currents	O
,	O
suggesting	O
that	O
when	O
palmitoylated	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
is	O
sufficiently	O
displaced	O
,	O
endogenously	O
released	O
AA	O
can	O
bind	O
to	O
the	O
inhibitory	O
site	O
.	O

These	O
findings	O
support	O
our	O
previous	O
hypothesis	O
that	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
'	O
s	O
palmitoyl	O
groups	O
directly	O
interact	O
with	O
an	O
inhibitory	O
site	O
on	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
to	O
block	O
N	O
-	O
current	O
inhibition	O
by	O
SP	B-Protein
.	O

Validation	O
of	O
a	O
method	O
for	O
the	O
quantitation	O
of	O
ghrelin	B-Protein
and	O
unacylated	O
ghrelin	B-Protein
by	O
HPLC	O
.	O

An	O
HPLC	O
/	O
UV	O
method	O
was	O
first	O
optimized	O
for	O
the	O
separation	O
and	O
quantitation	O
of	O
human	O
acylated	O
and	O
unacylated	O
(	O
or	O
des	O
-	O
acyl	O
)	O
ghrelin	B-Protein
from	O
aqueous	O
solutions	O
.	O

This	O
method	O
was	O
validated	O
by	O
an	O
original	O
approach	O
using	O
accuracy	O
profiles	O
based	O
on	O
tolerance	O
intervals	O
for	O
the	O
total	O
error	O
measurement	O
.	O

The	O
concentration	O
range	O
that	O
achieved	O
adequate	O
accuracy	O
extended	O
from	O
1	O
.	O
85	O
to	O
59	O
.	O
30microM	O
and	O
1	O
.	O
93	O
to	O
61	O
.	O
60microM	O
for	O
acylated	O
and	O
unacylated	O
ghrelin	B-Protein
,	O
respectively	O
.	O

Then	O
,	O
optimal	O
temperature	O
,	O
pH	O
and	O
buffer	O
for	O
sample	O
storage	O
were	O
determined	O
.	O

Unacylated	O
ghrelin	B-Protein
was	O
found	O
to	O
be	O
stable	O
in	O
all	O
conditions	O
tested	O
.	O

At	O
37	O
degrees	O
C	O
acylated	O
ghrelin	B-Protein
was	O
stable	O
at	O
pH	O
4	O
but	O
unstable	O
at	O
pH	O
7	O
.	O
4	O
,	O
the	O
main	O
degradation	O
product	O
was	O
unacylated	O
ghrelin	B-Protein
.	O

Finally	O
,	O
this	O
validated	O
HPLC	O
/	O
UV	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
binding	O
of	O
acylated	O
and	O
unacylated	O
ghrelin	B-Protein
to	O
liposomes	O
.	O

Phosphorylation	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
by	O
protein	O
kinase	O
A	O
regulates	O
its	O
neddylation	O
and	O
antiproliferative	O
effect	O
.	O

Expression	O
of	O
the	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
cul5	B-Protein
gene	O
in	O
endothelial	O
and	O
in	O
cancer	O
cell	O
lines	O
in	O
vitro	O
inhibits	O
cellular	O
proliferation	O
and	O
decreases	O
phosphorylation	O
of	O
MAPK	O
.	O

Structure	O
-	O
function	O
analysis	O
of	O
the	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
sequence	O
identified	O
consensus	O
sites	O
specific	O
for	O
phosphorylation	O
by	O
protein	O
kinases	O
A	O
and	O
C	O
(	O
PKA	O
and	O
PKC	O
)	O
and	O
a	O
Nedd8	B-Protein
protein	O
modification	O
site	O
.	O

Mutations	O
at	O
the	O
PKA	O
-	O
specific	O
site	O
in	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
(	O
(	O
S730A	O
)	O
VACM	B-Protein
-	I-Protein
1	I-Protein
)	O
sequence	O
resulted	O
in	O
increased	O
cellular	O
growth	O
and	O
the	O
appearance	O
of	O
a	O
Nedd8	B-Protein
-	O
modified	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
if	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
controls	O
its	O
neddylation	O
status	O
,	O
phosphorylation	O
by	O
PKC	O
,	O
and	O
ultimately	O
growth	O
.	O

Our	O
results	O
indicate	O
that	O
in	O
vitro	O
transfection	O
of	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
with	O
anti	O
-	O
VACM	B-Protein
-	I-Protein
1	I-Protein
-	O
specific	O
small	O
interfering	O
RNA	O
oligonucleotides	O
decreases	O
endogenous	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
concentration	O
and	O
increases	O
cell	O
growth	O
.	O

Western	O
blot	O
analysis	O
of	O
cell	O
lysates	O
immunoprecipitated	O
with	O
an	O
antibody	O
directed	O
against	O
a	O
PKA	O
-	O
specific	O
phosphorylation	O
site	O
and	O
probed	O
with	O
anti	O
-	O
VACM	B-Protein
-	I-Protein
1	I-Protein
-	O
specific	O
antibody	O
showed	O
that	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
was	O
decreased	O
in	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	B-Protein
-	I-Protein
1	I-Protein
cDNA	O
when	O
compared	O
with	O
the	O
cytomegalovirus	O
-	O
transfected	O
cells	O
.	O

This	O
change	O
was	O
associated	O
with	O
increased	O
modification	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
by	O
Nedd8	B-Protein
.	O

Induction	O
of	O
PKA	O
activity	O
with	O
forskolin	O
reduced	O
modification	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
by	O
Nedd8	B-Protein
.	O

Finally	O
,	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
cul5	B-Protein
cDNA	O
and	O
treated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
10	O
and	O
100	O
nm	O
)	O
to	O
induce	O
PKC	O
activity	O
grew	O
significantly	O
faster	O
than	O
the	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
antiproliferative	O
effect	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
is	O
dependent	O
on	O
its	O
posttranslational	O
modifications	O
and	O
will	O
help	O
in	O
the	O
design	O
of	O
new	O
anticancer	O
therapeutics	O
that	O
target	O
the	O
Nedd8	B-Protein
pathway	O
.	O

Recognition	O
of	O
lipopeptide	O
patterns	O
by	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
-	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
6	I-Protein
heterodimer	O
.	O

Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
(	O
TLR2	B-Protein
)	O
initiates	O
potent	O
immune	O
responses	O
by	O
recognizing	O
diacylated	O
and	O
triacylated	O
lipopeptides	O
.	O

Its	O
ligand	O
specificity	O
is	O
controlled	O
by	O
whether	O
it	O
heterodimerizes	O
with	O
TLR1	B-Protein
or	O
TLR6	B-Protein
.	O

We	O
have	O
determined	O
the	O
crystal	O
structures	O
of	O
TLR2	B-Protein
-	O
TLR6	B-Protein
-	O
diacylated	O
lipopeptide	O
,	O
TLR2	B-Protein
-	O
lipoteichoic	O
acid	O
,	O
and	O
TLR2	B-Protein
-	O
PE	O
-	O
DTPA	O
complexes	O
.	O

PE	O
-	O
DTPA	O
,	O
1	O
,	O
2	O
-	O
dimyristoyl	O
-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphoethanolamine	O
-	O
N	O
-	O
diethylenetriaminepentaacetic	O
acid	O
,	O
is	O
a	O
synthetic	O
phospholipid	O
derivative	O
.	O

Two	O
major	O
factors	O
contribute	O
to	O
the	O
ligand	O
specificity	O
of	O
TLR2	B-Protein
-	O
TLR1	B-Protein
or	O
TLR2	B-Protein
-	O
TLR6	B-Protein
heterodimers	O
.	O

First	O
,	O
the	O
lipid	O
channel	O
of	O
TLR6	B-Protein
is	O
blocked	O
by	O
two	O
phenylalanines	O
.	O

Simultaneous	O
mutation	O
of	O
these	O
phenylalanines	O
made	O
TLR2	B-Protein
-	O
TLR6	B-Protein
fully	O
responsive	O
not	O
only	O
to	O
diacylated	O
but	O
also	O
to	O
triacylated	O
lipopeptides	O
.	O

Second	O
,	O
the	O
hydrophobic	O
dimerization	O
interface	O
of	O
TLR2	B-Protein
-	O
TLR6	B-Protein
is	O
increased	O
by	O
80	O
%	O
,	O
which	O
compensates	O
for	O
the	O
lack	O
of	O
amide	O
lipid	O
interaction	O
between	O
the	O
lipopeptide	O
and	O
TLR2	B-Protein
-	O
TLR6	B-Protein
.	O

The	O
structures	O
of	O
the	O
TLR2	B-Protein
-	O
lipoteichoic	O
acid	O
and	O
the	O
TLR2	B-Protein
-	O
PE	O
-	O
DTPA	O
complexes	O
demonstrate	O
that	O
a	O
precise	O
interaction	O
pattern	O
of	O
the	O
head	O
group	O
is	O
essential	O
for	O
a	O
robust	O
immune	O
response	O
by	O
TLR2	B-Protein
heterodimers	O
.	O

Palmitoylation	O
regulates	O
epidermal	O
homeostasis	O
and	O
hair	O
follicle	O
differentiation	O
.	O

Palmitoylation	O
is	O
a	O
key	O
post	O
-	O
translational	O
modification	O
mediated	O
by	O
a	O
family	O
of	O
DHHC	O
-	O
containing	O
palmitoyl	O
acyl	O
-	O
transferases	O
(	O
PATs	O
)	O
.	O

Unlike	O
other	O
lipid	O
modifications	O
,	O
palmitoylation	O
is	O
reversible	O
and	O
thus	O
often	O
regulates	O
dynamic	O
protein	O
interactions	O
.	O

We	O
find	O
that	O
the	O
mouse	O
hair	O
loss	O
mutant	O
,	O
depilated	O
,	O
(	O
dep	O
)	O
is	O
due	O
to	O
a	O
single	O
amino	O
acid	O
deletion	O
in	O
the	O
PAT	O
,	O
Zdhhc21	B-Protein
,	O
resulting	O
in	O
protein	O
mislocalization	O
and	O
loss	O
of	O
palmitoylation	O
activity	O
.	O

We	O
examined	O
expression	O
of	O
Zdhhc21	B-Protein
protein	O
in	O
skin	O
and	O
find	O
it	O
restricted	O
to	O
specific	O
hair	O
lineages	O
.	O

Loss	O
of	O
Zdhhc21	B-Protein
function	O
results	O
in	O
delayed	O
hair	O
shaft	O
differentiation	O
,	O
at	O
the	O
site	O
of	O
expression	O
of	O
the	O
gene	O
,	O
but	O
also	O
leads	O
to	O
hyperplasia	O
of	O
the	O
interfollicular	O
epidermis	O
(	O
IFE	O
)	O
and	O
sebaceous	O
glands	O
,	O
distant	O
from	O
the	O
expression	O
site	O
.	O

The	O
specific	O
delay	O
in	O
follicle	O
differentiation	O
is	O
associated	O
with	O
attenuated	O
anagen	O
propagation	O
and	O
is	O
reflected	O
by	O
decreased	O
levels	O
of	O
Lef1	B-Protein
,	O
nuclear	B-Protein
beta	I-Protein
-	I-Protein
catenin	I-Protein
,	O
and	O
Foxn1	B-Protein
in	O
hair	O
shaft	O
progenitors	O
.	O

In	O
the	O
thickened	O
basal	O
compartment	O
of	O
mutant	O
IFE	O
,	O
phospho	O
-	O
ERK	O
and	O
cell	O
proliferation	O
are	O
increased	O
,	O
suggesting	O
increased	O
signaling	O
through	O
EGFR	B-Protein
or	O
integrin	O
-	O
related	O
receptors	O
,	O
with	O
a	O
parallel	O
reduction	O
in	O
expression	O
of	O
the	O
key	O
differentiation	O
factor	O
Gata3	B-Protein
.	O

We	O
show	O
that	O
the	O
Src	O
-	O
family	O
kinase	O
,	O
Fyn	B-Protein
,	O
involved	O
in	O
keratinocyte	O
differentiation	O
,	O
is	O
a	O
direct	O
palmitoylation	O
target	O
of	O
Zdhhc21	B-Protein
and	O
is	O
mislocalized	O
in	O
mutant	O
follicles	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
a	O
key	O
role	O
for	O
palmitoylation	O
in	O
regulating	O
developmental	O
signals	O
in	O
mammalian	O
tissue	O
homeostasis	O
.	O

Rapid	O
and	O
selective	O
detection	O
of	O
fatty	O
acylated	O
proteins	O
using	O
omega	O
-	O
alkynyl	O
-	O
fatty	O
acids	O
and	O
click	O
chemistry	O
.	O

Progress	O
in	O
understanding	O
the	O
biology	O
of	O
protein	O
fatty	O
acylation	O
has	O
been	O
impeded	O
by	O
the	O
lack	O
of	O
rapid	O
direct	O
detection	O
and	O
identification	O
methods	O
.	O

We	O
first	O
report	O
that	O
a	O
synthetic	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
analog	O
can	O
be	O
readily	O
and	O
specifically	O
incorporated	O
into	O
GAPDH	B-Protein
or	O
mitochondrial	O
3	B-Protein
-	I-Protein
hydroxyl	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
methylglutaryl	I-Protein
-	I-Protein
CoA	I-Protein
synthase	I-Protein
in	O
vitro	O
and	O
reacted	O
with	O
an	O
azido	O
-	O
biotin	O
probe	O
or	O
the	O
fluorogenic	O
probe	O
3	O
-	O
azido	O
-	O
7	O
-	O
hydroxycoumarin	O
using	O
click	O
chemistry	O
for	O
rapid	O
detection	O
by	O
Western	O
blotting	O
or	O
flat	O
bed	O
fluorescence	O
scanning	O
.	O

The	O
acylated	O
cysteine	O
residues	O
were	O
confirmed	O
by	O
MS	O
.	O

Second	O
,	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
is	O
preferentially	O
incorporated	O
into	O
transiently	O
expressed	O
H	B-Protein
-	I-Protein
or	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
(	O
but	O
not	O
nonpalmitoylated	O
K	B-Protein
-	I-Protein
Ras	I-Protein
)	O
,	O
compared	O
with	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
or	O
omega	O
-	O
alkynyl	O
-	O
stearate	O
,	O
via	O
an	O
alkali	O
sensitive	O
thioester	O
bond	O
.	O

Third	O
,	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
is	O
specifically	O
incorporated	O
into	O
endogenous	O
co	O
-	O
and	O
posttranslationally	O
myristoylated	O
proteins	O
.	O

The	O
competitive	O
inhibitors	O
2	O
-	O
bromopalmitate	O
and	O
2	O
-	O
hydroxymyristate	O
prevented	O
incorporation	O
of	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
and	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
into	O
palmitoylated	O
and	O
myristoylated	O
proteins	O
,	O
respectively	O
.	O

Labeling	O
cells	O
with	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
does	O
not	O
affect	O
membrane	O
association	O
of	O
N	B-Protein
-	I-Protein
Ras	I-Protein
.	O

Furthermore	O
,	O
the	O
palmitoylation	O
of	O
endogenous	O
proteins	O
including	O
H	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
could	O
be	O
easily	O
detected	O
using	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
as	O
label	O
in	O
cultured	O
HeLa	O
,	O
Jurkat	O
,	O
and	O
COS	O
-	O
7	O
cells	O
,	O
and	O
,	O
promisingly	O
,	O
in	O
mice	O
.	O

The	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
and	O
-	O
palmitate	O
analogs	O
used	O
with	O
click	O
chemistry	O
and	O
azido	O
-	O
probes	O
will	O
be	O
invaluable	O
to	O
study	O
protein	O
acylation	O
in	O
vitro	O
,	O
in	O
cells	O
,	O
and	O
in	O
vivo	O
.	O

Regulation	O
of	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
trafficking	O
and	O
function	O
by	O
palmitoylation	O
.	O

The	O
SNARE	O
(	O
soluble	O
N	O
-	O
ethylmaleimide	O
-	O
sensitive	O
fusion	O
protein	O
-	O
attachment	O
protein	O
receptor	O
)	O
protein	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
(	O
25	B-Protein
kDa	I-Protein
synaptosome	I-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
)	O
is	O
essential	O
for	O
regulated	O
exocytosis	O
in	O
neuronal	O
and	O
neuroendocrine	O
cells	O
.	O

Whereas	O
the	O
majority	O
of	O
SNARE	O
proteins	O
contain	O
transmembrane	O
domains	O
,	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
is	O
instead	O
anchored	O
to	O
membranes	O
by	O
the	O
palmitoylation	O
of	O
a	O
central	O
cysteine	O
-	O
rich	O
region	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
of	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
palmitoylation	O
and	O
how	O
this	O
modification	O
regulates	O
the	O
intracellular	O
trafficking	O
and	O
exocytotic	O
function	O
of	O
this	O
essential	O
protein	O
.	O

Regulation	O
of	O
synaptic	O
structure	O
and	O
function	O
by	O
palmitoylated	O
AMPA	O
receptor	O
binding	O
protein	O
.	O

AMPA	O
receptor	O
binding	O
protein	O
(	O
ABP	O
)	O
is	O
a	O
multi	O
-	O
PDZ	O
domain	O
scaffold	O
that	O
binds	O
and	O
stabilizes	O
AMPA	O
receptor	O
(	O
AMPAR	O
)	O
GluR2	B-Protein
/	O
3	B-Protein
subunits	O
at	O
synapses	O
.	O

A	O
palmitoylated	O
N	O
-	O
terminal	O
splice	O
variant	O
(	O
pABP	O
-	O
L	O
)	O
concentrates	O
in	O
spine	O
heads	O
,	O
whereas	O
a	O
non	O
-	O
palmitoylated	O
form	O
(	O
ABP	O
-	O
L	O
)	O
is	O
intracellular	O
.	O

We	O
show	O
that	O
postsynaptic	O
Sindbis	O
viral	O
expression	O
of	O
pABP	O
-	O
L	O
increased	O
AMPAR	O
mediated	O
mEPSC	O
amplitude	O
and	O
frequency	O
and	O
elevated	O
surface	O
levels	O
of	O
GluR1	B-Protein
and	O
GluR2	B-Protein
,	O
suggesting	O
an	O
increase	O
in	O
AMPA	O
receptors	O
at	O
individual	O
synapses	O
.	O

Spines	O
were	O
enlarged	O
and	O
more	O
numerous	O
and	O
nerve	O
terminals	O
contacting	O
these	O
cells	O
displayed	O
enlarged	O
synaptophysin	B-Protein
puncta	O
.	O

A	O
non	O
-	O
palmitoylated	O
pABP	O
-	O
L	O
mutant	O
(	O
C11A	O
)	O
did	O
not	O
change	O
spine	O
density	O
or	O
size	O
.	O

Exogenous	O
pABP	O
-	O
L	O
and	O
endogenous	O
GRIP	O
,	O
a	O
related	O
scaffold	O
,	O
colocalized	O
with	O
NPRAP	B-Protein
(	O
delta	O
-	O
catenin	O
)	O
,	O
to	O
which	O
ABP	O
and	O
GRIP	O
bind	O
,	O
and	O
with	O
cadherins	O
,	O
which	O
bind	O
NPRAP	B-Protein
.	O

Thus	O
postsynaptic	O
pABP	O
-	O
L	O
induces	O
pre	O
and	O
postsynaptic	O
changes	O
that	O
are	O
dependent	O
on	O
palmitoylation	O
and	O
likely	O
achieved	O
through	O
ABP	O
association	O
with	O
a	O
multi	O
-	O
molecular	O
cell	O
surface	O
signaling	O
complex	O
.	O

DELLA	O
proteins	O
restrain	O
germination	O
and	O
elongation	O
growth	O
in	O
Arabidopsis	O
thaliana	O
COP9	O
signalosome	O
mutants	O
.	O

The	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
is	O
an	O
evolutionarily	O
conserved	O
multiprotein	O
complex	O
with	O
an	O
essential	O
role	O
in	O
the	O
development	O
of	O
higher	O
eukaryotes	O
.	O

CSN	O
deconjugates	O
the	O
ubiquitin	B-Protein
-	O
related	O
modifier	O
NEDD8	B-Protein
from	O
the	O
cullin	O
subunit	O
of	O
cullin	O
-	O
RING	O
type	O
E3	O
ubiquitin	B-Protein
ligases	O
(	O
CRLs	O
)	O
,	O
and	O
CSN	O
-	O
mediated	O
cullin	O
deneddylation	O
is	O
required	O
for	O
full	O
CRL	O
activity	O
.	O

Although	O
several	O
plant	O
E3	O
CRL	O
functions	O
have	O
been	O
shown	O
to	O
be	O
compromised	O
in	O
Arabidopsis	O
csn	O
mutants	O
,	O
none	O
of	O
these	O
functions	O
have	O
so	O
far	O
been	O
shown	O
to	O
limit	O
growth	O
in	O
these	O
mutants	O
.	O

Here	O
,	O
we	O
examine	O
the	O
role	O
of	O
CSN	O
in	O
the	O
context	O
of	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
SCF	O
(	O
SLEEPY1	B-Protein
(	O
SLY1	B-Protein
)	O
)	O
,	O
which	O
promotes	O
gibberellic	O
acid	O
(	O
GA	O
)	O
-	O
dependent	O
responses	O
in	O
Arabidopsis	O
thaliana	O
.	O

We	O
show	O
that	O
csn	O
mutants	O
are	O
impaired	O
in	O
GA	O
-	O
and	O
SCF	O
(	O
SLY1	B-Protein
)	O
-	O
dependent	O
germination	O
and	O
elongation	O
growth	O
,	O
and	O
we	O
show	O
that	O
these	O
defects	O
correlate	O
with	O
an	O
accumulation	O
and	O
reduced	O
turnover	O
of	O
an	O
SCF	O
(	O
SLY1	B-Protein
)	O
-	O
degradation	O
target	O
,	O
the	O
DELLA	O
protein	O
REPRESSOR	B-Protein
-	I-Protein
OF	I-Protein
-	I-Protein
ga1	I-Protein
-	I-Protein
3	I-Protein
(	O
RGA	B-Protein
)	O
.	O

Genetic	O
interaction	O
studies	O
between	O
csn	O
mutants	O
and	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
of	O
RGA	B-Protein
and	O
its	O
functional	O
homologue	O
GIBBERELLIC	B-Protein
ACID	I-Protein
INSENSITIVE	I-Protein
(	O
GAI	B-Protein
)	O
further	O
reveal	O
that	O
RGA	B-Protein
and	O
GAI	B-Protein
repress	O
defects	O
of	O
germination	O
in	O
strong	O
csn	O
mutants	O
.	O

In	O
addition	O
,	O
we	O
find	O
that	O
these	O
two	O
DELLA	O
proteins	O
are	O
largely	O
responsible	O
for	O
the	O
elongation	O
defects	O
of	O
a	O
weak	O
csn5	B-Protein
mutant	O
allele	O
.	O

We	O
thus	O
conclude	O
that	O
an	O
impairment	O
of	O
SCF	O
(	O
SLY1	B-Protein
)	O
is	O
at	O
least	O
in	O
part	O
causative	O
for	O
the	O
germination	O
and	O
elongation	O
defects	O
of	O
csn	O
mutants	O
,	O
and	O
suggest	O
that	O
DELLA	O
proteins	O
are	O
major	O
growth	O
repressors	O
in	O
these	O
mutants	O
.	O

Designed	O
semisynthetic	O
protein	O
inhibitors	O
of	O
Ub	O
/	O
Ubl	O
E1	O
activating	O
enzymes	O
.	O

Semisynthetic	O
,	O
mechanism	O
-	O
based	O
protein	O
inhibitors	O
of	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
and	O
ubiquitin	O
-	O
like	O
modifier	O
(	O
Ubl	O
)	O
activating	O
enzymes	O
(	O
E1s	O
)	O
have	O
been	O
developed	O
to	O
target	O
E1	O
-	O
catalyzed	O
adenylation	O
and	O
thioesterification	O
of	O
the	O
Ub	B-Protein
/	O
Ubl	O
C	O
-	O
terminus	O
during	O
the	O
processes	O
of	O
protein	O
SUMOylation	O
and	O
ubiquitination	O
.	O

The	O
inhibitors	O
were	O
generated	O
by	O
intein	O
-	O
mediated	O
expressed	O
protein	O
ligation	O
using	O
a	O
truncated	O
Ub	B-Protein
/	O
Ubl	O
protein	O
(	O
SUMO	O
residues	O
1	O
-	O
94	O
;	O
Ub	B-Protein
residues	O
1	O
-	O
71	O
)	O
with	O
a	O
C	O
-	O
terminal	O
thioester	O
and	O
synthetic	O
tripeptides	O
having	O
a	O
C	O
-	O
terminal	O
adenosine	O
analogue	O
and	O
an	O
N	O
-	O
terminal	O
cysteine	O
residue	O
.	O

SUMO	O
-	O
AMSN	O
(	O
4a	O
)	O
and	O
Ub	B-Protein
-	O
AMSN	O
(	O
4b	O
)	O
contain	O
a	O
sulfamide	O
group	O
as	O
a	O
nonhydrolyzable	O
mimic	O
of	O
the	O
phosphate	O
group	O
in	O
the	O
cognate	O
Ub	B-Protein
/	O
Ubl	O
-	O
AMP	O
adenylate	O
intermediate	O
in	O
the	O
first	O
half	O
-	O
reaction	O
,	O
and	O
these	O
constructs	O
selectively	O
inhibit	O
SUMO	O
E1	O
and	O
Ub	O
E1	O
,	O
respectively	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

SUMO	O
-	O
AVSN	O
(	O
5a	O
)	O
and	O
Ub	B-Protein
-	O
AVSN	O
(	O
5b	O
)	O
contain	O
an	O
electrophilic	O
vinyl	O
sulfonamide	O
designed	O
to	O
trap	O
the	O
incoming	O
E1	O
cysteine	O
nucleophile	O
(	O
Uba2	B-Protein
Cys173	O
in	O
SUMO	O
E1	O
;	O
Uba1	B-Protein
Cys593	O
in	O
Ub	O
E1	O
)	O
in	O
the	O
second	O
half	O
-	O
reaction	O
,	O
and	O
these	O
constructs	O
selectively	O
,	O
covalently	O
,	O
and	O
stably	O
cross	O
-	O
link	O
to	O
SUMO	O
E1	O
and	O
Ub	B-Protein
E1	O
,	O
respectively	O
,	O
in	O
a	O
cysteine	O
nucleophile	O
-	O
dependent	O
manner	O
.	O

These	O
inhibitors	O
are	O
powerful	O
tools	O
to	O
probe	O
outstanding	O
mechanistic	O
questions	O
in	O
E1	O
function	O
and	O
can	O
also	O
be	O
used	O
to	O
study	O
the	O
biological	O
functions	O
of	O
E1	O
enzymes	O
.	O

Characterization	O
of	O
the	O
self	O
-	O
palmitoylation	O
activity	O
of	O
the	O
transport	O
protein	O
particle	O
component	O
Bet3	B-Protein
.	O

Bet3	B-Protein
,	O
a	O
transport	O
protein	O
particle	O
component	O
involved	O
in	O
vesicular	O
trafficking	O
,	O
contains	O
a	O
hydrophobic	O
tunnel	O
occupied	O
by	O
a	O
fatty	O
acid	O
linked	O
to	O
cysteine	O
68	O
.	O

We	O
reported	O
that	O
Bet3	B-Protein
has	O
a	O
unique	O
self	O
-	O
palmitoylating	O
activity	O
.	O

Here	O
we	O
show	O
that	O
mutation	O
of	O
arginine	O
67	O
reduced	O
self	O
-	O
palmitoylation	O
of	O
Bet3	B-Protein
,	O
but	O
the	O
effect	O
was	O
compensated	O
by	O
increasing	O
the	O
pH	O
.	O

Thus	O
,	O
arginine	O
helps	O
to	O
deprotonate	O
cysteine	O
such	O
that	O
it	O
could	O
function	O
as	O
a	O
nucleophile	O
in	O
the	O
acylation	O
reaction	O
which	O
is	O
supported	O
by	O
the	O
structural	O
analysis	O
of	O
non	O
-	O
acylated	O
Bet3	B-Protein
.	O

Using	O
fluorescence	O
spectroscopy	O
we	O
show	O
that	O
long	O
-	O
chain	O
acyl	O
-	O
CoAs	O
bind	O
with	O
micromolar	O
affinity	O
to	O
Bet3	B-Protein
,	O
whereas	O
shorter	O
-	O
chain	O
acyl	O
-	O
CoAs	O
do	O
not	O
interact	O
.	O

Mutants	O
with	O
a	O
deleted	O
acylation	O
site	O
or	O
a	O
blocked	O
tunnel	O
bind	O
to	O
Pal	O
-	O
CoA	O
,	O
only	O
the	O
latter	O
with	O
slightly	O
reduced	O
affinity	O
.	O

Bet3	B-Protein
contains	O
three	O
binding	O
sites	O
for	O
Pal	O
-	O
CoA	O
,	O
but	O
their	O
number	O
was	O
reduced	O
to	O
two	O
in	O
the	O
mutant	O
with	O
an	O
obstructed	O
tunnel	O
,	O
indicating	O
that	O
Bet3	B-Protein
contains	O
binding	O
sites	O
on	O
its	O
surface	O
.	O

Farnesyltransferase	O
inhibitors	O
in	O
myelodysplastic	O
syndrome	O
.	O

The	O
farnesyltransferase	O
inhibitors	O
(	O
FTIs	O
)	O
are	O
in	O
active	O
clinical	O
development	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
.	O

The	O
most	O
promising	O
activity	O
to	O
date	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
hematologic	O
malignancies	O
,	O
in	O
particular	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O

In	O
patients	O
with	O
MDS	O
,	O
two	O
nonpeptidomimetic	O
agents	O
,	O
tipifarnib	O
(	O
Zarnestra	O
,	O
Johnson	O
&	O
Johnson	O
,	O
New	O
Brunswick	O
,	O
NJ	O
)	O
and	O
lonafarnib	O
(	O
Sarasar	O
,	O
Schering	O
-	O
Plough	O
,	O
Kenilworth	O
,	O
NJ	O
)	O
have	O
been	O
the	O
most	O
extensively	O
studied	O
.	O

In	O
both	O
phase	O
I	O
and	O
phase	O
II	O
trials	O
,	O
tipifarnib	O
has	O
demonstrated	O
significant	O
efficacy	O
,	O
with	O
overall	O
response	O
rates	O
of	O
30	O
%	O
and	O
complete	O
remissions	O
in	O
about	O
15	O
%	O
.	O

Dose	O
-	O
limiting	O
adverse	O
effects	O
have	O
been	O
primarily	O
myelosuppression	O
,	O
although	O
fatigue	O
,	O
neurotoxicity	O
,	O
and	O
occasional	O
renal	O
dysfunction	O
have	O
required	O
dose	O
reductions	O
.	O

Lonafarnib	O
in	O
patients	O
with	O
MDS	O
has	O
also	O
resulted	O
in	O
clinical	O
responses	O
in	O
approximately	O
30	O
%	O
,	O
including	O
significant	O
improvements	O
in	O
platelet	O
counts	O
.	O

Lonafarnib	O
has	O
been	O
associated	O
primarily	O
with	O
diarrhea	O
and	O
other	O
gastrointestinal	O
toxicity	O
,	O
anorexia	O
,	O
and	O
nausea	O
,	O
which	O
has	O
limited	O
its	O
efficacy	O
.	O

Clinical	O
response	O
correlation	O
with	O
documentation	O
of	O
inhibition	O
of	O
farnesyltransferase	O
and	O
/	O
or	O
evidence	O
of	O
decreased	O
farnesylation	O
of	O
downstream	O
protein	O
targets	O
has	O
not	O
been	O
demonstrated	O
with	O
either	O
agent	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
activating	O
Ras	O
mutation	O
has	O
not	O
predicted	O
response	O
to	O
therapy	O
with	O
FTIs	O
in	O
MDS	O
and	O
AML	O
.	O

Despite	O
this	O
lack	O
of	O
evidence	O
,	O
significant	O
clinical	O
efficacy	O
of	O
the	O
FTIs	O
has	O
been	O
observed	O
in	O
MDS	O
,	O
on	O
a	O
par	O
with	O
the	O
efficacy	O
of	O
currently	O
available	O
chemotherapeutic	O
agents	O
,	O
leading	O
to	O
further	O
development	O
of	O
this	O
new	O
class	O
of	O
drugs	O
in	O
MDS	O
and	O
AML	O
.	O

An	O
S	O
-	O
acylation	O
switch	O
of	O
conserved	O
G	O
domain	O
cysteines	O
is	O
required	O
for	O
polarity	O
signaling	O
by	O
ROP	O
GTPases	O
.	O

Rho	O
GTPases	O
are	O
master	O
regulators	O
of	O
cell	O
polarity	O
.	O

For	O
their	O
function	O
,	O
Rhos	O
must	O
associate	O
with	O
discrete	O
plasma	O
membrane	O
domains	O
.	O

Rho	O
of	O
Plants	O
(	O
ROPs	O
)	O
or	O
RACs	O
comprise	O
a	O
single	O
family	O
.	O

Prenylation	O
and	O
S	O
-	O
acylation	O
of	O
hypervariable	O
domain	O
cysteines	O
of	O
Ras	O
and	O
Rho	O
GTPases	O
are	O
required	O
for	O
their	O
function	O
;	O
however	O
,	O
lipid	O
modifications	O
in	O
the	O
G	O
domain	O
have	O
never	O
been	O
reported	O
.	O

Reversible	O
S	O
-	O
acylation	O
involves	O
the	O
attachment	O
of	O
palmitate	O
(	O
C16	O
:	O
0	O
)	O
or	O
other	O
saturated	O
lipids	O
to	O
cysteines	O
through	O
a	O
thioester	O
linkage	O
and	O
was	O
implicated	O
in	O
the	O
regulation	O
of	O
signaling	O
.	O

Here	O
we	O
show	O
that	O
transient	O
S	O
-	O
acylation	O
of	O
Arabidopsis	O
AtROP6	B-Protein
takes	O
place	O
on	O
two	O
conserved	O
G	O
domain	O
cysteine	O
residues	O
,	O
C21	O
and	O
C156	O
.	O

C21	O
is	O
relatively	O
exposed	O
and	O
is	O
accessible	O
for	O
modification	O
,	O
but	O
C156	O
is	O
not	O
,	O
implying	O
that	O
its	O
S	O
-	O
acylation	O
involves	O
a	O
conformational	O
change	O
.	O

Fluorescence	O
recovery	O
after	O
photobleaching	O
beam	O
-	O
size	O
analysis	O
shows	O
that	O
S	O
-	O
acylation	O
of	O
AtROP6	B-Protein
regulates	O
its	O
membrane	O
-	O
association	O
dynamics	O
,	O
and	O
detergent	O
-	O
solubilization	O
studies	O
indicate	O
that	O
it	O
regulates	O
AtROP6	B-Protein
association	O
with	O
lipid	O
rafts	O
.	O

Site	O
-	O
specific	O
acylation	O
-	O
deficient	O
AtROP6	B-Protein
mutants	O
can	O
bind	O
and	O
hydrolyze	O
GTP	O
but	O
display	O
compromised	O
effects	O
on	O
polar	O
cell	O
growth	O
,	O
endocytic	O
uptake	O
of	O
the	O
tracer	O
dye	O
FM4	O
-	O
64	O
,	O
and	O
distribution	O
of	O
reactive	O
oxygen	O
species	O
.	O

These	O
data	O
reveal	O
an	O
S	O
-	O
acylation	O
switch	O
that	O
regulates	O
Rho	O
signaling	O
.	O

Simultaneous	O
C7	O
-	O
and	O
N1	O
-	O
prenylation	O
of	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
catalyzed	O
by	O
a	O
prenyltransferase	O
from	O
Aspergillus	O
oryzae	O
.	O

A	O
putative	O
prenyltransferase	O
gene	O
cTrpPT	B-Protein
was	O
amplified	O
from	O
Aspergillus	O
oryzae	O
DSM1147	O
,	O
cloned	O
into	O
pQE70	O
and	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
overproduced	O
His	O
(	O
6	O
)	O
-	O
CTrpPT	B-Protein
was	O
purified	O
to	O
near	O
homogeneity	O
and	O
incubated	O
with	O
L	O
-	O
tryptophan	O
or	O
tryptophan	O
-	O
containing	O
cyclic	O
dipeptides	O
in	O
the	O
presence	O
of	O
dimethylallyl	O
diphosphate	O
.	O

The	O
formation	O
of	O
the	O
enzyme	O
products	O
was	O
monitored	O
with	O
HPLC	O
.	O

It	O
was	O
shown	O
that	O
CTrpPT	B-Protein
differed	O
clearly	O
from	O
other	O
known	O
indole	O
prenyltransferases	O
in	O
several	O
aspects	O
.	O

This	O
enzyme	O
showed	O
higher	O
substrate	O
specificity	O
towards	O
aromatic	O
substrates	O
,	O
but	O
lower	O
regioselectivity	O
regarding	O
the	O
prenylation	O
position	O
than	O
other	O
indole	O
prenyltransferases	O
.	O

Cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
was	O
much	O
better	O
accepted	O
than	O
other	O
cyclic	O
dipeptides	O
tested	O
in	O
this	O
study	O
.	O

In	O
comparison	O
to	O
other	O
indole	O
prenyltransferases	O
with	O
one	O
dominant	O
enzyme	O
product	O
,	O
at	O
least	O
two	O
product	O
peaks	O
were	O
detected	O
in	O
the	O
reaction	O
mixtures	O
of	O
CTrpPT	B-Protein
.	O

(	O
1	O
)	O
H	O
-	O
and	O
(	O
13	O
)	O
C	O
-	O
NMR	O
analyses	O
,	O
including	O
long	O
-	O
range	O
(	O
1	O
)	O
H	O
-	O
(	O
13	O
)	O
C	O
connectivities	O
in	O
Heteronuclear	O
Multiple	O
-	O
Bond	O
Correlation	O
(	O
HMBC	O
)	O
and	O
Nuclear	O
Overhauser	O
Effect	O
Spectroscopy	O
(	O
NOESY	O
)	O
,	O
proved	O
the	O
structures	O
of	O
the	O
enzyme	O
products	O
as	O
C7	O
-	O
and	O
N1	O
-	O
prenylated	O
derivatives	O
with	O
a	O
ratio	O
of	O
1	O
:	O
1	O
.	O
2	O
using	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
as	O
substrate	O
.	O

The	O
K	O
(	O
M	O
)	O
values	O
were	O
determined	O
at	O
about	O
2	O
.	O
5	O
mM	O
for	O
dimethylallyl	O
diphosphate	O
and	O
0	O
.	O
3	O
mM	O
for	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
with	O
a	O
turnover	O
number	O
of	O
0	O
.	O
33	O
s	O
(	O
-	O
1	O
)	O
.	O

The	O
lipoatrophic	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
deficient	O
mouse	O
model	O
reveals	O
autophagy	O
in	O
mature	O
adipocytes	O
.	O

Adipose	O
tissue	O
lipoatrophy	O
caused	O
by	O
caveolin	O
gene	O
deletion	O
in	O
mice	O
is	O
not	O
linked	O
to	O
defective	O
adipocyte	O
differentiation	O
.	O

We	O
show	O
that	O
adipose	O
tissue	O
development	O
cannot	O
be	O
rescued	O
by	O
endothelial	O
specific	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
re	O
-	O
expression	O
,	O
indicating	O
primordial	O
role	O
of	O
caveolin	O
in	O
mature	O
adipocytes	O
.	O

Partial	O
or	O
total	O
caveolin	O
deficiency	O
in	O
adipocytes	O
induced	O
broad	O
protein	O
expression	O
defects	O
,	O
including	O
but	O
not	O
limited	O
to	O
previously	O
described	O
downregulation	O
of	O
insulin	B-Protein
receptor	I-Protein
.	O

Global	O
alterations	O
in	O
protein	O
turnover	O
,	O
and	O
accelerated	O
degradation	O
of	O
long	O
-	O
lived	O
proteins	O
were	O
found	O
in	O
caveolin	O
-	O
deficient	O
adipocytes	O
.	O

Lipidation	O
of	O
endogenous	O
LC3	O
autophagy	O
marker	O
and	O
distribution	O
of	O
GFP	B-Protein
-	O
LC3	O
into	O
aggregates	O
demonstrated	O
activated	O
autophagy	O
in	O
the	O
absence	O
of	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
in	O
adipocytes	O
.	O

Furthermore	O
,	O
electron	O
microscopy	O
revealed	O
autophagic	O
vacuoles	O
in	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
deficient	O
but	O
not	O
control	O
adipocytes	O
.	O

Surprisingly	O
,	O
significant	O
levels	O
of	O
lipidated	O
LC3	B-Protein
-	I-Protein
II	I-Protein
were	O
found	O
around	O
lipid	O
droplets	O
of	O
normal	O
adipocytes	O
,	O
maintained	O
in	O
nutrient	O
-	O
rich	O
conditions	O
or	O
isolated	O
from	O
fed	O
mice	O
,	O
which	O
do	O
not	O
display	O
autophagy	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
caveolin	O
deficiency	O
induce	O
autophagy	O
in	O
adipocytes	O
,	O
a	O
feature	O
that	O
is	O
not	O
a	O
physiological	O
response	O
to	O
fasting	O
in	O
normal	O
fat	O
cells	O
.	O

This	O
likely	O
resulted	O
from	O
defective	O
insulin	B-Protein
and	O
lipolytic	O
responses	O
that	O
converge	O
in	O
chronic	O
nutrient	O
shortage	O
in	O
adipocytes	O
lacking	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
pathological	O
situation	O
with	O
autophagy	O
as	O
an	O
adaptative	O
response	O
to	O
adipocyte	O
failure	O
.	O

Regulation	O
of	O
the	O
p53	B-Protein
pathway	O
by	O
ubiquitin	B-Protein
and	O
related	O
proteins	O
.	O

The	O
p53	B-Protein
tumour	O
suppressor	O
protein	O
is	O
subject	O
to	O
many	O
levels	O
of	O
control	O
,	O
including	O
modification	O
with	O
ubiquitin	B-Protein
and	O
related	O
proteins	O
such	O
as	O
SUMO	O
and	O
NEDD8	B-Protein
.	O

These	O
modifications	O
regulate	O
p53	B-Protein
at	O
a	O
number	O
of	O
levels	O
,	O
including	O
control	O
of	O
protein	O
turnover	O
,	O
alterations	O
in	O
sub	O
-	O
cellular	O
localization	O
and	O
changes	O
in	O
the	O
ability	O
to	O
regulate	O
gene	O
expression	O
.	O

Numerous	O
E3	O
ligases	O
that	O
can	O
mediate	O
these	O
modifications	O
of	O
p53	B-Protein
have	O
been	O
described	O
,	O
some	O
of	O
which	O
promote	O
conjugation	O
with	O
more	O
than	O
one	O
ubiquitin	B-Protein
-	O
like	O
protein	O
.	O

Understanding	O
the	O
complexity	O
of	O
this	O
mechanism	O
of	O
p53	B-Protein
regulation	O
will	O
help	O
in	O
the	O
development	O
of	O
therapeutic	O
drugs	O
that	O
function	O
to	O
modulate	O
these	O
events	O
.	O

Interplay	O
of	O
palmitoylation	O
and	O
phosphorylation	O
in	O
the	O
trafficking	O
and	O
localization	O
of	O
phosphodiesterase	B-Protein
10A	I-Protein
:	O
implications	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O

Phosphodiesterase	B-Protein
10A	I-Protein
(	O
PDE10A	B-Protein
)	O
is	O
a	O
striatum	O
-	O
enriched	O
,	O
dual	O
-	O
specific	O
cyclic	O
nucleotide	O
phosphodiesterase	O
that	O
has	O
gained	O
considerable	O
attention	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
psychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

As	O
such	O
,	O
a	O
PDE10A	B-Protein
-	O
selective	O
inhibitor	O
compound	O
,	O
MP	O
-	O
10	O
,	O
has	O
recently	O
entered	O
clinical	O
testing	O
.	O

Since	O
little	O
is	O
known	O
about	O
the	O
cellular	O
regulation	O
of	O
PDE10A	B-Protein
,	O
we	O
sought	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
govern	O
its	O
subcellular	O
localization	O
in	O
striatal	O
medium	O
spiny	O
neurons	O
.	O

Previous	O
reports	O
suggest	O
that	O
PDE10A	B-Protein
is	O
primarily	O
membrane	O
bound	O
and	O
is	O
transported	O
throughout	O
medium	O
spiny	O
neuron	O
axons	O
and	O
dendrites	O
.	O

Moreover	O
,	O
it	O
has	O
been	O
shown	O
in	O
PC12	O
cells	O
that	O
the	O
localization	O
of	O
the	O
major	O
splice	O
form	O
,	O
PDE10A2	B-Protein
,	O
may	O
be	O
regulated	O
by	O
protein	O
kinase	O
A	O
phosphorylation	O
at	O
threonine	O
16	O
(	O
Thr	O
-	O
16	O
)	O
.	O

Using	O
an	O
antibody	O
that	O
specifically	O
recognizes	O
phosphorylated	O
Thr	O
-	O
16	O
(	O
pThr	O
-	O
16	O
)	O
of	O
PDE10A2	B-Protein
,	O
we	O
provide	O
evidence	O
that	O
phosphorylation	O
at	O
Thr	O
-	O
16	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
PDE10A	B-Protein
subcellular	O
localization	O
in	O
vivo	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
in	O
primary	O
mouse	O
striatal	O
neuron	O
cultures	O
that	O
PDE10A	B-Protein
membrane	O
association	O
and	O
transport	O
throughout	O
dendritic	O
processes	O
requires	O
palmitoylation	O
of	O
cysteine	O
11	O
(	O
Cys	O
-	O
11	O
)	O
of	O
PDE10A2	B-Protein
,	O
likely	O
by	O
the	O
palmitoyl	O
acyltransferases	O
DHHC	B-Protein
-	I-Protein
7	I-Protein
and	O
-	B-Protein
19	I-Protein
.	O

Finally	O
,	O
we	O
show	O
that	O
Thr	O
-	O
16	O
phosphorylation	O
regulates	O
PDE10A	B-Protein
trafficking	O
and	O
localization	O
by	O
preventing	O
palmitoylation	O
of	O
Cys	O
-	O
11	O
rather	O
than	O
by	O
interfering	O
with	O
palmitate	O
-	O
lipid	O
interactions	O
.	O

These	O
data	O
support	O
a	O
model	O
whereby	O
PDE10A	B-Protein
trafficking	O
and	O
localization	O
can	O
be	O
regulated	O
in	O
response	O
to	O
local	O
fluctuations	O
in	O
cAMP	O
levels	O
.	O

Given	O
this	O
,	O
we	O
propose	O
that	O
excessive	O
striatal	O
dopamine	O
release	O
,	O
as	O
occurs	O
in	O
schizophrenia	O
,	O
might	O
exert	O
differential	O
effects	O
on	O
the	O
regulation	O
of	O
PDE10A	B-Protein
localization	O
in	O
the	O
two	O
striatal	O
output	O
pathways	O
.	O

Characterization	O
of	O
an	O
acyltransferase	O
acting	O
on	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
protein	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

We	O
have	O
identified	O
a	O
protein	O
-	O
acyltransferase	O
activity	O
in	O
membranes	O
from	O
mouse	O
fibroblasts	O
which	O
transfers	O
palmitate	O
from	O
palmitoyl	O
-	O
CoA	O
to	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
.	O

Specificity	O
of	O
acylation	O
has	O
been	O
confirmed	O
by	O
linkage	O
analysis	O
using	O
hydroxylamine	O
and	O
by	O
peptide	O
mapping	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
acylated	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
.	O

The	O
acylation	O
was	O
temperature	O
-	O
and	O
time	O
-	O
dependent	O
,	O
and	O
prevented	O
by	O
prior	O
boiling	O
of	O
membranes	O
,	O
consistent	O
with	O
an	O
enzymatic	O
process	O
.	O

The	O
activity	O
was	O
detected	O
in	O
membranes	O
,	O
but	O
not	O
cytosol	O
,	O
and	O
co	O
-	O
fractionated	O
on	O
Percoll	O
gradients	O
with	O
Golgi	O
markers	O
.	O

Cytosolic	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
from	O
mouse	O
fibroblasts	O
,	O
which	O
is	O
C	O
-	O
terminally	O
modified	O
at	O
its	O
CAAX	O
sequence	O
,	O
was	O
a	O
better	O
substrate	O
for	O
the	O
enzyme	O
that	O
recombinant	O
bacterially	O
expressed	O
,	O
unmodified	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
.	O

The	O
activity	O
could	O
be	O
solubilised	O
in	O
non	O
-	O
ionic	O
detergents	O
,	O
making	O
it	O
amenable	O
to	O
purification	O
.	O

Survival	O
defects	O
of	O
Cryptococcus	O
neoformans	O
mutants	O
exposed	O
to	O
human	O
cerebrospinal	O
fluid	O
result	O
in	O
attenuated	O
virulence	O
in	O
an	O
experimental	O
model	O
of	O
meningitis	O
.	O

Cryptococcus	O
neoformans	O
is	O
a	O
fungal	O
pathogen	O
that	O
encounters	O
various	O
microenvironments	O
during	O
growth	O
in	O
the	O
mammalian	O
host	O
,	O
including	O
intracellular	O
vacuoles	O
,	O
blood	O
,	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O

Because	O
the	O
CSF	O
is	O
isolated	O
by	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
we	O
hypothesize	O
that	O
CSF	O
presents	O
unique	O
stresses	O
that	O
C	O
.	O
neoformans	O
must	O
overcome	O
to	O
establish	O
an	O
infection	O
.	O

We	O
assayed	O
1	O
,	O
201	O
mutants	O
for	O
survival	O
defects	O
in	O
growth	O
media	O
,	O
saline	O
,	O
and	O
human	O
CSF	O
.	O

We	O
assessed	O
CSF	O
-	O
specific	O
mutants	O
for	O
(	O
i	O
)	O
mutant	O
survival	O
in	O
both	O
human	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
and	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
(	O
ii	O
)	O
survival	O
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
virulence	O
using	O
both	O
Caenorhabditis	O
elegans	O
and	O
rabbit	O
models	O
of	O
cryptococcosis	O
.	O

Thirteen	O
mutants	O
exhibited	O
significant	O
survival	O
defects	O
unique	O
to	O
CSF	O
.	O

The	O
mutations	O
of	O
three	O
of	O
these	O
mutants	O
were	O
recreated	O
in	O
the	O
clinical	O
serotype	O
A	O
strain	O
H99	O
:	O
deletions	O
of	O
the	O
genes	O
for	O
a	O
cation	O
ATPase	O
transporter	O
(	O
ena1	B-Protein
Delta	O
)	O
,	O
a	O
putative	O
NEDD8	B-Protein
ubiquitin	B-Protein
-	O
like	O
protein	O
(	O
rub1	B-Protein
Delta	O
)	O
,	O
and	O
a	O
phosphatidylinositol	B-Protein
4	I-Protein
-	I-Protein
kinase	I-Protein
(	O
pik1	B-Protein
Delta	O
)	O
.	O

Mutant	O
survival	O
rates	O
in	O
yeast	O
media	O
,	O
saline	O
,	O
and	O
BAL	O
fluid	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	O
type	O
;	O
however	O
,	O
survival	O
in	O
FBS	O
was	O
reduced	O
but	O
not	O
to	O
the	O
levels	O
in	O
CSF	O
.	O

These	O
mutant	O
strains	O
also	O
exhibited	O
decreased	O
intracellular	O
survival	O
in	O
macrophages	O
,	O
various	O
degrees	O
of	O
virulence	O
in	O
nematodes	O
,	O
and	O
severe	O
attenuation	O
of	O
survival	O
in	O
a	O
rabbit	O
meningitis	O
model	O
.	O

We	O
analyzed	O
the	O
CSF	O
by	O
mass	O
spectrometry	O
for	O
candidate	O
compounds	O
responsible	O
for	O
the	O
survival	O
defect	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
genes	O
required	O
for	O
C	O
.	O
neoformans	O
survival	O
in	O
CSF	O
ex	O
vivo	O
are	O
necessary	O
for	O
survival	O
and	O
infection	O
in	O
this	O
unique	O
host	O
environment	O
.	O

miR	B-Protein
-	I-Protein
148a	I-Protein
is	O
an	O
androgen	O
-	O
responsive	O
microRNA	O
that	O
promotes	O
LNCaP	O
prostate	O
cell	O
growth	O
by	O
repressing	O
its	O
target	O
CAND1	B-Protein
expression	O
.	O

Recent	O
advances	O
in	O
cancer	O
biology	O
reveal	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
cancer	O
-	O
related	O
genes	O
,	O
or	O
they	O
function	O
as	O
tumor	O
suppressors	O
or	O
oncogenes	O
.	O

In	O
prostate	O
cancer	O
,	O
evidence	O
has	O
accumulated	O
for	O
the	O
contribution	O
of	O
the	O
androgen	O
-	O
dependent	O
gene	O
network	O
to	O
tumor	O
growth	O
,	O
although	O
the	O
precise	O
functions	O
of	O
miRNAs	O
in	O
prostate	O
cancer	O
remain	O
to	O
be	O
investigated	O
.	O

Here	O
,	O
we	O
identified	O
androgen	O
-	O
responsive	O
miRNAs	O
by	O
the	O
short	O
RNA	O
sequencing	O
analysis	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
.	O

Among	O
10	O
miRNAs	O
with	O
known	O
sequences	O
,	O
we	O
have	O
determined	O
that	O
miR	B-Protein
-	I-Protein
148a	I-Protein
reduces	O
the	O
expression	O
of	O
cullin	B-Protein
-	I-Protein
associated	I-Protein
and	I-Protein
neddylation	I-Protein
-	I-Protein
dissociated	I-Protein
1	I-Protein
(	O
CAND1	B-Protein
)	O
,	O
a	O
negative	O
regulator	O
of	O
SKP1	B-Protein
-	O
Cullin1	B-Protein
-	O
F	O
-	O
box	O
(	O
SCF	O
)	O
ubiquitin	B-Protein
ligases	O
,	O
by	O
binding	O
to	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
CAND1	B-Protein
mRNA	O
.	O

CAND1	B-Protein
knockdown	O
by	O
small	O
interfering	O
RNA	O
promoted	O
the	O
proliferation	O
of	O
LNCaP	O
cells	O
.	O

Our	O
study	O
indicates	O
the	O
potential	O
contribution	O
of	O
miR	B-Protein
-	I-Protein
148a	I-Protein
to	O
the	O
growth	O
of	O
human	O
prostate	O
cancer	O
.	O

A	O
mechanistic	O
view	O
of	O
the	O
role	O
of	O
E3	O
in	O
sumoylation	O
.	O

Sumoylation	O
,	O
the	O
covalent	O
attachment	O
of	O
SUMO	O
(	O
Small	O
Ubiquitin	B-Protein
-	O
Like	O
Modifier	O
)	O
to	O
proteins	O
,	O
differs	O
from	O
other	O
Ubl	O
(	O
Ubiquitin	B-Protein
-	O
like	O
)	O
pathways	O
.	O

In	O
sumoylation	O
,	O
E2	O
ligase	O
Ubc9	B-Protein
can	O
function	O
without	O
E3	O
enzymes	O
,	O
albeit	O
with	O
lower	O
reaction	O
efficiency	O
.	O

Here	O
,	O
we	O
study	O
the	O
mechanism	O
through	O
which	O
E3	O
ligase	O
RanBP2	B-Protein
triggers	O
target	O
recognition	O
and	O
catalysis	O
by	O
E2	O
Ubc9	B-Protein
.	O

Two	O
mechanisms	O
were	O
proposed	O
for	O
sumoylation	O
.	O

While	O
in	O
both	O
the	O
first	O
step	O
involves	O
Ubc9	B-Protein
conjugation	O
to	O
SUMO	O
,	O
the	O
subsequent	O
sequence	O
of	O
events	O
differs	O
:	O
in	O
the	O
first	O
E2	O
-	O
SUMO	O
forms	O
a	O
complex	O
with	O
the	O
target	O
and	O
E3	O
,	O
followed	O
by	O
SUMO	O
transfer	O
to	O
the	O
target	O
.	O

In	O
the	O
second	O
,	O
Ubc9	B-Protein
-	O
SUMO	O
binds	O
to	O
the	O
target	O
and	O
facilitates	O
SUMO	O
transfer	O
without	O
E3	O
.	O

Using	O
dynamic	O
correlations	O
obtained	O
from	O
explicit	O
solvent	O
molecular	O
dynamic	O
simulations	O
we	O
illustrate	O
the	O
key	O
roles	O
played	O
by	O
allostery	O
in	O
both	O
mechanisms	O
.	O

Pre	O
-	O
existence	O
of	O
conformational	O
states	O
explains	O
the	O
experimental	O
observations	O
that	O
sumoylation	O
can	O
occur	O
without	O
E3	O
,	O
even	O
though	O
at	O
a	O
reduced	O
rate	O
.	O

Furthermore	O
,	O
we	O
propose	O
a	O
mechanism	O
for	O
enhancement	O
of	O
sumoylation	O
by	O
E3	O
.	O

Analysis	O
of	O
the	O
conformational	O
ensembles	O
of	O
the	O
complex	O
of	O
E2	O
conjugated	O
to	O
SUMO	O
illustrates	O
that	O
the	O
E2	O
enzyme	O
is	O
already	O
largely	O
pre	O
-	O
organized	O
for	O
target	O
binding	O
and	O
catalysis	O
;	O
E3	O
binding	O
shifts	O
the	O
equilibrium	O
and	O
enhances	O
these	O
pre	O
-	O
existing	O
populations	O
.	O

We	O
further	O
observe	O
that	O
E3	O
binding	O
regulates	O
allosterically	O
the	O
key	O
residues	O
in	O
E2	O
,	O
Ubc9	B-Protein
Asp100	O
/	O
Lys101	O
E2	O
,	O
for	O
the	O
target	O
recognition	O
.	O

Human	O
stanniocalcin	B-Protein
-	I-Protein
1	I-Protein
interacts	O
with	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
and	O
acts	O
as	O
a	O
SUMO	O
E3	O
ligase	O
.	O

Human	O
stanniocalcin	B-Protein
-	I-Protein
1	I-Protein
(	O
STC1	B-Protein
)	O
is	O
a	O
glycoprotein	O
that	O
has	O
been	O
implicated	O
in	O
different	O
physiological	O
process	O
,	O
including	O
angiogenesis	O
,	O
apoptosis	O
and	O
carcinogenesis	O
.	O

Here	O
we	O
identified	O
STC1	B-Protein
as	O
a	O
putative	O
molecular	O
marker	O
for	O
the	O
leukemic	O
bone	O
marrow	O
microenvironment	O
and	O
identified	O
new	O
interacting	O
protein	O
partners	O
for	O
STC1	B-Protein
.	O

Seven	O
selected	O
interactions	O
retrieved	O
from	O
yeast	O
two	O
-	O
hybrid	O
screens	O
were	O
confirmed	O
by	O
GST	B-Protein
-	O
pull	O
down	O
assays	O
in	O
vitro	O
.	O

The	O
N	O
-	O
terminal	O
region	O
was	O
mapped	O
to	O
be	O
the	O
region	O
that	O
mediates	O
the	O
interaction	O
with	O
cytoplasmic	O
,	O
mitochondrial	O
and	O
nuclear	O
proteins	O
.	O

STC1	B-Protein
interacts	O
with	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
several	O
proteins	O
that	O
have	O
been	O
shown	O
to	O
be	O
SUMOylated	O
and	O
localized	O
to	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O

Although	O
STC1	B-Protein
interacts	O
with	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
has	O
a	O
high	O
theoretical	O
prediction	O
score	O
for	O
a	O
SUMOylation	O
site	O
,	O
endogenous	O
co	O
-	O
immunoprecipitation	O
and	O
in	O
vitro	O
SUMOylation	O
assays	O
with	O
the	O
purified	O
recombinant	O
protein	O
could	O
not	O
detect	O
STC1	B-Protein
SUMOylation	O
.	O

However	O
,	O
when	O
we	O
tested	O
STC1	B-Protein
for	O
SUMO	O
E3	O
ligase	O
activity	O
,	O
we	O
found	O
in	O
an	O
in	O
vitro	O
assay	O
,	O
that	O
it	O
significantly	O
increases	O
the	O
SUMOylation	O
of	O
two	O
other	O
proteins	O
.	O

Confocal	O
microscopic	O
subcellular	O
localization	O
studies	O
using	O
both	O
transfected	O
cells	O
and	O
specific	O
antibodies	O
for	O
endogenous	O
STC1	B-Protein
revealed	O
a	O
cytoplasmic	O
and	O
nuclear	O
deposition	O
,	O
the	O
latter	O
in	O
the	O
form	O
of	O
some	O
specific	O
dot	O
-	O
like	O
substructure	O
resembling	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
a	O
new	O
role	O
for	O
STC1	B-Protein
in	O
SUMOylation	O
pathways	O
,	O
in	O
nuclear	O
bodies	O
.	O

Experimental	O
priapism	O
is	O
associated	O
with	O
increased	O
oxidative	O
stress	O
and	O
activation	O
of	O
protein	O
degradation	O
pathways	O
in	O
corporal	O
tissue	O
.	O

Priapism	O
is	O
a	O
debilitating	O
disease	O
for	O
which	O
there	O
is	O
at	O
present	O
no	O
clinically	O
accepted	O
pharmacological	O
intervention	O
.	O

It	O
has	O
been	O
estimated	O
that	O
priapism	O
lasting	O
more	O
than	O
24	O
h	O
in	O
patients	O
is	O
associated	O
with	O
a	O
44	O
-	O
90	O
%	O
rate	O
of	O
ED	O
.	O

In	O
this	O
investigation	O
,	O
we	O
determined	O
in	O
two	O
animal	O
models	O
of	O
priapism	O
(	O
opiorphin	B-Protein
-	O
induced	O
priapism	O
in	O
the	O
rat	O
and	O
priapism	O
in	O
a	O
mouse	O
model	O
of	O
sickle	O
cell	O
disease	O
)	O
if	O
there	O
is	O
evidence	O
for	O
an	O
increase	O
in	O
markers	O
of	O
oxidative	O
stress	O
in	O
corporal	O
tissue	O
.	O

In	O
both	O
animal	O
models	O
,	O
we	O
demonstrate	O
that	O
priapism	O
results	O
in	O
increased	O
levels	O
of	O
lipid	O
peroxidation	O
,	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
activity	O
and	O
oxidatively	O
damaged	O
proteins	O
in	O
corporal	O
tissue	O
.	O

Using	O
western	O
blot	O
analysis	O
,	O
we	O
demonstrated	O
there	O
is	O
upregulation	O
of	O
the	O
ubiquitination	O
ligase	O
proteins	O
,	O
Nedd	B-Protein
-	I-Protein
4	I-Protein
and	O
Mdm	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
the	O
lysosomal	O
autophage	O
protein	O
,	O
LC3	O
.	O

The	O
antiapoptotic	O
protein	O
,	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
,	O
was	O
also	O
upregulated	O
.	O

Overall	O
,	O
we	O
demonstrate	O
that	O
priapism	O
is	O
associated	O
with	O
increased	O
oxidative	O
stress	O
in	O
corporal	O
tissue	O
and	O
the	O
activation	O
of	O
protein	O
degradation	O
pathways	O
.	O

As	O
oxidative	O
stress	O
is	O
known	O
to	O
mediate	O
the	O
development	O
of	O
ED	O
resulting	O
from	O
several	O
etiologies	O
(	O
for	O
example	O
,	O
ED	O
resulting	O
from	O
diabetes	O
and	O
aging	O
)	O
,	O
we	O
suggest	O
that	O
damage	O
to	O
erectile	O
tissue	O
resulting	O
from	O
priapism	O
might	O
be	O
prevented	O
by	O
treatments	O
targeting	O
oxidative	O
stress	O
.	O

The	O
steady	O
-	O
state	O
repertoire	O
of	O
human	O
SCF	O
Ubiquitin	B-Protein
ligase	O
complexes	O
does	O
not	O
require	O
ongoing	O
Nedd8	B-Protein
conjugation	O
.	O

The	O
human	O
genome	O
encodes	O
69	O
different	O
F	O
-	O
box	O
proteins	O
(	O
FBPs	O
)	O
,	O
each	O
of	O
which	O
can	O
potentially	O
assemble	O
with	O
Skp1	B-Protein
-	O
Cul1	B-Protein
-	O
RING	O
to	O
serve	O
as	O
the	O
substrate	O
specificity	O
subunit	O
of	O
an	O
SCF	O
ubiquitin	B-Protein
ligase	O
complex	O
.	O

SCF	O
activity	O
is	O
switched	O
on	O
by	O
conjugation	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
to	O
Cul1	B-Protein
.	O

Cycles	O
of	O
Nedd8	B-Protein
conjugation	O
and	O
deconjugation	O
acting	O
in	O
conjunction	O
with	O
the	O
Cul1	B-Protein
-	O
sequestering	O
factor	O
Cand1	B-Protein
are	O
thought	O
to	O
control	O
dynamic	O
cycles	O
of	O
SCF	O
assembly	O
and	O
disassembly	O
,	O
which	O
would	O
enable	O
a	O
dynamic	O
equilibrium	O
between	O
the	O
Cul1	B-Protein
-	O
RING	O
catalytic	O
core	O
of	O
SCF	O
and	O
the	O
cellular	O
repertoire	O
of	O
FBPs	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
determined	O
the	O
cellular	O
composition	O
of	O
SCF	O
complexes	O
and	O
evaluated	O
the	O
impact	O
of	O
Nedd8	B-Protein
conjugation	O
on	O
this	O
steady	O
-	O
state	O
.	O

At	O
least	O
42	O
FBPs	O
assembled	O
with	O
Cul1	B-Protein
in	O
HEK	O
293	O
cells	O
,	O
and	O
the	O
levels	O
of	O
Cul1	B-Protein
-	O
bound	O
FBPs	O
varied	O
by	O
over	O
two	O
orders	O
of	O
magnitude	O
.	O

Unexpectedly	O
,	O
quantitative	O
mass	O
spectrometry	O
revealed	O
that	O
blockade	O
of	O
Nedd8	B-Protein
conjugation	O
led	O
to	O
a	O
modest	O
increase	O
,	O
rather	O
than	O
a	O
decrease	O
,	O
in	O
the	O
overall	O
level	O
of	O
most	O
SCF	O
complexes	O
.	O

We	O
suggest	O
that	O
multiple	O
mechanisms	O
including	O
FBP	O
dissociation	O
and	O
turnover	O
cooperate	O
to	O
maintain	O
the	O
cellular	O
pool	O
of	O
SCF	O
ubiquitin	B-Protein
ligases	O
.	O

Crystal	O
structure	O
of	O
UBA2	B-Protein
(	O
ufd	O
)	O
-	O
Ubc9	B-Protein
:	O
insights	O
into	O
E1	O
-	O
E2	O
interactions	O
in	O
Sumo	O
pathways	O
.	O

Canonical	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
(	O
UBLs	O
)	O
such	O
as	O
ubiquitin	B-Protein
,	O
Sumo	O
,	O
NEDD8	B-Protein
,	O
and	O
ISG15	B-Protein
are	O
ligated	O
to	O
targets	O
by	O
E1	O
-	O
E2	O
-	O
E3	O
multienzyme	O
cascades	O
.	O

The	O
Sumo	O
cascade	O
,	O
conserved	O
among	O
all	O
eukaryotes	O
,	O
regulates	O
numerous	O
biological	O
processes	O
including	O
protein	O
localization	O
,	O
transcription	O
,	O
DNA	O
replication	O
,	O
and	O
mitosis	O
.	O

Sumo	O
conjugation	O
is	O
initiated	O
by	O
the	O
heterodimeric	O
Aos1	B-Protein
-	O
Uba2	B-Protein
E1	O
enzyme	O
(	O
in	O
humans	O
called	O
Sae1	B-Protein
-	O
Uba2	B-Protein
)	O
,	O
which	O
activates	O
Sumo	O
'	O
s	O
C	O
-	O
terminus	O
,	O
binds	O
the	O
dedicated	O
E2	O
enzyme	O
Ubc9	B-Protein
,	O
and	O
promotes	O
Sumo	O
C	O
-	O
terminal	O
transfer	O
between	O
the	O
Uba2	B-Protein
and	O
Ubc9	B-Protein
catalytic	O
cysteines	O
.	O

To	O
gain	O
insights	O
into	O
details	O
of	O
E1	O
-	O
E2	O
interactions	O
in	O
the	O
Sumo	O
pathway	O
,	O
we	O
determined	O
crystal	O
structures	O
of	O
the	O
C	O
-	O
terminal	O
ubiquitin	B-Protein
fold	O
domain	O
(	O
ufd	O
)	O
from	O
yeast	O
Uba2	B-Protein
(	O
Uba2	B-Protein
(	O
ufd	O
)	O
)	O
,	O
alone	O
and	O
in	O
complex	O
with	O
Ubc9	B-Protein
.	O

The	O
overall	O
structures	O
of	O
both	O
yeast	O
Uba2	B-Protein
(	O
ufd	O
)	O
and	O
Ubc9	B-Protein
superimpose	O
well	O
on	O
their	O
individual	O
human	O
counterparts	O
,	O
suggesting	O
conservation	O
of	O
fundamental	O
features	O
of	O
Sumo	O
conjugation	O
.	O

Docking	O
the	O
Uba2	B-Protein
(	O
ufd	O
)	O
-	O
Ubc9	B-Protein
and	O
prior	O
full	O
-	O
length	O
human	O
Uba2	B-Protein
structures	O
allows	O
generation	O
of	O
models	O
for	O
steps	O
in	O
Sumo	O
transfer	O
from	O
Uba2	B-Protein
to	O
Ubc9	B-Protein
,	O
and	O
supports	O
the	O
notion	O
that	O
Uba2	B-Protein
undergoes	O
remarkable	O
conformational	O
changes	O
during	O
the	O
reaction	O
.	O

Comparisons	O
to	O
previous	O
structures	O
from	O
the	O
NEDD8	B-Protein
cascade	O
demonstrate	O
that	O
UBL	O
cascades	O
generally	O
utilize	O
some	O
parallel	O
E1	O
-	O
E2	O
interaction	O
surfaces	O
.	O

In	O
addition	O
,	O
the	O
structure	O
of	O
the	O
Uba2	B-Protein
(	O
ufd	O
)	O
-	O
Ubc9	B-Protein
complex	O
reveals	O
interactions	O
unique	O
to	O
Sumo	O
E1	O
and	O
E2	O
.	O

Comparison	O
with	O
a	O
previous	O
Ubc9	B-Protein
-	O
E3	O
complex	O
structure	O
demonstrates	O
overlap	O
between	O
Uba2	B-Protein
and	O
E3	O
binding	O
sites	O
on	O
Ubc9	B-Protein
,	O
indicating	O
that	O
loading	O
with	O
Sumo	O
and	O
E3	O
-	O
catalyzed	O
transfer	O
to	O
substrates	O
are	O
strictly	O
separate	O
steps	O
.	O

The	O
results	O
suggest	O
mechanisms	O
establishing	O
specificity	O
and	O
order	O
in	O
Sumo	O
conjugation	O
cascades	O
.	O

Farnesyl	O
cysteine	O
C	O
-	O
terminal	O
methyltransferase	O
activity	O
is	O
dependent	O
upon	O
the	O
STE14	B-Protein
gene	O
product	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Membrane	O
extracts	O
of	O
sterile	O
Saccharomyces	O
cerevisiae	O
strains	O
containing	O
the	O
a	O
-	O
specific	O
ste14	B-Protein
mutation	O
lack	O
a	O
farnesyl	O
cysteine	O
C	O
-	O
terminal	O
carboxyl	O
methyltransferase	O
activity	O
that	O
is	O
present	O
in	O
wild	O
-	O
type	O
a	O
and	O
alpha	O
cells	O
.	O

Other	O
a	O
-	O
specific	O
sterile	O
strains	O
with	O
ste6	B-Protein
and	O
ste16	B-Protein
mutations	O
also	O
have	O
wild	O
-	O
type	O
levels	O
of	O
the	O
farnesyl	O
cysteine	O
carboxyl	O
methyltransferase	O
activity	O
.	O

This	O
enzyme	O
activity	O
,	O
detected	O
by	O
using	O
a	O
synthetic	O
peptide	O
sequence	O
based	O
on	O
the	O
C	O
-	O
terminus	O
of	O
a	O
ras	O
protein	O
,	O
may	O
be	O
responsible	O
not	O
only	O
for	O
the	O
essential	O
methylation	O
of	O
the	O
farnesyl	O
cysteine	O
residue	O
of	O
a	O
mating	O
factor	O
,	O
but	O
also	O
for	O
the	O
methylation	O
of	O
yeast	O
RAS1	B-Protein
and	O
RAS2	B-Protein
proteins	O
and	O
possibly	O
other	O
polypeptides	O
with	O
similar	O
C	O
-	O
terminal	O
structures	O
.	O

We	O
demonstrate	O
that	O
the	O
farnesylation	O
of	O
the	O
cysteine	O
residue	O
in	O
the	O
peptide	O
is	O
required	O
for	O
the	O
methyltransferase	O
activity	O
,	O
suggesting	O
that	O
methyl	O
esterification	O
follows	O
the	O
lipidation	O
reaction	O
in	O
the	O
cell	O
.	O

To	O
show	O
that	O
the	O
loss	O
of	O
methyltransferase	O
activity	O
is	O
a	O
direct	O
result	O
of	O
the	O
ste14	B-Protein
mutation	O
,	O
we	O
transformed	O
ste14	B-Protein
mutant	O
cells	O
with	O
a	O
plasmid	O
complementing	O
the	O
mating	O
defect	O
of	O
this	O
strain	O
and	O
found	O
that	O
active	O
enzyme	O
was	O
produced	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
a	O
similar	O
transformation	O
of	O
cells	O
possessing	O
the	O
wild	O
-	O
type	O
STE14	B-Protein
gene	O
resulted	O
in	O
sixfold	O
overproduction	O
of	O
the	O
enzyme	O
.	O

Although	O
more	O
complicated	O
possibilities	O
cannot	O
be	O
ruled	O
out	O
,	O
these	O
results	O
suggest	O
that	O
STE14	B-Protein
is	O
a	O
candidate	O
for	O
the	O
structural	O
gene	O
for	O
a	O
methyltransferase	O
involved	O
in	O
the	O
formation	O
of	O
isoprenylated	O
cysteine	O
alpha	O
-	O
methyl	O
ester	O
C	O
-	O
terminal	O
structures	O
.	O

cDNA	O
sequence	O
,	O
in	O
vitro	O
synthesis	O
,	O
and	O
intramitochondrial	O
lipoylation	O
of	O
H	B-Protein
-	I-Protein
protein	I-Protein
of	O
the	O
glycine	O
cleavage	O
system	O
.	O

H	B-Protein
-	I-Protein
protein	I-Protein
is	O
a	O
component	O
of	O
the	O
glycine	O
cleavage	O
system	O
loosely	O
associated	O
with	O
the	O
mitochondrial	O
inner	O
membrane	O
and	O
has	O
lipoic	O
acid	O
as	O
a	O
prosthetic	O
group	O
.	O

cDNA	O
clones	O
encoding	O
H	B-Protein
-	I-Protein
protein	I-Protein
were	O
isolated	O
from	O
a	O
bovine	O
liver	O
cDNA	O
library	O
with	O
an	O
oligonucleotide	O
probe	O
from	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
NH2	O
-	O
terminal	O
region	O
.	O

DNA	O
sequence	O
analysis	O
and	O
deduced	O
amino	O
acid	O
sequence	O
showed	O
that	O
the	O
cDNAs	O
encoded	O
an	O
H	B-Protein
-	I-Protein
protein	I-Protein
precursor	O
of	O
173	O
amino	O
acids	O
including	O
a	O
48	O
-	O
amino	O
acid	O
presequence	O
.	O

Calculated	O
molecular	O
mass	O
of	O
the	O
precursor	O
and	O
mature	O
protein	O
without	O
lipoic	O
acid	O
were	O
18	O
,	O
790	O
and	O
13	O
,	O
846	O
,	O
respectively	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
a	O
major	O
mRNA	O
component	O
of	O
1	O
.	O
1	O
kilobases	O
and	O
a	O
minor	O
component	O
of	O
0	O
.	O
6	O
kilobase	O
.	O

The	O
result	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
two	O
adenylation	O
signals	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
cDNA	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
H	B-Protein
-	I-Protein
protein	I-Protein
cDNA	O
produced	O
a	O
19	O
-	O
kDa	O
protein	O
recognized	O
by	O
antibody	O
raised	O
to	O
chicken	O
H	B-Protein
-	I-Protein
protein	I-Protein
.	O

Bovine	O
liver	O
H	B-Protein
-	I-Protein
protein	I-Protein
precursor	O
has	O
no	O
lipoic	O
acid	O
prosthetic	O
group	O
.	O

When	O
incubated	O
with	O
isolated	O
bovine	O
liver	O
mitochondria	O
,	O
the	O
precursor	O
was	O
imported	O
into	O
mitochondria	O
,	O
processed	O
to	O
its	O
mature	O
form	O
with	O
a	O
molecular	O
mass	O
of	O
14	O
kDa	O
,	O
and	O
lipoylated	O
at	O
lysine	O
59	O
.	O

These	O
results	O
indicate	O
that	O
lipoylation	O
is	O
not	O
required	O
for	O
the	O
import	O
of	O
H	B-Protein
-	I-Protein
protein	I-Protein
precursor	O
into	O
mitochondria	O
and	O
H	B-Protein
-	I-Protein
protein	I-Protein
is	O
lipoylated	O
in	O
mitochondria	O
which	O
probably	O
contain	O
the	O
physiologically	O
active	O
form	O
of	O
lipoic	O
acid	O
as	O
well	O
as	O
the	O
enzyme	O
(	O
s	O
)	O
responsible	O
for	O
the	O
attachment	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
bovine	O
pro	B-Protein
-	I-Protein
opiomelanocortin	I-Protein
.	O

Tyrosine	O
sulfation	O
and	O
pyroglutamate	O
formation	O
,	O
a	O
mass	O
spectrometric	O
study	O
.	O

The	O
amino	O
-	O
terminal	O
fragment	O
of	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
i	O
.	O
e	O
.	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
)	O
and	O
joining	O
peptide	O
portions	O
of	O
pro	B-Protein
-	I-Protein
opiomelanocortin	I-Protein
have	O
been	O
purified	O
from	O
extracts	O
of	O
bovine	O
posterior	O
pituitaries	O
.	O

Peptides	O
were	O
purified	O
using	O
a	O
combination	O
of	O
reversed	O
-	O
phase	O
and	O
ion	O
-	O
exchange	O
batch	O
extraction	O
procedures	O
followed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

beta	B-Protein
-	I-Protein
Lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
consist	O
of	O
four	O
major	O
components	O
while	O
joining	O
peptide	O
was	O
found	O
to	O
consist	O
of	O
two	O
major	O
components	O
.	O

Fast	O
atom	O
bombardment	O
-	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
fragments	O
of	O
both	O
peptides	O
revealed	O
that	O
the	O
observed	O
heterogeneity	O
could	O
be	O
explained	O
in	O
terms	O
of	O
post	O
-	O
translational	O
modifications	O
.	O

beta	B-Protein
-	I-Protein
Lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
be	O
sulfated	O
at	O
tyrosine	O
residue	O
28	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
tyrosine	O
residue	O
in	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
is	O
situated	O
within	O
an	O
amino	O
acid	O
sequence	O
with	O
a	O
preponderance	O
of	O
glutamate	O
residues	O
.	O

Sulfation	O
of	O
this	O
amino	O
acid	O
residue	O
is	O
entirely	O
compatible	O
with	O
the	O
known	O
primary	O
structure	O
requirements	O
of	O
the	O
sulfotransferase	O
enzyme	O
located	O
in	O
the	O
trans	O
-	O
Golgi	O
fraction	O
.	O

Both	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
and	O
joining	O
peptide	O
were	O
found	O
to	O
have	O
pyroglutamate	O
at	O
their	O
amino	O
termini	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
cDNA	O
sequence	O
for	O
bovine	O
pro	B-Protein
-	I-Protein
opiomelanocortin	I-Protein
predicts	O
the	O
presence	O
of	O
glutamic	O
acid	O
at	O
position	O
1	O
of	O
both	O
peptides	O
.	O

Pyroglutamate	O
is	O
normally	O
formed	O
through	O
the	O
cyclization	O
of	O
glutamine	O
.	O

This	O
reaction	O
is	O
thought	O
to	O
be	O
catalyzed	O
by	O
a	O
pyroglutamate	O
forming	O
enzyme	O
located	O
within	O
the	O
secretory	O
granule	O
fraction	O
.	O

Under	O
certain	O
circumstances	O
peptides	O
with	O
glutamate	O
at	O
their	O
amino	O
termini	O
may	O
act	O
as	O
substrates	O
for	O
this	O
enzyme	O
.	O

ADP	O
-	O
ribosylation	O
of	O
proteins	O
in	O
brain	O
regions	O
of	O
rats	O
during	O
postnatal	O
development	O
.	O

Post	O
-	O
translational	O
modifications	O
of	O
chromatin	O
-	O
bound	O
proteins	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Processes	O
such	O
as	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
may	O
alter	O
the	O
interaction	O
of	O
these	O
proteins	O
with	O
DNA	O
and	O
consequently	O
affect	O
chromatin	O
conformation	O
and	O
the	O
binding	O
of	O
enzymes	O
and	O
other	O
molecules	O
involved	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

In	O
the	O
present	O
study	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
chromosomal	O
proteins	O
(	O
histone	B-Protein
and	O
non	O
-	O
histone	O
proteins	O
)	O
in	O
some	O
rat	O
brain	O
regions	O
during	O
postnatal	O
development	O
was	O
investigated	O
;	O
also	O
the	O
effect	O
of	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
EGF	B-Protein
)	O
on	O
this	O
process	O
in	O
fetal	O
brain	O
slices	O
was	O
studied	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	B-Protein
extracted	O
from	O
rat	O
cerebral	O
cortex	O
and	O
cerebellum	O
at	O
1	O
,	O
10	O
and	O
30	O
days	O
of	O
age	O
,	O
increases	O
from	O
1	O
to	O
10	O
days	O
of	O
age	O
(	O
i	O
.	O
e	O
.	O
the	O
period	O
of	O
maximal	O
cell	O
proliferation	O
)	O
and	O
decreases	O
thereafter	O
,	O
while	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
non	O
-	O
histone	O
proteins	O
(	O
NHPs	O
)	O
sharply	O
decreases	O
during	O
the	O
same	O
developmental	O
period	O
.	O

The	O
addition	O
of	O
EGF	B-Protein
to	O
fetal	O
brain	O
slices	O
causes	O
a	O
significant	O
increase	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	B-Protein
(	O
particularly	O
of	O
the	O
histone	B-Protein
H1	I-Protein
fraction	O
)	O
and	O
also	O
of	O
NHPs	O
and	O
microsomal	O
proteins	O
.	O

This	O
result	O
is	O
in	O
agreement	O
with	O
the	O
effect	O
of	O
EGF	B-Protein
as	O
a	O
mitogen	O
factor	O
,	O
previously	O
shown	O
in	O
astroglial	O
cell	O
cultures	O
.	O

Characterization	O
of	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
forms	O
of	O
the	O
gag	B-Protein
-	O
onc	O
fusion	O
proteins	O
of	O
three	O
isolates	O
of	O
feline	O
sarcoma	O
virus	O
:	O
phosphorylation	O
,	O
kinase	O
activity	O
,	O
acylation	O
,	O
and	O
kinetics	O
of	O
complex	O
formation	O
.	O

The	O
gag	B-Protein
-	O
onc	O
fusion	O
proteins	O
of	O
three	O
isolates	O
of	O
feline	O
sarcoma	O
virus	O
(	O
ST	O
-	O
FeSV	O
,	O
GA	O
-	O
FeSV	O
,	O
TP1	O
-	O
FeSV	O
)	O
from	O
a	O
stable	O
noncovalent	O
complex	O
with	O
two	O
cellular	O
phosphoproteins	O
,	O
pp90	B-Protein
and	O
pp50	B-Protein
.	O

These	O
two	O
phosphoproteins	O
are	O
the	O
same	O
phosphoproteins	O
which	O
have	O
been	O
shown	O
to	O
complex	O
with	O
the	O
transforming	O
proteins	O
of	O
Rous	O
sarcoma	O
virus	O
,	O
Fujinami	O
sarcoma	O
virus	O
,	O
Yamaguchi	O
73	O
virus	O
(	O
Lipsich	O
et	O
al	O
.	O
,	O
1982	O
)	O
,	O
and	O
PRCII	O
avian	O
sarcoma	O
virus	O
(	O
Adkins	O
et	O
al	O
.	O
,	O
1982	O
)	O
.	O

Both	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
gag	B-Protein
-	O
onc	O
fusion	O
proteins	O
are	O
phosphorylated	O
on	O
serine	O
,	O
threonine	O
,	O
and	O
tyrosine	O
;	O
however	O
,	O
quantitative	O
and	O
/	O
or	O
qualitative	O
differences	O
in	O
phosphorylation	O
of	O
the	O
two	O
species	O
were	O
apparent	O
.	O

Only	O
the	O
monomeric	O
form	O
of	O
the	O
gag	B-Protein
-	O
onc	O
proteins	O
was	O
able	O
to	O
undergo	O
tyrosine	O
specific	O
autophosphorylation	O
in	O
an	O
in	O
vitro	O
kinase	O
reaction	O
.	O

Both	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
forms	O
of	O
the	O
proteins	O
were	O
acylated	O
,	O
the	O
complex	O
-	O
associated	O
molecules	O
to	O
a	O
greater	O
degree	O
.	O

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
newly	O
synthesized	O
gag	B-Protein
-	O
onc	O
molecules	O
become	O
rapidly	O
incorporated	O
into	O
the	O
complex	O
and	O
that	O
a	O
significant	O
amount	O
of	O
these	O
molecules	O
remained	O
associated	O
with	O
the	O
complex	O
for	O
more	O
than	O
20	O
hr	O
.	O

Autoacylation	O
of	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
with	O
acyl	O
coenzyme	O
A	O
.	O

Rat	O
brain	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
(	O
PLP	B-Protein
)	O
is	O
known	O
to	O
contain	O
long	O
chain	O
,	O
covalently	O
bound	O
fatty	O
acids	O
.	O

In	O
the	O
course	O
of	O
characterizing	O
the	O
mechanism	O
of	O
acylation	O
,	O
we	O
found	O
that	O
the	O
isolated	O
PLP	B-Protein
,	O
in	O
the	O
absence	O
of	O
any	O
membrane	O
fraction	O
,	O
was	O
esterified	O
after	O
incubation	O
with	O
[	O
3H	O
]	O
palmitoyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
.	O

This	O
observation	O
demonstrated	O
that	O
the	O
protein	O
acts	O
as	O
both	O
an	O
acylating	O
enzyme	O
and	O
an	O
acceptor	O
.	O

Thus	O
,	O
acylation	O
occurs	O
by	O
an	O
autocatalytic	O
process	O
.	O

The	O
possibility	O
of	O
a	O
separate	O
acyltransferase	O
that	O
copurifies	O
with	O
PLP	B-Protein
was	O
essentially	O
excluded	O
by	O
adding	O
brain	O
subcellular	O
fractions	O
to	O
the	O
reaction	O
mixtures	O
and	O
by	O
changing	O
the	O
isolation	O
procedure	O
.	O

After	O
deacylation	O
,	O
the	O
protein	O
was	O
acylated	O
at	O
a	O
4	O
-	O
fold	O
greater	O
rate	O
,	O
suggesting	O
that	O
the	O
original	O
sites	O
were	O
reacylated	O
.	O

The	O
palmitoyl	O
-	O
CoA	O
concentration	O
followed	O
Michaelis	O
kinetics	O
,	O
confirming	O
that	O
spontaneous	O
acylation	O
was	O
not	O
occurring	O
.	O

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
the	O
reaction	O
entails	O
net	O
addition	O
of	O
acyl	O
groups	O
.	O

Although	O
fatty	O
acids	O
are	O
bound	O
via	O
an	O
O	O
-	O
ester	O
linkage	O
,	O
free	O
SH	O
groups	O
are	O
required	O
in	O
the	O
reaction	O
.	O

Denaturation	O
of	O
the	O
protein	O
by	O
sodium	O
dodecyl	O
sulfate	O
or	O
heat	O
inhibits	O
the	O
reaction	O
,	O
whereas	O
cerulenin	O
has	O
little	O
or	O
no	O
effect	O
.	O

PO	B-Protein
,	O
the	O
major	O
protein	O
in	O
peripheral	O
nerve	O
myelin	O
,	O
is	O
also	O
an	O
acylated	O
protein	O
,	O
but	O
it	O
was	O
not	O
labeled	O
upon	O
incubation	O
of	O
either	O
peripheral	O
myelin	O
or	O
the	O
isolated	O
protein	O
with	O
[	O
3H	O
]	O
palmitoyl	O
-	O
CoA	O
,	O
demonstrating	O
that	O
it	O
is	O
acylated	O
by	O
a	O
different	O
route	O
.	O

Several	O
synthetic	O
peptides	O
derived	O
from	O
PLP	B-Protein
sequences	O
with	O
sites	O
known	O
to	O
be	O
acylated	O
in	O
vivo	O
as	O
well	O
as	O
a	O
series	O
of	O
deacylated	O
PLP	B-Protein
tryptic	O
peptides	O
were	O
not	O
labeled	O
,	O
indicating	O
that	O
integrity	O
of	O
the	O
protein	O
is	O
required	O
for	O
acylation	O
.	O

Limited	O
proteolysis	O
and	O
peptide	O
mapping	O
showed	O
that	O
the	O
same	O
sites	O
are	O
acylated	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
suggesting	O
that	O
the	O
autocatalytic	O
acylation	O
reaction	O
is	O
physiological	O
.	O

Posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
spp	O
.	O

The	O
mechanism	O
for	O
"	O
NH4	O
+	O
switch	O
-	O
off	O
/	O
on	O
"	O
of	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
was	O
investigated	O
.	O

A	O
correlation	O
was	O
established	O
between	O
the	O
in	O
vivo	O
regulation	O
of	O
nitrogenase	O
activity	O
by	O
NH4Cl	O
or	O
glutamine	O
and	O
the	O
reversible	O
covalent	O
modification	O
of	O
dinitrogenase	O
reductase	O
.	O

Dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
DRAT	B-Protein
)	O
activity	O
was	O
detected	O
in	O
extracts	O
of	O
A	O
.	O
brasilense	O
with	O
NAD	O
as	O
the	O
donor	O
molecule	O
.	O

Dinitrogenase	B-Protein
reductase	I-Protein
-	I-Protein
activating	I-Protein
glycohydrolase	I-Protein
(	O
DRAG	B-Protein
)	O
activity	O
was	O
present	O
in	O
extracts	O
of	O
both	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
.	O

The	O
DRAG	B-Protein
activity	O
in	O
A	O
.	O
lipoferum	O
was	O
membrane	O
associated	O
,	O
and	O
it	O
catalyzed	O
the	O
activation	O
of	O
inactive	O
nitrogenase	O
(	O
by	O
covalent	O
modification	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
)	O
from	O
both	O
A	O
.	O
lipoferum	O
and	O
Rhodospirillum	O
rubrum	O
.	O

A	O
region	O
homologous	O
to	O
R	O
.	O
rubrum	O
draT	B-Protein
and	O
draG	B-Protein
was	O
identified	O
in	O
the	O
genomic	O
DNA	O
of	O
A	O
.	O
brasilense	O
as	O
a	O
12	O
-	O
kilobase	O
EcoRI	B-Protein
fragment	O
and	O
in	O
A	O
.	O
lipoferum	O
as	O
a	O
7	O
-	O
kilobase	O
EcoRI	B-Protein
fragment	O
.	O

It	O
is	O
concluded	O
that	O
a	O
posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
is	O
present	O
in	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
and	O
that	O
it	O
operates	O
via	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
as	O
it	O
does	O
in	O
R	O
.	O
rubrum	O
.	O

The	O
membrane	O
binding	O
domain	O
of	O
rod	O
cGMP	O
phosphodiesterase	O
is	O
posttranslationally	O
modified	O
by	O
methyl	O
esterification	O
at	O
a	O
C	O
-	O
terminal	O
cysteine	O
.	O

Retinal	O
rod	O
cGMP	O
phosphodiesterase	O
(	O
3	O
'	O
,	O
5	O
'	O
-	O
cyclic	O
-	O
GMP	O
phosphodiesterase	O
;	O
EC	O
3	O
.	O
1	O
.	O
4	O
.	O
35	O
;	O
PDE	O
)	O
,	O
a	O
key	O
regulatory	O
enzyme	O
involved	O
in	O
visual	O
excitation	O
,	O
is	O
one	O
of	O
several	O
outer	O
segment	O
membrane	O
proteins	O
that	O
are	O
carboxyl	O
methylated	O
in	O
the	O
presence	O
of	O
the	O
methyl	O
donor	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
[	O
3H	O
-	O
methyl	O
]	O
methionine	O
.	O

By	O
chromatographic	O
analyses	O
of	O
the	O
3H	O
-	O
methyl	O
amino	O
acid	O
generated	O
by	O
exhaustive	O
proteolysis	O
of	O
purified	O
PDE	O
,	O
followed	O
by	O
performic	O
acid	O
oxidation	O
of	O
the	O
digest	O
,	O
we	O
have	O
shown	O
that	O
this	O
modification	O
occurs	O
at	O
a	O
C	O
-	O
terminal	O
cysteine	O
residue	O
of	O
the	O
alpha	O
subunit	O
of	O
this	O
enzyme	O
.	O

When	O
PDE	O
is	O
subjected	O
to	O
limited	O
proteolysis	O
with	O
trypsin	O
,	O
a	O
3H	O
-	O
methylated	O
fragment	O
of	O
1000	O
daltons	O
or	O
less	O
is	O
rapidly	O
removed	O
prior	O
to	O
the	O
degradation	O
of	O
its	O
inhibitory	O
gamma	O
subunit	O
.	O

This	O
small	O
fragment	O
remains	O
membrane	O
bound	O
,	O
whereas	O
the	O
bulk	O
of	O
the	O
enzyme	O
is	O
released	O
,	O
indicating	O
that	O
a	O
domain	O
responsible	O
for	O
anchoring	O
PDE	O
to	O
the	O
membrane	O
is	O
located	O
near	O
the	O
C	O
terminus	O
.	O

Based	O
on	O
the	O
C	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
Cys	O
-	O
Cys	O
-	O
Val	O
-	O
Gln	O
predicted	O
from	O
the	O
alpha	O
cDNA	O
sequence	O
,	O
we	O
conclude	O
that	O
PDE	O
undergoes	O
posttranslational	O
modifications	O
,	O
including	O
the	O
proteolytic	O
removal	O
of	O
two	O
or	O
three	O
terminal	O
amino	O
acids	O
,	O
and	O
methyl	O
esterification	O
of	O
the	O
alpha	O
-	O
carboxyl	O
group	O
of	O
the	O
terminal	O
cysteine	O
residue	O
.	O

We	O
speculate	O
that	O
the	O
sulfhydryl	O
group	O
of	O
the	O
methylated	O
cysteine	O
is	O
also	O
lipidated	O
to	O
mediate	O
membrane	O
binding	O
.	O

These	O
modifications	O
may	O
play	O
an	O
important	O
role	O
in	O
delivering	O
the	O
nascent	O
PDE	O
chains	O
to	O
the	O
membrane	O
and	O
in	O
correctly	O
positioning	O
the	O
PDE	O
molecule	O
in	O
the	O
rod	O
disks	O
for	O
phototransduction	O
.	O

Purification	O
of	O
bacteriorhodopsin	B-Protein
and	O
characterization	O
of	O
mature	O
and	O
partially	O
processed	O
forms	O
.	O

Bacteriorhodopsin	B-Protein
(	O
BR	B-Protein
)	O
essentially	O
free	O
of	O
native	O
lipids	O
has	O
been	O
prepared	O
in	O
a	O
highly	O
stable	O
state	O
.	O

Purple	O
membrane	O
was	O
solubilized	O
in	O
Triton	O
X	O
-	O
100	O
and	O
BR	B-Protein
was	O
purified	O
by	O
size	O
exclusion	O
chromatography	O
using	O
3	O
-	O
[	O
cholamidopropyl	O
)	O
dimethylammonio	O
]	O
-	O
2	O
-	O
hydroxyl	O
-	O
1	O
-	O
propanesulfonic	O
acid	O
(	O
CHAPSO	O
)	O
detergent	O
at	O
pH	O
5	O
.	O

Molar	O
ratios	O
of	O
phospholipid	O
/	O
BR	B-Protein
ranged	O
from	O
0	O
.	O
4	O
to	O
0	O
.	O
05	O
corresponding	O
to	O
94	O
-	O
98	O
%	O
phospholipid	O
removal	O
.	O

Purified	O
BR	B-Protein
has	O
an	O
absorbance	O
ratio	O
(	O
A280nm	O
/	O
A548nm	O
)	O
of	O
1	O
.	O
5	O
-	O
1	O
.	O
6	O
in	O
the	O
dark	O
-	O
adapted	O
state	O
which	O
is	O
the	O
highest	O
purified	O
BR	B-Protein
/	O
protein	O
ratio	O
reported	O
to	O
date	O
.	O

The	O
purified	O
BR	B-Protein
in	O
CHAPSO	O
shows	O
maximum	O
stability	O
in	O
the	O
pH	O
range	O
5	O
.	O
0	O
-	O
5	O
.	O
5	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
profiles	O
of	O
native	O
purple	O
membrane	O
and	O
solubilized	O
BR	B-Protein
from	O
most	O
Halobacterium	O
halobium	O
JW	O
-	O
3	O
cultures	O
show	O
3	O
higher	O
molecular	O
weight	O
bands	O
in	O
addition	O
to	O
BR	B-Protein
.	O

Immunological	O
staining	O
and	O
amino	O
acid	O
sequencing	O
indicates	O
that	O
these	O
additional	O
proteins	O
are	O
partially	O
processed	O
forms	O
of	O
the	O
BR	B-Protein
precursor	O
protein	O
.	O

The	O
BR	B-Protein
preprotein	O
contains	O
13	O
additional	O
amino	O
acids	O
on	O
the	O
NH2	O
terminus	O
which	O
are	O
removed	O
by	O
post	O
-	O
translational	O
processing	O
in	O
at	O
least	O
four	O
steps	O
.	O

Isoelectric	O
focusing	O
separated	O
most	O
delipidated	O
and	O
non	O
-	O
delipidated	O
BR	O
samples	O
into	O
8	O
bands	O
.	O

Incomplete	O
BR	O
post	O
-	O
translational	O
processing	O
BR	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
multiplicity	O
of	O
isoelectric	O
BR	O
species	O
.	O

The	O
principal	O
components	O
have	O
pI	O
values	O
of	O
5	O
.	O
20	O
and	O
5	O
.	O
24	O
and	O
both	O
have	O
absorption	O
maxima	O
at	O
550	O
nm	O
,	O
characteristic	O
of	O
detergent	O
-	O
solubilized	O
BR	O
.	O

BR	B-Protein
in	O
Triton	O
X	O
-	O
100	O
or	O
nonylglucoside	O
,	O
delipidated	O
BR	O
in	O
CHAPSO	O
,	O
and	O
BR	B-Protein
in	O
intact	O
purple	O
membrane	O
all	O
have	O
a	O
dark	O
-	O
adapted	O
ratio	O
of	O
13	O
-	O
cis	O
to	O
all	O
-	O
trans	O
-	O
retinal	O
of	O
1	O
.	O
9	O
:	O
1	O
.	O

In	O
vivo	O
characterization	O
of	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
SV40	O
chromatin	O
and	O
large	B-Protein
T	I-Protein
antigen	I-Protein
by	O
immunofractionation	O
.	O

We	O
have	O
confirmed	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
large	B-Protein
T	I-Protein
antigen	I-Protein
of	O
SV40	O
by	O
using	O
antibodies	O
to	O
both	O
large	B-Protein
T	I-Protein
antigen	I-Protein
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
and	O
consequently	O
have	O
begun	O
to	O
characterize	O
how	O
this	O
post	O
-	O
translational	O
nuclear	O
modification	O
of	O
the	O
viral	O
protein	O
modulates	O
its	O
biological	O
functions	O
.	O

SV40	O
minichromosomal	O
subpopulation	O
containing	O
replicative	O
intermediate	O
DNA	O
was	O
shown	O
to	O
have	O
a	O
significantly	O
higher	O
affinity	O
for	O
anti	O
-	O
poly	O
(	O
ADP	O
-	O
Rib	O
)	O
-	O
Sepharose	O
than	O
viral	O
chromatin	O
fractions	O
containing	O
mature	O
minichromosomal	O
DNA	O
.	O

An	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
column	O
was	O
used	O
to	O
isolate	O
T	B-Protein
antigen	I-Protein
from	O
crude	O
extracts	O
by	O
two	O
different	O
approaches	O
:	O
(	O
1	O
)	O
large	B-Protein
T	I-Protein
antigen	I-Protein
was	O
labeled	O
with	O
[	O
35S	O
]	O
methionine	O
in	O
vivo	O
and	O
the	O
infected	O
cell	O
extract	O
was	O
immunofractionated	O
to	O
isolate	O
large	B-Protein
T	I-Protein
antigen	I-Protein
and	O
(	O
2	O
)	O
large	B-Protein
T	I-Protein
antigen	I-Protein
from	O
infected	O
cell	O
extracts	O
was	O
immunofractionated	O
followed	O
by	O
immunostaining	O
.	O

Using	O
these	O
techniques	O
,	O
1	O
-	O
10	O
%	O
of	O
the	O
total	O
T	B-Protein
antigen	I-Protein
from	O
infected	O
cells	O
was	O
found	O
to	O
be	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
.	O

Minichromosome	O
preparations	O
per	O
se	O
were	O
also	O
subjected	O
to	O
immunofractionation	O
on	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
.	O

The	O
high	O
level	O
of	O
retention	O
of	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
species	O
of	O
minichromosomes	O
on	O
this	O
matrix	O
suggested	O
that	O
this	O
post	O
-	O
translational	O
modification	O
of	O
viral	O
chromatin	O
may	O
be	O
related	O
to	O
those	O
steps	O
in	O
viral	O
replication	O
and	O
transcription	O
under	O
regulation	O
by	O
large	B-Protein
T	I-Protein
antigen	I-Protein
.	O

The	O
human	O
receptor	O
for	O
T	B-Protein
-	I-Protein
cell	I-Protein
growth	I-Protein
factor	I-Protein
.	O

Evidence	O
for	O
variable	O
post	O
-	O
translational	O
processing	O
,	O
phosphorylation	O
,	O
sulfation	O
,	O
and	O
the	O
ability	O
of	O
precursor	O
forms	O
of	O
the	O
receptor	O
to	O
bind	O
T	B-Protein
-	I-Protein
cell	I-Protein
growth	I-Protein
factor	I-Protein
.	O

The	O
T	B-Protein
-	I-Protein
cell	I-Protein
growth	I-Protein
factor	I-Protein
(	I-Protein
TCGF	I-Protein
)	I-Protein
receptor	I-Protein
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
peripheral	O
blood	O
T	O
-	O
cells	O
is	O
characterized	O
as	O
a	O
glycoprotein	O
with	O
an	O
apparent	O
Mr	O
=	O
55	O
,	O
000	O
that	O
contains	O
N	O
-	O
linked	O
and	O
O	O
-	O
linked	O
carbohydrate	O
with	O
only	O
approximately	O
33	O
,	O
000	O
daltons	O
of	O
peptide	O
structure	O
(	O
p33	B-Protein
)	O
as	O
evaluated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

There	O
are	O
two	O
N	O
-	O
linked	O
glycosylated	O
intermediate	O
precursor	O
forms	O
(	O
apparent	O
Mr	O
=	O
35	O
,	O
000	O
(	O
p35	B-Protein
)	O
and	O
37	O
,	O
000	O
(	O
p37	B-Protein
]	O
.	O

This	O
receptor	O
differs	O
from	O
the	O
TCGF	B-Protein
receptor	I-Protein
on	O
HUT	O
-	O
102B2	O
cells	O
(	O
apparent	O
Mr	O
=	O
50	O
,	O
000	O
)	O
because	O
of	O
differences	O
in	O
post	O
-	O
translational	O
processing	O
.	O

Experiments	O
with	O
the	O
carboxylic	O
ionophore	O
monensin	O
demonstrate	O
blockade	O
of	O
the	O
transition	O
of	O
the	O
p35	B-Protein
and	O
p37	B-Protein
receptor	O
precursor	O
forms	O
to	O
the	O
mature	O
receptor	O
,	O
presumably	O
secondary	O
to	O
inhibition	O
of	O
Golgi	O
-	O
associated	O
receptor	O
processing	O
.	O

We	O
identify	O
the	O
primary	O
translation	O
product	O
of	O
TCGF	B-Protein
receptor	I-Protein
mRNA	O
as	O
intermediate	O
in	O
size	O
between	O
the	O
p33	B-Protein
and	O
the	O
p35	B-Protein
/	O
p37	B-Protein
forms	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p33	B-Protein
,	O
p35	B-Protein
,	O
and	O
p37	B-Protein
precursor	O
forms	O
,	O
but	O
not	O
the	O
primary	O
translation	O
product	O
,	O
are	O
all	O
capable	O
of	O
binding	O
TCGF	B-Protein
.	O

Thus	O
,	O
the	O
removal	O
of	O
the	O
signal	O
peptide	O
and	O
/	O
or	O
conformational	O
changes	O
of	O
the	O
primary	O
translation	O
product	O
are	O
necessary	O
for	O
ligand	O
binding	O
;	O
however	O
,	O
the	O
extensive	O
post	O
-	O
translational	O
modifications	O
are	O
not	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
that	O
at	O
least	O
some	O
TCGF	B-Protein
receptors	I-Protein
are	O
phosphorylated	O
and	O
sulfated	O
,	O
and	O
that	O
TCGF	B-Protein
receptors	I-Protein
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
T	O
-	O
cells	O
are	O
more	O
heavily	O
sulfated	O
than	O
those	O
on	O
HUT	O
-	O
102B2	O
cells	O
.	O

The	O
effects	O
of	O
processing	O
inhibitors	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
the	O
intracellular	O
migration	O
of	O
glycoprotein	B-Protein
E2	I-Protein
of	O
mouse	O
hepatitis	O
virus	O
and	O
the	O
maturation	O
of	O
coronavirus	O
particles	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
tunicamycin	O
and	O
inhibitors	O
of	O
the	O
processing	O
of	O
N	O
-	O
linked	O
glycans	O
including	O
N	O
-	O
methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
,	O
castanospermine	O
,	O
mannodeoxynojirimycin	O
,	O
and	O
swainsonine	O
on	O
the	O
transport	O
of	O
glycoprotein	B-Protein
E2	I-Protein
and	O
the	O
intracellular	O
maturation	O
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
A59	O
.	O

Indirect	O
immunofluorescence	O
staining	O
with	O
monoclonal	O
antibodies	O
revealed	O
that	O
glycoprotein	B-Protein
E2	I-Protein
exhibits	O
different	O
antigenic	O
properties	O
depending	O
on	O
the	O
presence	O
and	O
on	O
the	O
structure	O
of	O
the	O
N	O
-	O
linked	O
oligosaccharides	O
and	O
that	O
efficient	O
transport	O
of	O
glycoprotein	B-Protein
E2	I-Protein
to	O
the	O
plasma	O
membrane	O
requires	O
the	O
removal	O
of	O
glucose	O
residues	O
.	O

In	O
the	O
presence	O
of	O
tunicamycin	O
in	O
the	O
nonglycosylated	O
E2	B-Protein
apoprotein	O
was	O
synthesized	O
in	O
normal	O
amounts	O
and	O
readily	O
acylated	O
throughout	O
the	O
infectious	O
cycle	O
.	O

This	O
E2	B-Protein
-	O
species	O
could	O
not	O
be	O
detected	O
on	O
the	O
surface	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
-	O
infected	O
cells	O
with	O
indirect	O
immunofluorescence	O
staining	O
or	O
lactoperoxidase	B-Protein
labeling	O
.	O

N	O
-	O
Methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
and	O
castanospermine	O
,	O
both	O
of	O
which	O
selectively	O
inhibited	O
the	O
processing	O
glucosidases	O
,	O
caused	O
a	O
drop	O
in	O
virion	O
formation	O
by	O
two	O
log	O
steps	O
and	O
a	O
drastic	O
delay	O
in	O
the	O
surface	O
expression	O
of	O
glycoprotein	B-Protein
E2	I-Protein
.	O

The	O
E2	B-Protein
species	O
synthesized	O
under	O
such	O
conditions	O
was	O
acylated	O
but	O
accumulated	O
intracellularly	O
in	O
a	O
compartment	O
distinct	O
from	O
the	O
Golgi	O
.	O

Concomitantly	O
,	O
synthesis	O
of	O
the	O
matrix	O
glycoprotein	B-Protein
E1	I-Protein
of	O
mouse	O
hepatitis	O
virus	O
A59	O
was	O
drastically	O
impaired	O
.	O

Mannodeoxynojirimycin	O
and	O
swainsonine	O
,	O
which	O
block	O
later	O
stages	O
of	O
the	O
processing	O
pathway	O
,	O
had	O
less	O
or	O
no	O
effect	O
on	O
the	O
transport	O
of	O
glycoprotein	B-Protein
E2	I-Protein
and	O
the	O
formation	O
of	O
virus	O
particles	O
.	O

Purification	O
and	O
postsynthetic	O
modifications	O
of	O
Friend	O
erythroleukemic	O
cell	O
high	O
mobility	O
group	O
protein	O
HMG	B-Protein
-	I-Protein
I	I-Protein
.	O

We	O
have	O
previously	O
detected	O
and	O
purified	O
a	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
nonhistone	O
chromatin	O
protein	O
having	O
extraction	O
and	O
acid	O
-	O
solubility	O
properties	O
like	O
the	O
low	O
molecular	O
weight	O
"	O
high	O
mobility	O
group	O
"	O
(	O
HMG	O
)	O
nuclear	O
proteins	O
.	O

We	O
show	O
here	O
that	O
the	O
electrophoretic	O
properties	O
and	O
the	O
amino	O
acid	O
composition	O
of	O
this	O
mouse	O
cell	O
"	O
HMG	O
-	O
like	O
"	O
protein	O
is	O
comparable	O
to	O
those	O
of	O
the	O
HMG	B-Protein
-	I-Protein
I	I-Protein
proteins	O
isolated	O
from	O
human	O
HeLa	O
S3	O
cells	O
,	O
African	O
green	O
monkey	O
cells	O
,	O
Ehrlich	O
ascites	O
mouse	O
cells	O
,	O
and	O
rat	O
fibroblast	O
cells	O
.	O

Therefore	O
,	O
we	O
have	O
also	O
designated	O
the	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
protein	O
as	O
HMG	B-Protein
-	I-Protein
I	I-Protein
.	O

In	O
common	O
with	O
the	O
other	O
HMG	O
proteins	O
the	O
Friend	O
cell	O
HMG	B-Protein
-	I-Protein
I	I-Protein
protein	O
can	O
undergo	O
a	O
variety	O
of	O
post	O
-	O
translational	O
biochemical	O
modifications	O
including	O
acetylation	O
,	O
ADP	O
-	O
ribosylation	O
,	O
glycosylation	O
,	O
and	O
phosphorylation	O
.	O

Surprisingly	O
,	O
in	O
the	O
course	O
of	O
these	O
studies	O
we	O
found	O
that	O
in	O
vivo	O
radiolabeling	O
experiments	O
revealed	O
that	O
only	O
two	O
minor	O
HMG	B-Protein
-	I-Protein
14	I-Protein
subspecies	O
(	O
and	O
/	O
or	O
possibly	O
a	O
minor	O
HMG	B-Protein
-	I-Protein
I	I-Protein
subspecies	O
)	O
are	O
phosphorylated	O
whereas	O
HMG	B-Protein
-	I-Protein
1	I-Protein
,	O
-	B-Protein
2	I-Protein
,	I-Protein
-	B-Protein
17	I-Protein
,	O
and	O
the	O
major	O
HMG	B-Protein
-	I-Protein
14	I-Protein
are	O
not	O
heavily	O
phosphorylated	O
.	O

In	O
vitro	O
sulfation	O
of	O
pulmonary	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
.	O

Surfactant	O
-	O
associated	O
protein	O
-	O
35	O
consists	O
of	O
a	O
group	O
of	O
phospholipid	O
-	O
associated	O
proteins	O
of	O
26	O
-	O
36	O
kDa	O
isolated	O
from	O
pulmonary	O
alveolar	O
surfactant	O
.	O

In	O
the	O
rat	O
,	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
is	O
synthesized	O
from	O
26	O
-	O
kDa	O
primary	O
translation	O
products	O
which	O
are	O
cotranslationally	O
acetylated	O
and	O
glycosylated	O
to	O
heterogeneous	O
30	O
and	O
34	O
kDa	O
forms	O
.	O

High	O
-	O
mannose	O
oligosaccharide	O
-	O
containing	O
precursors	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
are	O
processed	O
in	O
the	O
rough	O
endoplasmic	O
reticulum	O
and	O
Golgi	O
to	O
complex	O
-	O
type	O
oligosaccharides	O
,	O
resulting	O
in	O
a	O
mature	O
glycoprotein	O
which	O
exhibits	O
extensive	O
charge	O
heterogeneity	O
in	O
two	O
-	O
dimensional	O
isoelectric	O
focusing	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Much	O
of	O
this	O
charge	O
heterogeneity	O
is	O
related	O
to	O
terminal	O
sialylation	O
of	O
the	O
two	O
asparagine	O
-	O
linked	O
oligosaccharides	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
is	O
also	O
sulfated	O
.	O

Sulfation	O
of	O
the	O
30	O
and	O
34	O
kDa	O
forms	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
was	O
clearly	O
detected	O
in	O
primary	O
cultures	O
of	O
rat	O
Type	O
II	O
epithelial	O
cells	O
.	O

These	O
sulfated	O
isoforms	O
were	O
sensitive	O
to	O
endoglycosidase	O
F	O
digestion	O
,	O
but	O
resistant	O
to	O
neuraminidase	O
,	O
suggesting	O
that	O
sulfation	O
occurred	O
at	O
oligosaccharide	O
residues	O
other	O
than	O
sialic	O
acid	O
.	O

The	O
lack	O
of	O
sulfation	O
of	O
the	O
26	O
kDa	O
forms	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
and	O
the	O
resistance	O
of	O
the	O
sulfated	O
isoforms	O
to	O
endoglycosidase	B-Protein
H	I-Protein
digestion	O
are	O
consistent	O
with	O
Golgi	O
-	O
associated	O
sulfation	O
of	O
the	O
complex	O
type	O
oligosaccharides	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
.	O

Thus	O
,	O
sulfation	O
is	O
another	O
component	O
of	O
the	O
complex	O
post	O
-	O
translational	O
processing	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
,	O
which	O
includes	O
acetylation	O
,	O
hydroxylation	O
,	O
glycosylation	O
,	O
sialylation	O
,	O
sulfhydryl	O
-	O
dependent	O
oligomerization	O
and	O
sulfation	O
.	O

Effect	O
of	O
propeptide	O
mutations	O
on	O
post	O
-	O
translational	O
processing	O
of	O
factor	B-Protein
IX	I-Protein
.	O

Evidence	O
that	O
beta	O
-	O
hydroxylation	O
and	O
gamma	O
-	O
carboxylation	O
are	O
independent	O
events	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
Factor	B-Protein
IX	I-Protein
includes	O
glycosylation	O
,	O
cleavage	O
of	O
the	O
signal	O
peptide	O
and	O
propeptide	O
,	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
specific	O
glutamic	O
acid	O
residues	O
to	O
form	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
and	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
at	O
residue	O
64	O
to	O
form	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O

The	O
human	O
Factor	B-Protein
IX	I-Protein
cDNA	O
coding	O
sequence	O
was	O
modified	O
in	O
the	O
propeptide	O
region	O
(	O
residue	O
-	O
18	O
to	O
-	O
1	O
)	O
using	O
oligonucleotide	O
-	O
directed	O
site	O
-	O
specific	O
mutagenesis	O
,	O
and	O
the	O
altered	O
Factor	B-Protein
IX	I-Protein
cDNA	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
effects	O
of	O
the	O
mutations	O
on	O
proteolytic	O
processing	O
,	O
gamma	O
-	O
carboxylation	O
,	O
and	O
beta	O
-	O
hydroxylation	O
were	O
assessed	O
by	O
direct	O
structural	O
analysis	O
.	O

After	O
purification	O
,	O
the	O
molecular	O
weight	O
of	O
each	O
of	O
the	O
recombinant	O
Factor	B-Protein
IX	I-Protein
species	O
and	O
its	O
NH2	O
-	O
terminal	O
amino	O
acid	O
sequence	O
were	O
shown	O
to	O
be	O
identical	O
to	O
those	O
of	O
plasma	O
Factor	B-Protein
IX	I-Protein
.	O

gamma	O
-	O
Carboxyglutamic	O
acid	O
and	O
beta	O
-	O
hydroxyaspartic	O
acid	O
analyses	O
revealed	O
that	O
recombinant	O
wild	O
-	O
type	O
Factor	B-Protein
IX	I-Protein
contained	O
9	O
.	O
2	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
3	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
/	O
molecule	O
compared	O
with	O
11	O
.	O
4	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
39	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
in	O
plasma	O
Factor	B-Protein
IX	I-Protein
.	O

When	O
the	O
18	O
-	O
residue	O
propeptide	O
was	O
deleted	O
or	O
when	O
the	O
cells	O
were	O
grown	O
in	O
the	O
presence	O
of	O
sodium	O
warfarin	O
,	O
secreted	O
Factor	B-Protein
IX	I-Protein
contained	O
no	O
detectable	O
gamma	O
-	O
carboxyglutamic	O
acid	O
but	O
0	O
.	O
36	O
and	O
0	O
.	O
40	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
,	O
respectively	O
.	O

Point	O
mutations	O
leading	O
to	O
substitution	O
of	O
alanine	O
for	O
phenylalanine	O
at	O
residue	O
-	O
16	O
or	O
glutamic	O
acid	O
for	O
alanine	O
at	O
residue	O
-	O
10	O
contained	O
0	O
.	O
2	O
and	O
1	O
.	O
7	O
gamma	O
-	O
carboxyglutamic	O
acid	O
residues	O
,	O
respectively	O
,	O
and	O
0	O
.	O
2	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O

These	O
data	O
confirm	O
that	O
the	O
propeptide	O
mutations	O
made	O
do	O
not	O
interfere	O
with	O
proteolytic	O
processing	O
and	O
that	O
the	O
Factor	B-Protein
IX	I-Protein
propeptide	O
contains	O
a	O
recognition	O
site	O
that	O
designates	O
the	O
adjacent	O
glutamic	O
acid	O
-	O
rich	O
domain	O
for	O
gamma	O
-	O
carboxylation	O
.	O

In	O
contrast	O
,	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
64	O
is	O
an	O
independent	O
process	O
which	O
does	O
not	O
require	O
vitamin	O
K	O
and	O
is	O
mediated	O
through	O
a	O
hydroxylation	O
recognition	O
site	O
in	O
the	O
mature	O
Factor	B-Protein
IX	I-Protein
,	O
not	O
in	O
the	O
propeptide	O
.	O

(	O
Glu62	O
,	O
Ala30	O
,	O
Tyr8	O
)	O
n	O
serves	O
as	O
high	O
-	O
affinity	O
substrate	O
for	O
tyrosylprotein	O
sulfotransferase	O
:	O
a	O
Golgi	O
enzyme	O
.	O

Tyrosylprotein	O
sulfotransferase	O
,	O
the	O
enzyme	O
catalyzing	O
the	O
sulfation	O
of	O
proteins	O
on	O
tyrosine	O
residues	O
,	O
was	O
characterized	O
by	O
using	O
the	O
acidic	O
polymer	O
containing	O
tyrosine	O
(	O
Glu62	O
,	O
Ala30	O
,	O
Tyr8	O
)	O
n	O
(	O
referred	O
to	O
as	O
Glu	O
,	O
Ala	O
,	O
Tyr	O
)	O
as	O
exogenous	O
"	O
protein	O
"	O
substrate	O
.	O

After	O
subcellular	O
fractionation	O
of	O
a	O
bovine	O
adrenal	O
medulla	O
homogenate	O
,	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
found	O
to	O
be	O
highest	O
in	O
fractions	O
enriched	O
in	O
Golgi	O
membrane	O
vesicles	O
.	O

Tyrosylprotein	O
sulfotransferase	O
required	O
the	O
presence	O
of	O
a	O
nonionic	O
detergent	O
for	O
sulfation	O
of	O
exogenous	O
Glu	O
,	O
Ala	O
,	O
Tyr	O
,	O
indicating	O
an	O
orientation	O
of	O
the	O
catalytic	O
site	O
of	O
the	O
enzyme	O
toward	O
the	O
Golgi	O
lumen	O
.	O

Tyrosylprotein	O
sulfotransferase	O
was	O
solubilized	O
by	O
Triton	O
X	O
-	O
100	O
,	O
suggesting	O
that	O
the	O
enzyme	O
was	O
tightly	O
associated	O
with	O
the	O
Golgi	O
membrane	O
,	O
possibly	O
as	O
an	O
integral	O
membrane	O
protein	O
.	O

The	O
apparent	O
Golgi	O
localization	O
of	O
tyrosylprotein	O
sulfotransferase	O
was	O
supported	O
by	O
the	O
observation	O
that	O
tyrosine	O
sulfation	O
of	O
proteins	O
in	O
intact	O
cells	O
was	O
blocked	O
by	O
monensin	O
and	O
was	O
in	O
line	O
with	O
previous	O
observations	O
that	O
all	O
tyrosine	O
-	O
sulfated	O
proteins	O
known	O
so	O
far	O
are	O
secretory	O
.	O

Glu	O
,	O
Ala	O
,	O
Tyr	O
was	O
found	O
to	O
have	O
a	O
very	O
high	O
affinity	O
for	O
tyrosylprotein	O
sulfotransferase	O
(	O
apparent	O
Km	O
,	O
300	O
nM	O
)	O
,	O
similar	O
to	O
that	O
reported	O
for	O
certain	O
tyrosylprotein	O
kinases	O
.	O

While	O
this	O
may	O
suggest	O
some	O
similarity	O
between	O
these	O
enzymes	O
,	O
the	O
Golgi	O
localization	O
of	O
tyrosylprotein	O
sulfotransferase	O
segregates	O
tyrosine	O
sulfation	O
from	O
the	O
sites	O
of	O
tyrosine	O
phosphorylation	O
of	O
proteins	O
in	O
the	O
intact	O
cell	O
.	O

If	O
,	O
however	O
,	O
tyrosylprotein	O
sulfotransferase	O
was	O
allowed	O
to	O
react	O
with	O
cytoplasmic	O
proteins	O
by	O
using	O
a	O
nonionic	O
detergent	O
,	O
tyrosine	O
sulfation	O
of	O
tubulin	O
was	O
observed	O
.	O

Developmental	O
changes	O
in	O
the	O
modification	O
of	O
lysosomal	O
enzymes	O
in	O
Dictyostelium	O
discoideum	O
.	O

Evidence	O
has	O
been	O
found	O
for	O
a	O
generalized	O
change	O
in	O
the	O
post	O
-	O
translational	O
modification	O
of	O
lysosomal	O
enzymes	O
during	O
development	O
of	O
Dictyostelium	O
discoideum	O
.	O

The	O
physical	O
and	O
antigenic	O
properties	O
of	O
four	O
developmentally	O
regulated	O
lysosomal	O
enzymes	O
,	O
N	B-Protein
-	I-Protein
acetylglucosaminidase	I-Protein
,	O
beta	B-Protein
-	I-Protein
glucosidase	I-Protein
,	O
alpha	B-Protein
-	I-Protein
mannosidase	I-Protein
,	O
and	O
acid	B-Protein
phosphatase	I-Protein
,	O
have	O
been	O
examined	O
throughout	O
the	O
life	O
cycle	O
.	O

In	O
vegetative	O
cells	O
,	O
a	O
single	O
major	O
isoelectric	O
species	O
is	O
detected	O
for	O
each	O
enzymatic	O
activity	O
on	O
native	O
nonequilibrium	O
isoelectric	O
focusing	O
gels	O
.	O

Between	O
6	O
and	O
10	O
hr	O
of	O
development	O
,	O
all	O
activities	O
,	O
including	O
the	O
preformed	O
enzyme	O
,	O
become	O
less	O
negatively	O
charged	O
,	O
resulting	O
in	O
a	O
modest	O
but	O
reproducible	O
shift	O
in	O
the	O
isoelectric	O
focusing	O
pattern	O
.	O

This	O
alteration	O
is	O
not	O
detected	O
by	O
native	O
gel	O
electrophoresis	O
at	O
constant	O
pH	O
.	O

As	O
development	O
continues	O
,	O
the	O
specific	O
activity	O
of	O
beta	B-Protein
-	I-Protein
glucosidase	I-Protein
,	O
alpha	B-Protein
-	I-Protein
mannosidase	I-Protein
,	O
and	O
acid	B-Protein
phosphatase	I-Protein
continues	O
to	O
increase	O
and	O
coincidentally	O
,	O
new	O
,	O
less	O
acidic	O
isozymic	O
bands	O
of	O
activity	O
can	O
be	O
observed	O
on	O
both	O
gel	O
systems	O
.	O

Some	O
of	O
these	O
new	O
isozymes	O
accumulate	O
preferentially	O
in	O
anterior	O
cells	O
,	O
while	O
others	O
accumulate	O
preferentially	O
in	O
posterior	O
cells	O
of	O
migrating	O
slugs	O
.	O

N	B-Protein
-	I-Protein
Acetylglucosaminidase	I-Protein
does	O
not	O
increase	O
in	O
specific	O
activity	O
late	O
in	O
development	O
and	O
no	O
new	O
isozymic	O
species	O
appear	O
.	O

Using	O
a	O
monoclonal	O
antibody	O
that	O
reacts	O
with	O
sulfated	O
N	O
-	O
linked	O
oligosaccharides	O
shared	O
by	O
vegetative	O
lysosomal	O
enzymes	O
in	O
D	O
.	O
discoideum	O
,	O
the	O
antigenicity	O
of	O
the	O
developmental	O
isozymes	O
has	O
been	O
characterized	O
.	O

All	O
of	O
the	O
enzymatic	O
activity	O
present	O
during	O
vegetative	O
growth	O
and	O
early	O
development	O
is	O
immunoprecipitable	O
.	O

However	O
,	O
the	O
less	O
negatively	O
charged	O
isozymes	O
that	O
accumulate	O
after	O
aggregation	O
are	O
not	O
recognized	O
by	O
the	O
antibody	O
.	O

Nonantigenic	O
acid	O
phosphatase	O
and	O
alpha	B-Protein
-	I-Protein
mannosidase	I-Protein
are	O
found	O
in	O
both	O
anterior	O
and	O
posterior	O
cells	O
from	O
migrating	O
pseudoplasmodia	O
.	O

Since	O
each	O
enzyme	O
is	O
coded	O
by	O
a	O
single	O
structural	O
gene	O
,	O
these	O
results	O
suggest	O
that	O
the	O
isozymes	O
present	O
late	O
in	O
development	O
arise	O
from	O
the	O
synthesis	O
of	O
the	O
same	O
polypeptides	O
with	O
altered	O
post	O
-	O
translational	O
modifications	O
.	O

The	O
appearance	O
of	O
anterior	O
and	O
posterior	O
specific	O
isozymes	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
cell	O
type	O
specific	O
changes	O
in	O
the	O
glycoprotein	O
modification	O
pathway	O
for	O
newly	O
synthesized	O
proteins	O
.	O

Sulfation	O
of	O
lutropin	O
oligosaccharides	O
with	O
a	O
cell	O
-	O
free	O
system	O
.	O

Sulfate	O
is	O
covalently	O
linked	O
to	O
the	O
oligosaccharides	O
on	O
the	O
alpha	O
and	O
beta	O
subunits	O
of	O
bovine	O
lutropin	O
(	O
luteinizing	O
hormone	O
;	O
LH	O
)	O
but	O
not	O
to	O
those	O
on	O
human	O
chorionic	O
gonadotropin	O
(	O
hCG	O
)	O
.	O

Since	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
pituitary	O
and	O
placental	O
alpha	O
subunits	O
are	O
homologous	O
,	O
comparison	O
of	O
their	O
asparagine	O
-	O
linked	O
sugars	O
can	O
provide	O
information	O
regarding	O
tissue	O
specificity	O
of	O
oligosaccharide	O
maturation	O
.	O

To	O
characterize	O
this	O
post	O
-	O
translational	O
modification	O
,	O
we	O
have	O
developed	O
a	O
reconstituted	O
cell	O
-	O
free	O
sulfation	O
system	O
.	O

Sulfate	O
is	O
incorporated	O
into	O
exogenously	O
added	O
glycoproteins	O
by	O
sulfotransferases	O
from	O
Triton	O
X	O
-	O
100	O
-	O
lysed	O
Golgi	O
membranes	O
in	O
the	O
presence	O
of	O
3	O
'	O
-	O
phosphoadenosine	O
5	O
'	O
-	O
phospho	O
[	O
35S	O
]	O
sulfate	O
,	O
which	O
is	O
generated	O
from	O
[	O
35S	O
]	O
sulfate	O
by	O
a	O
ribosome	O
-	O
free	O
supernate	O
from	O
Krebs	O
ascites	O
tumor	O
cells	O
.	O

LH	O
is	O
sulfated	O
by	O
pituitary	O
and	O
liver	O
membranes	O
but	O
not	O
by	O
those	O
from	O
placenta	O
.	O

Desialylated	O
hCG	O
(	O
AshCG	O
)	O
is	O
sulfated	O
by	O
membranes	O
from	O
placenta	O
and	O
pituitary	O
,	O
but	O
not	O
liver	O
,	O
while	O
hCG	O
is	O
not	O
sulfated	O
by	O
any	O
of	O
these	O
membranes	O
.	O

Endoglycosidase	O
F	O
releases	O
all	O
the	O
incorporated	O
sulfate	O
from	O
LH	O
in	O
the	O
form	O
of	O
a	O
heterogeneous	O
mixture	O
of	O
mono	O
-	O
and	O
disulfated	O
oligosaccharides	O
.	O

In	O
contrast	O
,	O
the	O
sulfate	O
added	O
to	O
AshCG	O
is	O
apparently	O
attached	O
to	O
peptide	O
rather	O
than	O
oligosaccharide	O
.	O

As	O
found	O
with	O
the	O
cell	O
-	O
free	O
system	O
,	O
sulfate	O
metabolically	O
incorporated	O
into	O
LH	O
by	O
pituitary	O
cells	O
is	O
present	O
on	O
a	O
heterogeneous	O
population	O
of	O
mono	O
-	O
and	O
disulfated	O
oligosaccharides	O
.	O

Thus	O
the	O
cell	O
-	O
free	O
sulfation	O
system	O
accurately	O
duplicates	O
the	O
in	O
vivo	O
process	O
.	O

In	O
vivo	O
participation	O
of	O
a	O
high	O
potential	O
iron	O
-	O
sulfur	O
protein	O
as	O
electron	O
donor	O
to	O
the	O
photochemical	O
reaction	O
center	O
of	O
Rubrivivax	O
gelatinosus	O
.	O

We	O
have	O
found	O
that	O
the	O
only	O
high	O
redox	O
potential	O
electron	O
transfer	O
component	O
in	O
the	O
soluble	O
fraction	O
of	O
Rubrivivax	O
gelatinosus	O
TG	O
-	O
9	O
is	O
a	O
high	B-Protein
-	I-Protein
potential	I-Protein
iron	I-Protein
-	I-Protein
sulfur	I-Protein
protein	I-Protein
(	O
HiPIP	B-Protein
)	O
.	O

We	O
demonstrated	O
the	O
participation	O
of	O
this	O
HiPIP	B-Protein
in	O
the	O
photoinduced	O
electron	O
transfer	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

First	O
,	O
the	O
addition	O
of	O
HiPIP	B-Protein
to	O
purified	O
membranes	O
enhanced	O
the	O
rate	O
of	O
re	O
-	O
reduction	O
of	O
the	O
photooxidized	O
reaction	O
center	O
.	O

Second	O
,	O
the	O
photooxidation	O
of	O
HiPIP	B-Protein
was	O
observed	O
in	O
intact	O
cells	O
of	O
Ru	O
.	O
gelatinosus	O
TG	O
-	O
9	O
under	O
anaerobic	O
conditions	O
by	O
EPR	O
and	O
absorption	O
spectroscopies	O
.	O

Analysis	O
of	O
flash	O
-	O
induced	O
absorption	O
changes	O
showed	O
that	O
the	O
equilibration	O
of	O
positive	O
equivalents	O
between	O
the	O
reaction	O
center	O
and	O
HiPIP	B-Protein
occurs	O
in	O
less	O
than	O
1	O
ms	O
after	O
flash	O
excitation	O
.	O

The	O
complete	O
re	O
-	O
reduction	O
of	O
the	O
photooxidized	O
reaction	O
center	O
is	O
achieved	O
in	O
tens	O
of	O
milliseconds	O
.	O

The	O
turnover	O
of	O
a	O
cyt	O
bc1	O
is	O
also	O
involved	O
in	O
this	O
reaction	O
,	O
as	O
shown	O
by	O
a	O
slow	O
electrogenic	O
phase	O
of	O
the	O
membrane	O
potential	O
linked	O
to	O
this	O
process	O
.	O

Quantitation	O
of	O
procholecystokinin	B-Protein
and	O
its	O
products	O
in	O
plasma	O
by	O
processing	O
-	O
independent	O
analysis	O
.	O

A	O
procedure	O
for	O
processing	O
-	O
independent	O
quantitation	O
of	O
procholecystokinin	B-Protein
(	O
proCCK	B-Protein
)	O
and	O
its	O
products	O
has	O
been	O
applied	O
to	O
plasma	O
.	O

The	O
procedure	O
is	O
based	O
on	O
tryptic	O
cleavage	O
after	O
Lys61	O
and	O
Arg71	O
with	O
subsequent	O
monospecific	O
radioimmuno	O
-	O
analysis	O
of	O
fragment	O
62	O
-	O
71	O
of	O
human	O
proCCK	B-Protein
,	O
which	O
again	O
corresponds	O
to	O
fragment	O
1	O
-	O
10	O
of	O
CCK	B-Protein
-	O
22	O
.	O

The	O
detection	O
limit	O
of	O
the	O
analysis	O
was	O
0	O
.	O
2	O
pmol	O
/	O
l	O
.	O

Plasma	O
was	O
extracted	O
with	O
ethanol	O
.	O

In	O
plasma	O
from	O
13	O
healthy	O
volunteers	O
the	O
basal	O
concentration	O
with	O
the	O
above	O
-	O
mentioned	O
radioimmunoassay	O
was	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
.	O
)	O
before	O
,	O
and	O
13	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
pmol	O
/	O
l	O
after	O
,	O
incubation	O
with	O
trypsin	O
.	O

Two	O
hours	O
after	O
ingestion	O
of	O
a	O
mixed	O
meal	O
,	O
the	O
plasma	O
concentration	O
was	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
before	O
,	O
and	O
21	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
2	O
pmol	O
/	O
l	O
after	O
tryptic	O
cleavage	O
.	O

With	O
a	O
conventional	O
CCK	B-Protein
radioimmunoassay	O
specific	O
for	O
the	O
C	O
-	O
terminally	O
amidated	O
and	O
O	O
-	O
sulfated	O
bioactive	O
epitope	O
,	O
the	O
concentration	O
was	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
in	O
the	O
basal	O
state	O
and	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
pmol	O
/	O
l	O
2	O
h	O
after	O
a	O
meal	O
.	O

Tryptic	O
cleavage	O
did	O
not	O
increase	O
the	O
concentrations	O
of	O
amidated	O
,	O
bioactive	O
CCK	B-Protein
peptides	O
.	O

In	O
plasma	O
from	O
37	O
patients	O
with	O
the	O
carcinoid	O
syndrome	O
,	O
the	O
basal	O
concentration	O
of	O
proCCK	B-Protein
and	O
its	O
products	O
was	O
14	O
.	O
1	O
(	O
2	O
.	O
8	O
-	O
150	O
.	O
4	O
)	O
pmol	O
/	O
l	O
(	O
median	O
(	O
range	O
)	O
)	O
,	O
compared	O
with	O
0	O
.	O
3	O
(	O
0	O
-	O
18	O
.	O
8	O
)	O
pmol	O
/	O
l	O
for	O
carboxyamidated	O
CCK	B-Protein
.	O

Only	O
two	O
patients	O
had	O
significantly	O
elevated	O
CCK	B-Protein
concentrations	O
.	O

We	O
conclude	O
that	O
processing	O
-	O
independent	O
analysis	O
is	O
useful	O
for	O
quantitation	O
of	O
proCCK	B-Protein
and	O
its	O
products	O
in	O
plasma	O
,	O
since	O
it	O
quantitates	O
CCK	B-Protein
cell	O
secretion	O
more	O
accurately	O
than	O
conventional	O
CCK	B-Protein
assays	O
.	O

Synergistic	O
activation	O
of	O
rat	O
brain	O
phospholipase	B-Protein
D	I-Protein
by	O
ADP	O
-	O
ribosylation	O
factor	O
and	O
rhoA	B-Protein
p21	I-Protein
,	O
and	O
its	O
inhibition	O
by	O
Clostridium	O
botulinum	O
C3	B-Protein
exoenzyme	I-Protein
.	O

An	O
activator	O
of	O
rat	O
brain	O
phospholipase	B-Protein
D	I-Protein
(	O
PLD	B-Protein
)	O
that	O
is	O
distinct	O
from	O
the	O
already	O
identified	O
PLD	B-Protein
activator	O
,	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
ARF	O
)	O
,	O
was	O
partially	O
purified	O
from	O
bovine	O
brain	O
cytosol	O
by	O
a	O
series	O
of	O
chromatographic	O
steps	O
.	O

The	O
partially	O
purified	O
preparation	O
contained	O
a	O
22	O
-	O
kDa	O
substrate	O
for	O
Clostridium	O
botulinum	O
C3	B-Protein
exoenzyme	I-Protein
ADP	O
-	O
ribosyltransferase	O
,	O
which	O
strongly	O
reacted	O
with	O
anti	O
-	O
rhoA	B-Protein
p21	I-Protein
antibody	O
,	O
but	O
not	O
with	O
anti	O
-	O
rac1	B-Protein
p21	I-Protein
or	O
anti	O
-	O
cdc42Hs	B-Protein
p21	I-Protein
antibody	O
.	O

Treatment	O
of	O
the	O
partially	O
purified	O
PLD	B-Protein
-	O
activating	O
factor	O
with	O
both	O
C3	B-Protein
exoenzyme	I-Protein
and	O
NAD	O
significantly	O
inhibited	O
the	O
PLD	B-Protein
-	O
stimulating	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
rhoA	B-Protein
p21	I-Protein
is	O
,	O
at	O
least	O
in	O
part	O
,	O
responsible	O
for	O
the	O
PLD	B-Protein
-	O
stimulating	O
activity	O
in	O
the	O
preparation	O
.	O

Recombinant	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
expressed	O
in	O
and	O
purified	O
from	O
Sf9	O
cells	O
activated	O
rat	O
brain	O
PLD	B-Protein
in	O
a	O
concentration	O
-	O
and	O
GTP	O
gamma	O
S	O
(	O
guanosine	O
5	O
'	O
-	O
O	O
-	O
(	O
3	O
-	O
thiotriphosphate	O
)	O
)	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
recombinant	O
non	O
-	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
(	O
fused	O
to	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
)	O
expressed	O
in	O
Escherichia	O
coli	O
failed	O
to	O
activate	O
the	O
PLD	B-Protein
.	O

This	O
difference	O
cannot	O
be	O
explained	O
by	O
a	O
lower	O
affinity	O
of	O
non	O
-	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
for	O
GTP	O
gamma	O
S	O
,	O
as	O
the	O
rates	O
of	O
[	O
35S	O
]	O
GTP	O
gamma	O
S	O
binding	O
were	O
very	O
similar	O
for	O
both	O
recombinant	O
preparations	O
and	O
the	O
GTP	O
gamma	O
S	O
-	O
bound	O
form	O
of	O
non	O
-	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
did	O
not	O
induce	O
PLD	B-Protein
activation	O
.	O

Interestingly	O
,	O
recombinant	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
and	O
ARF	O
synergistically	O
activated	O
rat	O
brain	O
PLD	B-Protein
;	O
a	O
similar	O
pattern	O
was	O
seen	O
with	O
the	O
partially	O
purified	O
PLD	B-Protein
-	O
activating	O
factor	O
.	O

The	O
synergistic	O
activation	O
was	O
inhibited	O
by	O
C3	B-Protein
exoenzyme	I-Protein
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
recombinant	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
in	O
a	O
NAD	O
-	O
dependent	O
manner	O
.	O

Inhibition	O
correlated	O
with	O
the	O
extent	O
of	O
ADP	O
-	O
ribosylation	O
.	O

These	O
findings	O
suggest	O
that	O
rhoA	B-Protein
p21	I-Protein
regulates	O
rat	O
brain	O
PLD	B-Protein
in	O
concert	O
with	O
ARF	O
,	O
and	O
that	O
isoprenylation	O
of	O
rhoA	B-Protein
p21	I-Protein
is	O
essential	O
for	O
PLD	B-Protein
regulation	O
in	O
vitro	O
.	O

Farnesyltransferase	O
inhibitors	O
block	O
the	O
neurofibromatosis	O
type	O
I	O
(	O
NF1	O
)	O
malignant	O
phenotype	O
.	O

Neurofibromatosis	O
type	O
I	O
(	O
NF1	O
)	O
is	O
a	O
hereditary	O
tumor	O
and	O
developmental	O
disorder	O
whose	O
defective	O
gene	O
was	O
cloned	O
previously	O
.	O

The	O
protein	O
product	O
of	O
the	O
NF1	B-Protein
gene	O
,	O
neurofibromin	B-Protein
,	O
contains	O
a	O
domain	O
that	O
shows	O
significant	O
sequence	O
homology	O
to	O
the	O
known	O
catalytic	O
domains	O
of	O
mammalian	O
Ras	O
GTPase	O
-	O
activating	O
proteins	O
(	O
GAP	O
)	O
and	O
the	O
yeast	O
IRA1	B-Protein
and	O
IRA2	B-Protein
proteins	O
.	O

This	O
homologous	O
region	O
of	O
neurofibromin	B-Protein
has	O
been	O
shown	O
to	O
exhibit	O
GAP	O
activity	O
toward	O
Ras	O
proteins	O
.	O

Malignant	O
schwannoma	O
cell	O
lines	O
from	O
NF1	O
patients	O
contain	O
normal	O
levels	O
of	O
GAP	O
and	O
nonmutated	O
Ras	O
proteins	O
but	O
barely	O
detectable	O
levels	O
of	O
neurofibromin	B-Protein
,	O
based	O
on	O
genetic	O
mutations	O
in	O
the	O
NF1	B-Protein
gene	O
.	O

Because	O
these	O
cells	O
contain	O
constitutively	O
activated	O
Ras	O
.	O
GTP	O
,	O
it	O
has	O
been	O
proposed	O
that	O
neurofibromin	B-Protein
may	O
be	O
the	O
sole	O
negative	O
regulator	O
of	O
Ras	O
in	O
these	O
cells	O
.	O

Overall	O
,	O
these	O
results	O
have	O
implied	O
an	O
important	O
role	O
of	O
the	O
Ras	O
signaling	O
pathway	O
in	O
NF1	O
malignant	O
schwannomas	O
.	O

Recently	O
,	O
several	O
laboratories	O
have	O
developed	O
small	O
molecule	O
inhibitors	O
of	O
Ras	O
function	O
that	O
inhibit	O
the	O
enzyme	O
farnesyltransferase	O
(	O
FT	O
)	O
.	O

FT	O
-	O
mediated	O
post	O
-	O
translational	O
farnesylation	O
of	O
Ras	O
proteins	O
is	O
absolutely	O
necessary	O
for	O
Ras	O
function	O
since	O
this	O
modification	O
is	O
required	O
for	O
the	O
anchoring	O
of	O
Ras	O
proteins	O
to	O
the	O
plasma	O
cell	O
membrane	O
.	O

Although	O
previous	O
studies	O
have	O
shown	O
that	O
FT	O
inhibitors	O
can	O
block	O
the	O
growth	O
of	O
tumor	O
cells	O
carrying	O
mutant	O
Ras	O
proteins	O
,	O
it	O
remained	O
unclear	O
how	O
this	O
class	O
of	O
inhibitors	O
would	O
affect	O
tumor	O
cells	O
such	O
as	O
in	O
NF1	O
,	O
whose	O
malignant	O
growth	O
appears	O
to	O
be	O
mediated	O
by	O
up	O
-	O
regulation	O
of	O
wild	O
-	O
type	O
Ras	O
activity	O
.	O

Thus	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
BMS	O
-	O
186511	O
,	O
a	O
bisubstrate	O
analogue	O
inhibitor	O
of	O
FT	O
,	O
would	O
inhibit	O
the	O
malignant	O
growth	O
properties	O
of	O
a	O
cell	O
line	O
established	O
from	O
malignant	O
schwannoma	O
of	O
an	O
NF1	O
patient	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
malignant	O
growth	O
properties	O
of	O
ST88	O
-	O
14	O
cells	O
,	O
the	O
most	O
malignant	O
cell	O
line	O
among	O
several	O
well	O
-	O
characterized	O
NF1	O
cells	O
,	O
are	O
inhibited	O
by	O
BMS	O
-	O
186511	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Following	O
treatment	O
with	O
BMS	O
-	O
186511	O
,	O
ST88	O
-	O
14	O
cells	O
became	O
flat	O
,	O
nonrefractile	O
,	O
were	O
contact	O
-	O
inhibited	O
,	O
and	O
lost	O
their	O
ability	O
to	O
grow	O
in	O
soft	O
agar	O
.	O

In	O
the	O
drug	O
-	O
exposed	O
cells	O
,	O
Ras	O
proteins	O
were	O
prevented	O
from	O
FT	O
-	O
mediated	O
membrane	O
association	O
.	O

BMS	O
-	O
186511	O
was	O
found	O
to	O
specifically	O
inhibit	O
FT	O
,	O
but	O
not	O
geranylgeranyltransferase	O
I	O
,	O
a	O
closely	O
related	O
enzyme	O
.	O

Thus	O
,	O
it	O
is	O
conceivable	O
that	O
FT	O
inhibitors	O
may	O
ultimately	O
become	O
the	O
first	O
generation	O
of	O
drugs	O
against	O
the	O
malignant	O
phenotype	O
in	O
NF1	O
based	O
on	O
rational	O
insights	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
neurofibromin	B-Protein
.	O

A	O
novel	O
G	O
protein	O
alpha	O
subunit	O
containing	O
atypical	O
guanine	O
nucleotide	O
-	O
binding	O
domains	O
is	O
differentially	O
expressed	O
in	O
a	O
molluscan	O
nervous	O
system	O
.	O

We	O
described	O
the	O
characterization	O
of	O
a	O
novel	O
G	O
protein	O
alpha	O
subunit	O
,	O
G	B-Protein
alpha	I-Protein
a	I-Protein
.	O

cDNA	O
encoding	O
this	O
subunit	O
was	O
cloned	O
from	O
the	O
central	O
nervous	O
system	O
of	O
the	O
mollusc	O
Lymnaea	O
stagnalis	O
.	O

The	O
deduced	O
protein	O
contains	O
all	O
characteristic	O
guanine	O
nucleotide	O
-	O
binding	O
domains	O
of	O
G	O
alpha	O
subunits	O
but	O
shares	O
only	O
a	O
limited	O
degree	O
of	O
overall	O
sequence	O
identity	O
with	O
known	O
subtypes	O
(	O
approximately	O
30	O
%	O
)	O
.	O

Moreover	O
,	O
two	O
of	O
the	O
nucleotide	O
-	O
binding	O
domains	O
exhibit	O
salient	O
deviations	O
from	O
corresponding	O
sequences	O
in	O
other	O
G	O
protein	O
alpha	O
subunits	O
.	O

The	O
A	O
domain	O
,	O
determining	O
kinetic	O
features	O
of	O
the	O
GTPase	O
cycle	O
,	O
contains	O
a	O
markedly	O
unique	O
amino	O
acid	O
sequence	O
(	O
ILIIGGPGAGK	O
)	O
.	O

In	O
addition	O
,	O
the	O
C	O
domain	O
is	O
also	O
clearly	O
distinct	O
(	O
DVAGQRSL	O
)	O
.	O

The	O
presence	O
of	O
a	O
leucine	O
in	O
this	O
motif	O
,	O
instead	O
of	O
glutamic	O
acid	O
,	O
has	O
important	O
implications	O
for	O
hypotheses	O
concerning	O
the	O
GTPase	O
mechanism	O
.	O

In	O
contrast	O
to	O
other	O
G	O
alpha	O
subtypes	O
,	O
G	B-Protein
alpha	I-Protein
a	I-Protein
has	O
no	O
appropriate	O
N	O
-	O
terminal	O
residues	O
that	O
could	O
be	O
acylated	O
.	O

It	O
does	O
contain	O
the	O
strictly	O
conserved	O
arginine	O
residue	O
that	O
serves	O
as	O
a	O
cholera	O
toxin	O
substrate	O
in	O
G	B-Protein
alpha	I-Protein
s	I-Protein
and	O
G	O
alpha	O
t	O
but	O
lacks	O
a	O
site	O
for	O
ADP	O
-	O
ribosylation	O
by	O
pertussis	O
toxin	O
.	O

In	O
situ	O
hybridization	O
experiments	O
indicate	O
that	O
G	B-Protein
alpha	I-Protein
a	I-Protein
-	O
encoding	O
mRNA	O
is	O
expressed	O
in	O
a	O
limited	O
subpopulation	O
of	O
neurons	O
within	O
the	O
Lymnaea	O
brain	O
.	O

These	O
data	O
suggest	O
that	O
G	B-Protein
alpha	I-Protein
a	I-Protein
defines	O
a	O
separate	O
class	O
of	O
G	O
proteins	O
with	O
cell	O
type	O
-	O
specific	O
functions	O
.	O

Semisynthetic	O
chemical	O
modification	O
of	O
the	O
antifungal	O
lipopeptide	O
echinocandin	O
B	O
(	O
ECB	O
)	O
:	O
structure	O
-	O
activity	O
studies	O
of	O
the	O
lipophilic	O
and	O
geometric	O
parameters	O
of	O
polyarylated	O
acyl	O
analogs	O
of	O
ECB	O
.	O

Echinocandin	O
B	O
(	O
ECB	O
)	O
is	O
a	O
lipopeptide	O
composed	O
of	O
a	O
complex	O
cyclic	O
peptide	O
acylated	O
at	O
the	O
N	O
-	O
terminus	O
by	O
linoleic	O
acid	O
.	O

Enzymatic	O
deacylation	O
of	O
ECB	O
provided	O
the	O
peptide	O
"	O
nucleus	O
"	O
as	O
a	O
biologically	O
inactive	O
substrate	O
from	O
which	O
novel	O
ECB	O
analogs	O
were	O
generated	O
by	O
chemical	O
reacylation	O
at	O
the	O
N	O
-	O
terminus	O
.	O

Varying	O
the	O
acyl	O
group	O
revealed	O
that	O
the	O
structure	O
and	O
physical	O
properties	O
of	O
the	O
side	O
chain	O
,	O
particularly	O
its	O
geometry	O
and	O
lipophilicity	O
,	O
played	O
a	O
pivotal	O
role	O
in	O
determining	O
the	O
antifungal	O
potency	O
properties	O
of	O
the	O
analog	O
.	O

Using	O
CLOGP	O
values	O
to	O
describe	O
and	O
compare	O
the	O
lipophilicities	O
of	O
the	O
side	O
chain	O
fragments	O
,	O
it	O
was	O
shown	O
that	O
values	O
of	O
>	O
3	O
.	O
5	O
were	O
required	O
for	O
expression	O
of	O
antifungal	O
activity	O
.	O

Secondly	O
,	O
a	O
linearly	O
rigid	O
geometry	O
of	O
the	O
side	O
chain	O
was	O
the	O
most	O
effective	O
shape	O
in	O
enhancing	O
the	O
antifungal	O
potency	O
.	O

Using	O
these	O
parameters	O
as	O
a	O
guide	O
,	O
a	O
variety	O
of	O
novel	O
ECB	O
analogs	O
were	O
synthesized	O
which	O
included	O
arylacyl	O
groups	O
that	O
incorporated	O
biphenyl	O
,	O
terphenyl	O
,	O
tetraphenyl	O
,	O
and	O
arylethynyl	O
groups	O
.	O

Generally	O
the	O
glucan	O
synthase	O
inhibition	O
by	O
these	O
analogs	O
correlated	O
well	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
activities	O
and	O
was	O
likewise	O
influenced	O
by	O
the	O
structure	O
of	O
the	O
side	O
chain	O
.	O

These	O
structural	O
variations	O
resulted	O
in	O
enhancement	O
of	O
antifungal	O
activity	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
.	O

Some	O
of	O
these	O
analogs	O
,	O
including	O
LY303366	O
(	O
14a	O
)	O
,	O
were	O
effective	O
by	O
the	O
oral	O
route	O
of	O
administration	O
.	O

Fatty	O
acylation	O
of	O
the	O
rat	O
asialoglycoprotein	O
receptor	O
.	O

The	O
three	O
subunits	O
from	O
active	O
receptors	O
contain	O
covalently	O
bound	O
palmitate	O
and	O
stearate	O
.	O

Rat	O
hepatic	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomers	O
composed	O
of	O
three	O
homologous	O
glycoprotein	O
subunits	O
,	O
designated	O
rat	O
hepatic	B-Protein
lectins	I-Protein
(	I-Protein
RHL	I-Protein
)	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
and	O
3	B-Protein
.	O

ASGP	O
-	O
Rs	O
mediate	O
the	O
endocytosis	O
and	O
degradation	O
of	O
circulating	O
glycoconjugates	O
containing	O
terminal	O
N	O
-	O
acetylgalactosamine	O
or	O
galactose	O
,	O
including	O
desialylated	O
plasma	O
glycoproteins	O
.	O

We	O
have	O
shown	O
in	O
permeable	O
rat	O
hepatocytes	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
one	O
subpopulation	O
of	O
receptors	O
(	O
designated	O
State	O
2	O
ASGP	O
-	O
Rs	O
)	O
can	O
be	O
decreased	O
or	O
increased	O
,	O
respectively	O
,	O
by	O
ATP	O
and	O
palmitoyl	O
-	O
CoA	O
(	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
,	O
and	O
Oka	O
,	O
J	O
.	O
A	O
.	O
(	O
1993	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
268	O
,	O
27186	O
-	O
27190	O
)	O
.	O

We	O
proposed	O
that	O
a	O
reversible	O
and	O
cyclic	O
acylation	O
/	O
deacylation	O
process	O
may	O
regulate	O
ASGP	O
-	O
R	O
activity	O
during	O
endocytosis	O
,	O
receptor	O
-	O
ligand	O
dissociation	O
,	O
and	O
receptor	O
recycling	O
.	O

In	O
the	O
accompanying	O
paper	O
(	O
Zeng	O
,	O
F	O
-	O
Y	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21388	O
-	O
21395	O
)	O
,	O
we	O
show	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
affinity	O
-	O
purified	O
State	O
2	O
ASGP	O
-	O
Rs	O
is	O
decreased	O
by	O
treatment	O
with	O
hydroxylamine	O
under	O
mild	O
conditions	O
consistent	O
with	O
these	O
ASGP	O
-	O
Rs	O
being	O
fatty	O
acylated	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
chemical	O
method	O
to	O
determine	O
the	O
presence	O
of	O
covalently	O
-	O
bound	O
fatty	O
acids	O
in	O
individual	O
ASGP	O
-	O
R	O
subunits	O
.	O

The	O
affinity	O
-	O
purified	O
ASGP	O
-	O
R	O
preparations	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
under	O
nonreducing	O
conditions	O
,	O
and	O
the	O
gel	O
slices	O
containing	O
individual	O
RHL	O
subunits	O
were	O
treated	O
with	O
alkali	O
to	O
release	O
covalently	O
bound	O
fatty	O
acids	O
,	O
which	O
were	O
subsequently	O
analyzed	O
by	O
gas	O
chromatography	O
and	O
confirmed	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Both	O
stearic	O
and	O
palmitic	O
acids	O
were	O
detected	O
in	O
all	O
three	O
receptor	O
subunits	O
.	O

Pretreatment	O
of	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
before	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
reduced	O
the	O
content	O
of	O
both	O
fatty	O
acids	O
by	O
66	O
-	O
80	O
%	O
,	O
indicating	O
that	O
most	O
of	O
these	O
fatty	O
acids	O
are	O
attached	O
to	O
cysteine	O
residues	O
via	O
thioester	O
linkages	O
.	O

Furthermore	O
,	O
when	O
freshly	O
isolated	O
hepatocytes	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
[	O
3H	O
]	O
palmitate	O
,	O
all	O
three	O
RHL	O
subunits	O
in	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
were	O
metabolically	O
labeled	O
.	O

We	O
conclude	O
that	O
RHL1	B-Protein
,	O
RHL2	B-Protein
,	O
and	O
RHL3	B-Protein
are	O
modified	O
by	O
fatty	O
acylation	O
in	O
intact	O
cells	O
.	O

Terminal	O
marking	O
of	O
avian	O
triosephosphate	O
isomerases	O
by	O
deamidation	O
and	O
oxidation	O
.	O

Triosephosphate	B-Protein
isomerase	I-Protein
(	O
TPI	B-Protein
)	O
provides	O
an	O
excellent	O
model	O
for	O
terminal	O
marking	O
and	O
protein	O
degradation	O
.	O

Mammalian	O
TPI	B-Protein
is	O
terminally	O
modified	O
by	O
deamidation	O
at	O
Asn71	O
-	O
Gly	O
,	O
resulting	O
in	O
unfolding	O
,	O
dissociation	O
,	O
and	O
proteolysis	O
.	O

In	O
contrast	O
,	O
chicken	O
TPI	B-Protein
,	O
which	O
contains	O
a	O
lysine	O
at	O
position	O
71	O
,	O
is	O
terminally	O
modified	O
by	O
the	O
oxidation	O
of	O
Cys126	O
.	O

Thus	O
,	O
both	O
deamidation	O
and	O
oxidation	O
initiate	O
degradation	O
of	O
TPI	B-Protein
from	O
different	O
species	O
.	O

To	O
explore	O
the	O
terminal	O
marking	O
in	O
other	O
avians	O
,	O
we	O
have	O
purified	O
the	O
turkey	O
TPI	B-Protein
to	O
homogeneity	O
and	O
determined	O
its	O
characteristics	O
.	O

Although	O
the	O
molecular	O
properties	O
of	O
the	O
turkey	O
and	O
chicken	O
TPI	B-Protein
were	O
very	O
similar	O
,	O
their	O
tolerances	O
to	O
temperature	O
,	O
oxidants	O
,	O
and	O
alkaline	O
pH	O
were	O
very	O
different	O
.	O

For	O
example	O
,	O
chicken	O
TPI	B-Protein
was	O
inactivated	O
80	O
%	O
in	O
either	O
10	O
mM	O
oxidized	O
glutathione	O
or	O
H2O2	O
,	O
whereas	O
120	O
mM	O
GSSG	O
had	O
no	O
effect	O
on	O
turkey	O
TPI	B-Protein
,	O
and	O
>	O
120	O
mM	O
H2O2	O
was	O
needed	O
for	O
80	O
%	O
inactivation	O
.	O

Under	O
alkaline	O
conditions	O
that	O
cause	O
rapid	O
deamidation	O
of	O
the	O
mammalian	O
TPI	B-Protein
,	O
neither	O
avian	O
enzyme	O
deamidated	O
.	O

Chicken	O
TPI	B-Protein
,	O
however	O
,	O
aggregated	O
.	O

Aggregation	O
was	O
reversed	O
by	O
2	O
-	O
mercaptoethanol	O
.	O

Under	O
prolonged	O
exposure	O
to	O
milder	O
conditions	O
the	O
turkey	O
enzyme	O
was	O
completely	O
inactivated	O
and	O
deamidated	O
at	O
Asn15	O
-	O
Gly	O
.	O

Thus	O
,	O
there	O
are	O
marked	O
differences	O
in	O
the	O
susceptibility	O
of	O
these	O
two	O
avian	O
enzymes	O
to	O
oxidation	O
and	O
deamidation	O
,	O
and	O
their	O
terminal	O
marking	O
mechanisms	O
appear	O
to	O
be	O
different	O
.	O

Effects	O
of	O
lovastatin	O
on	O
adenylyl	O
cyclase	O
activity	O
and	O
G	O
proteins	O
in	O
GH4C1	O
cells	O
.	O

We	O
studied	O
the	O
effect	O
of	O
lovastatin	O
,	O
a	O
cholesterol	O
lowering	O
drug	O
,	O
on	O
the	O
basal	O
state	O
of	O
G	O
-	O
proteins	O
in	O
GH4C1	O
cells	O
.	O

Our	O
data	O
show	O
that	O
the	O
addition	O
of	O
lovastatin	O
markedly	O
decreased	O
the	O
amount	O
of	O
the	O
alpha	O
-	O
subunits	O
of	O
the	O
Gs	O
and	O
Gi	O
-	O
proteins	O
in	O
the	O
plasma	O
membrane	O
.	O

The	O
decrease	O
of	O
alpha	O
s	O
was	O
correlated	O
with	O
a	O
decrease	O
in	O
adenylyl	O
cyclase	O
activity	O
,	O
and	O
both	O
effects	O
were	O
reverted	O
by	O
the	O
presence	O
of	O
mevalonate	O
.	O

As	O
the	O
attachment	O
of	O
G	O
protein	O
subunits	O
to	O
the	O
membrane	O
is	O
dependent	O
on	O
gamma	O
-	O
subunit	O
prenylation	O
,	O
we	O
assume	O
that	O
the	O
mechanism	O
through	O
which	O
lovastatin	O
exerts	O
its	O
effects	O
on	O
G	O
-	O
proteins	O
is	O
the	O
lack	O
of	O
mevalonate	O
for	O
the	O
synthesis	O
of	O
prenyl	O
residues	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
some	O
of	O
the	O
effects	O
of	O
lovastatin	O
are	O
mediated	O
through	O
changes	O
in	O
the	O
basal	O
state	O
of	O
G	O
-	O
protein	O
in	O
the	O
membrane	O
and	O
consequently	O
on	O
adenylyl	O
cyclase	O
activity	O
.	O

The	O
neuroendocrine	O
precursor	O
7B2	B-Protein
is	O
a	O
sulfated	O
protein	O
proteolytically	O
processed	O
by	O
a	O
ubiquitous	O
furin	B-Protein
-	O
like	O
convertase	O
.	O

The	O
neuroendocrine	O
granule	O
-	O
associated	O
protein	O
7B2	B-Protein
,	O
unlike	O
many	O
other	O
neuroendocrine	O
precursor	O
proteins	O
stored	O
in	O
secretory	O
granules	O
,	O
carries	O
in	O
its	O
primary	O
structure	O
the	O
Arg	O
-	O
Xaa	O
-	O
Arg	O
/	O
Lys	O
-	O
Arg	O
processing	O
site	O
usually	O
found	O
in	O
constitutively	O
secreted	O
precursor	O
proteins	O
and	O
recognized	O
by	O
the	O
ubiquitously	O
expressed	O
convertase	O
,	O
furin	B-Protein
.	O

pro7B2	B-Protein
(	O
30	O
kDa	O
)	O
,	O
when	O
expressed	O
in	O
endocrine	O
(	O
AtT	O
-	O
20	O
,	O
PC12	O
,	O
and	O
GH4C1	O
)	O
or	O
non	O
-	O
endocrine	O
(	O
Ltk	O
-	O
)	O
cell	O
lines	O
using	O
recombinant	O
vaccinia	O
viruses	O
,	O
was	O
converted	O
to	O
a	O
23	O
-	O
kDa	O
form	O
.	O

Mutation	O
of	O
the	O
P4	O
Arg	O
to	O
Gly	O
completely	O
prevented	O
this	O
conversion	O
.	O

When	O
excess	O
pro7B2	B-Protein
was	O
coexpressed	O
with	O
the	O
pro	O
-	O
protein	O
convertases	O
PC1	B-Protein
,	O
PC2	B-Protein
,	O
or	O
furin	B-Protein
,	O
only	O
furin	B-Protein
could	O
induce	O
complete	O
processing	O
.	O

In	O
addition	O
,	O
coexpression	O
of	O
pro7B2	B-Protein
in	O
LoVo	O
cells	O
,	O
which	O
are	O
devoid	O
of	O
endogenous	O
furin	B-Protein
activity	O
,	O
with	O
each	O
one	O
of	O
the	O
three	O
convertases	O
,	O
showed	O
that	O
only	O
furin	B-Protein
was	O
able	O
to	O
induce	O
processing	O
of	O
this	O
precursor	O
.	O

pro7B2	B-Protein
processing	O
in	O
AtT	O
-	O
20	O
was	O
completely	O
abolished	O
when	O
protein	O
transport	O
into	O
Golgi	O
compartments	O
was	O
blocked	O
by	O
cell	O
incubation	O
at	O
either	O
15	O
or	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
monensin	O
or	O
brefeldin	O
A	O
.	O

Furthermore	O
,	O
pulse	O
-	O
chase	O
experiments	O
in	O
the	O
presence	O
of	O
Na2	O
[	O
35S	O
]	O
SO4	O
showed	O
that	O
pro7B2	B-Protein
is	O
Tyr	O
-	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
before	O
it	O
is	O
processed	O
.	O

These	O
results	O
demonstrate	O
that	O
pro7B2	B-Protein
is	O
first	O
processed	O
by	O
a	O
furin	B-Protein
-	O
like	O
enzyme	O
within	O
the	O
trans	O
-	O
Golgi	O
network	O
into	O
a	O
23	O
-	O
kDa	O
form	O
that	O
is	O
then	O
sequestered	O
into	O
secretory	O
granules	O
.	O

Molecular	O
cloning	O
of	O
ras	O
and	O
rap	O
genes	O
from	O
Entamoeba	O
histolytica	O
.	O

To	O
better	O
understand	O
growth	O
regulation	O
in	O
the	O
protozoan	O
parasite	O
Entamoeba	O
histolytica	O
,	O
ameba	O
genes	O
homologous	O
to	O
the	O
ras	O
oncogene	O
and	O
rap	O
(	O
Krev	B-Protein
-	I-Protein
1	I-Protein
)	O
anti	O
-	O
oncogene	O
were	O
cloned	O
.	O

Two	O
putative	O
ameba	O
ras	O
genes	O
(	O
Ehras1	B-Protein
and	O
Ehras2	B-Protein
)	O
were	O
identified	O
,	O
which	O
contain	O
205	O
and	O
203	O
amino	O
acid	O
(	O
aa	O
)	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
respectively	O
.	O

The	O
Ehras1	B-Protein
ORF	O
shows	O
an	O
91	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehras2	B-Protein
,	O
a	O
55	O
%	O
identity	O
with	O
Dictyostelium	O
discoideum	O
(	O
Dd	O
)	O
ras	B-Protein
,	O
and	O
a	O
47	O
%	O
identity	O
with	O
human	O
(	O
Hs	O
)	O
ras	O
.	O

Two	O
ameba	O
rap	O
genes	O
(	O
Ehrap1	B-Protein
and	O
Ehrap2	B-Protein
)	O
were	O
identified	O
,	O
both	O
of	O
which	O
contain	O
184	O
-	O
aa	O
ORFs	O
.	O

The	O
Ehrap1	B-Protein
ORF	O
shows	O
a	O
93	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehrap2	B-Protein
,	O
a	O
60	O
%	O
identity	O
with	O
Dd	O
rap	B-Protein
,	O
a	O
61	O
%	O
identity	O
with	O
Hs	O
Krev	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
a	O
45	O
%	O
identity	O
with	O
that	O
of	O
Ehras1	B-Protein
.	O

Conserved	O
aa	O
in	O
each	O
ameba	O
ras	O
and	O
rap	O
ORF	O
include	O
GTP	O
-	O
binding	O
sites	O
,	O
effector	O
site	O
,	O
site	O
of	O
ADP	O
-	O
ribosylation	O
by	O
Pseudomonas	O
exoenzyme	O
S	O
,	O
and	O
COOH	O
-	O
terminus	O
CAAX	O
.	O

As	O
all	O
Xs	O
=	O
Leu	O
or	O
Phe	O
,	O
ameba	O
ras	O
and	O
rap	O
proteins	O
may	O
be	O
gerenylgerenylated	O
and	O
not	O
farnesylated	O
.	O

Both	O
ras	O
and	O
rap	O
genes	O
are	O
transcribed	O
by	O
trophozoites	O
.	O

A	O
single	O
21	O
-	O
kDa	O
ameba	O
ras	O
protein	O
reacts	O
with	O
the	O
rat	O
Y13	O
-	O
259	O
anti	O
-	O
ras	O
monoclonal	O
antibody	O
,	O
which	O
is	O
located	O
on	O
the	O
cytosolic	O
side	O
of	O
the	O
plasma	O
membrane	O
.	O

These	O
are	O
the	O
first	O
ras	O
and	O
rap	O
genes	O
identified	O
from	O
a	O
protozoan	O
parasite	O
.	O

Isoprenylation	O
of	O
large	B-Protein
hepatitis	I-Protein
delta	I-Protein
antigen	I-Protein
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
hepatitis	O
delta	O
virus	O
assembly	O
.	O

Hepatitis	O
delta	O
virus	O
(	O
HDV	O
)	O
encodes	O
two	O
proteins	O
,	O
the	O
small	B-Protein
hepatitis	I-Protein
delta	I-Protein
antigen	I-Protein
(	O
SHDAg	B-Protein
)	O
and	O
large	B-Protein
hepatitis	I-Protein
delta	I-Protein
antigen	I-Protein
(	O
LHDAg	B-Protein
)	O
.	O

Both	O
proteins	O
are	O
identical	O
except	O
for	O
the	O
presence	O
of	O
additional	O
19	O
amino	O
acids	O
at	O
the	O
C	O
terminus	O
of	O
LHDAg	B-Protein
.	O

While	O
SHDAg	B-Protein
is	O
required	O
for	O
HDV	O
RNA	O
replication	O
,	O
LHDAg	B-Protein
inhibits	O
replication	O
and	O
is	O
required	O
together	O
with	O
hepatitis	O
B	O
surface	O
antigen	O
for	O
the	O
assembly	O
of	O
HDV	O
.	O

The	O
C	O
-	O
terminal	O
last	O
4	O
amino	O
acids	O
of	O
LHDAg	B-Protein
(	O
Cys	O
-	O
Arg	O
-	O
Pro	O
-	O
Gln	O
)	O
is	O
an	O
isoprenylation	O
motif	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
mutation	O
of	O
the	O
Cys	O
inhibited	O
the	O
assembly	O
of	O
HDV	O
.	O

In	O
order	O
to	O
discern	O
whether	O
this	O
effect	O
is	O
due	O
to	O
change	O
of	O
amino	O
acid	O
residue	O
or	O
abolition	O
of	O
isoprenylation	O
,	O
we	O
constructed	O
several	O
LHDAg	B-Protein
mutants	O
of	O
the	O
terminal	O
three	O
amino	O
acid	O
residues	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	B-Protein
by	O
cotransfection	O
experiments	O
.	O

We	O
also	O
made	O
GST	O
-	O
fusion	O
proteins	O
of	O
these	O
mutants	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
isoprenylated	O
in	O
rabbit	O
reticulocyte	O
lysate	O
system	O
.	O

We	O
found	O
that	O
some	O
,	O
but	O
not	O
all	O
,	O
of	O
the	O
substitutions	O
of	O
the	O
amino	O
acid	O
residues	O
other	O
than	O
the	O
Cys	O
also	O
inhibited	O
isoprenylation	O
and	O
that	O
the	O
status	O
of	O
isoprenylation	O
of	O
these	O
mutant	O
proteins	O
correlated	O
well	O
with	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	B-Protein
into	O
virions	O
.	O

This	O
result	O
indicates	O
that	O
isoprenylation	O
,	O
rather	O
than	O
the	O
primary	O
amino	O
acid	O
sequence	O
,	O
is	O
required	O
for	O
LHDAg	B-Protein
packaging	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
attachment	O
of	O
an	O
isoprenylation	O
motif	O
to	O
SHDAg	B-Protein
did	O
not	O
enable	O
it	O
to	O
be	O
packaged	O
with	O
HBsAg	B-Protein
and	O
that	O
the	O
deletions	O
of	O
any	O
5	O
amino	O
acids	O
in	O
the	O
last	O
15	O
amino	O
acids	O
(	O
amino	O
acids	O
196	O
to	O
210	O
)	O
unique	O
to	O
the	O
LHDAg	B-Protein
abolished	O
the	O
packaging	O
ability	O
.	O

In	O
contrast	O
,	O
the	O
deletion	O
of	O
33	O
amino	O
acids	O
(	O
amino	O
acids	O
163	O
to	O
195	O
)	O
upstream	O
of	O
the	O
last	O
C	O
-	O
terminal	O
19	O
amino	O
acids	O
of	O
LHDAg	B-Protein
did	O
not	O
interfere	O
with	O
its	O
packaging	O
ability	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
15	O
amino	O
acids	O
upstream	O
of	O
the	O
isoprenylation	O
site	O
of	O
LHDAg	B-Protein
are	O
also	O
essential	O
for	O
HDV	O
assembly	O
,	O
and	O
a	O
large	O
portion	O
of	O
the	O
alleged	O
C	O
-	O
terminal	O
Pro	O
/	O
Gly	O
-	O
rich	O
region	O
(	O
amino	O
acids	O
146	O
to	O
195	O
)	O
is	O
not	O
required	O
for	O
the	O
assembly	O
process	O
.	O

Involvement	O
of	O
lysine	O
residues	O
of	O
goat	O
serum	B-Protein
albumin	I-Protein
in	O
high	O
-	O
affinity	O
binding	O
of	O
bilirubin	O
.	O

Four	O
maleylated	O
derivatives	O
of	O
goat	O
serum	B-Protein
albumin	I-Protein
having	O
percent	O
modification	O
as	O
40	O
%	O
,	O
46	O
%	O
,	O
84	O
%	O
and	O
98	O
%	O
were	O
prepared	O
using	O
varying	O
molar	O
ratio	O
of	O
maleic	O
anhydride	O
over	O
protein	O
.	O

These	O
preparations	O
were	O
found	O
to	O
be	O
pure	O
,	O
both	O
with	O
respect	O
to	O
size	O
and	O
charged	O
as	O
judged	O
by	O
gel	O
filtration	O
and	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Maleylation	O
caused	O
significant	O
change	O
in	O
protein	O
conformation	O
as	O
revealed	O
by	O
the	O
change	O
in	O
Stokes	O
radius	O
and	O
frictional	O
ratio	O
of	O
serum	B-Protein
albumin	I-Protein
,	O
from	O
3	O
.	O
46	O
nm	O
and	O
1	O
.	O
28	O
to	O
4	O
.	O
96	O
nm	O
and	O
1	O
.	O
79	O
,	O
respectively	O
,	O
upon	O
98	O
%	O
modification	O
.	O

Immunodiffusion	O
results	O
of	O
native	O
and	O
modified	O
albumins	B-Protein
with	O
anti	O
-	O
goat	O
serum	B-Protein
albumin	I-Protein
antiserum	O
also	O
suggested	O
significant	O
conformational	O
changes	O
in	O
serum	B-Protein
albumin	I-Protein
upon	O
maleylation	O
.	O

About	O
88	O
%	O
reduction	O
in	O
bilirubin	O
binding	O
was	O
observed	O
after	O
modification	O
of	O
98	O
%	O
amino	O
groups	O
of	O
serum	B-Protein
albumin	I-Protein
as	O
studied	O
by	O
visible	O
difference	O
spectroscopy	O
at	O
pH	O
8	O
.	O
0	O
,	O
and	O
at	O
0	O
.	O
15	O
ionic	O
strength	O
.	O

Increase	O
in	O
ionic	O
strength	O
to	O
1	O
.	O
0	O
did	O
not	O
lead	O
to	O
any	O
significant	O
reversal	O
in	O
bilirubin	O
binding	O
.	O

These	O
results	O
prove	O
the	O
involvement	O
of	O
lysine	O
residues	O
in	O
bilirubin	O
-	O
albumin	B-Protein
interaction	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
Schizosaccharomyces	O
pombe	O
YPT5	O
protein	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
analysis	O
of	O
processing	O
mutants	O
.	O

SpYPT5p	B-Protein
is	O
a	O
member	O
of	O
the	O
rab	O
/	O
YPT	O
small	O
GTP	O
-	O
binding	O
protein	O
family	O
,	O
which	O
is	O
believed	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
intracellular	O
trafficking	O
.	O

The	O
protein	O
sequence	O
terminates	O
with	O
a	O
CXC	O
motif	O
,	O
and	O
in	O
our	O
previous	O
report	O
(	O
Newman	O
,	O
C	O
.	O
M	O
.	O
H	O
.	O
,	O
Giannakouros	O
,	O
T	O
.	O
,	O
Hancock	O
,	O
J	O
.	O
F	O
.	O
,	O
Fawell	O
,	O
E	O
.	O
H	O
.	O
,	O
Armstrong	O
,	O
J	O
.	O
,	O
and	O
Magee	O
,	O
A	O
.	O
I	O
.	O
(	O
1992	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
267	O
,	O
11329	O
-	O
11336	O
)	O
we	O
have	O
shown	O
that	O
SpYPT5p	B-Protein
is	O
prenylated	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
where	O
geranylgeranylation	O
was	O
confirmed	O
,	O
and	O
carboxyl	O
-	O
methylated	O
.	O

In	O
order	O
to	O
dissect	O
the	O
role	O
of	O
prenylation	O
of	O
each	O
cysteine	O
,	O
we	O
have	O
generated	O
C	O
-	O
terminal	O
mutants	O
where	O
either	O
one	O
or	O
both	O
cysteine	O
(	O
s	O
)	O
were	O
replaced	O
by	O
serine	O
and	O
expressed	O
them	O
in	O
vitro	O
in	O
reticulocyte	O
lysates	O
and	O
in	O
vivo	O
in	O
transfected	O
COS	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
both	O
cysteines	O
of	O
the	O
CXC	O
motif	O
are	O
prenylated	O
but	O
that	O
the	O
rate	O
of	O
prenylation	O
of	O
the	O
two	O
cysteines	O
is	O
different	O
.	O

The	O
upstream	O
cysteine	O
was	O
found	O
to	O
be	O
preferentially	O
prenylated	O
in	O
reticulocyte	O
lysates	O
unless	O
cytosol	O
from	O
COS	O
cells	O
was	O
added	O
.	O

A	O
separate	O
activity	O
could	O
therefore	O
be	O
required	O
for	O
prenylation	O
of	O
the	O
second	O
cysteine	O
,	O
or	O
the	O
presence	O
of	O
an	O
additional	O
factor	O
is	O
needed	O
to	O
allow	O
accumulation	O
of	O
doubly	O
prenylated	O
SpYPT5p	B-Protein
.	O

However	O
,	O
the	O
modification	O
of	O
the	O
upstream	O
cysteine	O
is	O
not	O
a	O
prerequisite	O
for	O
the	O
prenylation	O
of	O
the	O
other	O
.	O

Furthermore	O
,	O
gene	O
replacement	O
in	O
Schizosaccharomyces	O
pombe	O
revealed	O
that	O
each	O
cysteine	O
of	O
the	O
CXC	O
motif	O
can	O
individually	O
support	O
function	O
.	O

Carboxyl	O
methylation	O
occurred	O
only	O
on	O
protein	O
which	O
had	O
been	O
prenylated	O
on	O
the	O
C	O
-	O
terminal	O
cysteine	O
and	O
was	O
required	O
for	O
efficient	O
membrane	O
binding	O
in	O
vitro	O
.	O

Bet2p	B-Protein
and	O
Mad2p	B-Protein
are	O
components	O
of	O
a	O
prenyltransferase	O
that	O
adds	O
geranylgeranyl	O
onto	O
Ypt1p	B-Protein
and	O
Sec4p	B-Protein
.	O

Three	O
different	O
prenyltransferases	O
have	O
been	O
identified	O
in	O
yeast	O
and	O
higher	O
cells	O
,	O
the	O
farnesyltransferase	O
and	O
the	O
type	O
I	O
and	O
type	O
II	O
geranylgeranyltransferases	O
(	O
GGTase	O
)	O
.	O

The	O
farnesyltransferase	O
and	O
GGTase	O
-	O
I	O
modify	O
peptides	O
in	O
vitro	O
with	O
the	O
CAAX	O
(	O
C	O
,	O
Cys	O
;	O
A	O
,	O
aliphatic	O
residue	O
;	O
X	O
,	O
terminal	O
amino	O
acid	O
)	O
consensus	O
motif	O
.	O

These	O
enzymes	O
are	O
heterodimers	O
that	O
have	O
different	O
beta	O
-	O
subunits	O
and	O
a	O
shared	O
alpha	O
-	O
subunit	O
.	O

In	O
yeast	O
,	O
the	O
RAM2	B-Protein
gene	O
encodes	O
this	O
alpha	O
-	O
subunit	O
.	O

RAM2	B-Protein
is	O
also	O
homologous	O
to	O
MAD2	B-Protein
,	O
a	O
yeast	O
gene	O
whose	O
product	O
has	O
been	O
implicated	O
in	O
the	O
feedback	O
control	O
of	O
mitosis	O
.	O

We	O
have	O
shown	O
that	O
Bet2p	B-Protein
is	O
a	O
component	O
of	O
the	O
yeast	O
GGTase	O
-	O
II	O
(	O
refs	O
6	O
,	O
12	O
)	O
that	O
geranylgeranylates	O
Ypt1p	B-Protein
,	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
that	O
mediates	O
transport	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
complex	O
.	O

Here	O
we	O
report	O
that	O
Mad2p	B-Protein
is	O
a	O
component	O
of	O
this	O
enzyme	O
.	O

Bet2p	B-Protein
forms	O
a	O
complex	O
with	O
Mad2p	B-Protein
that	O
appears	O
to	O
bind	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
farnesyl	O
pyrophosphate	O
.	O

The	O
efficient	O
transfer	O
of	O
geranylgeranyl	O
onto	O
small	O
GTP	O
-	O
binding	O
proteins	O
requires	O
the	O
presence	O
of	O
an	O
additional	O
activity	O
.	O

Vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
activity	O
,	O
prothrombin	B-Protein
mRNA	O
,	O
and	O
prothrombin	B-Protein
production	O
in	O
two	O
cultured	O
rat	O
hepatoma	O
cell	O
lines	O
.	O

The	O
presence	O
of	O
under	O
-	O
gamma	O
-	O
carboxylated	O
forms	O
of	O
plasma	O
prothrombin	B-Protein
is	O
a	O
marker	O
for	O
human	O
primary	O
hepatocellular	O
carcinoma	O
.	O

A	O
rat	O
hepatoma	O
cell	O
line	O
(	O
7777	O
)	O
which	O
was	O
previously	O
shown	O
to	O
secrete	O
undercarboxylated	O
prothrombin	B-Protein
when	O
grown	O
as	O
a	O
solid	O
tumor	O
has	O
now	O
been	O
grown	O
in	O
monolayer	O
culture	O
.	O

This	O
cell	O
line	O
has	O
a	O
decreased	O
activity	O
of	O
the	O
microsomal	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
when	O
compared	O
to	O
a	O
control	O
(	O
H4IIEC3	O
)	O
hepatoma	O
line	O
,	O
does	O
not	O
increase	O
intracellular	O
prothrombin	B-Protein
concentrations	O
in	O
response	O
to	O
vitamin	O
K	O
depletion	O
,	O
and	O
secretes	O
undercarboxylated	O
prothrombin	B-Protein
even	O
when	O
grown	O
in	O
vitamin	O
K	O
supplemented	O
media	O
.	O

Prothrombin	B-Protein
gene	O
expression	O
in	O
the	O
7777	O
cell	O
line	O
,	O
as	O
measured	O
by	O
prothrombin	B-Protein
mRNA	O
levels	O
,	O
was	O
not	O
altered	O
in	O
the	O
7777	O
cell	O
line	O
.	O

This	O
cell	O
line	O
appears	O
to	O
be	O
a	O
model	O
for	O
assessing	O
the	O
cellular	O
alterations	O
responsible	O
for	O
undercarboxylated	O
prothrombin	B-Protein
excretion	O
by	O
human	O
hepatocellular	O
tumors	O
.	O

A	O
novel	O
N	O
-	O
terminal	O
motif	O
for	O
palmitoylation	O
of	O
G	O
-	O
protein	O
alpha	O
subunits	O
.	O

We	O
have	O
examined	O
the	O
post	O
-	O
translational	O
processing	O
of	O
G	O
alpha	O
subunits	O
expressed	O
endogenously	O
in	O
rat	O
PC12	O
and	O
NG108	O
-	O
15	O
rat	O
/	O
mouse	O
hybrid	O
cells	O
,	O
and	O
after	O
transfection	O
of	O
cDNA	O
expression	O
constructs	O
into	O
COS	O
cells	O
.	O

Thioester	O
-	O
linked	O
palmitoylation	O
of	O
alpha	B-Protein
o	I-Protein
,	O
alpha	B-Protein
s	I-Protein
,	O
alpha	B-Protein
q	I-Protein
/	O
alpha	B-Protein
11	I-Protein
and	O
alpha	B-Protein
12	I-Protein
has	O
been	O
detected	O
by	O
metabolic	O
labelling	O
with	O
[	O
3H	O
]	O
palmitate	O
and	O
immunoprecipitation	O
.	O

Palmitoylation	O
of	O
alpha	B-Protein
o	I-Protein
occurs	O
post	O
-	O
translationally	O
in	O
cells	O
treated	O
with	O
protein	O
-	O
synthesis	O
inhibitors	O
,	O
suggesting	O
possible	O
dynamic	O
acylation	O
.	O

Palmitoylation	O
of	O
the	O
C	O
-	O
terminal	O
CAAX	O
motif	O
has	O
been	O
excluded	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
alpha	B-Protein
o	I-Protein
has	O
been	O
used	O
to	O
implicate	O
the	O
site	O
of	O
modification	O
as	O
a	O
cysteine	O
residue	O
next	O
to	O
the	O
N	O
-	O
terminal	O
myristoylated	O
glycine	O
,	O
in	O
a	O
novel	O
protein	O
-	O
lipid	O
modification	O
motif	O
Met	O
-	O
Gly	O
-	O
Cys	O
.	O

The	O
non	O
-	O
palmitoylated	O
alpha	B-Protein
o	I-Protein
mutant	O
is	O
still	O
myristoylated	O
but	O
shows	O
reduced	O
membrane	O
binding	O
,	O
suggesting	O
that	O
reversible	O
palmitoylation	O
may	O
regulate	O
G	O
alpha	O
localization	O
and	O
function	O
.	O

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
Rab	O
geranylgeranyl	O
transferase	O
and	O
demonstration	O
of	O
its	O
role	O
as	O
a	O
Rab	O
escort	O
protein	O
.	O

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
rat	O
Rab	O
geranylgeranyl	O
transferase	O
confirms	O
identity	O
of	O
the	O
protein	O
with	O
the	O
human	O
choroideremia	B-Protein
gene	O
product	O
and	O
its	O
resemblance	O
to	O
Rab3A	B-Protein
guanine	I-Protein
nucleotide	I-Protein
dissociation	I-Protein
inhibitor	I-Protein
(	O
GDI	B-Protein
)	O
,	O
which	O
binds	O
prenylated	O
Rabs	O
.	O

In	O
biochemical	O
assays	O
we	O
demonstrate	O
that	O
component	O
A	O
binds	O
unprenylated	O
Rab1A	B-Protein
,	O
presents	O
it	O
to	O
the	O
catalytic	O
component	O
B	O
,	O
and	O
remains	O
bound	O
to	O
it	O
after	O
the	O
geranylgeranyl	O
transfer	O
reaction	O
.	O

In	O
the	O
absence	O
of	O
detergents	O
,	O
the	O
reaction	O
terminates	O
when	O
all	O
of	O
component	O
A	O
is	O
occupied	O
with	O
prenylated	O
Rab	O
.	O

Detergents	O
allow	O
multiple	O
rounds	O
of	O
catalysis	O
,	O
apparently	O
by	O
dissociating	O
the	O
component	O
A	O
-	O
Rab	O
complex	O
and	O
thus	O
allowing	O
recycling	O
of	O
component	O
A	O
.	O

Within	O
the	O
cell	O
,	O
component	O
A	O
may	O
be	O
regenerated	O
by	O
transferring	O
its	O
prenylated	O
Rab	O
to	O
a	O
protein	O
acceptor	O
,	O
such	O
as	O
Rab3A	B-Protein
GDI	I-Protein
.	O

In	O
view	O
of	O
its	O
function	O
in	O
escorting	O
Rab	O
proteins	O
during	O
and	O
presumably	O
after	O
the	O
prenyl	O
transfer	O
reaction	O
,	O
we	O
propose	O
to	O
rename	O
component	O
A	O
as	O
Rab	O
escort	O
protein	O
(	O
REP	O
)	O
.	O

A	O
genetic	O
defect	O
in	O
REP	O
underlies	O
human	O
choroideremia	B-Protein
,	O
a	O
disease	O
of	O
retinal	O
degeneration	O
.	O

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
:	O
glycoprotein	B-Protein
IX	I-Protein
is	O
primarily	O
myristoylated	O
while	O
glycoprotein	O
Ib	O
is	O
palmitoylated	O
.	O

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
was	O
studied	O
with	O
special	O
emphasis	O
on	O
the	O
myristoylation	O
and	O
palmitoylation	O
of	O
the	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
complex	O
.	O

Guinea	O
pig	O
megakaryocytes	O
were	O
purified	O
and	O
separated	O
into	O
subpopulations	O
at	O
different	O
phases	O
of	O
maturation	O
.	O

Cells	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
[	O
3H	O
]	O
palmitate	O
,	O
or	O
[	O
3H	O
]	O
acetate	O
to	O
study	O
endogenous	O
protein	O
acylation	O
.	O

Cycloheximide	O
was	O
used	O
to	O
distinguish	O
between	O
cotranslational	O
and	O
posttranslational	O
acylation	O
and	O
hydroxylamine	O
to	O
distinguish	O
between	O
thioester	O
and	O
amide	O
linkages	O
.	O

After	O
incubations	O
,	O
delipidated	O
proteins	O
or	O
GPIb	O
complex	O
subunits	O
,	O
immunoprecipitated	O
with	O
PG	O
-	O
1	O
,	O
AN	O
-	O
51	O
or	O
FMC	O
-	O
25	O
monoclonal	O
antibody	O
,	O
were	O
separated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
assessed	O
by	O
fluorography	O
.	O

Radiolabeled	O
fatty	O
acids	O
bound	O
to	O
GPIX	B-Protein
and	O
GPIb	O
were	O
also	O
analyzed	O
by	O
high	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
scintillation	O
spectrometry	O
.	O

With	O
[	O
3H	O
]	O
myristic	O
acid	O
and	O
[	O
3H	O
]	O
acetate	O
,	O
GPIX	B-Protein
was	O
found	O
to	O
be	O
a	O
major	O
myristoylated	O
protein	O
in	O
megakaryocytes	O
and	O
CHRF	O
-	O
288	O
cells	O
.	O

Myristic	O
acid	O
was	O
linked	O
to	O
GPIX	B-Protein
by	O
an	O
amide	O
bond	O
,	O
and	O
this	O
process	O
occurred	O
cotranslationally	O
.	O

With	O
[	O
3H	O
]	O
acetate	O
,	O
GPIb	O
was	O
primarily	O
palmitoylated	O
,	O
but	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
GPIb	O
was	O
acylated	O
with	O
about	O
equal	O
mounts	O
of	O
myristic	O
acid	O
and	O
palmitic	O
acids	O
.	O

Both	O
fatty	O
acids	O
were	O
linked	O
to	O
GPIb	O
by	O
thioester	O
bonds	O
,	O
and	O
acylation	O
was	O
posttranslational	O
.	O

The	O
myristoylation	O
of	O
GPIX	B-Protein
while	O
the	O
palmitoylation	O
of	O
GPIb	O
occurred	O
throughout	O
megakaryocyte	O
maturation	O
.	O

Myristoylation	O
and	O
palmitoylation	O
may	O
have	O
different	O
functions	O
relevant	O
to	O
the	O
assembly	O
of	O
the	O
GPIb	O
complex	O
in	O
megakaryocytes	O
.	O

The	O
inhibition	O
of	O
phosphoenolpyruvate	B-Protein
carboxykinase	I-Protein
following	O
in	O
vivo	O
chronic	O
phenobarbital	O
treatment	O
in	O
the	O
rat	O
is	O
due	O
to	O
a	O
post	O
-	O
translational	O
event	O
.	O

Chronic	O
treatment	O
of	O
rats	O
with	O
phenobarbital	O
has	O
been	O
reported	O
to	O
decrease	O
gluconeogenesis	O
in	O
rat	O
hepatocytes	O
by	O
a	O
50	O
%	O
inhibition	O
of	O
phosphoenolpyruvate	B-Protein
(	I-Protein
P	I-Protein
-	I-Protein
pyruvate	I-Protein
)	I-Protein
carboxykinase	I-Protein
activity	O
[	O
Argaud	O
,	O
D	O
.	O
,	O
Halimi	O
,	O
S	O
.	O
,	O
Catelloni	O
,	O
F	O
.	O
&	O
Leverve	O
,	O
X	O
.	O
(	O
1991	O
)	O
Biochem	O
.	O
J	O
.	O
280	O
,	O
663	O
-	O
669	O
]	O
.	O

Contrary	O
to	O
the	O
current	O
knowledge	O
of	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
regulation	O
,	O
we	O
failed	O
to	O
find	O
a	O
diminution	O
of	O
either	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
protein	O
(	O
by	O
using	O
a	O
polyclonal	O
antibody	O
)	O
or	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
mRNA	O
,	O
in	O
the	O
liver	O
of	O
rats	O
treated	O
with	O
phenobarbital	O
for	O
2	O
weeks	O
.	O

Kinetic	O
studies	O
of	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
activity	O
,	O
measured	O
by	O
either	O
carboxylation	O
of	O
P	O
-	O
pyruvate	O
or	O
decarboxylation	O
of	O
oxaloacetate	O
,	O
revealed	O
a	O
decrease	O
in	O
both	O
V	O
(	O
max	O
)	O
and	O
Km	O
after	O
phenobarbital	O
treatment	O
,	O
whereas	O
the	O
nutritional	O
state	O
affected	O
only	O
the	O
V	O
(	O
max	O
)	O
,	O
as	O
expected	O
.	O

Assessment	O
of	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
specificity	O
was	O
confirmed	O
by	O
the	O
full	O
inhibition	O
of	O
the	O
enzyme	O
with	O
its	O
specific	O
inhibitor	O
3	O
-	O
mercaptopicolinate	O
in	O
the	O
micromolar	O
range	O
.	O

P	B-Protein
-	I-Protein
Pyruvate	I-Protein
carboxykinase	I-Protein
,	O
purified	O
either	O
by	O
ammonium	O
sulfate	O
fractionation	O
or	O
by	O
immunoprecipitation	O
,	O
exhibited	O
a	O
similar	O
decrease	O
in	O
affinity	O
after	O
phenobarbital	O
treatment	O
.	O

Although	O
the	O
molecular	O
mass	O
does	O
not	O
appear	O
to	O
be	O
altered	O
,	O
the	O
pH	O
sensitivity	O
to	O
3	O
-	O
mercaptopicolinate	O
inhibition	O
and	O
the	O
enzyme	O
recovery	O
after	O
immunoprecipitation	O
both	O
seemed	O
to	O
be	O
affected	O
.	O

This	O
leads	O
us	O
to	O
propose	O
that	O
the	O
effect	O
of	O
chronic	O
phenobarbital	O
treatment	O
on	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
activity	O
is	O
not	O
the	O
result	O
of	O
transcriptional	O
regulation	O
but	O
is	O
exerted	O
at	O
the	O
post	O
-	O
translational	O
level	O
.	O

Regulation	O
by	O
cAMP	O
of	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
endothelial	B-Protein
nitric	I-Protein
-	I-Protein
oxide	I-Protein
synthase	I-Protein
(	O
type	O
3	O
)	O
in	O
cardiac	O
myocytes	O
.	O

Cardiac	O
myocytes	O
express	O
the	O
nitric	O
-	O
oxide	O
synthase	O
isoform	O
originally	O
identified	O
in	O
endothelial	O
cells	O
,	O
termed	O
eNOS	B-Protein
or	O
NOS3	B-Protein
,	O
where	O
it	O
plays	O
a	O
role	O
in	O
regulating	O
myocyte	O
responsiveness	O
to	O
both	O
adrenergic	O
and	O
muscarinic	O
cholinergic	O
autonomic	O
nervous	O
system	O
agonists	O
.	O

eNOS	B-Protein
in	O
endothelial	O
cells	O
has	O
been	O
shown	O
to	O
undergo	O
extensive	O
post	O
-	O
translational	O
processing	O
,	O
and	O
in	O
cardiac	O
myocytes	O
as	O
well	O
as	O
endothelial	O
cells	O
,	O
eNOS	B-Protein
has	O
been	O
shown	O
to	O
be	O
targeted	O
to	O
plasmalemmal	O
caveolae	O
,	O
a	O
process	O
that	O
is	O
dependent	O
on	O
myristoylation	O
and	O
palmitoylation	O
.	O

Other	O
post	O
-	O
translational	O
modifications	O
essential	O
for	O
the	O
correct	O
subcellular	O
targeting	O
of	O
eNOS	B-Protein
have	O
not	O
been	O
described	O
previously	O
.	O

We	O
demonstrate	O
,	O
using	O
[	O
35S	O
]	O
methionine	O
pulse	O
-	O
chase	O
experiments	O
,	O
that	O
native	O
eNOS	B-Protein
in	O
adult	O
rat	O
ventricular	O
myocytes	O
is	O
initially	O
translated	O
as	O
a	O
nonpalmitoylated	O
150	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
associated	O
with	O
cytosolic	O
and	O
intracellular	O
membrane	O
-	O
enriched	O
fractions	O
.	O

This	O
is	O
subsequently	O
processed	O
to	O
a	O
palmitoylated	O
135	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
found	O
only	O
in	O
a	O
sarcolemma	O
-	O
enriched	O
membrane	O
fraction	O
.	O

Forskolin	O
,	O
an	O
agent	O
that	O
elevates	O
intracellular	O
cAMP	O
,	O
rapidly	O
inhibited	O
processing	O
of	O
the	O
150	O
-	O
kDa	O
isoform	O
to	O
the	O
135	O
-	O
kDa	O
isoform	O
and	O
transport	O
of	O
eNOS	B-Protein
to	O
the	O
sarcolemma	O
,	O
effects	O
paralleled	O
by	O
protein	O
kinase	O
A	O
-	O
dependent	O
phosphorylation	O
of	O
the	O
larger	O
eNOS	B-Protein
isoform	O
.	O

Forskolin	O
also	O
decreased	O
palmitoylation	O
of	O
the	O
135	O
-	O
kDa	O
isoform	O
,	O
although	O
it	O
did	O
not	O
accelerate	O
depalmitoylation	O
of	O
sarcolemmal	O
eNOS	B-Protein
,	O
as	O
determined	O
by	O
pulse	O
-	O
chase	O
experiments	O
with	O
[	O
3H	O
]	O
palmitate	O
.	O

Thus	O
,	O
post	O
-	O
translational	O
processing	O
of	O
a	O
150	O
-	O
kDa	O
isoform	O
of	O
myocyte	O
eNOS	B-Protein
appears	O
to	O
be	O
necessary	O
for	O
intracellular	O
trafficking	O
of	O
the	O
enzyme	O
to	O
sarcolemmal	O
caveolae	O
.	O

Both	O
the	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
eNOS	B-Protein
appear	O
to	O
be	O
modified	O
by	O
changes	O
in	O
intracellular	O
cAMP	O
,	O
an	O
effect	O
that	O
may	O
have	O
important	O
implications	O
for	O
cardiac	O
myocyte	O
responsiveness	O
to	O
autonomic	O
agonists	O
in	O
vivo	O
.	O

Direct	O
demonstration	O
of	O
geranylgeranylation	O
and	O
farnesylation	O
of	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
in	O
vivo	O
.	O

It	O
has	O
recently	O
been	O
reported	O
that	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
protein	O
can	O
be	O
modified	O
in	O
vitro	O
by	O
farnesylation	O
or	O
geranylgeranylation	O
.	O

However	O
,	O
a	O
previous	O
analysis	O
of	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
prenylation	O
in	O
vivo	O
found	O
only	O
farnesylated	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
.	O

In	O
this	O
report	O
it	O
is	O
shown	O
that	O
under	O
normal	O
conditions	O
,	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
is	O
farnesylated	O
in	O
vivo	O
and	O
when	O
cells	O
are	O
treated	O
with	O
the	O
farnesyl	O
transferase	O
inhibitors	O
B956	O
or	O
B957	O
,	O
farnesylation	O
is	O
inhibited	O
and	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
becomes	O
geranylgeranylated	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

These	O
results	O
have	O
strong	O
implications	O
in	O
the	O
design	O
of	O
anticancer	O
drugs	O
based	O
on	O
inhibition	O
of	O
prenylation	O
.	O

The	O
alpha	B-Protein
7	I-Protein
integrin	I-Protein
as	O
a	O
target	O
protein	O
for	O
cell	O
surface	O
mono	O
-	O
ADP	O
-	O
ribosylation	O
in	O
muscle	O
cells	O
.	O

A	O
membrane	B-Protein
-	I-Protein
associated	I-Protein
arginine	I-Protein
-	I-Protein
specific	I-Protein
mono	I-Protein
-	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
was	O
purified	O
215	O
,	O
000	O
-	O
fold	O
from	O
rabbit	O
skeletal	O
muscle	O
and	O
its	O
gene	O
was	O
isolated	O
from	O
a	O
skeletal	O
muscle	O
cDNA	O
library	O
.	O

The	O
enzyme	O
was	O
a	O
glycosylphosphatidyl	O
-	O
inositol	O
-	O
linked	O
protein	O
,	O
present	O
on	O
the	O
surface	O
of	O
differentiated	O
skeletal	O
muscle	O
myoblasts	O
(	O
myotubes	O
)	O
.	O

Following	O
incubation	O
of	O
cultured	O
,	O
intact	O
myotubes	O
with	O
[	O
adenylate	O
-	O
32P	O
]	O
NAD	O
and	O
analysis	O
by	O
SDS	O
-	O
PAGE	O
,	O
a	O
major	O
radiolabeled	O
protein	O
of	O
97	O
/	O
140	O
kDa	O
(	O
reduced	O
/	O
nonreduced	O
conditions	O
)	O
was	O
observed	O
.	O

It	O
was	O
identified	O
as	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
based	O
on	O
its	O
size	O
,	O
binding	O
to	O
a	O
laminin	O
affinity	O
column	O
,	O
immunoprecipitation	O
with	O
a	O
monoclonal	O
antibody	O
,	O
and	O
partial	O
amino	O
acid	O
sequencing	O
.	O

Since	O
ADP	B-Protein
-	I-Protein
ribosylarginine	I-Protein
hydrolase	I-Protein
,	O
the	O
enzyme	O
responsible	O
for	O
cleavage	O
of	O
the	O
ADP	O
-	O
ribosylarginine	O
bond	O
and	O
a	O
component	O
with	O
the	O
transferase	O
of	O
a	O
putative	O
ADP	O
-	O
ribosylation	O
cycle	O
,	O
is	O
cytosolic	O
,	O
whereas	O
the	O
transferase	O
is	O
attached	O
via	O
a	O
GPI	O
-	O
anchor	O
to	O
the	O
cell	O
surface	O
,	O
the	O
processing	O
of	O
ADP	O
-	O
ribosylated	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
was	O
investigated	O
.	O

32P	O
label	O
was	O
rapidly	O
removed	O
from	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylated	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
,	O
a	O
process	O
inhibited	O
by	O
free	O
ADP	O
-	O
ribose	O
or	O
p	O
-	O
nitrophenylthymidine	O
-	O
5	O
'	O
-	O
monophosphate	O
,	O
alternative	O
substrates	O
for	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O

The	O
processed	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
was	O
not	O
susceptible	O
to	O
subsequent	O
ADP	O
-	O
ribosylation	O
,	O
although	O
the	O
amount	O
of	O
surface	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
remained	O
constant	O
.	O

During	O
the	O
processing	O
,	O
no	O
loss	O
of	O
label	O
was	O
observed	O
from	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
radiolabeled	O
with	O
[	O
14C	O
]	O
NAD	O
,	O
containing	O
14C	O
in	O
the	O
nicotinamide	O
-	O
proximal	O
ribose	O
,	O
consistent	O
with	O
a	O
degradation	O
of	O
the	O
ADP	O
-	O
ribose	O
moiety	O
by	O
a	O
cell	O
surface	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O

Thus	O
,	O
cell	O
surface	O
ADP	O
-	O
ribosylation	O
,	O
in	O
contrast	O
to	O
intracellular	O
ADP	O
-	O
ribosylation	O
,	O
is	O
not	O
readily	O
reversed	O
by	O
the	O
presently	O
known	O
ADP	B-Protein
-	I-Protein
ribosylarginine	I-Protein
hydrolase	I-Protein
and	O
seems	O
to	O
operate	O
outside	O
the	O
postulated	O
ADP	O
-	O
ribosylation	O
cycle	O
.	O

[	O
Isoprenylated	O
proteins	O
and	O
cell	O
proliferation	O
:	O
regulators	O
and	O
effectors	O
of	O
Ras	O
proteins	O
]	O

Ras	O
proteins	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
cellular	O
proliferation	O
.	O

They	O
are	O
189	O
amino	O
acid	O
monomeric	O
GTP	O
-	O
binding	O
proteins	O
that	O
cycle	O
between	O
an	O
inactive	O
GDP	O
-	O
bound	O
and	O
the	O
active	O
GTP	O
-	O
bound	O
state	O
,	O
and	O
carry	O
a	O
slow	O
intrinsic	O
GTPase	O
activity	O
.	O

Ras	O
proteins	O
are	O
activated	O
by	O
growth	O
promoting	O
signals	O
incoming	O
from	O
receptor	O
tyrosine	O
kinases	O
via	O
SH2	O
domain	O
and	O
SH3	O
domain	O
containing	O
adapter	O
proteins	O
and	O
the	O
Ras	O
exchange	O
factor	O
Sos	O
,	O
as	O
well	O
as	O
from	O
serpentine	O
receptors	O
via	O
the	O
beta	O
gamma	O
subunits	O
of	O
heterotrimeric	O
G	O
proteins	O
and	O
the	O
Ras	O
exchange	O
factor	O
Ras	B-Protein
-	I-Protein
GRF	I-Protein
(	O
or	O
Cdc25	B-Protein
)	O
.	O

Proteins	O
that	O
can	O
stimulate	O
the	O
GTPase	O
activity	O
of	O
Ras	O
(	O
GAPs	O
)	O
ensure	O
that	O
following	O
mitogenic	O
stimulations	O
,	O
they	O
return	O
to	O
their	O
inactive	O
GDP	O
-	O
bound	O
state	O
;	O
amongst	O
these	O
proteins	O
are	O
p120	B-Protein
-	I-Protein
GAP	I-Protein
,	O
neurofibomin	B-Protein
(	O
the	O
product	O
of	O
the	O
susceptibility	O
gene	O
to	O
type	O
I	O
neurofibromatosis	O
)	O
,	O
as	O
well	O
as	O
the	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
tetrakisphosphate	O
-	O
dependent	O
GAPIP4BF	B-Protein
.	O

Several	O
effectors	O
have	O
been	O
identified	O
that	O
mediate	O
the	O
biological	O
effects	O
of	O
Ras	O
.	O

The	O
serine	O
/	O
threonine	O
kinase	O
Raf	B-Protein
-	I-Protein
1	I-Protein
,	O
as	O
well	O
as	O
the	O
closely	O
related	O
protein	O
B	B-Protein
-	I-Protein
Raf	I-Protein
,	O
elicit	O
the	O
ERK	O
cascade	O
of	O
MAP	O
kinases	O
.	O

Phosphatidylinositol	O
-	O
3	O
-	O
OH	O
kinase	O
is	O
involved	O
in	O
the	O
activation	O
of	O
the	O
Rac	O
/	O
Rho	O
family	O
proteins	O
that	O
play	O
a	O
role	O
in	O
the	O
control	O
of	O
actin	O
polymerisation	O
,	O
as	O
well	O
as	O
in	O
growth	O
control	O
,	O
RalGDS	B-Protein
,	O
RGL	O
and	O
Rlf	B-Protein
,	O
are	O
responsible	O
for	O
the	O
activation	O
of	O
the	O
Ras	O
-	O
related	O
protein	O
Ral	B-Protein
.	O

Recent	O
evidence	O
,	O
using	O
effector	O
domain	O
mutants	O
of	O
Ras	O
,	O
demonstrates	O
that	O
these	O
pathways	O
cooperate	O
to	O
elicit	O
the	O
growth	O
promoting	O
effects	O
of	O
Ras	O
proteins	O
.	O

Inhibition	O
of	O
the	O
prenylation	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
but	O
not	O
H	B-Protein
-	I-Protein
or	O
N	B-Protein
-	I-Protein
Ras	I-Protein
,	O
is	O
highly	O
resistant	O
to	O
CAAX	O
peptidomimetics	O
and	O
requires	O
both	O
a	O
farnesyltransferase	O
and	O
a	O
geranylgeranyltransferase	O
I	O
inhibitor	O
in	O
human	O
tumor	O
cell	O
lines	O
.	O

The	O
farnesyltransferase	O
(	O
FTase	O
)	O
inhibitor	O
FTI	O
-	O
277	O
is	O
highly	O
effective	O
at	O
blocking	O
oncogenic	O
H	B-Protein
-	I-Protein
Ras	I-Protein
but	O
not	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
processing	O
and	O
signaling	O
.	O

While	O
inhibition	O
of	O
processing	O
and	O
signaling	O
of	O
oncogenic	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
is	O
more	O
sensitive	O
to	O
the	O
geranylgeranyltransferase	O
I	O
(	O
GGTase	O
I	O
)	O
inhibitor	O
GGTI	O
-	O
286	O
than	O
it	O
is	O
to	O
FTI	O
-	O
277	O
in	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
-	O
transformed	O
NIH3T3	O
cells	O
,	O
the	O
sensitivity	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
as	O
well	O
as	O
H	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
to	O
the	O
CAAX	O
peptidomimetics	O
in	O
human	O
tumor	O
cell	O
lines	O
is	O
not	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
panel	O
of	O
five	O
human	O
carcinoma	O
cell	O
lines	O
from	O
pancreatic	O
,	O
pulmonary	O
,	O
and	O
bladder	O
origins	O
all	O
express	O
H	B-Protein
-	I-Protein
,	O
N	B-Protein
-	I-Protein
,	O
and	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
and	O
their	O
respective	O
prenylation	O
sensitivities	O
to	O
the	O
FTase	O
and	O
GGTase	O
I	O
inhibitors	O
is	O
variable	O
.	O

In	O
all	O
of	O
the	O
cell	O
lines	O
investigated	O
,	O
the	O
prenylation	O
of	O
N	B-Protein
-	I-Protein
Ras	I-Protein
was	O
highly	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
and	O
in	O
two	O
of	O
the	O
cell	O
lines	O
,	O
N	B-Protein
-	I-Protein
Ras	I-Protein
showed	O
slight	O
sensitivity	O
to	O
GGTI	O
-	O
298	O
,	O
an	O
analog	O
of	O
GGTI	O
-	O
286	O
.	O

Although	O
the	O
prenylation	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
was	O
also	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
complete	O
inhibition	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
even	O
at	O
high	O
concentrations	O
of	O
FTI	O
-	O
277	O
and	O
/	O
or	O
GGTI	O
-	O
298	O
was	O
never	O
achieved	O
.	O

The	O
prenylation	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
highly	O
resistant	O
to	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
.	O

Most	O
significantly	O
,	O
treatment	O
of	O
human	O
tumor	O
cell	O
lines	O
with	O
both	O
inhibitors	O
was	O
required	O
for	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
prenylation	O
.	O

In	O
one	O
cell	O
line	O
,	O
the	O
human	O
lung	O
adenocarcinoma	O
A	O
-	O
549	O
,	O
prenylation	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
was	O
highly	O
resistant	O
even	O
when	O
co	O
-	O
treated	O
with	O
both	O
inhibitors	O
.	O

Furthermore	O
,	O
soft	O
agar	O
experiments	O
demonstrated	O
that	O
in	O
all	O
the	O
human	O
tumor	O
cell	O
lines	O
tested	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
prenylation	O
was	O
not	O
necessary	O
for	O
inhibition	O
of	O
anchorage	O
-	O
independent	O
growth	O
.	O

In	O
addition	O
,	O
although	O
GGTI	O
-	O
298	O
had	O
very	O
little	O
effect	O
on	O
soft	O
agar	O
growth	O
,	O
the	O
combination	O
of	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
resulted	O
in	O
significant	O
growth	O
inhibition	O
.	O

Therefore	O
,	O
the	O
results	O
demonstrate	O
that	O
while	O
FTI	O
-	O
277	O
inhibits	O
N	B-Protein
-	I-Protein
Ras	I-Protein
and	O
H	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
in	O
the	O
human	O
tumor	O
cell	O
lines	O
evaluated	O
,	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
requires	O
both	O
an	O
FTase	O
inhibitor	O
as	O
well	O
as	O
a	O
GGTase	O
I	O
inhibitor	O
,	O
and	O
that	O
inhibition	O
of	O
human	O
tumor	O
growth	O
in	O
soft	O
agar	O
does	O
not	O
require	O
inhibition	O
of	O
oncogenic	O
K	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
.	O

Pro108	O
is	O
important	O
for	O
folding	O
and	O
stabilization	O
of	O
adrenal	B-Protein
ferredoxin	I-Protein
,	O
but	O
does	O
not	O
influence	O
the	O
functional	O
properties	O
of	O
the	O
protein	O
.	O

The	O
truncated	O
mutant	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
107	O
)	O
-	O
peptide	O
of	O
bovine	O
adrenal	B-Protein
ferredoxin	I-Protein
was	O
expressed	O
as	O
apoprotein	O
in	O
Escherichia	O
coli	O
BL21	O
and	O
could	O
be	O
reconstituted	O
to	O
the	O
holoform	O
by	O
chemical	O
or	O
enzymatic	O
methods	O
.	O

The	O
reconstituted	O
protein	O
had	O
spectroscopic	O
,	O
functional	O
and	O
redox	O
properties	O
similar	O
to	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
-	O
peptide	O
of	O
adrenal	B-Protein
ferredoxin	I-Protein
,	O
into	O
which	O
the	O
cluster	O
was	O
inserted	O
upon	O
expression	O
in	O
the	O
same	O
Escherichia	O
coli	O
strain	O
.	O

Rate	O
of	O
in	O
vitro	O
cluster	O
insertion	O
into	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
107	O
)	O
apoprotein	O
was	O
much	O
lower	O
than	O
for	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
apoprotein	O
under	O
identical	O
conditions	O
.	O

Comparative	O
thermodynamic	O
studies	O
with	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
-	O
peptide	O
indicated	O
that	O
removal	O
of	O
Pro108	O
resulted	O
in	O
an	O
extensive	O
decrease	O
of	O
the	O
overall	O
stability	O
of	O
the	O
protein	O
in	O
either	O
oxidation	O
state	O
.	O

The	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
107	O
)	O
-	O
peptide	O
showed	O
a	O
higher	O
sensitivity	O
to	O
urea	O
denaturation	O
and	O
had	O
a	O
sensibly	O
lower	O
denaturation	O
temperature	O
,	O
44	O
.	O
8	O
degrees	O
C	O
,	O
compared	O
with	O
51	O
.	O
7	O
degrees	O
C	O
for	O
mutant	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
.	O

The	O
stability	O
of	O
the	O
reduced	O
state	O
of	O
both	O
mutants	O
is	O
slightly	O
lower	O
than	O
that	O
of	O
the	O
oxidized	O
state	O
indicating	O
that	O
this	O
protein	O
region	O
does	O
not	O
undergo	O
major	O
structural	O
changes	O
upon	O
reduction	O
.	O

A	O
novel	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	I-Protein
monoclonal	O
antibody	O
recognizes	O
an	O
epitope	O
within	O
the	O
tyrosine	O
sulfate	O
motif	O
of	O
human	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
and	O
blocks	O
recognition	O
of	O
both	O
P	B-Protein
-	I-Protein
and	O
L	B-Protein
-	I-Protein
selectin	I-Protein
.	O

Interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	I-Protein
(	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
)	O
mediate	O
the	O
earliest	O
"	O
rolling	O
"	O
of	O
leukocytes	O
on	O
the	O
lumenal	O
surface	O
of	O
endothelial	O
cells	O
at	O
sites	O
of	O
inflammation	O
.	O

Previously	O
,	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
shown	O
to	O
be	O
the	O
primary	O
mediator	O
of	O
interactions	O
between	O
neutrophils	O
and	O
P	B-Protein
-	I-Protein
selectin	I-Protein
,	O
but	O
studies	O
on	O
the	O
ability	O
of	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
to	O
mediate	O
interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
other	O
subsets	O
of	O
leukocytes	O
have	O
yielded	O
variable	O
and	O
conflicting	O
results	O
.	O

A	O
novel	O
IgG	O
monoclonal	O
antibody	O
(	O
MoAb	O
)	O
to	O
human	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
was	O
generated	O
,	O
and	O
the	O
specificity	O
of	O
this	O
MoAb	O
was	O
confirmed	O
by	O
both	O
flow	O
cytometric	O
analysis	O
and	O
Western	O
blotting	O
of	O
cells	O
transfected	O
with	O
human	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
.	O

This	O
newly	O
developed	O
MoAb	O
,	O
KPL1	O
,	O
inhibited	O
interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
expressing	O
COS	O
cells	O
and	O
either	O
HL60	O
cells	O
,	O
neutrophils	O
,	O
or	O
lymphocytes	O
.	O

Furthermore	O
,	O
KPL1	O
completely	O
inhibited	O
interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
either	O
purified	O
CD4	B-Protein
T	O
cells	O
or	O
neutrophils	O
in	O
a	O
flow	O
assay	O
under	O
physiological	O
conditions	O
,	O
but	O
had	O
no	O
effect	O
on	O
interactions	O
of	O
T	O
cells	O
or	O
neutrophils	O
with	O
E	B-Protein
-	I-Protein
selectin	I-Protein
.	O

In	O
addition	O
,	O
KPL1	O
blocked	O
interactions	O
between	O
lymphoid	O
cells	O
transfected	O
with	O
L	B-Protein
-	I-Protein
selectin	I-Protein
and	O
COS	O
cells	O
expressing	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
.	O

The	O
KPL1	O
epitope	O
was	O
mapped	O
to	O
a	O
site	O
within	O
a	O
consensus	O
tyrosine	O
sulfation	O
motif	O
of	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
,	O
previously	O
shown	O
to	O
be	O
essential	O
for	O
interaction	O
with	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
now	O
shown	O
to	O
be	O
essential	O
for	O
interaction	O
with	O
L	B-Protein
-	I-Protein
selectin	I-Protein
,	O
and	O
to	O
be	O
distinct	O
from	O
the	O
epitope	O
identified	O
by	O
the	O
PL1	O
function	O
blocking	O
anti	O
-	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
MoAb	O
.	O

Two	O
-	O
color	O
flow	O
cytometry	O
of	O
normal	O
leukocytes	O
showed	O
that	O
while	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
(	O
CD16	O
(	O
+	O
)	O
)	O
,	O
monocytes	O
,	O
CD4	B-Protein
and	O
CD8	O
T	O
cells	O
,	O
and	O
alpha	O
/	O
beta	O
and	O
gamma	O
/	O
delta	O
T	O
cells	O
were	O
uniformly	O
positive	O
for	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
,	O
B	O
cells	O
expressed	O
low	O
levels	O
of	O
the	O
KPL1	O
epitope	O
.	O

This	O
low	O
level	O
of	O
KPL1	O
staining	O
was	O
also	O
observed	O
immunohistologically	O
in	O
germinal	O
centers	O
,	O
which	O
had	O
no	O
detectable	O
KPL1	O
staining	O
,	O
whereas	O
T	O
-	O
cell	O
areas	O
(	O
interfollicular	O
region	O
)	O
were	O
positive	O
for	O
KPL1	O
.	O

Interestingly	O
,	O
plasma	O
cells	O
in	O
situ	O
and	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
-	O
dependent	O
myeloma	O
cell	O
lines	O
were	O
KPL1	O
(	O
+	O
)	O
.	O

Thus	O
,	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
is	O
expressed	O
on	O
essentially	O
all	O
blood	O
neutrophils	O
,	O
NK	O
cells	O
,	O
B	O
cells	O
,	O
T	O
cells	O
,	O
and	O
monocytes	O
.	O

Variation	O
in	O
tyrosine	O
sulfation	O
during	O
B	O
-	O
cell	O
differentiation	O
may	O
affect	O
the	O
ability	O
of	O
B	O
cells	O
to	O
interact	O
with	O
P	B-Protein
-	I-Protein
and	O
L	B-Protein
-	I-Protein
selectin	I-Protein
.	O

Modification	O
of	O
yeast	O
Cdc53p	B-Protein
by	O
the	O
ubiquitin	B-Protein
-	O
related	O
protein	O
rub1p	B-Protein
affects	O
function	O
of	O
the	O
SCFCdc4	B-Protein
complex	O
.	O

The	O
RUB1	B-Protein
/	O
NEDD	B-Protein
-	I-Protein
8	I-Protein
family	O
of	O
ubiquitin	B-Protein
-	O
related	O
genes	O
is	O
widely	O
represented	O
among	O
eukaryotes	O
.	O

Here	O
we	O
report	O
that	O
Cdc53p	B-Protein
in	O
Saccharomyces	O
cerevisiae	O
,	O
a	O
member	O
of	O
the	O
Cullin	O
family	O
of	O
proteins	O
,	O
is	O
stably	O
modified	O
by	O
the	O
covalent	O
attachment	O
of	O
a	O
single	O
Rub1p	B-Protein
molecule	O
.	O

Two	O
genes	O
have	O
been	O
identified	O
that	O
are	O
required	O
for	O
Rub1p	B-Protein
conjugation	O
to	O
Cdc53p	B-Protein
.	O

The	O
first	O
gene	O
,	O
designated	O
ENR2	B-Protein
,	O
encodes	O
a	O
protein	O
with	O
sequence	O
similarity	O
to	O
the	O
amino	O
-	O
terminal	O
half	O
of	O
the	O
ubiquitin	B-Protein
-	O
activating	O
enzyme	O
.	O

By	O
analogy	O
with	O
Aos1p	B-Protein
,	O
we	O
infer	O
that	O
Enr2p	B-Protein
functions	O
in	O
a	O
bipartite	O
Rub1p	B-Protein
-	O
activating	O
enzyme	O
.	O

The	O
second	O
gene	O
is	O
SKP1	B-Protein
,	O
shown	O
previously	O
to	O
be	O
required	O
for	O
some	O
ubiquitin	B-Protein
-	O
conjugation	O
events	O
.	O

A	O
deletion	O
allele	O
of	O
ENR2	B-Protein
is	O
lethal	O
with	O
temperature	O
-	O
sensitive	O
alleles	O
of	O
cdc34	B-Protein
and	O
enhances	O
the	O
phenotypes	O
of	O
cdc4	B-Protein
,	O
cdc53	B-Protein
,	O
and	O
skp1	B-Protein
,	O
strongly	O
implying	O
that	O
Rub1p	B-Protein
conjugation	O
to	O
Cdc53p	B-Protein
is	O
required	O
for	O
optimal	O
assembly	O
or	O
function	O
of	O
the	O
E3	O
complex	O
SCFCdc4	B-Protein
.	O

Consistent	O
with	O
this	O
model	O
,	O
both	O
enr2delta	B-Protein
and	O
an	O
allele	O
of	O
Cdc53p	B-Protein
that	O
is	O
not	O
Rub1p	B-Protein
modified	O
,	O
render	O
cells	O
sensitive	O
to	O
alterations	O
in	O
the	O
levels	O
of	O
Cdc4p	B-Protein
,	O
Cdc34p	B-Protein
,	O
and	O
Cdc53p	B-Protein
.	O

A	O
novel	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
,	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
,	O
that	O
is	O
prenylated	O
and	O
contains	O
homology	O
to	O
cPLA2	B-Protein
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
membrane	O
-	O
bound	O
,	O
calcium	O
-	O
independent	O
PLA2	O
,	O
named	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
.	O

The	O
sequence	O
encodes	O
a	O
541	O
-	O
amino	O
acid	O
protein	O
containing	O
a	O
domain	O
with	O
significant	O
homology	O
to	O
the	O
catalytic	O
domain	O
of	O
the	O
85	O
-	O
kDa	O
cPLA2	B-Protein
(	O
cPLA2	B-Protein
-	I-Protein
alpha	I-Protein
)	O
.	O

cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
does	O
not	O
contain	O
the	O
regulatory	O
calcium	O
-	O
dependent	O
lipid	O
binding	O
(	O
CaLB	O
)	O
domain	O
found	O
in	O
cPLA2	B-Protein
-	I-Protein
alpha	I-Protein
.	O

However	O
,	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
does	O
contain	O
two	O
consensus	O
motifs	O
for	O
lipid	O
modification	O
,	O
a	O
prenylation	O
motif	O
(	O
-	O
CCLA	O
)	O
at	O
the	O
C	O
terminus	O
and	O
a	O
myristoylation	O
site	O
at	O
the	O
N	O
terminus	O
.	O

We	O
present	O
evidence	O
that	O
the	O
isoprenoid	O
precursor	O
[	O
3H	O
]	O
mevalonolactone	O
is	O
incorporated	O
into	O
the	O
prenylation	O
motif	O
of	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
.	O

Interestingly	O
,	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
demonstrates	O
a	O
preference	O
for	O
arachidonic	O
acid	O
at	O
the	O
sn	O
-	O
2	O
position	O
of	O
phosphatidylcholine	O
as	O
compared	O
with	O
palmitic	O
acid	O
.	O

cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
encodes	O
a	O
3	O
-	O
kilobase	O
message	O
,	O
which	O
is	O
highly	O
expressed	O
in	O
heart	O
and	O
skeletal	O
muscle	O
,	O
suggesting	O
a	O
specific	O
role	O
in	O
these	O
tissues	O
.	O

Identification	O
of	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
reveals	O
a	O
newly	O
defined	O
family	O
of	O
phospholipases	O
A2	O
with	O
homology	O
to	O
cPLA2	B-Protein
-	I-Protein
alpha	I-Protein
.	O

A	O
practical	O
diagnostic	O
test	O
for	O
choroideremia	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
aimed	O
to	O
establish	O
a	O
practical	O
diagnostic	O
test	O
for	O
choroideremia	O
(	O
CHM	O
)	O
and	O
to	O
show	O
its	O
application	O
in	O
a	O
family	O
with	O
the	O
clinical	O
diagnosis	O
of	O
choroideremia	O
.	O

DESIGN	O
:	O
Case	O
series	O
.	O

PARTICIPANTS	O
:	O
Sixteen	O
males	O
from	O
13	O
families	O
with	O
clinically	O
documented	O
CHM	O
and	O
unaffected	O
normal	O
males	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

METHODS	O
:	O
Protein	O
extracted	O
from	O
either	O
leukocytes	O
or	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
lymphocytes	O
was	O
subjected	O
to	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Immunoblot	O
analysis	O
of	O
the	O
protein	O
was	O
performed	O
with	O
two	O
monoclonal	O
antibodies	O
,	O
one	O
against	O
the	O
CHM	B-Protein
gene	O
product	O
,	O
Rab	B-Protein
escort	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
REP	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
and	O
the	O
other	O
against	O
the	O
alpha	O
-	O
subunit	O
of	O
farnesyl	O
transferase	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformation	O
polymorphism	O
analysis	O
using	O
primers	O
for	O
the	O
exons	O
of	O
the	O
CHM	B-Protein
gene	O
.	O

Where	O
altered	O
mobility	O
of	O
the	O
DNA	O
fragments	O
was	O
detected	O
,	O
direct	O
sequencing	O
of	O
that	O
exon	O
was	O
compared	O
with	O
the	O
published	O
normal	O
sequence	O
.	O

RESULTS	O
:	O
The	O
authors	O
detected	O
REP	B-Protein
-	I-Protein
1	I-Protein
in	O
protein	O
samples	O
extracted	O
from	O
lymphoblastoid	O
cell	O
lines	O
from	O
female	O
carriers	O
but	O
not	O
from	O
CHM	O
males	O
.	O

The	O
authors	O
also	O
showed	O
the	O
absence	O
of	O
REP	B-Protein
-	I-Protein
1	I-Protein
in	O
the	O
peripheral	O
leukocytes	O
of	O
males	O
affected	O
with	O
CHM	O
.	O

In	O
one	O
male	O
who	O
lacked	O
REP	B-Protein
-	I-Protein
1	I-Protein
,	O
direct	O
sequencing	O
of	O
exon	O
7	O
showed	O
a	O
cytosine	O
-	O
to	O
-	O
thymine	O
transition	O
mutation	O
(	O
Arg293X	O
)	O
in	O
the	O
CHM	B-Protein
gene	O
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
diagnosis	O
of	O
CHM	O
can	O
be	O
confirmed	O
simply	O
by	O
immunoblot	O
analysis	O
with	O
anti	O
-	O
REP	B-Protein
-	I-Protein
1	I-Protein
antibody	O
,	O
showing	O
the	O
absence	O
of	O
REP	B-Protein
-	I-Protein
1	I-Protein
protein	O
in	O
peripheral	O
blood	O
samples	O
.	O

Because	O
all	O
known	O
mutations	O
in	O
the	O
CHM	B-Protein
gene	O
create	O
stop	O
codons	O
that	O
truncate	O
the	O
protein	O
product	O
and	O
result	O
in	O
absence	O
of	O
REP	B-Protein
-	I-Protein
1	I-Protein
,	O
the	O
authors	O
predict	O
that	O
most	O
patients	O
with	O
CHM	O
can	O
be	O
diagnosed	O
by	O
this	O
procedure	O
.	O

Mutations	O
in	O
orthologous	O
genes	O
in	O
human	O
spondyloepimetaphyseal	O
dysplasia	O
and	O
the	O
brachymorphic	O
mouse	O
.	O

The	O
osteochondrodysplasias	O
are	O
a	O
genetically	O
heterogeneous	O
group	O
of	O
disorders	O
affecting	O
skeletal	O
development	O
,	O
linear	O
growth	O
and	O
the	O
maintenance	O
of	O
cartilage	O
and	O
bone	O
.	O

We	O
have	O
studied	O
a	O
large	O
inbred	O
Pakistani	O
family	O
with	O
a	O
distinct	O
form	O
of	O
recessively	O
inherited	O
spondyloepimetaphyseal	O
dysplasia	O
(	O
SEMD	O
)	O
and	O
mapped	O
a	O
gene	O
associated	O
with	O
this	O
dwarfing	O
condition	O
to	O
chromosome	O
10q23	O
-	O
24	O
,	O
a	O
region	O
syntenic	O
with	O
the	O
locus	O
for	O
the	O
brachymorphic	O
mutation	O
on	O
mouse	O
chromosome	O
19	O
.	O

We	O
identified	O
two	O
orthologous	O
genes	O
,	O
ATPSK2	B-Protein
and	O
Atpsk2	B-Protein
,	O
encoding	O
novel	O
ATP	O
sulfurylase	O
/	O
APS	O
kinase	O
orthologues	O
in	O
the	O
respective	O
regions	O
of	O
the	O
human	O
and	O
mouse	O
genomes	O
.	O

We	O
characterized	O
a	O
nonsense	O
mutation	O
in	O
ATPSK2	B-Protein
in	O
the	O
SEMD	O
family	O
and	O
a	O
missense	O
mutation	O
in	O
the	O
region	O
of	O
Atpsk2	B-Protein
encoding	O
the	O
APS	O
kinase	O
activity	O
in	O
the	O
brachymorphic	O
mouse	O
.	O

ATP	O
sulfurylase	O
/	O
APS	O
kinase	O
catalyses	O
the	O
metabolic	O
activation	O
of	O
inorganic	O
sulfate	O
to	O
PAPS	O
,	O
the	O
universal	O
donor	O
for	O
post	O
-	O
translational	O
protein	O
sulfation	O
in	O
all	O
cell	O
types	O
.	O

The	O
cartilage	O
-	O
specificity	O
of	O
the	O
human	O
and	O
mouse	O
phenotypes	O
provides	O
further	O
evidence	O
of	O
the	O
critical	O
role	O
of	O
sulfate	O
activation	O
in	O
the	O
maturation	O
of	O
cartilage	O
extracellular	O
matrix	O
molecules	O
and	O
the	O
effect	O
of	O
defects	O
in	O
this	O
process	O
on	O
the	O
architecture	O
of	O
cartilage	O
and	O
skeletogenesis	O
.	O

Apoprotein	B-Protein
B100	I-Protein
has	O
a	O
prolonged	O
interaction	O
with	O
the	O
translocon	O
during	O
which	O
its	O
lipidation	O
and	O
translocation	O
change	O
from	O
dependence	O
on	O
the	O
microsomal	O
triglyceride	O
transfer	O
protein	O
to	O
independence	O
.	O

When	O
lipid	O
synthesis	O
is	O
limited	O
in	O
HepG2	O
cells	O
,	O
apoprotein	B-Protein
B100	I-Protein
(	O
apoB100	B-Protein
)	O
is	O
not	O
secreted	O
but	O
rapidly	O
degraded	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O

To	O
investigate	O
apoB100	B-Protein
biosynthesis	O
and	O
secretion	O
further	O
,	O
the	O
physical	O
and	O
functional	O
states	O
of	O
apoB100	B-Protein
destined	O
for	O
either	O
degradation	O
or	O
lipoprotein	O
assembly	O
were	O
studied	O
under	O
conditions	O
in	O
which	O
lipid	O
synthesis	O
,	O
proteasomal	O
activity	O
,	O
and	O
microsomal	O
triglyceride	O
transfer	O
protein	O
(	O
MTP	O
)	O
lipid	O
-	O
transfer	O
activity	O
were	O
varied	O
.	O

Cells	O
were	O
pretreated	O
with	O
a	O
proteasomal	O
inhibitor	O
(	O
which	O
remained	O
with	O
the	O
cells	O
throughout	O
the	O
experiment	O
)	O
and	O
radiolabeled	O
for	O
15	O
min	O
.	O

During	O
the	O
chase	O
period	O
,	O
labeled	O
apoB100	B-Protein
remained	O
associated	O
with	O
the	O
microsomes	O
.	O

Furthermore	O
,	O
by	O
crosslinking	O
sec61beta	B-Protein
to	O
apoB100	B-Protein
,	O
we	O
showed	O
that	O
apoB100	B-Protein
remained	O
close	O
to	O
the	O
translocon	O
at	O
the	O
same	O
time	O
apoB100	B-Protein
-	O
ubiquitin	B-Protein
conjugates	O
could	O
be	O
detected	O
.	O

When	O
lipid	O
synthesis	O
and	O
lipoprotein	O
assembly	O
/	O
secretion	O
were	O
stimulated	O
by	O
adding	O
oleic	O
acid	O
(	O
OA	O
)	O
to	O
the	O
chase	O
medium	O
,	O
apoB100	B-Protein
was	O
deubiquitinated	O
,	O
and	O
its	O
interaction	O
with	O
sec61beta	B-Protein
was	O
disrupted	O
,	O
signifying	O
completion	O
of	O
translocation	O
concomitant	O
with	O
the	O
formation	O
of	O
lipoprotein	O
particles	O
.	O

MTP	O
participates	O
in	O
apoB100	B-Protein
translocation	O
and	O
lipoprotein	O
assembly	O
.	O

In	O
the	O
presence	O
of	O
OA	O
,	O
when	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
was	O
inhibited	O
at	O
the	O
end	O
of	O
pulse	O
labeling	O
,	O
apoB100	B-Protein
secretion	O
was	O
abolished	O
.	O

In	O
contrast	O
,	O
when	O
the	O
labeled	O
apoB100	B-Protein
was	O
allowed	O
to	O
accumulate	O
in	O
the	O
cell	O
for	O
60	O
min	O
before	O
adding	O
OA	O
and	O
the	O
inhibitor	O
,	O
apoB100	B-Protein
lipidation	O
and	O
secretion	O
were	O
no	O
longer	O
impaired	O
.	O

Overall	O
,	O
the	O
data	O
imply	O
that	O
during	O
most	O
of	O
its	O
association	O
with	O
the	O
endoplasmic	O
reticulum	O
,	O
apoB100	B-Protein
is	O
close	O
to	O
or	O
within	O
the	O
translocon	O
and	O
is	O
accessible	O
to	O
both	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
and	O
lipoprotein	O
-	O
assembly	O
pathways	O
.	O

Furthermore	O
,	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
seems	O
to	O
be	O
necessary	O
only	O
for	O
early	O
translocation	O
and	O
lipidation	O
events	O
.	O

